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Summary 
Enzyme  linked  immunosorbent  assay  (ELISA)  is  a  useful  "initial  screening  test" 
for  the  detection  of  a  particular  drug  class  for  example  opiates.  It  is  a  rapid, 
highly  sensitive  and  in  most  laboratories  automated  procedure.  This  is  highly 
beneficial  in  a  busy  toxicology  laboratory  with  high  sample  throughput  as  a 
means  of  eliminating  negative  samples.  Appropriate  cross  reactivity  of  the  ELISA 
kits  with  a  range  of  drugs  or  drug  metabolites  within  a  drug  class  is  essential  to 
the  success  of  this  screening  method. 
Liquid  chromatography-tandem  mass  spectrometry  (LC-MS-MS)  combines 
selective  chromatographic  and  mass  selective  detection  of  analytes.  It  has 
established  itself  as  a  complementary  technique  to  gas  chromatography-mass 
spectrometry  (GC-MS)  in  the  analysis  of  less  volatile  compounds  and/or  high 
molecular  weight  compounds  and  an  increasing  number  of  laboratories  are  using 
it.  A  major  advantage  of  LC  is  that  unlike  GC,  time-consuming  derivatisation 
steps  are  not  generally  required: 
The  aim  of  this  study  was  to  investigate  the  potential  use  of  ELISA  and  LC-MS-MS 
in  combination  and  as  individual  techniques,  for  the  detection  of  drugs  of  abuse 
in  biological  matrices. 
An  ELISA  method  was  validated  for  the  detection  of  buprenorphine  in  urine 
samples  and  the  results  were  compared  with  an  in-house  LC-MS-MS  method.  69 
urine  samples  were  received  into  the  laboratory  as  routine  samples  and  from 
volunteers  on  the  Subutex®  treatment  programme.  The  limit  of  detection  (LOD) 
was  calculated  as  0.5  ng/mL  buprenorphine.  The  intra-day  (n=20)  and  inter-day 
precision  (n=100)  were  good  (6.4  and  12.9  %  respectively).  The  kit 
demonstrated  appropriate  cross  reactivity  with  norbuprenorphine  at  low  and 
high  concentrations.  21  urine  samples  were  confirmed  positive  and  48  samples 
were  confirmed  negative  by  LC-MS-MS.  Using  a  cut-off  value  of  0.5  ng/mL 
buprenorphine,  the  immunoassay  demonstrated  a  sensitivity  and  specificity  of 
100%. 
An  ELISA  method  was  validated  for  the  detection  of  amphetamines,  cocaine, 
benzodiazepines  and  opiates  in  hair.  The  kits  for  each  drug  class  demonstrated AV 
high  sensitivity  with  LOD  values  <_  0.1  ng/mg  using  a  10  mg  hair  sample,  good 
precision  (intra-day  <9%,  inter-day  <  18  %)  and  appropriate  cross  reactivity  with 
analytes  found  in  hair.  The  method  was  applied  successfully  for  the  screening  of 
post-mortem  samples  as  discussed  in  chapters  6-8.  However  more  data  is 
required  to  determine  if  the  cut-off  values  recommended  by  the  Society  of  Hair 
Testing  for  amphetamines,  cocaine  and  opiates  are  suitable  for  screening  hair 
samples. 
This  ELISA  method  was  also  validated  for  the  detection  of  methamphetamine  in 
hair  and  the  results  compared  to  GC-MS  as  part  of  collaboration  with  the 
National  Institute  of  Scientific  Investigation  in  South  Korea.  29  scalp  hair 
samples  were  obtained  as  routine  cases  submitted  to  the  forensic  toxicology 
laboratory  in  South  Korea  by  the  police.  28  of  these  samples  were  screened  and 
confirmed  as  positive  using  a  cut-off  concentration  of  0.5  ng/mg 
d-methamphetamine.  The  ELISA  demonstrated  a  sensitivity  and  specificity  of 
97  %  and  100  %  respectively  using  this  cut-off  concentration.  The  ELISA  kit 
demonstrated  appropriate  cross-reactivity  with  d-methamphetamine  and  did  not 
cross-react  to  any  significant  extent  with  the  licit  1-methamphetamine  isomer. 
The  intra-day  and  inter-day  assay  precisions  were  good  (7.4  %  and  7.6  % 
respectively).  The  LOD  was  calculated  as  0.05  ng/mg  d-methamphetamine  using 
a  10  mg  hair  sample. 
The  study  in  chapter  7  was  designed  to  compare  the  ELISA  method  with  a 
validated  LC-MS-MS  method  for  the  detection  of  9  benzodiazepines  in  hair.  The 
LC-MS-MS  method  provided  the  sensitivity  necessary  to  quantify  benzodiazepine 
levels  in  post-mortem  hair  samples.  Mild  alkaline  extraction  conditions  and  an 
incubation  time  of  16  hours  were  demonstrated  to  be  suitable  for  the  extraction 
of  benzodiazepines  in  the  LC-MS-MS  method.  13  out  of  16  hair  samples  were 
screened  and  confirmed  as  positive.  The  benzodiazepines  detected  included 
diazepam,  nordiazepam,  temazepam,  oxazepam,  nitrazepam,  and  lorazepam. 
Using  a  cut-off  concentration  of  0.1  ng/mg  oxazepam,  the  ELISA  method 
demonstrated  a  sensitivity  and  specificity  of  100  %  and  81  %  respectively, 
compared  with  LC-MS-MS  results. 
Also  in  chapter  7,  a  preliminary  study  into  the  use  of  a  diazepam  molecularly 
imprinted  polymer  (MIP)  is  described  for  the  successful  detection  of xv 
benzodiazepines  in  post-mortem  hair  samples.  The  molecularly  imprinted  solid- 
phase  extraction  (MISPE)  method  was  compared  to  the  classical  solid-phase 
extraction  (SPE)  method  for  10  hair  samples.  The  MISPE  method  detected  a 
higher  number  of  diazepam  positive  case  samples  than  the  classial  SPE  method 
because  of  the  higher  extraction  recovery  of  the  MISPE  method  and  the  excellent 
molecular  recognition  of  the  template  molecule  (diazepam)  imparted  by  the 
imprinting  process.  The  MISPE  method  also  demonstrated  selectivity  for  other 
benzodiazepine  analogues.  MISPE  could  be  used  as  a  complementary  method  to 
classical  SPE  for  the  detection  of  benzodiazepines  in  post-mortem  hair  samples. 
An  LC-MS-MS  method  was  developed  and  validated  for  the  simultaneous 
identification  and  quantification  of  opiates,  cocaine  and  its  metabolites, 
amphetamines  and  diazepam  and  its  metabolites  from  one  hair  sample  without 
roots  (8-30  mg)  and  root  samples  (in  some  cases  <1  mg)  as  described  in  chapter 
8.  The  method  was  applied  to  17  post-mortem  hair  samples,  detecting  at  least 
one  drug  class  in  16  out  of  17  samples.  The  results  of  the  analysis  were 
compared  to  GC-MS  results  obtained  by  in-house  methods. 
Overall,  the  LC-MS-MS  method  showed  good  correlation  results  for  the  opiates 
compared  to  the  GC-MS  method.  6-MAM  was  however  detected  in  more  root 
segments  and  segments  excluding  roots  by  LC-MS-MS.  Morphine  was  detected  in 
a  greater  number  of  root  segments  by  LC-MS-MS  compared  to  GC-MS.  However 
morphine  was  detected  in  a  greater  number  of  segments  excluding  roots  by  GC- 
MS.  Codeine  and  dihydrocodeine  were  also  detected  in  a  greater  number  of  root 
segments  and  segments  excluding  roots  by  GC-MS.  The  cocaine  results  showed 
excellent  qualitative  correlation  between  the  LC-MS-MS  and  GC-MS  methods  for 
cocaine  and  benzoylecgonine.  The  GC-MS  method  did  however  extract  greater 
concentrations  of  cocaine  and  its  metabolites  compared  to  LC-MS-MS  due  to  the 
higher  recovery  of  the  drug  group  specific  GC-MS  method.  Cocaethytene  and 
EME  were  detected  in  some  samples  by  LC-MS-MS  where  GC-MS  detected  none. 
As  a  result  of  the  lower  recovery  of  the  LC-MS-MS  method  for  opiates  and 
cocaine  and  its  metabolites  compared  to  the  GC-MS  method,  there  may  be  some 
cases  where  the  GC-MS  method  would  detect  the  analytes  where  the  LC-MS-MS 
method  would  not.  This  has  been  demonstrated  in  3  samples  for  morphine  and 
in  6  samples  for  codeine. xvi 
The  LC-MS-MS  method  analysed  for  and  detected  amphetamines  in  samples  that 
were  not  tested  for  amphetamines  by  GC-MS.  In  1  sample  that  was  tested  by 
both  methods,  amphetamine  was  detected  in  the  root  sample  by  LC-MS-MS 
where  GC-MS  failed  to  detect  it.  Also  a  greater  concentration  of  amphetamine 
was  extracted  using  the  LC-MS-MS  method  in  the  segment  without  roots. 
The  LC-MS-MS  method  was  useful  for  the  analysis  of  17  drugs  of  abuse  in  post- 
mortem  hair  samples  in  forensic  toxicology  cases.  Using  this  method,  it  is 
possible  to  obtain  maximum  information  from  1  hair  sample  which  is  extremely 
useful  when  the  sample  weight  is  limited.  The  ability  of  the  LC-MS-MS  method 
to  extract  and  analyse  a  greater  number  of  drug  groups  from  one  hair  sample 
highlights  the  advantages  of  using  this  method  over  GC-MS  which  targets 
individual  drug  groups  and  requires  splitting  of  the  sample.  This  method  is 
particularly  applicable  for  implementation  in  the  forensic  toxicology  laboratory 
at  the  University  of  Glasgow  where  currently  GC-MS  methods  that  target 
individual  drug  groups  are  used  for  routine  hair  screening  and  confirmation. xvii 
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Enzyme  linked  immunosorbent  assay  (ELISA)  is  well  established  and  routinely 
practiced  in  forensic  and  toxicological  analyses  as  an  "initial  screening  test"  for 
drugs  of  abuse  in  blood  and  urine  samples.  ELISAs  have  more  recently  been 
adapted  to  detect  and  semi-quantify  a  wide  range  of  drugs  or  drug  metabolites 
in  a  variety  of  less  conventional  biological  matrices  such  as  hair  and  oral  fluid. 
ELISA  is  a  highly  sensitive  method  for  determining  the  amount  of  drug  present  in 
a  sample  by  means  of  an  enzyme-catalysed  change  in  absorbance  signal.  In 
drugs  of  abuse  screening,  ELISA  serves  as  a  useful  means  of  eliminating  negative 
samples  from  further  confirmatory  tests  and  also  identifying  any  drug  class  that 
requires  confirmation  by  a  second  step  test  such  as  liquid  chromatography- 
tandem  mass  spectrometry  (LC-MS-MS). 
The  use  of  liquid  chromatography-mass  spectrometry  (LC-MS)  in  all  areas  of 
analytical  chemistry  has  increased  exponentially  from  1990.  The  development 
of  a  suitable  interface  for  coupling  LC  to  MS  in  the  form  of  atmospheric  pressure 
ionisation  (API)  is  responsible  for  the  success  of  the  technique.  LC-MS  has  many 
attractive  features  for  analytical  toxicologists  including  the  direct  analysis  of 
polar,  less  volatile  and  high  molecular  weight  compounds.  Prior  to  its 
availability,  LC  was  used  with  an  ultraviolet  (UV)  detection  system  for 
compounds  that  were  not  suitable  for  gas  chromatography-mass  spectrometry 
(GC-MS).  Unlike  GC-MS,  time-consuming  derivatisation  steps  are  generally  not 
required  in  LC-MS.  The  combination  of  selective  LC  with  mass-selective 
detection  provides  two  pieces  of  information  gained  from  chromatography  and 
MS  data,  which  is  highly  specific  to  a  particular  analyte.  LC-MS  also  provides  the 
flexibility  required  for  screening  or  quantification. 
Hair  testing  for  drugs  of  abuse  has  been  an  area  of  interest,  particularly  over  the 
last  decade.  It  is  a  useful  sample  for  establishing  drug  use  over  the  weeks  or 
even  months  prior  to  collection,  depending  on  the  length  of  the  hair  sample  and 
the  stability  of  the  drug  within  the  hair.  This  has  led  to  its  international 
application  in  many  areas  of  forensic  and  clinical  toxicology.  Hair  results  are 
currently  used  to  complement  blood  or  urine  analysis. Introduction  Chapter  1,2 
An  investigation  into  the  potential  use  of  ELISA  and  LC-MS-MS  for  the 
complementary  detection  of  drugs  of  abuse  in  urine  and  hair  is  described  in  this 
thesis.  An  LC-MS-MS  method  was  developed  and  validated  as  described  in 
chapter  8  for  the  identification  and  quantification  of  a  wide  range  of  drugs  of 
abuse  in  hair.  This  method  will  be  implemented  in  the  forensic  toxicology 
laboratory  at  the  University  of  Glasgow  initially  as  a  complementary  technique 
to  the  drug  group  specific  GC-MS  methods  currently  being  used  for  routine  hair 
screening  and  confirmation. 2  Hair 
2.1  Introduction 
Testing  human  hair  for  the  presence  of  drugs  is  an  extremely  useful  toot  in 
forensic  and  clinical  toxicology  and  has  been  applied  internationally.  It  has  been 
used  to  investigate  drug-related  deaths',  in  employee  screening',  to  assess 
physical  fitness  to  obtain  a  driving  license;,  to  monitor  compliance  or  abstinence 
in  drug  treatment  programmes',  in  child  custody'  and  criminal  cases6,  in  military 
court-martials7,  in  sports  testing8  and  to  monitor  pre-natal  drug  exposure.  ' 
Hair  analysis  is  useful  for  establishing  drug  use  over  the  weeks  or  even  months 
prior  to  collection,  depending  on  the  length  of  the  hair  sample  and  the  stability 
of  the  drug  within  the  hair.  In  contrast,  blood  and  urine  samples  only  provide 
information  on  drug  use  related  to  time  intervals  of  hours  to  a  few  days  prior  to 
collection.  Hair  analysis  is  particularly  useful  in  cases  where  proof  of  abstinence 
from  drug  use  is  required  for  example  in  workplace  testing.  It  is  well  known  that 
both  parent  drugs  and  metabolites  incorporate  into  hair  where  often  only 
metabolites  are  detected  in  blood  and  urine. 
Hair  testing  offers  several  advantages  over  more  conventional  blood  and  urine 
testing.  It  is  difficult  to  adulterate  a  hair  sample  and  hair  is  unaffected  by 
short-term  abstinence.  It  is  a  stable  and  biologically  inert  material  and  it  can 
retain  drugs  for  extended  time  periods.  The  first  forensic  case  involving  the 
detection  of  a  poison  in  human  scalp  hair  was  the  detection  of  arsenic  in  1857. 
The  hair  had  been  collected  from  a  body  exhumed  eleven  years  after  burial.  " 
Hair  is  a  readily  accessible  and  non-invasive  choice  of  sample  which  can  be 
collected  under  close  supervision.  This  excludes  the  embarrassment  and  lack  of 
privacy  associated  with  urine  collection.  In  addition,  it  is  usually  possible  to 
collect  a  second  representative  sample  for  analysis  if  the  sample  integrity  is  in 
question. 
Hair  stability  is  such  that  it  can  be  stored  at  ambient  temperature  indefinitely, 
without  refrigeration.  Storage  and  transportation  of  hair  samples  is  easier  and 
the  analysis  does  not  require  to  be  carried  out  immediately. Hair  Chapter  2,4 
Although  hair  testing  is  extremely  useful,  there  are  still  many  controversial 
issues  surrounding  it  which  need  to  be  addressed.  These  include  conflicting  data 
on  the  exact  contribution  of  external  drug  contamination  and  the  effectiveness 
of  decontamination  procedures.  There  is  the  possibility  of  bias  from 
cosmetically  treated  hair  and  also  hair  from  individuals  of  different  cultures.  In 
addition,  the  exact  mechanism  of  drug  incorporation  is  not  yet  known.  Until 
these  issues  are  resolved,  hair  testing  should  not  be  used  as  a  single  source  of 
evidence  in  a  toxicological  investigation  but  should  be  used  in  combination  with 
blood  and  urine  analysis,  to  provide  information  on  both  acute  and  chronic  drug 
use  or  to  rule  out  the  role  of  drugs  in  a  case.  The  consensus  opinion  of  the 
Society  of  Forensic  Toxicologists  (SOFT)  in  1990  was  that  "Hair  may  be  a  useful 
specimen  in  forensic  investigations  when  supported  by  other  evidence  of  drug 
use.  ""  Since  then  the  Society  has  not  changed  its  opinion  on  hair  testing.  The 
issues  contributing  to  a  lack  of  a  firm  scientific  basis  are  discussed  in  subsequent 
sections  of  this  chapter  and  are  partly  responsible  for  the  current  opinion  of  the 
SOFT. 
2.2  Hair  Physiology 
2.2.1  Introduction 
Despite  the  lack  of  conclusive  scientific  knowledge  on  drug  incorporation 
mechanisms,  the  contribution  of  external  contamination  and  inter-individual 
variations,  an  integral  part  of  the  accurate  interpretation  of  hair  results  is  to 
have  an  understanding  of  hair  structure  and  growth.  Therefore  this  is  discussed 
in  sections  2.2.2-2.4.4. 
2.2.2  Structure 
Hair  tissue  is  a  complex  cross-linked  polymeric  network,  which  is  synthesised  in 
the  hair  follicle.  It  contains  functional  chemical  groups  such  as  acidic,  basic  and 
peptide  groups  which  can  potentially  bind  to  small  drug  molecules.  Hair  is 
composed  of  65-95  %  protein,  1-9  %  lipids,  0.1-5  %  pigments  (melanin)  and  small 
quantities  of  water,  polysaccharides  and  trace  elements.  " Hair  Chapter  2,5 
The  hair  shaft  consists  of  three  distinct  layers  namely  the  cuticle,  cortex  and 
medulla  (Figure  2-1).  Pigment  granules  are  present  in  the  cortex  and  medulla 
and  their  presence  or  absence  can  affect  drug  incorporation.  These  structural 
components  are  discussed  in  more  detail  in  sections  2.2.2.1-2.2.2.4. 
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Figure  2-1  Schematic  diagram  of  the  hair  follicle13  (©  2007  by  Taylor  &  Francis  Group,  LLC) 
The  layers  are  distinguishable  by  microscopy.  Figure  2-2  shows  a  scanning 
electron  microscope  (SEM)  image  of  the  surface  of  a  hair  taken  in  the  University 
of  Glasgow.  The  flattened  cuticle  scales  are  visible.  The  raised  cuticle  scales 
are  typical  of  damage  resulting  from  everyday  haircare  such  as  brushing. 
l---  Epidermis 
-  Hair  fiber Hair 
Figure  2-2  SEM  image  (x  1000)  of  the  surface  of  a  hair 
2.2.2.1  Cuticle 
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The  function  of  the  cuticle  is  to  attach  the  shaft  to  the  follicle  and  to  protect 
the  inner  fibres.  In  human  hair,  the  cuticle  is  made  up  of  six  to  ten  layers14  of 
imbricated  (flattened)  scales  which  are  formed  by  the  keratinisation  of  specific 
cells  during  post-follicular  development.  The  scales  in  the  different  layers 
narrowly  overlap  with  one  another  and  always  point  from  the  root  (proximal 
end)  to  the  tip  (distal  end).  Different  species  have  characteristically  shaped 
cuticle  scales  which  can  be  used  for  species  identification.  Hair  can  become 
damaged  or  destroyed  following  exposure  to  heat,  light,  chemical  treatments 
and  mechanical  abrasion.  If  the  cuticle  gets  damaged,  drugs  can  be  removed 
more  readily  from  hair.  12,15 
2.2.2.2  Cortex 
The  cortex  constitutes  the  bulk  of  the  hair  shaft  and  is  made  up  of  long  fibres  of 
sulfur  rich  keratin.  It  is  mainly  responsible  for  the  stability  and  retention  of 
structural  features  in  hair  and  contributes  most  to  the  mechanical  strength  of 
the  hair  fibre.  "  Fusi  can  be  present  between  the  fibres  in  the  cortex.  These  are 
small  areas  filled  with  fluid  in  the  living  section  of  the  hair  root  but  as  the  hair 
grows  and  dehydrates,  they  become  air  spaces  which  can  be  distributed 
throughout  the  hair  shaft. Hair 
2.2.2.3  Medulla 
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The  medulla  may  be  present  in  the  core  of  the  cortex.  In  human  hair,  it  can  be 
present  in  various  forms,  or  absent  for  example  in  fine  vellus  hair.  If  present,  it 
can  be  continuous  or  interspersed  with  air  spaces  throughout  the  hair  shaft.  In 
human  hair,  the  medulla  is  usually  present  in  the  fragmented  form  or  is  absent; 
it  is  rarely  in  the  continuous  form.  Mongoloid  hair  is  the  exception  to  this  as  it 
usually  possesses  continuous  medullae.  The  medulla  can  be  complex  in  beard 
hair  and  may even  possess  a  double  medulla.  12  It  is  usually  amorphous  in 
appearance  but  different  species  demonstrate  differently  shaped  medullae. 
The  medullar  cells  at  the  follicle  are  loosely  packed  together.  These  cells 
become  dehydrated  to  form  vacuoles  further  away  from  the  follicle.  Generally, 
the  number  of  medullar  cells  increases  with  hair  shaft  diameter.  Fine  hairs  may 
for  example  possess  only  a  cuticle  and  cortex  while  thicker  hairs  may  possess  a 
relatively  high  number  of  medullar  cells. 
2.2.2.4  Pigment  Granules 
Pigment  granules  are  present  mainly  in  the  cortex,  to  a  lesser  extent  in  the 
medulla  and  rarely  in  the  cuticle.  Melanin  is  the  main  pigment  in  hair  and  is 
made  in  melanosomes,  which  are  specialist  organelles  contained  in  melanocytes 
within  the  apex  of  the  dermal  papilla.  It  is  transferred  into  the  cells  migrating 
from  the  hair  follicle  bulb  and  distributed  throughout  the  body  of  the  hair  shaft. 
Pigment  formation  (follicular  melanogenesis)  occurs  in  four  stages.  Tyrosinase 
and  protein  are  the  basic  structural  components  in  the  first  stage,  followed  by 
the  formation  of  an  inner  membrane  in  which  melanin  is  synthesised  and 
accumulates.  The  metanosome  is  finally  transformed  into  a  melanin  particle  and 
transferred  into  cortical  and  medulla  keratinocytes  which  then  distribute  the 
pigment  through  the  shaft.  This  whole  process  is  regulated  by  enzymes, 
structural  and  regulatory  proteins,  transporters  and  receptors  and  their  ligands 
during  the  anagen  phase  of  the  hair  growth  cycle. 
Hair  colour  is  genetically  controlled  and  there  is  a  diverse  range  of  pigmentation 
phenotypes.  The  type,  quantity,  size  and  distribution  of  pigment  granules  are 
responsible  for  imparting  hair  colour.  There  is  now  thought  to  be  four  types  of Hair  Chapter  2,8 
pigment  responsible  for  the  diversity  in  hair  colour  namely  pheomelanin, 
oxypheomelanin,  eumelanin  and  oxyeumelanin.  76  Oxypheomelanin  and 
oxyeumelanin  are  the  oxidative  products  of  pheometanin  and  eumelanin 
pigments  respectively,  induced  by  the  presence  of  hydrogen  peroxide. 
A  four  class  system  has  been  proposed  for  defining  hair  colour  according  to  its 
melanin  content.  "  The  study  demonstrated  that  black  to  dark  brown  hair 
contains  virtually  intact  eumelanin  whereas  brown  hair  contains  more  of  the 
oxidative  breakdown  product,  oxyeumelanin.  Furthermore,  blonde  hair  contains 
large  quantities  of  oxyeumelanin.  The  study  also  showed  that  the  traditional 
view  of  mixed-type  melanins  in  brown/chestnut  hair  produced  from  the  same 
melanocyte  is  incorrect  since  only  eumelanin  and  oxyeumelanin  were  found. 
The  author  concluded  that  the  diversity  of  hair  colour  results  from  eumelanin 
and  pheomelanin  at  different  degrees  of  structural  integrity. 
2.3  Hair  Follicle 
Hair  follicles  are  small  sacs  surrounding  the  hair  root,  embedded  in  the  skin's 
epidermal  epithelium  and  lie  approximately  3-4  mm  below  the  surface  of  the 
skin.  They  are  connected  with  the  sebaceous  and  apocrine  glands  and  also 
eccrine  sweat  glands  in  the  axillary  and  pubic  areas. 
The  hair  follicle  consists  of  several  layers  of  cells.  The  outer  root  sheath  (ORS) 
is  part  of  the  epidermis  and  surrounds  the  other  layers.  The  inner  root  sheath 
(IRS)  region  encases  the  growing  hair  fibre.  Hair  cells  are  synthesised  in  the  hair 
follicle  bulb  by  extensive  mitotic  activity  and  move  upward  to  form  the  body  of 
the  hair  fibre  and  the  IRS.  The  adjacent  region  (keratogenous  zone)  is  where 
the  hair  keratinises,  hardens  and  solidifies.  The  final  region  is  the  permanent 
hair  where  the  hair  cells  have  dehydrated  to  form  the  hair  shaft. 
2.4  Hair  Growth 
Hair  grows  out  of  the  epidermis  and  is  synthesised  in  the  hair  follicle.  Hair 
growth  begins  in  cells  present  in  a  germination  centre  (matrix)  which  is  found  in 
the  base  of  the  follicle.  As  cell  division  occurs,  the  cells  become  larger  and 
elongate  out  of  the  matrix  into  the  keratogenous  zone.  They  produce  melanin Hair  Chapter  2,9 
pigment  in  this  zone  and  keratinise  into  long  fibres  through  the  cross-linking  of 
amino  acid  functional  groups  such  as  the  sulfhydryl  group  in  cysteine.  The  cells 
gradually  die  and  their  decomposition  involves  the  release  of  cell  nuclei  and  the 
elimination  of  water. 
Human  head  hair  can  be  found  in  one  of  three  growth  stages;  anagen,  catagen  or 
telogen  (Figure  2-3).  The  size  and  the  shape  of  the  hair  roots  differ  depending 
on  the  particular  growth  stage  that  the  hair  is  in.  Hair  growth  is  an  intermittent 
cyclic  process  which  alternates  between  periods  of  growth  and  dormancy.  The 
hair  growth  process  and  growth  rate  is  different  between  body  regions  and  even 
within  a  single  region.  12  The  different  stages  and  rates  of  growth  are  described 
in  more  detail  in  sections  2.4.1-2.4.4. 
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Figure  2-3  Different  stages  of  the  hair  growth  cycle13  (©  2007  by  Taylor  &  Francis  Group, 
LLC) 
2.4.1  Anagen 
Anagen  is  the  first  growth  phase  in  which  the  follicle  develops  and  the  hair  is 
produced.  Hair  grows  for  varying  amounts  of  time  depending  on  the  anatomical 
region,  usually  continuing  between  7  to  94  weeks"  but  potentially  lasting  several 
years.  In  the  anagen  phase,  there  is  an  increase  in  mitotic  activity  of  the  matrix 
cells  at  the  base  of  the  hair  follicle.  Newly  divided  cells  elongate  to  form  thin 
filaments  which  grow  upwards  into  the  follicular  canal.  The  cells  differentiate 
into  the  cortex,  cuticle  and  medulla  and  the  hair  begins  to  keratinise  to  produce 
a  new  hair.  After  the  follicle  is  fully  grown,  it  is  elongated  to  at  least  six  times 
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its  original  length  in  the  resting  phase.  "  Nutrients  and  drugs,  supplied  by  a 
blood  capillary,  are  incorporated  into  the  hair  shaft  during  this  phase. 
Approximately  85  %  of  hairs  in  the  posterior  vertex  region  of  the  scalp  are  in  the 
anagen  phase  at  any  one  time,  while  the  other  15  %  are  in  the  resting  (tetogen) 
phase.  "  Hair  in  the  anagen  phase  has  characteristic  dark  roots  as  it  contains 
pigment  granules  which  extend  into  the  root  bulb.  It  also  possesses  a  follicular 
tag,  which  is  a  clear  piece  of  tissue  surrounding  the  hair  shaft  near  the  root. 
The  presence  of  the  follicular  tag  can  indicate  if  a  hair  has  been  removed  by 
unnatural  means,  for  example  during  a  violent  attack.  As  the  follicular  tag  is 
made  up  of  cells,  it  can  provide  a  source  of  deoxyribonucleic  acid  (DNA)  for 
testing  purposes  and  can  be  used  to  determine  the  sex  of  the  hair. 
2.4.2  Catagen 
Following  the  active  growth  stage  of  a  new  hair,  mitotic  activity  of  the  matrix 
cells  suddenly  ceases  and  the  catagen  phase  begins.  Catagen  is  a  short 
transitional  growth  phase  between  active  growth  and  resting.  Hair  can  remain 
in  this  phase  for  approximately  2-3  weeks  and  grows  at  a  slower  rate  than  hair  in 
the  anagen  phase.  A  mass  of  keratin  cells  forms  at  the  base  of  the  hair  shaft, 
which  separates  from  the  follicle.  During  this  process,  the  follicle  bulb  is 
partially  destroyed  and  the  dermal  papilla  contracts  as  the  follicle  approaches 
the  resting  phase.  Hair  roots  in  this  phase  can  possess  characteristics  of  hair  in 
either  anagen  or  telogen. 
2.4.3  Telogen 
Telogen  is  the  final  phase  in  the  hair  growth  cycle,  in  which  follicular  activity 
ceases  and  the  follicle  rests.  The  hair  becomes  completely  detached  from  the 
bulb  and  is  retained  in  the  follicular  canal.  Consequently,  the  hair  can  be  easily 
pulled  out  or  plucked  from  the  scalp.  Roots  of  telogen  hairs  are  either  clear  or 
white  as  they  are  lacking  pigment  granules.  Telogen  hairs  do  not  have  follicular 
tags  but  instead  have  root  sheaths  which  are  pieces  of  tissue  attached  to  the 
root. 
The  length  of  time  the  hair  cells  spend  in  the  telogen  phase  depends  on  the  body 
area  and  age  of  the  individual.  Scalp  hair  can  be  in  the  resting  phase  for  about Hair  Chapter  2,11 
3-4  months  however  this  can  last  2-6  years,  depending  on  anatomical  region.  " 
The  old  hair  is  forced  out  through  the  scalp  surface  as  a  new  hair  shaft  grows. 
After  the  telogen  phase,  another  growth  cycle  begins. 
2.4.4  Growth  Rate 
Hair  growth  rate  is  not  clearly  defined  and  it  can  vary  greatly  between 
individuals  and  in  different  and  also  in  the  same  body  regions  on  a  particular 
individual.  This  is  because  not  all  hair  is  growing  at  any  one  given  time  and  the 
percentage  of  follicles  in  the  anagen  phase  varies.  Human  scalp  hair  is  generally 
assumed  to  grow  at  a  rate  of  0.35  mm/day  for  males  and  females.  However  a 
range  of  0.07-0.78  mm/day  was  observed  in  one  study  where  82  %  of  the  test 
population  had  a  growth  rate  in  the  range  of  0.32-0.46  mm/day.  13 
Hair  type  and  anatomical  location  are  most  influential  in  determining  growth 
rate  however  gender,  race  and  age  can  also  affect  growth  rate.  Scalp  hair  has  a 
faster  growth  rate  than  axillary  and  pubic  hair,  white  beard  hair  has  the  slowest 
growth  rate.  Scalp  hair  growth  rate  is  faster  in  females  than  males,  is  faster  in 
Caucasians  than  Asians  and  tends  to  decrease  with  age.  "  Growth  rate  is  also 
influenced  by  seasonal  changes,  nutrition,  genetic  make-up,  endocrine 
dysfunction  and  pregnancy.  "  These  factors  affecting  growth  rate  must  be 
considered  in  the  interpretation  of  hair  results. 
2.5  Drug  Incorporation  Mechanisms  into  Hair 
Several  studies  have  been  carried  out  in  an  attempt  to  explain  the  factors  that 
influence  drug  incorporation  into  hair  from  the  bloodstream.  1809'20'2'  However  an 
exact  mechanism  has  not  yet  been  established.  This  is  partly  due  to  the  limited 
number  of  controlled  drug  administration  studies  in  humans  that  involve  the 
collection  of  plasma,  hair  and  sweat  samples.  22 
There  are  three  proposed  models  for  incorporation  of  drugs  entering  into  the 
hair  (Figure  2-4).  These  are  (1)  active  or  passive  diffusion  from  the  bloodstream 
into  the  dermal  papilla,  (2)  diffusion  from  sweat  and  other  secretions 
surrounding  the  growing  or  mature  hair  fibre,  or  (3)  external  drug  contamination 
from  vapours  or  powders  that  diffuse  into  the  mature  hair  fibre.  The  most  likely Hair  Chapter  2,12 
model  is  probably  a  combination  of  all  of  these  routes  of  incorporation  however 
the  importance  of  the  different  routes  has  not  been  determined  and  will  vary 
depending  on  the  drug  and  also  between  individuals.  For  interpretation 
purposes,  the  incorporation  route  via  the  bloodstream  is  the  most  significant 
when  information  on  for  example  dose  taken  or  time  of  drug  intake  is  required. 
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Figure  2-4  Three  models  of  drug  incorporation  into  hair"  (©  2007  by  Taylor  &  Francis  Group, 
LLC) 
2.5.1  Incorporation  from  the  Bloodstream 
The  hair  follicle  is  provided  with  a  good  blood  supply.  Any  drugs  circulating  in 
the  bloodstream  will  also  be  passed  to  the  hair  follicle.  Drugs  passively  diffuse 
through  the  cell  membrane  from  the  bloodstream  into  matrix  cells  of  the 
growing  hair  positioned  at  the  base  of  the  follicle.  The  diffusion  rate  across  the Hair  Chapter  2,13 
membrane  is  related  to  drug  Upophilicity  and  the  pH  gradient  between  the 
plasma  and  the  hair  cell.  This  will  be  discussed  later  in  sections  2.6.1  and  2.6.2. 
This  incorporation  model,  also  known  as  the  passive  diffusion  model,  proposes 
that  as  the  hair  grows  out  from  the  scalp,  the  drugs  form  bands  in  the  hair  that 
are  directly  proportional  to  the  concentration  present  in  the  bloodstream  at  the 
time  the  hair  was  formed.  The  passive  diffusion  model  is  supported  by  the 
findings  of  a  study  in  which  the  dose  of  methoxyphenamine  ingested  by  five 
individuals  correlated  well  with  the  concentration  of  drug  detected  in  the  hair. 
Methoxyphenamine  was  found  to  move  along  the  hair  shaft  with  a  growth  rate  of 
0.40-0.46  mm/day  and  demonstrated  no  diffusion.  " 
The  passive  diffusion  model  forms  the  basis  of  segmental  hair  analysis  in  which 
measured  hair  segments  from  the  root  to  the  tip  are  analysed  to  determine  an 
individual's  prior  drug  use.  Based  on  the  assumption  that  hair  grows  at  a 
constant  rate  of  1.0  cm/month,  the  position  of  drugs  along  the  hair  shaft  can  be 
directly  linked  to  the  time  at  which  the  drug  was  ingested. 
As  mentioned  previously,  there  are  other  routes  of  drug  incorporation  into  hair 
and  there  is  evidence  supporting  the  fact  that  the  passive  diffusion  model  is  an 
oversimplification  of  the  incorporation  process.  Although  there  is  a  good 
correlation  between  the  dose  of  drug  ingested  and  the  concentration  detected  in 
hair  for  some  drugs,  this  is  not  the  case  for  others.  There  was  a  poor  correlation 
between  the  morphine  dose  and  concentration  detected  in  hair  of  cancer 
patients  being  administered  with  therapeutic  doses  of  morphine.  "  In  contrast 
with  the  predictions  of  the  passive  diffusion  model,  higher  morphine 
concentrations  were  detected  in  the  hair  of  patients  exposed  to  the  lowest  doses 
using  radioimmunoassay  (RIA).  Drug  concentrations  in  hair  have  also  been  shown 
to  vary  significantly  in  individuals  receiving  the  same  dose.  25  In  addition;  there 
is  also  some  evidence  to  suggest  that  the  position  of  the  drug  along  the  hair 
shaft  does  not  correlate  with  time  of  exposure.  " 
A  further  discrepancy  with  this  model  is  that  parent  drug  to  metabolite  ratios  in 
blood  do  not  correlate  with  those  in  hair.  Cocaine  is  for  example  predominantly 
found  in  hair,  despite  its  short  half-life  in  blood  (0.7-1.5  hr).  Although  hair,  in 
particular  the  bulb,  contains  cytochrome  P450  enzymes  capable  of  drug 
metabolism,  it  does  so  less  readily  than  other  organs.  26 Hair  Chapter  2,14 
As  a  result  of  the  discrepancies  associated  with  the  passive  diffusion  model  and 
the  apparent  complexity  involved  with  drug  incorporation  into  hair,  a  multi- 
compartment  model  has  been  proposed  to  include  incorporation  from  sweat  and 
other  secretions  and  also  incorporation  from  external  contamination. 
2.5.2  Incorporation  from  Sweat,  Other  Secretions  and  External 
Contamination 
The  multi-compartment  model  shown  in  Figure  2-4  includes  the  incorporation 
route  via  the  bloodstream  into  the  dermal  papilla  as  well  as  by  sweat  and  sebum 
bathing  the  mature  hair  fibre.  The  model  also  considers  external  drug 
contamination  through  vapours  or  powders  as  a  route  for  potential  incorporation 
into  the  mature  hair  fibre. 
It  is  widely  accepted  that  drugs  and  their  metabolites  are  excreted  in  sweat27'28 
and  there  are  some  studies  which  investigate  this  in  relation  to  drug 
incorporation  into  hair.  As  hair  is  very  porous  and  can  increase  its  weight  by 
18  %  by  absorption  of  liquids,  drugs  can  be  easily  transferred  into  hair  from 
sweat.  29  Deuterated  cocaine  was  detected  in  multiple  segments  after  a  single 
dose,  supporting  the  evidence  that  sweat  or  other  secretions  are  a  possible  route 
for  drug  incorporation  into  hair.  30  It  has  also  been  proposed  that  differences  in 
drug  concentrations  found  in  hair  could  be  attributed  to  secretion  variability 
between  individuals.  Different  concentrations  of  cocaine  were  detected  in  the 
sweat  of  individuals  receiving  the  same  dose.  25  Sebum  was  shown  to  deposit 
insignificant  quantities  of  cocaine,  flunitrazepam  and  nicotine  onto  the  hair.  31 
Both  in  vitro  and  in  vivo  experiments  have  been  conducted  in  an  attempt  to 
differentiate  between  drugs  deposited  in  hair  from  external  sources  and  drugs 
which  have  been  ingested,  with  markedly  different  results.  Rhodamine  dye  was 
found  to  penetrate  the  hair  at  the  cuticle  scale  junctions  and  further  along  the 
non-keratinous  cell  membrane  complex  after  soaking  in  a  solution.  "  In  contrast 
an  in  vivo  experiment  using  mice  found  that  fluorescein  and  rhodamine  were 
deposited  mainly  in  the  cortex  and  the  medulla.  "  The  dyes,  whether 
incorporated  in  vitro  or  in  vivo,  could  not  be  removed  by  extensive  wash 
procedures  making  interpretation  of  analytical  results  difficult. Hair  Chapter  2,15 
Several  decontamination  procedures  have  been  recommended  recently  for 
differentiation  between  external  drug  contamination  and  ingested  drug.  These 
will  be  discussed  in  section  2.10.  Although  drugs  deposited  on  the  hair  from  the 
external  environment  can  be  removed  by  a  decontamination  procedure,  it  has 
been  shown  that  a  small  fraction  of  these  drugs  are  able  to  penetrate  the  cuticle 
of  the  hair  shaft,  therefore  affecting  the  true  results  of  hair  testing. 
2.5.3  Binding  Mechanisms 
The  mechanisms  of  drug  binding  in  hair  are  not  fully  understood  but  melanin  and 
keratin  hair  components  have  been  suggested  as  potential  sites  of  interaction. 
Drug  binding  to  melanin  was  identified  more  than  four  decades  ago13  and  there 
have  since  been  many  studies  in  this  area  which  have  investigated  the  binding  of 
a  variety  of  drugs  with  different  physicochemical  properties. 
Melanin  pigment  is  a  potyanionic  indolequinone  based  polymer  that  will 
potentially  interact  with  positively  charged  (cationic)  molecules.,  '  This 
interaction  may  explain  the  preferential  incorporation  of  some  basic  drugs  into 
pigmented  hair  over  non-pigmented  hair.  19'34,35,36  Basic  drugs  exist  as  cationic 
molecules  at  physiological  pH  and  could  preferentially  interact  with  the  melanin 
in  pigmented  hair  by  electrostatic  forces  between  the  cationic  functional  groups 
and  the  anionic  carboxylic  groups  on  the  surface  of  the  melanin  polymer. 
Depending  on  the  structure  of  the  bound  drug,  the  electrostatic  binding  can  be 
strengthened  by  van  der  Waals  forces,  hydrophobic  interactions,  charge  transfer 
reactions  and  covalent  bonding. 
It  has  been  suggested  that  the  most  important  association  of  drugs  with  melanin 
occurs  during  melanin  synthesis  at  which  time  the  drug  molecules  become 
entrapped  within  the  melanin  polymer.  "  Therefore  drug  incorporation  into  hair 
may  relate  to  melanin  content  in  the  melanocyte. 
The  in  vitro  binding  of  cocaine,  benzoylecgonine,  amphetamine  and 
N-acetylamphetamine  to  synthetic  melanin  subtypes  has  been  studied.  The 
results  indicated  that  the  more  basic  drugs  (cocaine  and  amphetamine)  bind  to 
eumelanins  and  mixed  eumelanin  /pheomelanins  to  different  degrees  but  do  not 
bind  to  pure  pheomelanin.  The  net  neutral  molecules  (benzoylecgonine  and 
N-acetylamphetamine)  did  not  bind  to  any  melanin  subtype.  " Hair  Chapter  2,16 
A  number  of  in  vivo  experiments  using  dark-agouti  (DA)  rats  (which  have  no 
sweat  glands)  were  carried  out  in  Japan  and  the  results  demonstrated  that  the 
plasma  concentration  was  not  the  major  factor  affecting  drug  incorporation  into 
hair  but  rather  the  physicochemical  properties  of  the  drugs.  37'38  Although  the 
conclusions  of  these  experiments  cannot  be  directly  applied  to  human  hair  as  it 
is  more  complex  than  DA  rat  hair  which  only  contains  eumelanin,  the 
relationship  between  incorporation  rate  and  drug  basicity  and  melanin  affinity  is 
relevant.  Hence  these  relationships  are  discussed  in  section  2.7. 
There  are  few  studies  which  address  the  issue  of  drug  binding  to  keratin  in  hair. 
Human  studies  in  subjects  with  grey  hair  have  shown  that  various  drugs  can  be 
detected  in  the  pigmented  and  non-pigmented  hair  shafts  of  these  individuals. 
This  supports  the  proposition  that  keratin  has  an  important  role  in  drug  binding 
to  hair.  Various  studies  have  detected  higher  concentrations  in  the  pigmented 
hair  shafts  compared  to  the  non-pigmented  (white)  hair  shafts.  39i40  This  could  be 
explained  by  the  presence  of  a  strong  ionic  interaction  between  the  positively 
charged  drugs  and  the  negatively  charged  melanin  polymer  which  is  absent  in 
non-pigmented  hair. 
2.6  Drug  Properties  Influencing  Incorporation 
There  are  a  number  of  physicochemical  properties  which  influence  drug 
incorporation  into  hair,  the  main  ones  being  lipophilicity,  basicity  and  melanin 
affinity.  Hair  structure  and  cosmetic  treatments  also  have  a  significant  effect 
on  drug  binding  in  hair  (discussed  in  section  2.7).  Other  factors  affecting 
incorporation  are  bioavailability,  the  pKa  value,  plasma  elimination  half-life, 
volume  of  distribution  and  cell  membrane  permeability.  ' 
2.6.1  Lipophilicity 
Due  to  the  chemical  nature  of  the  cell  membrane,  non-polar,  more  lipophilic 
parent  drugs  are  more  likely  to  pass  through  from  the  bloodstream  to  the  hair 
forming  cells  than  polar,  more  hydrophilic  drug  metabolites.  "  This  would 
explain  why  parent  drug  concentrations  in  hair  are  mostly  higher  than  their 
respective  metabolites.  Greater  incorporation  of  parent  drugs  can  be 
advantageous  when  trying  to  distinguish  heroin  use  from  prescribed  morphine  or Hair  Chapter  2,17 
codeine  use  for  example.  A  positive  correlation  of  0.770  was  found  to  exist 
between  lipophilicity  and  incorporation  rate  into  rat  hair  for  nineteen  basic 
drugs  of  abuse.  37 
2.6.2  Basicity 
Drug  ionisation  at  physiological  pH  influences  the  extent  of  incorporation  into 
hair.  Basic  drugs  exist  as  cationic  molecules  at  physiological  pH  and  should 
preferentially  bind  to  melanin  in  pigmented  hair.  Codeine  which  is  a  weak  base 
and  cationic  at  physiological  pH  was  incorporated  more  into  rat  hair  to  a  greater 
extent  than  phenobarbital,  which  is  a  weak  acid  and  is  not  cationic  at 
physiological  pH.  26  The  conclusion  from  this  study  was  that  at  a  given  plasma 
concentration,  there  is  a  greater  concentration  of  cationic  drugs  incorporated 
into  hair  than  anionic  drugs. 
Basic  drugs  were  found  to  have  higher  incorporation  rates  into  hair  compared  to 
more  acidic  and  neutral  drugs  in  a  study  examining  the  incorporation  rate  of 
twenty  acidic,  basic  and  neutral  drugs  of  abuse  into  rat  hair.  37  Cocaine  had  the 
highest  incorporation  rate  and  THCA  had  the  lowest.  There  was  a  3600  fold 
difference  observed  between  their  incorporation  rates. 
Amphetamine  incorporates  into  both  pigmented  and  non-pigmented  hair  to  a 
greater  extent  than  its  non-basic  analogue  N-acetylamphetamine.  19  Two  basic 
benzodiazepines,  flurazepam  and  medazepam,  were  shown  to  have  relatively 
high  incorporation  rates  in  a  study  into  the  rate  of  incorporation  of  eight 
benzodiazepines  into  rat  hair.  42 
2.6.3  Melanin  Affinity 
Drug  incorporation  into  hair  can  be  influenced  by  pigmentation  i.  e.  melanin 
content  of  hair.  As  discussed  in  section  2.5.3,  melanin  polymers  possess  many 
negatively  charged  carboxylic  acid  groups  in  their  structure  which  attract 
positively  charged  basic  drug  molecules  under  physiological  conditions.  Melanin 
affinity  is  therefore  associated  with  drug  basicity. 
Experiments  were  carried  out  to  test  the  melanin  affinity  of  twenty  drugs  of 
abuse.  Each  drug  displayed  a  different  affinity  for  melanin  binding,  however Hair  Chapter  2,18 
cocaine  had  the  highest  affinity,  followed  by  benzphetamine  and  phencyclidine. 
The  correlation  coefficient  for  a  graph  of  melanin  affinity  versus  cocaine 
incorporation  rate  into  hair  was  0.947  and  this  direct  relationship  supports  the 
evidence  that  melanin  content  in  hair  is  strongly  related  to  drug  incorporation 
into  hair.  37  In  controlled  oral  codeine  administration  studies,  a  significantly 
positive  relationship  (R2  =  0.73)  was  found  to  exist  between  codeine 
concentrations  in  hair  and  the  total  melanin  concentration  present.  43  This 
contrasts  with  findings  for  more  neutral  and  acidic  drugs  such  as 
11-nor-A9-tetrahydrocannabinot-  9-carboxylic  acid  (THC-COOH)  and 
N-acetylamphetamine  where  a  lack  of  correlation  between  concentrations  of 
these  drugs  in  hair  to  hair  melanin  content  has  been  observed.  19;  37 
In  an  animal  study  involving  Long  Evans  rats,  six  phenethylamines  were  detected 
at  relatively  high  concentrations  in  black  hair  however  none  were  detected  in 
white  hair  collected  from  the  same  rats.  These  findings  indicate  that  the 
presence  of  melanin  strongly  influences  the  retention  and  incorporation  of  basic 
drugs.  " 
2.6.4  Chemical  Structure 
Drug-melanin  binding  is  affected  by  the  presence  of  different  para-substituents 
on  the  benzene  ring  of  methamphetamine.  Nitro-,  amino-,  methytenedioxy-, 
methoxy-  and  bromo-  groups  all  showed  relatively  higher  melanin  affinities  than 
the  unsubstituted  methamphetamine.  45 
A  study  into  the  incorporation  rates  of  seven  phenethytamine  analogues  in  rat 
hair  roots  also  found  different  incorporation  rates  for  each  analogue,  supporting 
the  evidence  that  changes  in  the  drug  functional  groups  greatly  affect  drug 
incorporation  into  hair.  ' 
2.7  Bias  in  Hair  Testing 
Bias  in  drug  testing  can  be  defined  as  an  increased  chance  of  detecting  drugs  in 
one  group  of  individuals  over  another  when  both  groups  have  been  exposed  to  or 
used  the  same  quantity  of  drugs.  In  hair  testing,  bias  can  appear  in  two  main 
situations:  (1)  Two  individuals  ingest  the  same  quantity  of  drug  but  due  to Hair  Chapter  2,19 
biological  or  genetic  reasons,  one  individual  does  not  incorporate  as  much  drug 
into  the  hair  as  the  other,  producing  a  false  negative  result;  (2)  Two  individuals 
who  are  not  drug  users  are  exposed  to  drugs  from  their  surrounding 
environment.  Due  to  biological,  genetic  or  cultural  reasons  one  individual 
incorporates  the  drugs  more  readily  into  the  hair  from  the  environment  and 
retains  them  longer  than  the  other  individual,  producing  a  false  positive  result. 
The  effect  of  hair  bias  remains  an  unresolved  issue  with  hair  testing. 
Cosmetically  treated  hair  incorporates  drugs  more  readily  than  untreated  hair  as 
it  has  structural  damage  and  residual  chemicals.  When  a  drug  penetrates  the 
hair  it  can  either  bind  or  be  removed  through  normal  hygiene  practices  or 
decontamination  as  part  of  the  hair  testing  procedure  in  the  laboratory.  Bias  is 
associated  with  melanin  content  which  facilitates  drug  binding.  Different  hair 
treatments  associated  with  Africans  and  other  ethnic  groups  are  more  prone  to 
environmental  contamination  leading  to  false  positive  results. 
Cosmetic  treatments  such  as  dyeing,  bleaching,  chemical  straightening  and 
permanent  waving  reduce  the  binding  of  drugs  in  hair  as  these  processes  damage 
the  hair  structure.  After  these  treatments,  drug  concentrations  can  decrease  by 
50-80  %  of  their  original  concentration.  "  This  is  an  important  consideration  for 
interpretation  of  hair  analysis  results  since  a  change  in  drug  concentration  is 
induced  by  cosmetic  treatments.  Products  used  for  these  treatments  are  strong 
bases  which  can  cause  hair  damage.  Commonly  used  bleaching  and  dyeing 
formulas  are  combinations  of  hydrogen  peroxide  and  an  agent  containing 
ammonium  hydroxide.  Ethanol  and  natural  pigments  are  also  used  for  bleaching 
and  dyeing  respectively.  46  In  bleaching  formulas,  ammonium  hydroxide  opens 
the  cuticle  scales  which  aid  the  entry  of  drugs.  Hydrogen  peroxide  is  also  a 
strong  oxidant  which  attacks  the  melanin  pigment  resulting  in  decolourisation  of 
hair.  In  dyeing  formulas,  natural  pigments  dye  the  hair  to  a  desired  colour. 
Chemical  straightening  and  permanent  waving  causes  the  hair  to  become  porous 
and  permeable  as  the  cuticle  is  disrupted.  47  In  addition,  some  of  the  cosmetic 
products  that  are  applied  to  hair  to  add  shine  after  chemical  straightening  can 
aid  transfer  and  binding  of  drugs.  " 
All  of  the  above  mentioned  cosmetic  treatments  can  change  the  hair 
ultrastructure,  resulting  in  drugs  being  lost  from  the  hair  matrix,  or  they  can Hair  Chapter  2,20 
become  incorporated  more  easily  into  the  hair  matrix  following  exposure  to 
external  contamination.  "  The  increased  risk  of  obtaining  false  positive  hair 
analysis  results,  due  to  drug  uptake  by  sweat  or  sebum,  has  been  demonstrated 
for  bleached  and  permanently  waved  hair  but  not  to  a  great  extent.  49 
Hair  collected  from  a  female  drug  addict  who  had  brown  hair  with  strands  of 
bleached  hair  was  tested.  "  3-fold  higher  concentrations  of  cocaine  and  codeine 
were  found  in  the  brown  hair  compared  with  the  bleached  hair.  A  decrease  in 
benzodiazepine,  cocaine  and  opiate  concentrations  was  found  in  hair  that  had 
been  bleached  in  vitro  in  another  study.  "  The  effect  of  bleaching  and  dyeing 
hair  on  the  concentrations  of  opiates,  cocaine,  cannabinoids  and  nicotine  has 
also  been  investigated.  '  Bleaching  was  found  to  produce  lower  drug 
concentrations  than  dyeing.  In  this  study,  the  degree  of  hair  damage  was  also 
identified  as  a  factor  affecting  drug  concentrations;  the  more  damaged  the  hair, 
the  greater  the  loss  of  drug. 
Several  studies  have  shown  that  some  drugs  incorporate  into  hair  with  higher 
melanin  content  and  therefore  there  may  be  a  bias  in  drug  testing  in  hair  from 
different  races.  Generally,  Caucasian  hair  incorporates  smaller  quantities  of 
drugs  compared  to  African  hair.  Significantly  more  cocaine  was  detected  in 
male  African  American  hair  than  male  and  female  black/brown  Caucasian  hair.  52 
An  animal  study  found  that  in  cases  of  high  codeine  intake  by  guinea  pigs,  black 
pigmented  hair  incorporated  the  highest  concentration  compared  with  white 
non-pigmented  hair.  34  Another  animal  study  noted  that  black  pigmented  rat  hair 
incorporated  a  higher  methadone  concentration  (21-fold)  than  white  non- 
pigmented  hair.  53 
Morphological  differences  have  been  identified  between  black  African  hair  and 
hair  from  Caucasians  and  Asians.  The  African  hair  samples  contained  a  tightly 
interwoven  mat  of  hair  shafts  and  many  hair  shafts  were  knotted,  broken  and 
inter-locked  in  comparison  with  Caucasian  and  Asian  hair  samples.,  '  This 
damage  to  hair  structure  through  twisting  in  African  hair  could  explain  the 
differential  drug  binding  observed  between  races  since  drugs  have  to  first 
penetrate  the  cuticle  which  is  made  easier  by  the  damage.  " 
It  is  important  to  consider  any  wash  procedures  carried  out  in  the  laboratory 
which  may  affect  the  concentration  of  drug  that  is  detected  in  the  sample.  It  is Hair  Chapter  2,21 
good  laboratory  practice,  on  receiving  a  sample,  to  note  the  physical  condition 
of  the  hair  and  the  type  of  cosmetic  treatment,  if  any. 
An  attempt  was  made  to  correct  for  racial  bias  observed  in  hair  samples,  using 
dyes,  which  can  provide  additional  information  on  the  permeability  and  binding 
capacity  of  hair.  55  The  authors  concluded  that  although  the  method  was  useful, 
it  would  be  difficult  to  implement  this  process  as  part  of  a  production  system. 
Other  studies  have  found  no  bias  and  have  proposed  that  differences  in  drug 
levels  observed  in  hair  from  various  races  are  probably  due  to  different  rates  of 
drug  use.  56,57  A  statistical  analysis  has  been  conducted  on  reported  drug  levels  in 
hair  where  the  hair  colour  was  indicated.  "  There  were  differences  in  the  drug 
levels  detected  in  the  differently  coloured  hair  samples;  however,  these  were 
not  significant.  The  authors  of  the  study  propose  that  although  hair  colour  does 
contribute  to  drug  incorporation  in  hair,  its  contribution  is  yet  to  be  detected 
statistically. 
2.8  Collection  of  Hair  Samples 
It  is  necessary  to  consider  a  number  of  important  factors  when  analysing  hair 
samples.  These  include  the  method  of  collection  used:  whether  the  sample  was 
collected  from  a  living  or  deceased  subject;  any  potential  contamination  which 
may  result  during  the  collection  of,  for  example  post-mortem  samples;  the 
sample  size;  and  the  anatomical  location  of  the  hair. 
2.8.1  Methods  of  Collection 
In  post-mortem  cases,  hair  samples  should  be  collected  prior  to  the  post-mortem 
examination  to  prevent  them  from  getting  wet  or  contaminated  with  blood. 
Head  hair  is  collected  from  the  posterior  vertex  region  and  is  either  plucked 
from  the  scalp  (in  which  case  the  roots  will  be  present)  or  cut  as  closely  as 
possible  to  the  scalp.  General  Practitioners  or  solicitors  normally  collect  hair 
samples  from  living  individuals  and  in  these  cases  the  hair  is  cut  as  closely  as 
possible  to  the  scalp. 
The  results  of  segmental  analysis  are  meaningless  if  the  collection  and  handling 
of  the  sample  is  inappropriate.  Therefore,  it  is  essential  to  obtain  a  sample  that Hair  Chapter  2,22 
has  been  correctly  aligned  with  the  root  and  tip  ends  clearly  labelled.  If  this  is 
not  done,  each  segment  will  contain  different  portions  of  the  hair  strand 
therefore  representing  longer  and  overlapping  time  periods. 
Plucked  hair  may  be  advantageous  over  cut  hair  in  some  instances  for  example  in 
an  acute  fatal  poisoning  case  resulting  in  a  delayed  death.  In  this  situation,  a 
period  of  2-3  days  in  a  coma  may  yield  negative  blood  and  urine  results  due  to 
elimination  and  cut  hair  may  also  be  negative.  " 
Plucked  or  cut  hair  samples  are  collected  and  stored  inside  hair  collection  kits  at 
ambient  temperature.  The  kits  contain  a  circular  piece  of  aluminium  foil  which 
has  an  area  labelled  "root  end".  After  the  "root  ends"  are  aligned,  the  sample 
is  wrapped  in  the  foil  and  placed  in  an  envelope  clearly  labelled  with  the  case 
details.  The  envelope  is  then  placed  in  a  plastic  evidence  bag  and  sealed  with 
adhesive  tape.  Figure  2-5  shows  a  typical  hair  collection  kit. 
Figure  2-5  Typical  hair  collection  kit 
2.8.2  Sample  Size 
The  sample  size  required  for  analysis  varies  between  laboratories.  It  depends  on 
the  number  of  analyses  to  be  carried  out  using  different  extraction 
methodologies  and  also  on  the  sensitivity  of  the  analytical  method.  A  bundle  of 
hair  from  the  posterior  vertex  of  approximately  "pencil  thickness"  is  normally 
sufficient  for  testing,  but  this  depends  on  the  amount  of  hair  a  particular 
individual  possesses.  In  thin-haired  or  bald  subjects  for  example,  it  may  be 
necessary  to  collect  the  hair  further  down  the  head  from  the  posterior  vertex. 
ý"ý;  'ý  ': 
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Sample  sizes  ranging  from  a  single  hair  to  200  mg  hair  have  been  reported  in  the 
literature.  " 
It  is  generally  best  to  have  as  large  a  sample  size  as  possible  to  ensure  the 
detection  of  low  drug  concentrations  for  example  in  date-rape  cases  where  the 
subject  has  potentially  ingested  a  single  dose  of  drug. 
2.8.3  Sample  Selection 
There  are  three  basic  hair  types  on  the  human  body  namely  vellus,  intermediate 
and  terminal  hair.  Vellus  hair  is  fine,  short  and  non-pigmented  and  is  found  on 
eyelids  and  forehead.  Intermediate  hair  is  of  medium  length  and  diameter  and 
is  found  on  the  arms  and  legs  of  adults.  Terminal  hair  is  coarse,  pigmented  and 
has  a  large  diameter  and  is  found  on  the  scalp,  beard,  armpit  and  pubic  region. 
The  different  hair  types  form  due  to  differences  in  the  hair  follicles. 
Ambosexual  hair  follicles  are  influenced  by  hormones  and  change  during  puberty 
e.  g.  pubic  and  armpit  regions. 
For  the  purpose  of  hair  analysis,  head  hair  from  the  posterior  vertex  region  of 
the  scalp  is  normally  chosen  as  it  does  not  grow  at  such  a  variable  rate 
compared  to  hair  in  other  body  regions  and  is  less  affected  by  differences  in  age 
and  sex.  In  addition,  there  is  a  greater  and  more  constant  percentage  of  hair  in 
the  anagen  growth  phase  in  this  region.  Beard,  axillary  and  pubic  hair  have  also 
been  used  for  drug  analysis59'60  but  does  not  offer  any  significant  advantages  over 
head  hair  testing  as  hair  from  these  regions  are  also  exposed  to  sources  of 
contamination.  The  drug  concentrations  in  these  hair  types  vary  for  an 
individual  depending  on  the  location  of  the  hair  sample.  This  has  been 
attributed  to  a  number  of  factors  such  as  the  presence  of  apocrine  glands,  blood 
supply,  telogen/anagen  ratios  and  hair  growth  rate  in  different  body  regions.  ' 
The  location  of  the  hair  sample  is  an  important  consideration  as  the  biology  of 
hair  from  different  body  regions  and  sources  of  contamination  vary,  influencing 
the  interpretation  of  results. Hair 
2.8.3.1  Scalp  Hair 
Chapter  2,24 
Scalp  hair  is  the  easiest,  most  accessible  sample  to  obtain  but  as  there  are  hairs 
in  various  growth  phases  on  the  head,  the  sampling  area  is  crucial.  The  growth 
rate  is  highest  in  scalp  hair  therefore  it  displays  the  greatest  variability.  The 
ducts  of  the  sebaceous  gland  empty  directly  into  the  hair  follicle  and  so  the  hair 
shaft  gets  exposed  to  sebum  before  it  grows  out  from  the  skin.  Scalp  hair  can 
also  be  contaminated  by  sweat  gland  secretions,  cosmetic  treatments  and 
contaminants  from  the  air,  water  or  dust. 
2.8.3.2  Beard  Hair 
Beard  hair  is  thick;  the  follicles  are  relatively  large  and  grow  at  the  slowest  rate. 
Beard  follicles  are  different  from  other  follicles  as  the  ducts  of  the  sebaceous 
glands  do  not  discharge  into  the  follicle  but  onto  the  surface  of  the  skin. 
Consequently,  beard  hair  may  be  less  contaminated  by  sebum  than  scalp  hair 
and  hence  may  be  the  sample  of  choice  a  few  days  after  drug  use.  Beard  hair 
can  however  become  contaminated  with  pieces  of  epidermis  through  shaving  and 
by  environmental  exposure. 
2.8.3.3  Pubic  Hair 
Analysis  of  pubic  hair  may  be  necessary  when  there  is  no  scalp  hair  available.  It 
may  be  less  contaminated  from  environmental  exposure  or  cosmetic  treatment 
but  it  may  however  be  contaminated  with  urine  and  sebaceous,  apocrine  and 
eccrine  gland  secretions  and  is  not  a  convenient  sample  to  collect.  12'15 
Segmental  analysis  would  not  be  appropriate  for  the  analysis  of  pubic  hair  as 
interpretation  of  results  would  not  be  possible  due  to  variable  growth  rates. 
2.9  Drug  Stability  in  Hair 
The  stability  of  drugs  in  hair  depends  on  the  morphological  and  physicochemical 
properties  of  the  hair.  The  concept  of  diffusion  bridges  in  hair  fibres  was 
investigated  as  a  potential  means  of  drug  molecules  entering  into  and  out  of  the 
hair  fibre.  "  Aqueous  solutions  of  codeine,  dihydrocodeine  and  morphine  were 
shown  to  diffuse.  A  hypothesis  was  formed  that  organic  substances  may  be Hair  Chapter  2,25 
linked  to  the  non-keratinous  (morphological)  hair  regions  and  that  these  regions 
provide  diffusion  bridges  for  small  molecules  when  water  is  present.  These 
diffusion  bridges  could  be  a  route  for  external  contamination  to  enter  the  hair  or 
loss  of  endogenous  drug  from  the  hair.  This  phenomenon  was  further  supported 
in  another  study  which  used  fluorescence  microscopy  to  investigate  the  diffusion 
of  Rhodamine  B  dye  by  staining  the  hair  fibres.  " 
Various  studies  on  drug  stability  in  hair  have  investigated  the  effect  of  cosmetic 
treatments,  such  as  dyeing,  bleaching  and  permanent  waving.  ",  ",  "  The  results 
are  in  agreement  that  drug  concentrations  decrease  in  hair  that  has  been 
exposed  to  these  treatments.  Repeated  shampooing  does  not  have  a  significant 
effect  on  the  drug  concentration  of  hair.  63 
Opiate  concentrations  in  hair  were  found  to  decrease  dramatically  after 
bleaching,  permanent  waving  and  UV  exposure.  "'  UV  damages  hair  as  free 
radicals  are  formed  when  UV  light  is  absorbed  by  amino  acids  such  as  cysteine, 
phenylalanine,  tyrosine  and  tryptophan  and  this  causes  disulfide  bonds  within 
the  hair  to  break.  14 
Bleaching  and  exposure  to  water  or  soil  for  six  months,  as  well  as  exposure  to 
tap  water  for  4  weeks,  was  found  to  result  in  formerly  positive  hair  samples 
producing  negative  results.  64 
2.10  Decontamination 
As  hair  grows  out  of  the  epidermis,  it  is  exposed  to  the  environment,  including 
any  potential  drug  contamination  which  may  be  present  in  the  surroundings. 
Sweat  and  other  body  secretions  could  also  be  regarded  as  contamination 
although  it  is  not  from  an  external  source.  The  "bathing"  of  a  mature  hair  in 
sweat  could  result  in  the  broadening  of  the  drug  band  previously  incorporated 
through  the  bloodstream.  Decontamination  or  "washing"  of  hair  samples  is 
therefore  used  to  allow  an  accurate  interpretation  of  results,  by  removing  any 
loosely  bound  external  drug  contamination  as  well  as  gels,  mousses,  oils  and 
everyday  dirt  which  may  be  present  on  the  hair.  This  step  can  help  to  make  the 
hair  extract  cleaner,  reducing  potential  interferents  which  may  be  present.  In 
addition  to  this,  it  can  minimise  the  number  of  false  positive  results. Hair  Chapter  2,26 
All  decontamination  procedures  are  based  on  the  assumption  that  exogenous 
drugs  deposited  in  hair  from  the  environment  are  loosely  bound  to  the  surface  of 
the  hair.  It  is  a  necessary  step  in  the  hair  testing  procedure  since  the  amount  of 
drug  present  in  hair  through  ingestion  is  low  compared  with  that  in  the 
environment.  Several  authors  have  however  reached  the  conclusion  that  no 
washing  procedure  would  be  100  %  effective  in  removing  external  contamination 
in  any  contamination  situation  . 
13,63,  '  There  are  still  many  more  decontamination 
experiments  which  need  to  be  performed  in  order  to  determine  the  exact  set  of 
conditions  in  which  a  procedure  succeeds  or  fails.  An  attempt  should  be  made  in 
these  studies  to  mimic  real-life  contamination  scenarios  but  the  design  of  these 
wilt  be  based  on  preconceptions. 
There  is  currently  no  standard  decontamination  procedure  for  hair.  It  is  difficult 
to  standardise  a  decontamination  procedure  since  it  is  not  known  if  all  of  the 
external  contamination  has  been  removed  or  if  drug  incorporated  into  the  hair 
shaft  through  ingestion  is  being  removed.  Several  authors  have  shown  that  some 
decontamination  procedures  remove  drug  present  in  the  hair  shaft  through 
systemic  exposure.  ",  "  In  addition,  passive  drug  contamination  has  been  found 
within  the  hair  and  not  just  on  the  surface.  "  Furthermore  it  has  been  suggested 
that  the  extent  of  hair  damage  may  affect  the  quantity  of  drug  which  is  lost 
from  the  hair  shaft.  Highly  damaged  hair  is  more  porous  and  hence  is  more 
likely  to  lose  a  greater  quantity  of  drug  present  in  the  shaft  through  systemic 
exposure.  " 
In  general  the  less  polar  solvents  remove  less  externally  bound  drug  as  the 
solvent  does  not  swell  the  hair  as  much  as  more  polar  solvents.  BB  Among  the 
agents  used  for  decontaminating  hair  are  aqueous  media  such  as  phosphate 
buffer"  and  detergents69  as  well  as  organic  solvents  such  as,  ethanol",  acetone", 
dichloromethane'Z  and  methanol.  71  Decontamination  with  organic  solvents  is 
currently  preferred  over  washing  with  aqueous  media  as  it  does  not  result  in  hair 
swelling  however  it  may  not  remove  all  externally  incorporated  drugs.  " 
Dichloromethane  has  been  shown  to  only  remove  the  loosely  adhering  cocaine  in 
hair.  74  Furthermore  it  was  shown  to  be  as  equally  effective  as  phosphate  buffer 
in  removing  loosely  bound  cocaine,  which  in  contrast  was  found  to  remove  some 
of  the  more  tightly  bound  drug.  72  A  washing  procedure  should  be  a  compromise Hair  Chapter  2,27 
where  sufficient  external  contamination  is  removed  but  incorporated  drugs  are 
not. 
The  identification  of  unique  drug  metabolites  could  be  used  to  distinguish 
passive  contamination  and  actual  drug  ingestion.  Careful  consideration  must  be 
given  to  the  interpretation  of  metabolite  data  however  as  cocaine  and  heroin 
metabolites  can  be  produced  during  the  parent  drug  degradation. 
Benzoylecgonine  has  been  detected  in  hair  contaminated  once  with  cocaine. 
Hydrolysis  of  cocaine  to  form  benzoylecgonine  can  occur  in  the  presence  of 
sweat  or  during  personal  hygiene  practices  and  also  due  to  the  presence  of 
enzymes  in  matrix  cells.  "  Another  study  found  that  heroin  contaminants  can 
enter  into  the  hair  matrix  and  become  transformed  into  significant 
concentrations  of  6-monoacetylmorphine  (6-MAM),  morphine  and  codeine 
metabolites.  78  In  these  hydrolysis  situations,  cut-off  values  and  metabolite  to 
drug  ratios  are  of  limited  use  for  evaluating  passive  contamination.  It  is  ideal  to 
detect  unique  drug  metabolites  which  are  produced  by  the  body  only  as  a  result 
of  pharmacological  processing  of  the  drugs  as  these  could  only  be  present  as  a 
result  of  actual  drug  use.  A  negative  hair  testing  result  can  be  used  as  a  means 
of  ruling  out  either  drug  use  or  contact  with  drugs  however  a  positive  hair 
testing  result  cannot  be  used  as  a  definitive  sign  of  drug  use  and  should  be 
confirmed  with  blood  and/or  urine  results. 
2.11  Sample  Preparation 
Sample  preparation  is  one  of  the  most  important  steps  in  hair  analysis  yet  this 
varies  between  laboratories,  with  some  selecting  to  cut  the  hair  while  others 
select  to  grind  it  into  powder  form. 
Powdered  hair  is  thought  to  be  more  homogeneous  and  suitable  for  comparative 
studies.  75  Hair  that  was  ground  using  a  traditional  ball  mill  at  room  temperature 
produced  better  qualitative  and  quantitative  results  for  drugs  of  abuse  compared 
to  cut  hair  due  to  the  greater  surface  area  in  contact  with  the  extraction 
medium.  "  Another  study  which  used  a  cryogenic  grinding  device  confirmed 
these  findings  when  ground  hair  produced  better  quantitative  results.  However 
cut  hair  was  shown  to  be  the  better  preparation  method  for  qualitative  results Hair  Chapter  2,28 
for  drugs  of  abuse.  "  A  common  finding  with  the  hair  grinding  method  is  that 
there  is  a  significant  loss  of  hair  fragments  retained  in  the  ball  mill.  One 
laboratory  noted  that  the  differences  between  cutting  and  grinding  were  not 
very  large  and  recommended  a  fast  cutting  procedure  with  a  razor,  scalpel  or 
scissors.  " 
2.12  Extraction  Methods 
Several  different  extraction  procedures  have  been  reported  for  the  extraction  of 
drugs  and  their  metabolites  from  the  hair  matrix.  Some  of  these  include  acidic 
hydrolysis",  alkaline  hydrolysis82,  enzymatic  hydrolysis",  direct  solvent83  or 
buffer  extraction84  and  other  less  conventional  methods  such  as  supercritical 
fluid  extraction8'  and  subcritical  fluid  extraction.  86 
Following  the  removal  of  the  drugs  and  their  metabolites  from  the  hair  matrix, 
the  extraction  procedures  used  are  very  similar  to  those  used  for  blood  and  urine 
testing.  "  Solid-phase  extraction  (SPE)  using  different  kinds  of  columns  51,73,88,89°82 
and  liquid-liquid  extraction  (LLE)11'91,9'  are  commonly  used  but  less  conventional 
methods  such  as  solid-phase  micro-extraction  (SPME)92°93  and  molecularly 
imprinted  solid  phase  extraction  (MISPE)94°95  have  also  been  reported. 
The  two  main  types  of  extraction  involve  digestion  of  the  hair  matrix  and 
extraction  of  drug  from  the  undigested  hair  matrix  with  subsequent  extraction 
using  SPE  or  LLE.  Extraction  conditions  cited  in  the  literature  differ  in  pH, 
temperature  and  duration  of  extraction.  The  extraction  method  chosen  for  a 
particular  drug  depends  on  its  chemical  properties,  such  as  pKa  value,  as  well  as 
its  chemical  stability.  For  example,  sodium  hydroxide  is  a  good  solvent  for  drug 
extraction  mainly  because  of  the  destruction  of  the  protein  hair  matrix  however 
it  is  not  suitable  for  6-MAM  which  is  chemically  unstable  in  sodium  hydroxide. 
Enzymatic  and  direct  solvent  extractions  using  methanol  for  example,  are  less 
harsh  than  alkaline  hydrolysis  methods,  which  can  destroy  the  drug  as  mentioned 
above.  Extractions  using  B-glucuronidase  and  methanol  do  not  completely 
dissolve  the  hair  matrix  and  are  advantageous  in  drug  screening.  96  Alkaline  and 
acidic  hydrolysis  extractions  are  however  very  efficient  as  they  completely 
solubilise  the  hair  matrix,  producing  better  drug  recoveries  than  direct Hair  Chapter  2,29 
extraction  with  organic  solvents.  Therefore  if  a  drug  is  chemically  stable, 
hydrolysis  extraction  methods  are  preferred. 
A  potential  problem  associated  with  hydrolysis  extraction  is  that  drug 
metabolites  may  be  formed,  which  could  result  in  false  results.  An  example  of 
this  is  6-MAM,  which  can  degrade  during  acidic  or  alkaline  hydrolysis  to  form 
morphine.  The  choice  of  extraction  is  also  influenced  by  the  analytical  method 
to  be  used  in  the  subsequent  analysis. 
2.13  Analytical  Methods 
Radioimunoassay  (RIA)  was  predominately  used  for  hair  testing  for  drugs  of 
abuse  before  the  introduction  of  mass  selective  detectors  in  GC-MS  systems.  87 
Opiates  were  first  detected  using  RIA  in  the  hair  of  heroin  abusers  in  1979  and  it 
initiated  many  investigations  into  drugs  of  abuse  in  hair.  Since  then,  various 
methods  including  other  immunoassays  such  as  enzyme  linked  immunosorbent 
assay  (ELISA)  or  chromatographic  techniques  have  been  reported.  Immunoassays 
are  useful  as  screening  tests  due  to  their  sensitivity,  speed  and  simple  use. 
However  immunoassays  are  usually  semi-quantitative  since  the  kits  are  specific 
to  a  group  of  target  drugs  or  drug  metabolites  rather  than  a  single  target  drug. 
Identification  and  quantification  is  carried  out  using  chromatographic  techniques 
which  have  been  coupled  with  MS  for  excellent  sensitivity  and  selectivity. 
Gas  chromatography  (GC)  coupled  with  mass  spectrometry  (MS)  is  the  most 
commonly  used  chromatographic  method  and  has  been  widely  applied  in  the 
detection  of  drugs  of  abuse  in  hair.  ",  "  35,37,38'  , 51,50  Ion  spray  liquid 
chromatography-mass  spectrometry  (LC-MS)  is  also  used  now  and  is  becoming 
more  popular  due  to  its  high  sensitivity  and  shorter  analysis  time  as  unlike  GC- 
MS,  there  is  no  derivatisation  step  required.  97  Capillary  zone  electrophoresis  has 
also  been  applied  in  quantitative  hair  analysis.  98'99 
2.14  Current  International  Hair  Testing  Guidelines 
The  role  of  hair  testing  in  toxicological  applications  has  been  widely  discussed 
among  various  scientific  bodies  such  as  the  Society  of  Hair  Testing  (SoHT), Hair  Chapter  2,30 
Society  of  Forensic  Toxicologists  (SOFT)  and  the  Substance  Abuse  and  Mental 
Health  Services  Administration  (SAMHSA). 
In  2004,  international  representatives  of  the  SoHT  published  a  set  of 
recommendations  for  laboratories  carrying  out  hair  testing  in  forensic  cases.,  " 
The  areas  agreed  upon  include;  sampling,  shipping  and  storage; 
decontamination;  hair  disintegration  and  extraction;  screening  test;  criteria  for 
mass  spectrometric  analysis;  analysis  of  specific  drug  classes  such  as  opiates, 
cocaine,  amphetamines  and  cannabinoids;  cut-off  values;  and  internal  and 
external  quality  control  protocols.  Higher  cut-off  values  than  those 
recommended  by  the  SoHT  have  been  proposed  by  SAMHSA  for  amphetamines 
and  marijuana  after  consulting  mainly  with  commercial  hair  testing  companies.  "' 31 
3  Immunoassay 
3.1  Introduction 
The  application  of  immunoassays  as  "initial  screening  tests"  for  drugs  of  abuse  in 
urine  specimens  is  well  established  and  routinely  practiced.  Immunoassays  have 
also  been  adapted  as  "initial  screening  tests"  for  detecting  the  presence  of 
drugs  and  drug  metabolites  in  a  variety  of  other  biological  matrices. 
Immunoassays  are  generally  defined  as  analytical  systems  that  depend  on 
specific  antigen-antibody  reactions  for  detecting  target  analyte(s)  in  different 
sample  matrices.  In  drugs  of  abuse  screening,  immunoassay  serves  as  a  useful 
means  of  eliminating  negative  specimens  from  further  confirmatory  tests  and 
also  identifying  any  drug  class  that  requires  confirmation  by  a  second  step  test. 
International  guidelines  for  substance  abuse  management,  including  scientific 
protocols  for  initial  drug  screening  and  confirmatory  analysis,  have  been 
developed  by  a  number  of  government  agencies,  professional  organisations  and 
forensic  or  clinical  societies.  Immunoassay  systems  have  mainly  been  designed 
to  meet  the  guidelines  stipulated  by  the  Substance  Abuse  and  Mental  Health 
Services  Administration  (SAMHSA).  SAMHSA  has  provided  cut-off  values  and 
quality  control  requirements  for  initial  drug  screening  in  workplace  testing  which 
were  published  in  the  Federal  Register  in  2004.98  A  sample  containing  drugs 
below  the  cut-off  is  reported  as  negative  for  screening.  However,  if  a  sample 
screens  in  the  initial  test  as  positive,  a  confirmatory  test  that  exploits  a 
different  chemical  principle  to  immunoassay  is  used  to  specifically  identify  and 
quantify  the  presence  of  a  drug  and/or  metabolite.  The  joint  Forensic 
Toxicology  Laboratory  Guidelines  provided  by  the  Society  of  Forensic 
Toxicologists  and  American  Academy  of  Forensic  Sciences  (SOFT/AAFS)  specifies 
a  minimal  requirement  for  laboratories  to  perform  immunoassay.  "  A  second 
immunoassay  can  be  used  to  support  the  initial  screening  result  prior  to 
confirmation  but  cannot  be  used  to  confirm  the  results  of  another  immunoassay 
result. Immunoassay 
3.2  General  Overview 
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In  the  last  35  years,  analytical  methods  that  rely  on  specific  analyte  recognition 
by  high  affinity  binding  proteins  have  been  applied  in  many  diverse  areas  of 
biochemical  analysis  to  the  extent  that  they  are  now  regarded  as  representing  a 
standard  analytical  principle.  Although  there  are  various  kinds  of  naturally 
occurring  high  affinity  specific  binding  proteins  such  as  hormone  receptors,  it  is 
the  unique  properties  of  antibodies  including  their  high  affinity,  specificity  and 
range  of  antibody-antigen  binding  reactions  that  have  resulted  in  their 
widespread  use  in  protein  binding  assays  in  routine  analyses  and  also  in  research. 
Antibodies  have  some  advantages  compared  with  other  binding  proteins.  They 
are  stable,  soluble  and  abundant.  There  are  standard  procedures  for  antibody 
preparation,  selection,  isolation,  coupling  and  immobilisation.  They  are  suitable 
for  the  detection  of  antigens  and  non-antigenic  small  molecules  (molecular 
weight  >  150  amu).  They  are  available  as  a  polyclonal  mixture  (with  related 
binding  specificities  for  a  variety  of  analytes)  or  as  a  monoclonal  mixture  (with  a 
single  binding  specificity  for  a  particular  analyte).  They  can  be  modified  and 
systematically  improved  with  recombinant  DNA  methods.  "' 
There  are  many  different  immunoassay  systems  however  all  commonly  rely  on 
the  specific  molecular  recognition  of  antigen-antibody  binding  interactions  to 
detect  minute  drug  quantities  in  complex  biological  matrices.  The  antigen- 
antibody  binding  pair  has  been  described  as  "a  form  of  ligand  and  receptor 
binding  pair".  103  Most  immunoassays  use  a  label  attached  to  either  the  antigen 
(ligand)  or  the  antibody  (receptor)  which  is  fundamental  to  the  measurement  of 
the  binding  interactions  between  the  pair.  Immunoassays  are  named  according 
to  the  label  used  in  the  particular  system.  A  label  is  any  substance  which  can  be 
chemically  attached  to  either  an  antigen  or  antibody  to  enable  a  measurable 
property  necessary  for  the  specific  immunoassay.  Some  examples  of  the  types  of 
label  chosen  for  adequate  sensitivity  include  radioisotopes,  fluorescence  and 
enzymes. 
Immunoassays  for  small  molecules  such  as  drugs  of  abuse  operate  as  a 
competitive  immunoassay.  Free  drug  in  the  sample  competes  with  drug- 
derivative  reagent  for  the  binding  sites  on  a  specified  amount  of  antibody. Immunoassay  Chapter  3,33 
Drugs  of  abuse  molecules  are  known  as  `haptens'  since  they  are  not  naturally 
immunogenic  and  have  to  be  coupled  to  an  antigenic  carrier  molecule  to  induce 
antibody  formation.  Central  to  the  development  of  a  successful  competitive 
immunoassay  system  is  the  design  and  synthesis  of  two  suitable  haptens,  namely 
one  for  "immunogen"  and  the  other  for  drug  derivative.  103  The  immunogen  is 
designed  to  produce  a  selective  antibody  with  the  required  reactivity 
characteristics  when  introduced  into  a  suitable  host  animal.  The  "activated 
drug  derivative"  possesses  a  suitable  molecular  linker  to  allow  coupling  to  a 
carrier  or  labelling  molecule.  The  drug  derivative  has  a  similar  chemical 
structure  and  immunogenic  properties  to  the  analyte(s)  of  interest  and  this 
enables  successful  competition  between  the  free  drug  in  the  sample  and  the 
drug  derivative  reagent  for  antibody  binding. 
There  are  two  types  of  competitive  immunoassay,  heterogeneous  and 
homogeneous,  depending  if  there  are  additional  steps  in  the  process  to  separate 
the  "antibody  bound"  complexes  from  the  "free"  drug  in  the  sample  and/or 
"free"  drug  derivative  in  the  reaction  mixture.  Heterogeneous  immunoassays 
such  as  enzyme  linked  immunosorbent  assay  (ELISA)  use  washing  for  example  to 
remove  the  unbound  labels,  leading  to  an  increase  in  the  signal  to  noise  ratio  as 
the  background  noise  from  the  labels  has  been  removed  as  well  as  potential 
sample  matrix  effects.  Heterogeneous  assays  can  therefore  achieve  lower 
sensitivity  levels  compared  with  homogeneous  assays. 
3.3  Enzyme  Linked  Immunosorbent  Assay  (ELISA) 
ELISA  has  become  the  most  widely  used  immunoassay  technology  since  its 
development  in  1971-1972.103  An  array  of  commercially  available  ELISA  kits  has 
been  developed  specifically  for  the  purposes  of  drug  testing  in  the  forensic 
toxicology  field.  These  have  been  applied  in  the  detection  of  drugs  of  abuse  in  a 
variety  of  biological  matrices  including  blood104'105,  urine  'ob,,  07'108,,  09,  serum, 
hair  84,108'109,,,  0,,,,,,,:,,  13'  oral  fluid  108,109,114,115,  meconium,  sweat  and  vitreous 
humor.  103,116 
ELISA  is  a  solid  phase,  heterogeneous,  competitive  immunoassay  system  used  for 
the  highly  sensitive  detection  of  small  drug  molecules.  The  amount  of  bound Immunoassay  Chapter  3,34 
antigen  or  antibody  is  measured  by  a  signal  change  produced  by  enzymatic 
catalysis. 
The  ELISA  tests  are  performed  using  microtitre  plates  coated  with  antibodies 
with  a  high  affinity  to  the  target  drug.  ELISA  kits  are  supplied  as  microtitre 
plates  (normally  supplied  as  12  x8  well  strips),  enzyme  labelled  drug  derivative, 
substrate  and  stop  reagent  (Figure  3-1). 
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Figure  3-1  Typical  contents  of  an  ELISA  kit  as  supplied  by  manufacturer 
A  suitable  aliquot  of  sample,  standard  or  control  is  added  to  the  corresponding 
well,  usually  in  duplicate,  followed  by  the  enzyme  conjugate.  The  reaction 
mixture  is  then  left  to  incubate  for  typically  45-60  minutes  to  allow  adequate 
time  for  drug  binding,  enhancing  assay  sensitivity.  During  the  incubation  period, 
the  enzyme  conjugate  competes  with  the  drug  in  the  sample  for  the  antibody 
binding  sites  on  the  wells.  The  most  commonly  used  enzyme  for  drug  ELISA  is 
horseradish  peroxidase  (HRP).  Azide  buffer  preservatives  should  be  avoided  as 
they  affect  ELISA  performance  by  inhibiting  the  HRP  enzyme. 
The  wells  are  washed  with  deionised  water  or  phosphate  buffer  in  order  to 
remove  any  unbound  drug  that  may  be  present  in  the  sample  or  any  residual 
enzyme  conjugate  remaining  in  the  wells.  Blood  samples  with  high  haemoglobin 
levels  can  react  with  3,3',  5,5'-tetramethylbenzidine  (TMB)  substrate  used  for 
the  final  colour  development,  resulting  in  high  background  noise.  This  washing 
step  removes  any  background  noise,  effectively  improving  the  assay  sensitivity. Immunoassay 
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TMB,  a  chromogenic  substrate  containing  hydrogen  peroxide,  is  then  added  to 
the  wells  and  develops  a  blue  colour  with  any  bound  enzyme  conjugate.  The 
colour  development  is  a  result  of  the  enzyme  label  catalysing  the  oxidation  of 
TMB  in  the  presence  of  hydrogen  peroxide.  The  darker  the  blue  colour,  the 
greater  the  amount  of  bound  enzyme  conjugate  present  and  the  lesser  the 
amount  of  bound  drug.  The  addition  of  dilute  acid,  such  as  hydrochloric  acid, 
ends  the  catalytic  reaction  and  hence  the  blue  colour  development.  The  well 
contents  are  turned  yellow  which  allows  greater  sensitivity  and  a  better 
separation  of  absorbance  values  compared  with  the  blue  colour  produced  by  the 
TMB  substrate,  resulting  in  better  discrimination  between  positive  and  negative 
results.  A  spectrophotometer  is  used  to  calculate  the  result  by  measuring  the 
absorbance  value  at  450  nm.  The  various  steps  forming  part  of  the  ELISA 
procedure  are  illustrated  in  Figure  3-2. 
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Figure  3-2  General  schematic  of  ELISA  procedure'  17 
The  absorbance  value  is  inversely  proportional  to  the  concentration  of  drug  in 
the  sample.  A  sample  producing  an  absorbance  value  less  than  that  produced  by 
the  relevant  cut-off  standard  is  considered  a  presumptive  positive  whereas  a 
sample  producing  an  absorbance  value  greater  than  or  equal  to  the  cut-off 
standard  is  considered  negative.  The  result  is  regarded  as  "qualitative"  or 
"semi-quantitative"  and  the  quantity  of  drug  and/or  metabolite  in  any  sample 
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cannot  be  determined  by  immunoassay.  The  assay  is  "semi-quantitative"  since 
the  result  represents  the  total  contribution  of  all  the  compounds  in  the  sample 
that  can  compete  for  antibody  binding  sites  and  is  normally  not  a  definitive 
measurement  resulting  from  binding  of  the  target  analyte. 
3.4  Antibodies 
3.4.1  Action  and  Structure 
In  immunoassay  systems,  the  antibodies  are  the  active  components  derived  from 
animal  blood.  Antigens  are  the  specific  part  of  the  immunogen  that  are 
recognised  by  and  react  with  antibodies.  Antibodies  are  proteins  which  are 
produced  by  the  B-lymphocytes  of  the  immune  system.  The  body  manufactures 
antibodies  in  an  attempt  to  destroy  the  antigen  molecule.  The  antibodies  bind 
to  and  block  antigen  activity. 
Antibodies  make  up  a  group  of  globular  serum  proteins  called  immunoglobulins 
(Igs).  There  are  five  main  classes  of  immunoglobulins  namely  IgM,  IgG,  IgA,  IgD 
and  IgE.  IgG  is  a  150,000  Dalton  glycoprotein  and  the  predominant  fraction  in 
serum  which  contains  the  antibodies  and  hence  is  mainly  used  in  drug  screening 
tests.  102  The  antibody  reagent  must  be  of  high  purity  for  the  purposes  of  binding 
affinity,  specificity  and  cross-reactivity  and  so  IgG  fractions  are  purified  by 
affinity  chromatography. 
A  typical  antibody  molecule  has  two  identical  antigen  binding  sites  which  are 
specific  to  the  antigen  which  caused  the  immune  response.  The  structure  of  an 
antibody  molecule  consists  of  four  protein  chains,  two  of  which  are  heavy  (H) 
identical  chains  and  two  of  which  are  light  (L)  identical  chains.  The  H  and  L 
chains  in  IgG  for  example  are  420  and  215  residues  respectively.  "'  They  are  held 
together  by  disulfide  bridges  to  form  a  Y-shape.  Each  antibody  molecule  can 
bind  2  molecules  at  one  time,  on  each  `arm'  of  the  Y-shape.  There  are  variable 
(V)  regions  of  the  H  and  L  chains  positioned  at  the  tips  of  the  Y  `arms'.  The 
amino  acid  sequence  in  these  regions  varies  significantly  between  antibodies. 
An  H  chain  variable  region  and  an  L  chain  variable  region  together  form  a  unique 
binding  site,  which  accounts  for  the  high  antibody  specificity.  The  "tail"  of  the 
Y-shaped  antibody  molecule  is  formed  by  the  constant  (C)  regions  of  the  H Immunoassay  Chapter  3,37 
chains  which  are  responsible  for  distribution  in  the  body  and  for  the  mechanisms 
involved  in  antigen  disposal,  show  very  little  variation  in  amino  acid  sequence 
between  antibodies.  "'  Immunoglobulin  molecules  demonstrate  flexibility, 
particularly  at  the  "hinge  regions"  of  the  H  chains  as  this  aids  their  binding  to 
adjacent  specific  antigens  and  also  allows  the  aggregation  of  soluble  antigens.  "' 
A  typical  two-dimensional  structure  of  an  antibody  is  illustrated  in  Figure  3.3. 
The  H  chains  are  represented  in  blue  while  the  L  chains  are  in  red. 
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Figure  3-3  Typical  two-dimensional  antibody  structure'  18 
3.4.2  Immune  Response 
Antibody  production  is  stimulated  by  introducing  an  antigen  into  a  host  animal 
such  as  a  rabbit.  The  primary  immune  response  is  the  selective  proliferation  and 
differentiation  of  B  and  T  lymphocyte  cells  that  occurs  the  first  time  the  body  is 
exposed  to  a  given  antigen.  During  this  phase,  there  is  a  time  lag  of  about  7 
days  before  antibody-secreting  cells  are  produced.  It  takes  about  10-17  days 
following  the  initial  exposure  to  antigen  to  generate  the  maximum  response  to 
antibody  production,  which  is  relatively  small  compared  to  the  secondary 
response.  "'  The  secondary  immune  response  is  specific  and  occurs  when  the 
body  has  had  at  least  one  prior  exposure  to  the  same  antigen.  A  faster,  larger 
and  more  prolonged  response  is  produced  due  to  the  presence  of  long-lived 
memory  cells.  Figure  3-4  shows  the  differences  between  the  primary  and Immunoassay  Chapter  3,38 
secondary  immune  responses  for  antibody  concentrations  in  blood  serum  over 
time. 
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Figure  3-4  Primary  and  secondary  immune  responses  for  antibody  concentrations  in  blood 
serum  over  time19 
IgM  specific  antibodies  are  initially  produced  in  the  primary  immune  response 
followed  later  by  IgG.  IgG  is  produced  during  the  late  primary  immune  response 
and  also  during  the  secondary  immune  response.  It  is  used  in  protein  binding 
assays  for  routine  analyses  and  research  since  it  is  the  predominant  fraction  in 
serum  and  also  because  IgG  antibodies  bind  to  antigen  with  a  higher  affinity  than 
IgM  antibodies.  "' 
3.4.3  Antigen-Antibody  Binding 
Antigen-antibody  binding  is  a  reversible  process.  In  high-affinity  binding 
interactions,  the  ease  of  association  outweighs  the  ease  of  dissociation.  During 
association,  repulsive  forces  between  atoms  on  the  antibody-binding  site 
(paratope)  and  the  antigenic  determinant  region  (epitope)  of  the  specific 
protein  antigen  are  overcome  so  that  subsequently,  attractive  interactions  such 
as  hydrogen  bonds,  ionic  bonds  and  van  der  Waals  forces  can  occur. 
A  collision  between  the  antigen  and  antibody  must  take  place  before  an 
interaction  is  established.  The  collision  rate  depends  on  the  diffusion  rate, 
which,  in  turn,  is  affected  by  molecular  shape  and  mass,  reactant  mobility  and 
temperature.  Hence,  haptens  generally  associate  more  readily  with  their Immunoassay  Chapter  3,39 
specific  antibodies  than  large  antigens.  As  well  as  temperature,  other 
physicochemical  conditions  which  influence  antigen-antibody  binding  in  an 
aqueous  environment  include  pH,  ionic  strength  and  the  presence  of  other  ionic 
species  in  the  sample  that  could  also  potentially  bind.  The  effects  of  these 
conditions  are  discussed  in  section  3.5. 
Antigen-antibody  interactions  reach  equilibrium  slower  when  the  antigen  or 
antibody  is  immobilised  to  a  solid  phase  surface,  such  as  microtitre  wells, 
compared  to  when  both  are  free  to  diffuse.  This  is  because  the  potential  for 
interactions  in  microtitre  wells  is  reduced  since  the  area  is  small  and  the  antigen 
or  antibody  is  localised.  Consequently,  many  automated  immunoassays  requiring 
short  incubation  times  exploit  either  the  use  of  microparticulate  solid  phase 
material  or  binding  reactions  occurring  in  the  liquid  phase. 
Antibodies  bind  strongly  to  antigens  in  a  similar  way  to  enzyme-substrate 
binding,  via  a  "lock  and  key"  mechanism  (Figure  3-5).  They  do  not  bind  via 
covalent  chemical  bonds  but  via  electrostatic  forces,  van  der  Waals  forces, 
hydrogen  bonds  and  hydrophobic  bonds.  Binding  therefore  depends  upon  short 
range  factors  hence  the  need  for  a  highly  specific  association  between  antibody 
and  antigen.  Antigen  binding  can  be  reversed  by  high  salt  concentration,  low 
pH,  denaturing  agents  such  as  urea,  organic  solvents,  heat  and  competitive 
antigens. 
labelled 
antigen 
(limited) 
Figure  3-5  Antigen-antibody  binding  mechanism102 
antibody 
(limited) 
analyte 
I 
ed 
Immunoassays  can  be  designed  using  polyclonat  or  monoclonal  antibodies 
depending  on  how  the  antibodies  are  manufactured.  Polyctonal  antibodies  bind Immunoassay  Chapter  3,40 
less  specifically  and  so  are  useful  for  screening  for  a  group  of  related  drugs  such 
as  opiates.  Monoclonal  antibodies  on  the  other  hand  are  highly  specific  for  a 
particular  drug  such  as  morphine. 
3.5  Variables  Influencing  Evaluation  of  Results 
3.5.1  Inter-Individual  Variations 
Inter-individual  variations,  diet  and  medication  are  some  of  the  contributing 
variables  that  can  influence  the  outcome  and  interpretation  of  immunoassay 
results.  Pharmacogenetic  and  physiological  variations  exist  between  every 
individual  and  these  ultimately  affect  the  drug  metabolism  and  excretion 
profile.  Ingestion  of  certain  foods  or  medication  can  result  in  the  need  for  more 
complex  interpretation  of  drug  screening  results.  "',  "' 
3.5.2  Sample  Adulteration 
There  are  many  readily  available  adulterants  and  urine  substitutes  that  are 
designed  to  defeat  drugs  tests.  Some  of  these  are  produced  specifically  for 
"passing"  a  urine  drug  test,  while  others  are  common  household  products. 
These  can  be  easily  researched  or  purchased  via  the  Internet.  A  recent  search 
using  the  Internet  and  psychiatric  and  medical  literature  identified  a 
comprehensive  list  of  products,  compounds  and  tampering  methods,  including 
data  on  their  efficacy.  "'  Methods  for  tampering  with  a  sample  can  be  associated 
with  three  basic  categories:  in  vivo  adulteration  which  is  the  ingestion  of  a 
chemical  prior  to  sample  collection  such  as  sample  dilution  by  excessive  water 
consumption;  in  vitro  adulteration  which  is  the  addition  of  a  foreign  substance  to 
a  sample  after  collection;  and  urine  substitution  which  occurs  when  a  sample 
negative  for  drugs  is  substituted  for  a  drug  positive  sample  during  sampling. 
SAMHSA  (2004)  guidelines  recommend  that  a  number  of  validity  checks  are 
carried  out  for  urine  drug  screens,  including  temperature,  pH,  creatinine, 
specific  gravity  (when  creatinine  <  20  mg/100  ml-)  and  tests  for  oxidising 
adulterants.  "' 
In  vitro  adulteration  can  pose  a  problem  in  immunoassay;  particularly  in  urine 
testing  since  it  can  potentially  interfere  with  the  immunoassay  detection  system Immunoassay  Chapter  3,41 
by  decreasing  absorbance  rates124  or  convert  a  target  drug  into  a  compound  that 
is  not  detected  by  screening  or  confirmation  methods.  "'  The  commercially 
available  in  vitro  products  are  marketed  under  a  variety  of  brand  names  but  are 
essentially  limited  to  the  same  active  ingredients  including:  glutaraldehyde, 
sodium  or  potassium  nitrate,  pyridinium  chlorochromate  (PCC)  and 
peroxide/peroxidase.  There  is  conflicting  results  in  terms  of  the  tampering 
effectiveness  of  these  adulterants  in  producing  false  negative  immunoassay 
results.  The  discrepancy  in  effectiveness  is  probably  due  to  differences  in  the 
urine  drug  concentrations  and/or  the  concentration  of  adulterant.  "'  Both 
AdultaCheck  6  and  Intect  7  urine  test  strips  were  shown  to  successfully  detect 
the  presence  of  glutaraldehyde,  nitrite  and  PCC  in  urine  and  could  be  used  as  a 
means  of  checking  sample  integrity.  126  The  presence  of  some  in  vitro  household 
products  such  as  sodium  chloride,  bleach,  vinegar,  Visin&  eye  drops, 
detergent/soap,  ammonia,  aspirin,  ibuprofen,  riboflavin  (vitamin  B2)  and  golden 
seal  tea  have  been  shown  to  interfere  with  immunoassay  by  affecting  drug 
binding.  121,122'123,,  240250279128 
3.5.3  Cross  Reactants 
Antibodies  developed  for  a  particular  drug  can  cross-react  with  other 
structurally  related  or  unrelated  drugs  or  even  endogenous  compounds  present 
in  the  sample  matrix.  Cross  reactivity  is  a  measurement  of  antibody  response  to 
substances  that  are  not  the  target  analyte.  An  understanding  of  assay  cross 
reactivity  and  potential  interference  is  crucial  in  the  interpretation  of 
immunoassay  results.  Some  structurally  unrelated  medications  can  possess  three 
dimensional  conformations  that  have  a  weak  but  sufficient  binding  affinity  for 
some  particular  antibodies.  ` 
The  presence  of  over  the  counter  sympathomimetic  amines,  pseudoephedrine 
and  diphenhydramine,  in  blood  samples  taken  from  non-decomposed  bodies, 
produced  a  large  proportion  of  false  positive  screening  results  using  an 
amphetamines  ELISA  system.  12'  It  was  proposed  that  ingestion  of  over  the 
counter  medication,  pholcodine,  was  the  cause  of  four  false  positive  hair  results 
for  samples  that  had  been  screened  using  an  opiates  ELISA  system.  "'  This 
finding  was  supported  in  another  study  where  pholcodine,  rifampicin  and 
ofloxacin  were  found  to  cross  react  with  an  opiates  ELISA  system.  "'  Some Immunoassay  Chapter  3,42 
examples  of  other  published  cases  include  the  cross  reactivity  of  oxaprozin  with 
a  benzodiazepines  assay  and  ranitidine  with  a  methamphetamine  assay.  "',  "I 
Some  sample  pretreatment  procedures  have  been  proposed  to  reduce  the  effects 
of  immunoassay  cross reactivity  such  as  the  use  of  glucuronidase  hydrolysis  to 
enhance  the  sensitivity  of  the  benzodiazepines  assay.  "' 
As  well  as  the  potential  presence  of  drugs  and/or  adulterants  in  a  sample,  there 
may  be  cross  reactive  endogenous  sample  components  present  such  as 
putrefactive  amines.  Phenethylamine  could  be  present  in  decomposed  blood 
and  it  has  been  reported  to  contribute  to  a  large  proportion  of  false  positive 
results  due  to  its  cross-reactivity  with  an  amphetamines  ELISA  system.  "" 
Phenethylamine  is  structurally  very  similar  to  amphetamine,  differing  only  by  a 
methyl  group  (Figure  3-6).  Furthermore,  the  sensitivity  of  the  ELISA  screening 
was  shown  to  increase  from  87.2  %  to  93.6  %  when  the  known  decomposed  blood 
samples  were  removed  from  the  analysis.  127 
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Figure  3-6  Molecular  structures  of  amphetamine  and  phenethylamine 
3.6  Coupling 
In  order  to  be  immunogenic,  molecules  have  to  have  a  molecular  weight 
>  5000  amu.  Drugs  of  abuse  molecules  are  known  as  `haptens'  since  they  have 
relatively  low  molecular  weights  of  100-500  amu  and  are  not  naturally 
immunogenic.  Haptens  are  transformed  to  immunogens  by  coupling  to  a 
macromolecule  such  as  bovine  serum  albumin  (BSA),  for  example  20-30  hapten 
molecules  per  BSA  molecule.  102'132'133  Coupling  produces  an  immunogen  capable 
of  manufacturing  antibodies  specific  to  free  hapten  which  binds  with  high 
affinity.  When  a  particular  hapten  complexes  with  an  antibody-binding  site,  or 
paratope,  it  is  generally  located  in  a  cavity  which  possesses  functional  groups  of 
the  peptide  residues  and  backbone  that  are  complementary  in  structure  to  the 
binding  regions  of  the  hapten  molecule.  High  affinity  paratopes  often  produce 
complexes  in  which  the  hapten  is  buried  by  80-90  %  or  more.  102 Immunoassay  Chapter  3,43 
The  site  of  coupling  is  a  crucial  consideration  as  it  determines  the  antibody 
specificity.  The  coupling  site  affects  the  cross-reactivity  of  the  antibody  and 
can  be  altered  to  increase  or  decrease  the  cross-reactivity  as  required.  An 
example  is  the  coupling  site  on  morphine.  When  the  morphine  molecule  is 
coupled  through  the  3-position,  the  antibody  demonstrates  a  higher  cross- 
reactivity  with  codeine  than  morphine.  This  is  because  codeine  has  a  greater 
structural  similarity  with  the  immunising  group  coupled  to  the  3-position 
compared  to  morphine  itself.  In  contrast,  if  the  morphine  is  coupled  through 
the  nitrogen,  the  cross  reactivity  of  morphine  is  higher  than  codeine  as  morphine 
has  a  greater  structural  similarity  to  the  molecule  coupled  through  the  nitrogen 
compared  to  codeine.  Figure  3.7  shows  the  molecular  structure  of  morphine  and 
codeine  with  the  two  potential  coupling  sites  indicated  on  morphine. 
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Figure  3.7  Molecular  structures  of  morphine  and  codeine  with  potential  coupling  sites 
indicated  on  morphine 
3.7  Advantages  of  ELISA 
Radioimmunoassay  (RIA)  has  been  used  in  the  past  as  a  screening  technique  due 
to  its  reliability  and  its  ability  to  detect  low  drug  levels  in  a  wide  range  of 
biological  samples  whilst  remaining  relatively  unaffected  by  sample  matrix 
effects.  The  use  of  radioactively  labelled  material  does  however  prevent  its 
performance  out  with  safe  areas  and  consequently  a  non-radioactive  technique 
such  as  ELISA  is  a  safer  and  highly  sensitive  alternative.  ELISA  and  RIA  were 
evaluated  as  screening  procedures  for  post-mortem  samples  for  nine  major  drug 
classes  and  ELISA  was  found  to  be  a  suitable  alternative  to  RIA.  134 Immunoassay  Chapter  3,44 
From  a  practical  viewpoint,  the  reagents  used  in  ELISA  have  a  longer  shelf  life 
than  RIA  reagents  which  are  limited  due  to  radioactive  decay.  ELISA  lends  itself 
well  to  automation  and  high  throughput  while  RIA  does  not.  In  addition,  RIA 
screening  takes  a  longer  time  than  ELISA  screening,  is  more  labour  intensive  and 
presents  a  higher  risk  of  carry-over.  "' 
ELISA  is  a  fast  and  sensitive  technique  which  can  be  used  to  screen  large 
numbers  of  unknown  samples.  There  is  no  need  to  extract  blood  and  urine 
samples,  which  only  require  dilution  with  phosphate  buffer.  Although  an 
extraction  is  required  for  hair  screening,  this  takes  a  relatively  short  time. 
Small  sample  sizes  are  used  in  ELISA  so  matrix  effects  are  minimised  as  there  is 
less  background  interference  with  the  developing  colour. 
ELISA  systems  show  varying  degrees  of  cross-reactivity  for  the  detection  of  drugs 
within  a  class.  It  is  useful  to  detect  the  presence  of  a  variety  of  drugs  within  the 
same  drug  class.  ELISA  kits  have  been  adapted  for  specific  use  for  drug 
detection  in  a  variety  of  biological  matrices.  The  cocaine  ELISA  system  for  urine 
for  example  targets  benzoylecgonine,  while  the  cocaine  ELISA  system  for  hair 
targets  cocaine. 
3.8  Disadvantages  of  ELISA 
Drug  immunoassays  produce  "semi-quantitative"  results  since  the  assay  result 
represents  the  summative  contribution  of  all  drugs  from  a  particular  drug  class 
in  a  sample  that  can  compete  for  antibody  binding  and  is  generally  not 
representative  of  a  single  target  analyte. 
Absolute  specificity,  based  solely  on  a  binding  reaction,  is  not  achievable  and 
this  might  be  interpreted  as  a  limitation  of  ELISA.  Irrespective  of  the  type  of 
binding  protein  assay,  there  is  a  possibility  that  structurally  related  or  unrelated 
drugs  or  even  endogenous  compounds  present  in  the  sample  matrix  could  cross- 
react  with  the  binding  protein  in  the  assay.  Due  to  the  increasing  availability  of 
many  new  over  the  counter  and  prescription  medications,  it  is  essential  that  the 
manufacturers  of  ELISA  kits  continually  update  the  cross  reactivity  studies  to 
allow  accurate  evaluation  of  immunoassay  results. Immunoassay  Chapter  3,45 
A  major  limitation  of  using  immunoassay  in  forensic  toxicology  is  that  antibodies 
are  commercially  available  for  a  relatively  small  number  of  drugs,  mainly  for 
drugs  of  abuse  as  there  is  a  large  market  for  these  kits.  New  kits  are  being 
manufactured  to  try  to  meet  requirements  however  this  is  a  huge  task  and  is 
continually  changing  with  the  availability  of  new  drugs.  ELISA  assays  for  new 
drugs  of  abuse  such  as  methylphenidate  (Ritalin®),  fluoxetine  (Prozac®), 
zolpidem  (Ambien®),  sertraline  (Zoloft®)  as  well  as  other  drugs  such  as 
paracetamol  have  recently  been  introduced  onto  the  market.  136 46 
4  Liquid  Chromatography-Mass  Spectrometry 
4.1  Introduction 
A  combination  of  liquid  chromatography  and  mass  spectrometry  (LC-MS)  is  a 
valuable  analytical  tool  in  various  fields.  The  development  of  a  suitable  LC-MS 
interface  that  allows  the  LC  mobile  phase  to  pass  into  the  mass  spectrometer, 
which  is  held  under  vacuum,  is  central  to  the  increasing  number  of  published  LC- 
MS  applications  over  the  last  few  decades.  LC-MS  has  established  itself  as  a 
complementary  technique  to  gas  chromatography-mass  spectrometry  (GC-MS)  in 
the  analysis  of  less  volatile  compounds  and/or  high  molecular  weight 
compounds.  "'  It  has  been  estimated  that  almost  70  %  of  routine  samples  in  the 
toxicology  laboratory  can  be  analysed  by  LC.  133  A  clear  advantage  of  LC  is  that 
unlike  GC,  time-consuming  derivatisation  steps  are  not  generally  required.  An 
important  practical  advantage  of  LC-MS  over  GC-MS  is  that  the  optimisation  of 
ionisation  and  MS  parameters  can  be  performed  by  the  continuous  infusion  of  a 
dilute  solution  of  the  analyte  into  the  ion  source,  without  the  involvement  of 
chromatography. 
Since  the  amount  of  energy  transferred  to  the  molecule  during  the  ionisation 
process  is  small,  electrospray  ionisation  (ESI)  is  known  as  a  soft  ionisation 
technique.  As  a  result,  pseudo  molecular  ions  [M  +  H]  '  or  [M  -  H]  "are  readily 
formed,  generally  with  little  or  no  molecular  fragmentation  resulting  in  limited 
structural  information.  It  is  however  suitable  for  quantitative  analysis  and 
benefits  the  sensitivity  of  MS-MS  analysis  as  most  of  the  total  ion  count  (TIC) 
relates  to  one  precursor  ion  in  MS-MS  mode.  The  formation  of  other  charged 
species  such  as  clusters  with  solvents  such  as  acetonitrite  ACN  [M  +  42]  +  and 
methanol  [M  +  32]  +  or  adducts  with  sodium  [M  +  23]  ',  ammonium  [M  +  18]  +  or 
potassium  [M  +  39]  +  have  been  described  for  some  compounds  under  the  soft 
ionisation  ESI  technique.  The  use  of  cluster  ions  or  adducts  as  precursor  ions  can 
lead  to  poor  reproducibility  so  the  protonated  or  deprotonated  pseudo  molecular 
ions  should  be  used  where  possible. 
LC-ESI-MS/MS  has  been  used  to  analyse  various  drugs  of  abuse  including 
opioids134,135,136,137,138,139,140  benzodiazepineSl4lol42,143,144,145,146,147 
amphetamines2,137,148,149 
and  cocaine  and  its  metabolites134,135,137P  139P  150P  151  as  in  this  thesis,  as  well  as Liquid  chromatography-mass  spectrometry  Chapter  4,47 
other  drugs  of  abuse  such  as  cannabinoids139''s'''58  and  LSD'59''6o  in  a  variety  of 
biological  matrices.  Some  studies  have  developed  ESI  methods  for  screening  and 
quantifying  drugs  from  multiple  drug  classes. 
97,141,143,161,162 
In  this  thesis,  a  Thermo  Finnigan  LCQTM'  Deca  XP  Plus  instrument  was  used  for 
method  development  and  validation.  The  instrument  has  three  main 
components  namely  an  LC  system,  ESI  interface  and  a  mass  spectrometer 
detection  system;  hence  these  will  be  discussed  in  subsequent  sections  of  this 
chapter. 
4.1.1  Liquid  Chromatography 
LC  is  a  powerful  separation  technique  that  can  be  operated  in  both  normal- 
phase  (NP)  and  reverse-phase  (RP)  mode.  Both  modes  of  chromatography  rely 
on  two  phases,  namely  the  stationary  phase  and  mobile  phase.  Generally,  the 
separation  is  achieved  by  differential  migration  of  analytes  through  a 
microparticulate  solid  stationary  phase.  A  liquid  mobile  phase  consisting  of  a 
single  solvent  or  buffer/solvent  mixture  is  degassed,  filtered  and  blended  (if  a 
mixture  is  required)  before  flowing  through  the  stationary  phase  to  elute  the 
analytes.  All  analytes  differ  in  polarity  and  are  therefore  retained  on  the 
stationary  phase  for  different  amounts  of  time.  Furthermore,  analytes  will 
respond  differently  depending  on  the  type  of  stationary  phase  and  mobile  phase 
system  used. 
In  NP  chromatography  (NPC),  the  stationary  phase  is  of  higher  polarity  than  that 
of  the  mobile  phase  hence  is  commonly  used  for  the  analysis  of  relatively  non- 
polar  analytes.  Silica  is  used  as  the  stationary  phase  in  combination  with  non- 
polar  solvents  such  as  dichloromethane  and  hexane.  Since  these  solvents  are 
hazardous  to  health  and  the  environment,  NPC  is  avoided  in  most  Laboratories.  "' 
In  LC-MS  applications  however,  RP  chromatography  (RPC)  using  aqueous  mobile 
phases  has  been  the  most  widely  applied.  RPC  is  suitable  for  the  analysis  of 
polar  analytes  since  the  polarity  of  the  mobile  phase  is  higher  than  that  of  the 
stationary  phase.  There  is  a  range  of  non-polar  silica-bonded  stationary  phases 
available,  with  C18  being  the  most  popular.  The  solvents  typically  used  for  the 
mobile  phase,  in  combination  with  an  aqueous  buffer  are  acetonitrile  and 
methanol,  which  are  less  hazardous  and  easier  to  handle  compared  with  the Liquid  chromatography-mass  spectrometry  Chapter  4,48 
solvents  used  in  NPC.  NPC  may  however  be  more  suited  in  the  analysis  of  drug 
enantiomers,  for  example,  which  require  chiral  stationary  phases. 
4.2  Liquid  Chromatography-Mass  Spectrometry 
4.2.1  Mobile  Phase  Composition  and  Flow  Rate 
The  composition  of  the  mobile  phase,  type  and  concentration  of  buffer  and 
organic  modifier  are  extremely  significant  as  they  affect  the  separation  and 
ionisation  of  analytes.  1  One  study  demonstrated  that  formic  acid  produced  a 
response  that  was  10  times  higher  than  trifluoroacetic  acid  using  a  low  buffer 
strength  of  2-3  mmol/L.  765  The  separation  ability  however  decreases  as  the 
buffer  strength  decreases.  A  high  organic  percentage  of  the  mobile  phase 
favours  ion  formation  as  solvent  evaporation  efficiency  is  improved  and  hence 
the  ion  yield  passing  into  the  mass  analyser  is  increased.  "'  Therefore,  a 
compromise  between  chromatographic  separation  and  ion  signal  intensity  has  to 
be  reached. 
Usually,  the  LC-MS  mobile  phase  is  comprised  of  an  aqueous  buffer  and  an 
organic  solvent.  Buffer  selection  is  important  not  only  to  achieve  and  control 
the  pH  of  the  LC  mobile  phase  but  also  because  of  some  practical 
considerations.  In  LC-MS,  non-volatile  buffers  should  be  avoided  as  they  wilt 
precipitate  in  the  ion  source,  resulting  in  clogging  and  impaired  instrument 
performance  i.  e.  reduction  in  signal  intensity  due  to  competition  between 
analyte  ions  and  electrolyte  ions  for  conversion  to  gas  phase  ions.  Therefore 
volatile  buffers  such  as  ammonium  formate,  ammonium  acetate,  acetic  acid  and 
ammonia  must  be  used.  Low  buffer  concentrations  should  be  used  to  prevent 
saturation  of  the  surface  of  the  droplet,  preventing  the  analyte  from  passing 
into  the  gaseous  phase  and  ultimately  lowering  its  response.  At  high  buffer 
concentrations  (>  10  mM),  the  ionisation  efficiency  is  affected  and  the 
relationship  between  detector  response  and  concentration  is  not  linear.  166 Liquid  chromatography-mass  spectrometry 
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Figure  4-2  Decrease  in  analyte 
response  with  increasing  electrolytes  167 
A  pre-requisite  of  ESI  is  that  the  analyte  exists  as  an  ion  in  solution  therefore  the 
pH  of  the  mobile  phase  should  be  carefully  selected  depending  on  the  pKa  of  the 
analytes  of  interest  and  usually  contains  a  small  amount  of  volatile  acid  or  base. 
A  general  rule  of  thumb  is  `basic  analyte,  acidic  mobile  phase  and  vice  versa'.  163 
This  is  because  an  acidic  mobile  phase  contains  an  excess  of  H+  ions  which  would 
ionise  basic  analytes  by  the  addition  of  a  proton.  Conversely,  a  basic  mobile 
phase  contains  an  excess  of  OH'  ions  which  would  cause  deprotonation  of  acidic 
analytes.  The  mobile  phase  carrying  the  analytes  of  interest  is  passed  into  the 
atmospheric  pressure  ionisation  (API)  source  (typically  in  pL/min)  through  a 
fused  silica  inner  capillary  which  is  inserted  through  the  sample  inlet  and  ESI 
needle  (Figure  4-3). 
As  well  as  the  composition  of  the  mobile  phase,  the  flow  rate  also  affects 
ionisation.  Higher  signal  to  noise  (S/N)  ratios  are  achieved  at  lower  flow  rates 
since  solvent  evaporation  is  more  efficient  and  ultimately  the  transmission  of  gas 
phase  ions  into  the  vacuum  region  is  improved.  163  This  explains  why  a  drying  gas 
(nitrogen)  and  a  high  probe  temperature  e.  g.  300  °C  are  used  to  assist  droplet 
formation  and  solvent  evaporation. Liquid  chromatography-mass  spectrometry 
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There  are  a  wide  variety  of  LC  columns  available  to  the  analyst  but  one 
important  consideration  in  selecting  an  appropriate  column  is  that  a  higher 
organic  concentration  in  the  mobile  phase  improves  the  ionisation  efficiency.  If 
a  more  retentive  column  is  used,  the  organic  content  can  be  increased  in  the 
mobile  phase  without  losing  chromatographic  retention.  "'  Analyte  retention  on 
a  column  depends  on  the  polarity  of  the  analyte  and  stationary  phase.  The  most 
widely  used  columns  contain  a  chemically  modified  silica  stationary  phase,  the 
most  popular  stationary  phase  being  one  in  which  a  C18  alkyl  group  is  bonded  to 
the  silica  surface. 
The  two  basic  types  of  stationary  phase  have  been  discussed  in  section  4.1.1, 
however,  the  binding  sites  on  the  stationary  phase  can  be  end-capped  to 
improve  chromatographic  performance  and  increase  column  stability.  An 
example  is  the  use  of  polar  end-capping  with  bonding  of  C18  alkyl  chains,  is  a 
successful  approach  for  the  reproducible  retention  of  polar  analytes  such  as 
quaternary  ammonium  compounds  under  highly  aqueous  conditions.  "' 
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The  nature  of  the  ESI  interface  is  such  that  lower  mobile  phase  flow  rates  are 
necessary  for  more  efficient  mobile  phase  evaporation  and  improved  ionisation 
of  analytes.  Narrow-bore  columns  are  therefore  favourable  for  ESI.  Typical 
dimensions  are  150  mm  in  length  with  a  2.1  mm  internal  diameter.  A  reduction 
in  the  column  bore  size  results  in  a  decrease  in  the  column  volume.  Since  ESI  is 
a  concentration  dependent  process,  this  will  result  in  a  higher  concentration  of 
analyte  per  unit  volume  of  mobile  phase,  thereby  increasing  the  analyte  signal. 
The  choice  of  column  dimensions  and  particle  size  dictates  the  maximum  load  on 
the  column  and  the  flow  rate  that  can  be  used.  Small  particles  in  narrow-bore 
columns  allow  a  shorter  analysis  time  and  improved  selectivity  but  the 
backpressure  of  the  column  has  to  be  compensated  for  by  a  lower  flow  rate. 
4.3  Electrospray  Ionisation 
ESI  and  atmospheric  pressure  chemical  ionisation  (APCI)  are  regarded  as  the 
golden  standards  of  LC-MS.  1°  They  are  complementary  techniques,  with  most 
analytes  being  sufficiently  ionised  by  either  or  both  ion  sources.  "'  Furthermore, 
the  two  ion  sources  are  usually  interchangeable  within  the  same  instrument.  In 
recent  years  however  the  family  of  API  sources  has  expanded  to  include 
atmospheric  pressure  photo-ionisation  (APPI),  atmospheric  pressure  laser 
ionisation  (APLI)  and  sonic  spray  ionisation  (SSI),  which  have  all  contributed  to 
the  analytical  potential  of  LC-MS.  Other  ion  sources  include  thermospray 
ionisation  (TSI),  particle  beam  ionisation  (PBI),  fast  atom  bombardment  (FAB), 
desorption  electrospray  ionisation  (DESI)  and  matrix-assisted  laser  desorption 
ionisation  (MALDI). 
Electrospray  ionisation  (ESI)  was  the  first  developed  API  source  and  to  date  is  the 
most  frequently  used  ionisation  mode  used  in  analytical  toxicology.  "'  A 
literature  review  of  metabolism  studies  for  drugs  of  abuse  and  prescription  drugs 
published  in  2000  reported  that  ESI  was  used  in  73  %  of  methods,  with  APCI  being 
used  in  23  %  of  methods.  71  ES!  allows  the  determination  of  thermolabile,  high 
molecular  weight  compounds  such  as  proteins'"'  and/or  highly  polar  compounds 
such  as  quaternary  ammonium  compounds  and  herbicides.  169 Liquid  chromatography-mass  spectrometry  Chapter  4,52 
The  general  ESI  process  involves  four  stages;  droplet  formation  from  the  LC 
mobile  phase,  charging  of  droplets,  desolvation  of  droplets  and  formation  of 
analyte  ions  (Figure  4-4).  A  high  voltage  (typically  3-5  kV)  is  applied  to  the  ESI 
needle  which  is  sufficient  to  nebulise  the  liquid  into  highly  charged  droplets  on 
exiting  the  needle.  Depending  on  the  voltage  polarity,  nebulised  droplets 
containing  the  ionised  analytes  can  be  positively  or  negatively  charged.  For 
example,  if  a  positive  voltage  is  used  then  the  droplets  will  be  positively 
charged.  These  charged  droplets  are  subsequently  desolvated  before  passing 
through  the  ion  sweep  cone  and  into  the  analyser.  Analyte  ions  are  obtained 
directly  from  the  liquid  mobile  phase  droplets  so  thermally  labile  compounds  do 
not  suffer  from  degradation. 
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As  droplet  size  decreases,  the  charged  species  move  closer  together  and  are 
repulsed.  When  this  repulsion  on  the  droplet  surface  is  overcome  by  the 
cohesive  forces  of  the  surface  tension,  a  coulombic  explosion  results  where 
micro  droplets  with  radii  of  -10  %  those  of  the  parent  droplets  are  formed.  166  A 
series  of  these  explosions  occur  until  gas  phase  ions  are  produced  from  direct 
emission  of  the  micro  droplets  then  the  sample  ions  enter  into  the  API  stack  via 
an  ion  transfer  capillary  (Figure  4-5). Liquid  chromatography-mass  spectrometry  Chapter  4,53 
The  ESI  needle  is  orthogonal  to  the  axis  of  the  ion  transfer  capillary  that  carries 
the  ions  to  the  mass  analyser.  The  reason  for  this  is  to  keep  the  ion  transfer 
capillary  clean.  The  ion  sweep  cone  is  a  mechanical  barrier  that  prevents  large 
droplets  and  particulates  from  entering  the  ion  transfer  capillary. 
Ions  from  the  ion  transfer  capillary  pass  through  the  tube  lens  which  has  a 
voltage  applied  to  it  to  focus  the  ions  towards  the  opening  of  the  skimmer. 
From  the  skimmer,  ions  move  towards  the  ion  optics  assembly  which  focuses  ions 
from  the  API  source  to  the  mass  analyser. 
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Figure  4-5  Cross-sectional  view  of  the  API  stack168 
4.4  Ion  Optics 
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In  the  LCQTM'  Deca  XP  Plus  system,  the  ion  optics  consists  of  one  quadrupole,  one 
octapole,  separated  by  an  interoctapole  lens  which  helps  with  ion  focusing.  The 
quadrupole  and  octapole  are  an  array  of  square  and  cylindrical  rods  respectively, 
which  act  as  ion  transmission  devices.  An  RF  voltage  and  DC  offset  voltage  is 
applied  to  the  rods  to  create  an  electric  field  that  guides  the  selected  ions  of 
particular  m/z  along  the  axis  of  the  quadrupole/octapole  into  the  mass  analyser. 
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4.5  Ion  Trap  Mass  Analyser 
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The  ion  trap  mass  analyser  is  also  known  as  the  quadrupole  ion  trap  mass 
analyser  and  has  been  described  as  a  three-dimensional  quadrupole.  1  It 
consists  of  three  stainless  steel  electrodes:  the  entrance  endcap  electrode,  the 
exit  endcap  electrode;  and  the  ring  or  `doughnut'  electrode  (Figure  4-6).  The 
two  endcap  electrodes  are  hemispherical  and  are  positioned  above  and  below 
the  ring  electrode,  to  form  a  hyperbolic  cavity.  They  each  have  a  small  hole  in 
their  centres  to  permit  the  passage  of  ions  into  and  out  of  the  ion  trap. 
When  sample  ions  of  a  specified  m/z  are  held  in  a  static  position  or  `trapped',  a 
radiofrequency  (RF)  voltage  is  applied  to  the  endcap  electrodes  and  the 
amplitude  of  the  RF  voltage  applied  to  the  ring  electrode  is  ramped  in  order  to 
facilitate  ion  ejection  from  the  trap.  As  the  voltage  on  the  ring  electrode  is 
increased,  trapped  ions  are  selectively  ejected  out  through  the  exit  lens  by 
increasing  m/z  into  the  ion  detection  system.  Following  the  completed  scan 
cycle,  other  ions  are  admitted  into  the  trap  and  the  process  is  repeated.  As  the 
ion  trap  operates  in  this  mode,  it  is  defined  as  a  pulsed  mass  analyser.  166  Ion 
trap  mass  analysers  allow  MS-MS  analysis  by  isolating  specific  product  ions  and 
fragmenting  them  by  collision  induced  dissociation. 
Helium  is  present  within  the  ion  trap  and  is  used  as  a  damping  gas  and  collision 
activation  partner  to  greatly  enhance  sensitivity  and  mass  spectral  resolution. 
When  sample  ions  enter  the  trap,  they  collide  with  helium  atoms  therefore 
reducing  their  kinetic  energy  and  the  amplitude  of  their  oscillations.  As  a  result, 
the  ions  migrate  to  the  centre  of  the  cavity  where  they  are  tightly  focused  in  a 
long,  narrow  cloud.  Helium  atoms  are  also  used  in  tandem  mass  spectrometry 
(MS-MS)  for  collision  induced  dissociation  of  precursor  ions  to  product  ions. Liquid  chromatography-mass  spectrometry 
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Figure  4-6  Cross-sectional  view  of  the  mass  analyser  168 
4.6  Detector 
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Selected  ions  are  passed  from  the  ion  trap  mass  analyser  to  the  detector  system. 
This  system  contains  a  conversion  dynode  and  an  electron  multiplier.  An  ion 
strikes  the  surface  of  the  conversion  dynode,  readily  emitting  secondary 
particles  (Figure  4-7).  These  secondary  particles  are  then  focused  by  the  curved 
surface  of  the  conversion  dynode  and  are  accelerated  into  the  electron 
multiplier  by  means  of  a  voltage  gradient.  The  electron  multiplier  contains  a 
cathode  and  an  anode.  If  the  secondary  particles  from  the  conversion  dynode 
strike  the  inner  walls  of  the  electron  multiplier  cathode  with  sufficient  energy, 
electrons  will  be  ejected.  These  electrons  are  accelerated  further  into  the 
cathode  by  a  potential  gradient.  As  the  cathode  is  funnel-shaped,  the  electrons 
continue  to  strike  the  inner  walls  of  the  cathode,  creating  an  electron  cascade 
which  results  in  a  measurable  electric  signal  (current)  and  typically  a  signal  gain 
of  106-107.166  The  current  is  then  converted  to  a  voltage  by  an  electrometer 
circuit  for  processing  and  recorded  by  the  MS  data  system. 
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Figure  4-7  Cross  sectional  view  of  the  ion  detection  system  showing  the  electron  multiplier 
and  conversion  dynode168 
4.7  Matrix  Effects 
A  major  problem  with  generating  ions  using  API  techniques  is  matrix  effects 
(MEs)  from  biological  matrices  such  as  blood,  urine  and  hair.  Ion  suppression  or 
enhancement  of  analyte  ionisation  by  co-eluting  compounds  is  known  as  matrix 
effects.  MEs  depend  mainly  on  the  sample  matrix,  sample  preparation  method, 
quality  of  chromatographic  separation,  mobile  phase  additives  and  type  of 
ionisation  used.  The  exact  mechanism  of  MEs  is  yet  to  be  established  but  it  is 
generally  believed  to  originate  from  the  competition  between  an  analyte  and 
the  co-eluting  matrix  component  in  the  ion  source.  ESI  is  particularly  prone  to 
matrix  effects,  more  so  than  APCI.  This  is  because  of  the  presence  of  excess 
reagent  ions  which  produce  charged  species  in  APCI;  hence  the  APCI  ionisation 
process  is  less  susceptible  to  MEs.  163 
Since  analyte  ionisation  depends  on  the  matrix  constituents  present,  this  can 
pose  problems  when  the  matrix  is  not  consistent  between  individuals.  As  a 
result,  validation  parameters  such  as  limit  of  detection  (LOD),  limit  of Liquid  chromatography-mass  spectrometry  Chapter  4,57 
quantitation  (LOQ),  linearity,  precision  and  accuracy  will  be  affected. 
Therefore  an  evaluation  of  MEs  should  form  a  central  part  of  the  validation  of 
any  LC-MS  procedure.  The  use  of  deuterated  internal  standards  helps  to 
minimise  MEs  since  they  elute  close  to  the  analyte  and  are  therefore  affected  by 
matrix  constituents  in  the  same  way  as  the  analyte. 
Two  different  approaches  have  been  described  in  the  literature  for  assessing 
MEs.  The  first  approach  involves  the  continuous  infusion  of  a  solution  of  the 
analyte  into  the  mobile  phase  from  the  column  via  a  post-column  T-connection 
and  a  syringe  pump.  13'"4  Simultaneously,  an  injection  of  extracted  blank  matrix 
is  performed.  A  constant  signal  in  the  detector  is  produced  unless  compounds 
are  present  which  suppress  or  enhance  ionisation.  Such  compounds  would  result 
in  a  decreased  or  increased  signal  respectively.  Potential  MEs  and  their 
retention  times  can  be  identified  by  monitoring  the  detector  response  following 
the  injection  of  blank  extracted  matrix  components.  A  strategy  for  assessing  the 
MEs  quantitatively  is  to  determine  the  peak  areas  of  analyte  in  two  different 
sets  of  samples.  The  first  set  consists  of  standards  prepared  in  neat  mobile 
phase  (set  A).  The  second  set  are  extracts  using  blank  matrix  from  different 
sources  which  are  spiked  after  extraction  (set  B).  From  this  data,  the  ME  (%)  can 
be  calculated  by  dividing  set  B  by  set  A  and  multiplying  by  100.15  Values  greater 
than  100  %  are  indicative  of  ion  enhancement  while  values  less  than  100  %  are 
indicative  of  ion  suppression. 58 
5  Buprenorphine  in  Urine 
5.1  Buprenorphine 
Buprenorphine  is  a  semi-synthetic  opioid  derivative  of  thebaine.  It  has  a 
chemical  structure  which  is  closely  related  to  morphine  (Figure  5-1)  and  at  low 
doses  (typically  0.3-0.6  mg  intravenous  or  intramuscular)  is  a  powerful  analgesic, 
with  25  -  40  times  the  potency  of  morphine.  "'  The  binding  potential  of  opioids 
to  brain  receptors  is  related  to  analgesia  therefore  buprenorphine  binds  tightly 
to  the  p-  and  K-opioid  brain  receptors,  acting  as  a  partial  agonist  and  antagonist 
when  bound  to  the  respective  receptor  types.  "'  In  nave  users,  buprenorphine 
demonstrates  agonist  activity,  similar  to  morphine  while  in  addicts  it  acts  as  an 
antagonist,  producing  withdrawal  symptoms.  The  kinetics  of  the  opioid 
receptors  is  slow;  hence  the  duration  of  action  is  long-lived.  "' 
Buprenorphine  was  developed  by  Reckitt  Et  Colman  Products  with  a  view  to 
producing  a  useful  analgesic  with  greater  safety  and  a  lower  chance  of  abuse 
compared  with  other  opiate  agonists.  13  Buprenorphine  has  been  prescribed  in 
the  United  States  since  the  early  1980s  under  the  tradename  Buprenex®  and  in 
most  European  countries  as  Temgesic®  as  a  treatment  for  pain  relief  (especially 
for  surgical  purposes)  and  in  anaesthesiology.  More  recently,  it  has  been 
identified  as  an  alternative  medication  to  methadone  for  the  treatment  of 
heroin  addiction.  Under  the  tradename  Subutex®,  high  dose  tablets  (0.4,2  and 
8  mg)  are  administered  sublingually  for  this  purpose. 
In  Scotland  from  2006-2007,  the  number  of  buprenorphine  prescriptions  for  use 
in  drug  dependence  was  9,100  compared  to  457,045  methadone  prescriptions.  ` 
Buprenorphine  has  not  been  identified  as  a  contributor  in  either  drug-related 
deaths  or  impaired  driving  in  the  Strathclyde  region  of  Scotland  in  1995- 
2007.1  .  576.177  Another  study  into  drug-related  deaths  in  Edinburgh  and  Glasgow  in 
1990-1992  found  buprenorphine  to  be  present  in  one  case  M  The  authors 
concluded  that  the  small  number  of  positive  samples  implied  that  the  drug  is 
very  unlikely  to  cause  death.  However  it  is  more  likely  that  buprenorphine  was 
not  commonly  prescribed  at  that  time  for  the  treatment  of  heroin  addiction. Buprenorphine  in  Urine  Chapter  5,59 
In  contrast,  buprenorphine  is  used  widely  in  France  for  the  treatment  of  90,000 
heroin  addicts184  where,  in  fact,  a  black  market  has  developed  with  frequent 
misuse  by  intravenous  injection.  "'  Furthermore,  buprenorphine  abuse  by 
intravenous  injection  of  crushed  tablets  meant  for  sublingual  use  contributed  to 
the  deaths  of  20  heroin  addicts.  "'  A  study  in  the  Nord-Pas-de-Calais  region  of 
France  in  2003-2004  which  tested  for  drugs  of  abuse  in  1000  urine  samples 
collected  from  truck  drivers  confirmed  the  presence  of  buprenorphine  in  1.8  %  of 
positive  samples.  "' 
5.2  Pharmacokinetics,  Metabolism  and  Excretion 
The  pharmacokinetic  and  physicochemical  data  for  buprenorphine  are  shown  in 
Table  5-1. 
Table  5-1  Pharmacokinetic  and  physicochemical  data  for  buprenorphine176 
Half  Life  (hr)  Vd  (L/kg)  Protein 
Binding  (%)  p' 
Buprenorphine  2-4  2.5  96  8.5,10.0 
Buprenorphine  is  rapidly  metabolised  in  the  liver  by  the  cytochrome  P450 
CYP3A4  system.  During  metabolism,  it  becomes  N-dealkylated  to  form 
norbuprenorphine,  which  is  also  pharmacologically  active  (Figure  5-1). 
Buprenorphine  is  predominantly  cleared  from  plasma  by  biliary  excretion 
following  conjugation  with  glucuronic  acid  or  N-dealkylation  and  conjugation. 
However  a  small  amount  of  drug  and  metabolites  is  cleared  slowly  by  the 
kidney.  "'  Within  144  hours  of  a  single  intramuscular  dose  of  radiolabelled 
buprenorphine,  95  %  is  eliminated  with  68  %  radioactivity  measured  in  the  faeces 
and  27  %  in  the  urine.  176 Buprenorphine  in  Urine 
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Blood  concentrations  of  buprenorphine  can  be  very  low  since  only  low  doses  are 
required  in  the  treatment  of  pain  due  to  its  high  potency.  A2  mg  sublingual 
dose  of  buprenorphine  administered  to  6  healthy  adults  produced  an  average 
peak  plasma  concentration  of  1.6  ng/mL  after  1.3  hours.  116  Opiate-dependent 
subjects  taking  an  8  mg  sublingual  dose  of  buprenorphine  each  day  as  part  of 
their  maintenance  therapy  were  shown  to  have  a  plasma  drug  concentration 
range  of  1-8  ng/mL.  187  Therapeutic  concentrations  of  free  buprenorphine  in 
urine  can  also  be  low  (less  than  1  ng/mL),  requiring  sensitive  methods  of 
detection.  "6,  t76,184  In  contrast,  free  buprenorphine  and  norbuprenorphine 
concentrations  greater  than  20  ng/mL  urine  have  been  observed  in  cases  of 
abuse.  106'184'188 
5.3  Toxicity 
Symptoms  associated  with  buprenorphine  overdose  include  confusion,  dizziness, 
pinpoint  pupils,  hallucinations,  hypotension,  respiratory  difficulty,  seizures  and 
coma.  Concentrations  found  in  the  blood  and  urine  of  a  drug  addict  who  had 
died  following  intravenous  injection  of  buprenorphine  were  3.0  and  616  ng/mL 
buprenorphine  and  3.1  and  48  ng/mL  norbuprenorphine  respectively.  ",  Average 
post-mortem  concentrations  found  in  the  blood  and  urine  of  20  heroin  addicts 
who  had  intravenously  injected  buprenorphine  meant  for  sublingual  use  were  8.4 
and  172  ng/mL  buprenorphine  and  2.6  and  67  ng/mL  norbuprenorphine.  185 
More  than  150  fatal  overdoses  involving  the  combined  use  of  buprenorphine  and 
psychotropic  drugs  (in  particular  benzodiazepines  and  neuroleptics)  have  been 
reported  in  France.  ""  A  study  in  Singapore  also  highlighted  that  concurrent 
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administration  of  buprenorphine  and  benzodiazepines  was  potentially  fatal.  "' 
Interestingly,  an  Australian  study  reported  a  greater  number  of  opioid  toxicity 
symptoms  in  relation  to  methadone  consumption  compared  to  buprenorphine  in 
concurrent  benzodiazepine  users.  192 
5.4  Previously  Reported  Methods  of  Analysis 
Buprenorphine  detection  in  urine  has  been  reported  using 
immunoassay106'107,,  84,193,194,  thin  layer  chromatography195,  high  performance  liquid 
chromatography  (HPLC)193,196' 
GC_MS194,197,198  and  LC_!  S.  106,107,184,186'191'199 
ELISA  has  been  widely  used  for  the  determination  of  buprenorphine  in  urine  for  a 
number  of  different  purposes.  It  has  proved  useful  in  the  rapid  screening  of 
large  numbers  of  post-mortem  samples184i191  and  also  in  a  clinical  setting  for  the 
rapid  measurement  of  urine  concentrations  in  maintainence  programmes.  107084,194 
ELISA  has  also  been  applied  in  the  urine  testing  of  truck  drivers  in  France  in  the 
interests  of  road  safety.  181 
As  discussed  in  chapter  3,  this  method  of  detection  is  highly  sensitive  but  is  not 
specific  due  to  the  potential  antibody  cross  reactivity  with  drug  metabolites  and 
other  structurally  similar  compounds  other  than  the  target  drug.  A 
buprenorphine  ELISA  system  by  the  International  Diagnostics  Systems 
Corporation  showed  no  cross-reactivity  with  dihydrocodeine,  ethylmorphine,  6- 
monoacetylmorphine,  pholcodine,  propoxyphene,  dextromoramide, 
dextrometorphan,  codeine,  morphine,  methadone  and  EDDP.  184  Another 
buprenorphine  ELISA  system  by  the  Immunalysis  Corporation  demonstrated  no 
cross-reactivity  with  dihydrocodeine,  codeine,  morphine,  methadone,  EDDP, 
tramadol  and  propoxyphene.  107  Standard  buprenorphine  immunoassays  cross- 
react  with  the  major  metabolite,  norbuprenorphine  to  a  relatively  high  extent 
depending  on  the  concentration  of  norbuprenorphine  that  is  present.  This  is  an 
advantage  since  norbuprenorphine  concentrations  are  generally  higher  than 
buprenorphine  concentrations.  116,107097099 
A  recently  published  HPLC  method  describes  the  combined  use  of  solid-phase 
extraction  and  an  HPLC  system  using  diode  array  detection  (DAD)  to  detect 
buprenorphine  and  norbuprenorphine  in  urine  samples  obtained  from  drug Buprenorphine  in  Urine  Chapter  5,62 
addicts  on  a  therapy  programme.  197  The  advantages  of  using  this  method  include 
the  use  of  small  sample  volumes,  high  extraction  efficiencies  for  both 
compounds  (>_  97  %)  as  well  as  good  levels  of  precision  (<_  4.9  %)  and  highly 
purified  extracts.  The  LOD  was  determined  to  be  0.5  ng/mL  and  0.2  ng/mL  for 
buprenorphine  and  norbuprenorphine  respectively.  One  urine  sample  taken  from 
a  patient  who  was  receiving  16  mg/day  buprenorphine  contained  51.7  ng/mL 
buprenorphine  and  50.4  ng/mL  norbuprenorphine.  A  disadvantage  of  using  this 
method  is  that  the  linearity  range  for  both  compounds  was  10.0-1500  ng/mL 
which  is  acceptable  for  quantification  of  the  sample  concentrations  in  this  study 
but  would  need  to  be  extended  to  include  lower  concentrations  if  lower  doses 
were  being  administered.  As  mentioned  previously,  therapeutic  urine 
concentrations  as  low  as  1  ng/mL  free  buprenorphine  have  been  observed.  106 
The  first  HPLC  method  with  electrochemical  detection  for  the  detection  of 
buprenorphine  and  norbuprenorphine  in  urine  samples  was  published  15  years 
ago.  793  The  extraction  involved  a  three-step  alkaline  toluene  extraction  and 
reported  limits  of  detection  were  0.2  ng/mL  buprenorphine  and  0.15  ng/mL 
norbuprenorphine.  The  HPLC  results  in  this  study  were  compared  to  RIA  which 
was  only  able  to  detect  buprenorphine  concentrations  higher  than  1  ng/mL. 
A  GC-MS  method  involving  solid-phase  extraction  has  been  reported  to  analyse 
buprenorphine  and  norbuprenorphine  in  urine  after  therapeutic  doses,  which 
was  linear  from  1-100  ng/mL.  198  Urine  samples  were  hydrolysed  using  B- 
glucuronidase  and  subsequently  converted  to  their  methyl  derivatives  by 
extractive  alkylation.  The  LOD  for  both  compounds  was  determined  to  be 
0.2  ng/mL,  with  high  recovery  values  of  92  %  and  104  %  for  buprenorphine  and 
norbuprenorphine  respectively.  Free  norbuprenorphine  was  detected  in  urine  in 
the  range  of  0.4-1.7  ng/mL  following  a  single  0.2  mg  sublingual  dose  of 
Temgesic®.  Buprenorphine  levels  were  however  below  the  method's  detection 
limit.  A  more  recent  GC-MS  method  involving  liquid-liquid  extraction  of  urine 
was  developed  for  the  purposes  of  monitoring  buprenorphine  withdrawal 
protocols,  which  was  linear  up  to  2000  ng/mL  for  buprenorphine  and 
norbuprenorphine.  197  Like  the  previously  mentioned  GC-MS  method,  urine 
samples  were  hydrolysed  using  B-glucuronidase  to  cleave  the  conjugates  but  a 
different  derivatisation  method  involving  bis  (trimethylsilyl)  trifluoroacetamide 
(BSTFA)  containing  trimethylchlorosilane  (TMCS)  was  used.  A  higher  LOD  was Buprenorphine  in  Urine  Chapter  5,63 
found  for  buprenorphine  and  norbuprenorphine  (1  ng/mL  for  both)  compared  to 
the  other  method  mentioned,  with  lower  recovery  values  of  59  %  and  58  % 
respectively.  Buprenorphine  and  norbuprenorphine  concentration  ranges  were 
28-1458  ng/mL  and  28-1843  ng/mL  respectively. 
There  have  been  several  LC-MS  methods  published  over  the  last  decade  for  the 
determination  of  buprenorphine  and  norbuprenorphine  in  urine.  This  is  mainly 
because  of  easier  sample  pre-treatment  required  for  LC-MS  compared  to  GC-MS 
which  requires  a  derivatisation  step. 
LC-ESI-MS  with  a  single  quadrupole  mass  spectrometer  was  used  to  detect  both 
compounds  using  a  linear  LC  gradient  system  in  a  variety  of  matrices  including 
urine,  blood  and  hair.  "'  Urine  samples  were  hydrolysed  overnight  with  6- 
glucuronidase  and  the  analytes  isolated  using  a  single  liquid-liquid  extraction 
step  with  a  mixture  of  chloroform  /propan-2-of/heptane  (25:  10:  65,  v/v/v). 
Extraction  recovery  for  buprenorphine  was  greater  than  80  %  and  the  LOQ  was 
0.2  ng/mL,  which  is  more  sensitive  than  the  GC-MS  methods  discussed 
previously.  The  LC-ESI-MS  method  was  used  for  confirmation  after  ELISA 
screening  and  was  shown  to  be  more  sensitive  than  ELISA,  detecting 
buprenorphine  in  7  urine  samples  which  screened  as  negative  using  ELISA  at  a 
cut-off  value  of  0.5  ng/mL. 
Another  reported  LC-ESI-MS  method  for  buprenorphine  and  norbuprenorphine 
detection  in  urine  used  a  single  quadrupole  mass  spectrometer  supplied  from  a 
different  manufacturer.  Both  compounds  were  separated  by  gradient  elution 
following  liquid-liquid  extraction  with  1-chlorobutane  and  pH  alteration  to 
alkaline  conditions.  "'  The  LOQvalue  for  buprenorphine  was  higher  (0.5  ng/mL) 
and  extraction  recovery  similar  (average  87  %)  using  this  method  compared  to 
the  LC-ESI-MS  method  described  previously. 
An  LC-ESI-MS-MS  method  has  been  developed  for  the  rapid  screening  and 
quantification  of  buprenorphine  and  its  metabolites.  199  The  authors  evaluated 
three  approaches  in  the  study  including:  the  direct  injection  of  diluted  urine  to 
measure  conjugated  metabolites;  the  direct  injection  of  diluted  urine  after 
enzymatic  hydrolysis  for  quantification  of  buprenorphine  and  norbuprenorphine; 
and  the  quantification  of  buprenorphine  and  norbuprenorphine  after  enzymatic 
hydrolysis  and  SPE  clean-up.  It  was  concluded  that  the  direct  analysis  of Buprenorphine  in  Urine  Chapter  5,64 
glucuronide  conjugates  was  an  acceptable  screening  method  but  that  the  direct 
analysis  of  free  drug  sometimes  required  SPE  clean-up  to  improve  the  LC-MS 
sensitivity  20-fold,  especially  in  cases  where  both  buprenorphine  and 
norbuprenorphine  were  below  the  cut-off  value. 
5.5  Aim  of  Study 
At  the  time  of  this  study,  the  Immunalysis®  ELISA  kit  had  just  become 
commercially  available  for  the  detection  of  buprenorphine  in  urine.  The  aim  of 
the  work  was  to  validate  the  ELISA  test  and  to  apply  it  in  the  analysis  of  real 
samples.  The  screening  results  were  compared  with  an  in-house  LC-MS-MS 
method. 
5.6  Experimental 
5.6.1  Samples 
A  total  of  69  urine  samples  were  tested  in  the  study.  7  of  these  samples  were 
obtained  from  volunteers  on  the  Subutex®  treatment  programme  at  the  Turning 
Point  Drugs  Crisis  Centre,  Glasgow  while  the  other  62  samples  were  routine 
samples  which  had  been  submitted  to  the  University  laboratory  for 
buprenorphine  testing. 
5.6.2  Chemicals 
Buprenorphine,  norbuprenorphine,  buprenorphine-d4  and  norbuprenorphine-d3, 
dihydrocodeine,  codeine,  morphine,  tramadot,  propoxyphene,  methadone  and 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine  (EDDP)  were  obtained  from 
LGC  Promochem  (Teddington,  UK).  Buprenorphine  Direct  ELISA  kits  were 
obtained  from  the  Immunalysis  Corporation  (Pomona,  CA,  USA).  The  kits 
contained  a  96-well  antibody-coated  microplate,  buprenorphine  conjugate 
labelled  with  horseradish  peroxidase  (HRP),  substrate  solution  containing 
3,3',  5,5'-tetramethylbenzidine  (TMB)  and  hydrogen  peroxide  and  stop  solution 
containing  1N  hydrochloric  acid.  Phosphate  buffer  saline  (0.1  M,  pH  7.0)  was 
used  to  dilute  urine  samples  in  the  ELISA  test  and  this  was  also  obtained  from 
the  Immunalysis  Corporation.  Disposable  75  x  12  mm  borosilicate  glass  culture Buprenorphine  in  Urine  Chapter  5,65 
tubes  for  ELISA  were  obtained  from  VWR  International,  UK.  HPLC  grade 
methanol,  acetonitrile,  acetone,  dichloromethane,  glacial  acetic  acid, 
ammonium  hydroxide,  formic  acid  and  potassium  dihydrogen  phosphate  were 
obtained  from  BDH  (Poole,  UK).  Ammonium  formate  and  B-glucuronidase  crude 
solution  were  obtained  from  Sigma-Aldrich  (Dorset,  UK).  Bond  Elut  Certify®  LRC 
SPE  columns  (130  mg,  10  mL)  were  obtained  from  Crawford  Scientific 
(Strathaven,  UK). 
5.6.3  Standard  Solutions 
Individual  drug  stock  standard  solutions  and  deuterated  drug  standards  were 
obtained  as  100  pg/mL  prepared  in  methanol.  A  combined  working  drug  solution 
of  buprenorphine  and  norbuprenorphine  was  prepared  at  1  pg/mL  by  100-fold 
dilution  with  methanol.  This  was  achieved  by  adding  25  pL  of  100  pg/mL  drug 
solution  into  a  25  mL  volumetric  flask  and  making  up  the  volume  to  the  25  mL 
mark  with  methanol.  A  combined  working  deuterated  standard  solution  of  the 
buprenorphine-d4  and  norbuprenorphine-d3  standards  was  also  prepared  at 
1  pg/mL  in  the  same  way  as  the  working  drug  solution. 
5.6.4  Extraction  Solutions  and  Mobile  Phase 
5.6.4.1  Preparation  of  1  M,  pH  5  Sodium  Acetate  Buffer 
42.9  g  of  sodium  acetate  trihydrate  and  10.4  mL  of  concentrated  (17  M)  glacial 
acetic  acid  was  dissolved  in  400  mL  of  deionised  water,  the  pH  was  adjusted  to 
5.0  with  1M  acetic  acid  and  the  solution  made  up  to  500  mL with  deionised 
water. 
5.6.4.2  Preparation  of  0.01  M,  pH  3.0  Acetic  Acid 
286  µL  of  concentrated  (17  M)  glacial  acetic  acid  was  placed  in  a  500  mL 
volumetric  flask  and  this  was  made  up  to  volume  with  deionised  water. 
5.6.4.3  Preparation  of  0.1  M,  pH  6.0  Phosphate  Buffer 
1.70  g  of  potassium  hydrogen  phosphate  and  12.14  g  of  potassium  dihydrogen 
phosphate  were  weighed  into  a1L  beaker.  800  mL  deionised  water  was  added Buprenorphine  in  Urine  Chapter  5,66 
and  the  solid  was  dissolved  by  stirring.  After  the  solid  had  dissolved,  the  pH  of 
the  solution  was  adjusted  to  6.0  using  IM  potassium  hydroxide  solution.  The 
solution  was  then  transferred  into  a1L  volumetric  flask  and  was  made  up  to  the 
1L  mark  with  deionised  water. 
5.6.4.4  Preparation  of  Mobile  Phase 
The  mobile  phase  consisted  of  a  mixture  of  aqueous  buffer  and  acetonitrile.  To 
prepare  the  3  mM  ammonium  formate  +  0.001  %  formic  acid  aqueous  buffer, 
0.189  g  of  ammonium  formate  and  10  µL  of  concentrated  formic  acid  were 
added  to  a1L  volumetric  flask  and  made  up  to  the  mark  with  deionised  water. 
5.6.5  Instrumentation 
ELISA  analysis  of  urine  samples  was  carried  out  using  a  MiniPrep  75  automatic 
pipettor  purchased  from  Tecan  (San  Jose,  CA).  The  microplate  wells  were 
washed  and  read  using  a  Columbus  Plus  washer  system  and  a  Sunrise  Remote  EIA 
autoreader  from  Tecan  (Grödlg,  Austria). 
LC-MS-MS  analysis  was  carried  out  using  a  Surveyor  HPLC  system  with  an  LCQ 
Advantage  ion  trap  mass  spectrometer  (Thermo  Finnigan,  San  Jose,  CA,  USA). 
Chromatographic  separation  was  performed  using  a  Gemini  Cis  column  (150  mm 
x  2.0  mm  ID,  5  µm  particle  size),  fitted  with  a  guard  column  with  identical 
packing  material  (4  mm  x  2.0  mm,  5  pm  particle  size)  (Phenomenex,  Torrance, 
.  CA,  USA). 
5.6.6  ELISA  and  LC-MS-MS  Methods 
5.6.6.1  ELISA 
Each  ELISA  run  contained  a  set  of  calibrators  consisting  of  a  blank  and  spiked 
urine  samples  at  a  concentration  of  0.5,1  and  5  ng/mL  buprenorphine  (cut-off 
value  0.5  ng/mL).  This  cut-off  value  was  also  used  in  another  ELISA  study  which 
screened  93  buprenorphine  positive  urine  samples  and  produced  no  FN  results 
when  compared  to  a  validated  LC-ESI-MS  method.  "' Buprenorphine  in  Urine  Chapter  5,67 
A  high  positive  control  (10  ng/mL)  and  a  negative  control  provided  with  the  kit 
were  used  to  check  kit  performance.  These  controls  were  distributed  to  wells  at 
the  beginning  and  end  of  the  plate  to  check  instrument  drift.  Each  calibrator, 
control  and  sample  was  vortex  mixed  after  10-fold  dilution  with  phosphate 
buffer.  The  on-line  dilution  was  achieved  by  adding  100  pL  of  urine  to  900  pL 
phosphate  buffer  saline  (pH  7.0). 
20  pL  of  diluted  calibrator,  control  or  sample  was  added  to  the  wells  in  duplicate 
followed  by  100  pL  of  enzyme  conjugate.  The  plate  was  then  left  in  the  dark  at 
room  temperature  for  an  incubation  period  of  1  hour.  After  incubation,  the 
wells  were  washed  6  times  with  deionised  water  in  order  to  remove  any  unbound 
sample  or  residual  enzyme  conjugate  which  may  be  left  in  the  wells.  100  pL  of 
TMB  substrate  reagent  was  then  added  and  the  plate  was  left  to  incubate  in  the 
dark  at  room  temperature  for  a  further  30  minutes.  After  30  minutes,  the 
catalytic  reaction  was  stopped  by  adding  100  pL  of  stop  reagent  (containing  1N 
hydrochloric  acid)  to  each  well.  The  contents  of  the  wells  turned  yellow 
following  addition  of  the  stop  reagent  to  enable  the  chromophore  to  be  detected 
at  450  nm.  A  reference  wavelength  of  620  nm  was  used.  The  absorbance 
readings  were  inversely  proportional  to  the  concentration  of  buprenorphine 
and/or  norbuprenorphine  present  in  the  sample. 
5.6.6.2  LC-MS-MS 
The  LC-MS-MS  method  was  an  in-house  method  that  had  already  been  developed 
and  validated  by  Dr  Hazel  Torrance  within  the  forensic  toxicology  laboratory  at 
the  University  of  Glasgow. 
5.6.6.2.1  Sample  Preparation 
The  calibration  graph  was  constructed  from  spiked  urine  samples  in  the 
concentration  range  5-200  ng/mL  for  buprenorphine  and  norbuprenorphine.  To 
achieve  this,  the  appropriate  amount  of  working  drug  solution  at  1  pg/mL  (5,10, 
25,50,100  and  200  pL)  was  added  to  1  mL  blank  urine.  100  ng  (100  NL)  of 
working  deuterated  standard  solution  at  I  pg/mL  was  also  added  to  each  test 
tube.  A  blank  urine  sample  was  prepared  without  any  drugs  or  deuterated 
standards,  as  well  as  another  blank  urine  sample  with  only  deuterated  standards 
to  assess  any  contamination  which  may  be  present.  1  mL  of  acetate  buffer Buprenorphine  in  Urine  Chapter  5,68 
(pH  5.0,1  M)  was  added  to  each  test  tube  along  with  40  pL  of  B-glucuronidase 
crude  solution  (helix  pomatia).  The  samples  were  placed  in  an  oven  for  3  hours 
at  60  °C  and  after  cooling,  3  mL  of  phosphate  buffer  (pH  6.0,0.1  M)  was  added 
to  each  sample,  followed  by  vortex  mixing.  The  pH  of  each  sample  was  adjusted 
to  pH  6.0  using  1M  potassium  hydroxide.  The  samples  were  then  centrifuged  at 
2500  rpm  for  10  minutes. 
5.6.6.2.2  Extraction  Procedure 
Bond  Elut  Certify®  LRC  cartridges  were  conditioned  with  2  mL  methanol, 
followed  by  2  mL  phosphate  buffer  (0.1  M,  pH  6.0).  The  samples  were  then 
applied  to  the  cartridges  and  allowed  to  drip  through  without  a  vacuum  to  allow 
maximum  time  for  analyte-sorbent  interactions.  The  cartridges  were  washed 
with  1  mL  deionised  water  followed  by  0.5  mL  acetic  acid  (0.01  M,  pH  3.3)  and 
dried  under  full  vacuum  for  10  minutes.  50  pL  of  methanol  was  added  to  each 
cartridge  and  the  cartridges  dried  under  full  vacuum  for  2  minutes.  4  mL 
acetone/dichloromethane  (1:  1  v/v)  was  then  added  to  further  wash  the 
cartridges.  The  basic  analytes  were  eluted  with  2x1.5  mL  ethyl  acetate  with  2 
%  ammonia.  The  extracts  were  blown  down  under  nitrogen  at  30  °C  and 
reconstituted  in  80  pL  mobile  phase  (initial  conditions  3  mM  ammonium  formate 
+  0.001  %  formic  acid:  acetonitrile  (75:  25  v/v)). 
5.6.6.2.3  Analysis 
The  column  temperature  was  maintained  at  35  °C.  LC  was  carried  out  using  a 
mixture  of  3  mM  ammonium  formate  +  0.001%  formic  acid  in  water  (solvent  A) 
and  acetonitrile  (solvent  B)  at  a  flow  rate  of  0.3  mL/min.  The  gradient  elution 
programme  was  75  %-20  %  solvent  A  within  15  minutes.  The  %  of  solvent  A  was 
decreased  to  10  %  between  15-17  minutes  and  was  held  at  10  %  solvent  A  for  17- 
22  minutes.  After  this  time,  initial  mobile  phase  conditions  were  restored  for  5 
minutes.  A  divert  valve  taking  LC  flow  to  waste  was  used  for  the  first  3  minutes 
and  for  the  last  7  minutes  of  the  programme  in  order  to  preserve  the  MS  source. 
All  MS  data  was  collected  in  electrospray  positive  ion  mode.  The  capillary 
temperature,  sheath  and  auxiliary  gas  flow  rates  and  collision  energies  were 
optimised  for  each  analyte.  The  following  settings  were  applied  throughout  the 
analysis:  capillary  temperature  280  °C;  sheath  and  auxiliary  gas  flow  rates  were 
set  to  20  and  15  units  on  the  data  system  arbitrary  scale  and  collision  energies Buprenorphine  in  Urine  Chapter  5,69 
were  36  %  for  buprenorphine  and  32  %  for  norbuprenorphine.  The  probe  voltage 
used  was  4.5  W.  Internal  standard  data  was  collected  in  selected  ion 
monitoring  (SIM)  mode  and  anaLytes  were  identified  on  the  basis  of  their  full 
MS-MS  spectra.  Buprenorphine  produced  a  pseudo-molecular  ion  of  m/z  468, 
with  a  major  product  ion  of  m/z  414  while  norbuprenorphine  produced  a  pseudo- 
molecular  ion  of  m/z  414,  with  a  major  daughter  ion  of  m/z  396.  Quantification 
was  carried  out  using  the  major  product  ion  to  deuterated  drug  standard  ratio. 
5.7  ELISA  Method  Validation 
In  the  method  validation,  all  spiked  samples  were  analysed  according  to  the 
ELISA  procedure  described  in  section  5.6.6.1. 
5.7.1  Dose  Response  Curve 
A  dose  response  curve  was  produced  over  the  concentration  range  0.5  ng/mL- 
100  ng/mL  buprenorphine.  This  was  achieved  by  spiking  1  mL  blank  urine  with 
the  appropriate  volume  of  buprenorphine  solution  at  0.1  pg/mL  (5,10,100  pL) 
for  the  lower  concentrations  and  1  pg/mL  (25,50,100  NL)  for  the  higher 
concentrations.  The  spiked  urine  standards  were  0.5,1,10,25,50  and 
100  ng/mL  buprenorphine. 
5.7.2  LOD  and  Assay  Precision 
The  LOD  was  calculated  from  the  mean  B/Bo  (%)  value  (A0)  and  standard 
deviation  (s)  of  the  B/Bo  (%)  values  for  48  confirmed  negative  post-mortem  urine 
samples.  "'  The  use  of  post-mortem  urine  negatives  in  the  determination  of  the 
assay  LOD  is  more  accurate  than  using  blank  urine  collected  from  a  living 
individual.  The  possible  presence  of  interfering  compounds  in  post-mortem 
urine  may  affect  the  assay  LOD.  Spiked  urine  standards  were  prepared  at  low 
concentrations  (0.25,0.5  and  1  ng/mL  buprenorphine)  and  the  B/Bo  (%)  value 
calculated  for  the  LOD  was  matched  to  the  B/Bo  (%)  value  of  the  spiked 
calibrator  to  determine  the  LOD  in  ng/mL. 
Equation  5-1:  LOD  =  AO  -3s Buprenorphine  in  Urine  Chapter  5,70 
Assay  precision  was  tested  at  the  cut-off  value  of  0.5  ng/mL  buprenorphine.  To 
achieve  this  concentration,  5  pL  of  0.1  pg/mL  buprenorphine  solution  was  added 
to  1  mL  blank  urine. 
Within-sample  precision  (n=10)  was  calculated  from  10  readings  of  the  same 
spiked  urine  sample.  Intra-day  precision  (n=20)  of  the  absorbance  readings  was 
calculated  from  duplicate  readings  of  10  spiked  urine  samples.  The  intra-day 
precision  experiment  was  carried  out  on  five  separate  days  to  calculate  the 
inter-day  precision  (n=100). 
5.7.3  Cross  Reactivity 
A  buprenorphine  and  norbuprenorphine  dose  response  graph  was  produced  to 
calculate  norbuprenorphine  cross  reactivity.  The  buprenorphine  dose  response 
curve  consisted  of  4  spiked  urine  samples  at  0.5,1,5  and  10  ng/mL 
buprenorphine.  This  was  achieved  by  spiking  I  mL  blank  urine  with  5,10,50  and 
100  pL  of  0.1  pg/mL  buprenorphine  solution.  The  norbuprenorphine  dose 
response  graph  consisted  of  3  spiked  urine  samples  at  1,5  and  10  ng/mL 
norbuprenorphine.  This  was  achieved  by  spiking  1  mL  blank  urine  with  10,50 
and  100  pL  of  0.1  pg/mL  norbuprenorphine  solution. 
Graphs  of  B/Bo  (%)  vs  Concentration  (ng/mL)  were  plotted  manually  on  log-log 
graph  paper.  The  best  fit  line  was  drawn  through  the  points  for  the 
buprenorphine  and  norbuprenorphine  graphs.  The  concentration  of 
buprenorphine  producing  the  same  B/Bo  (%)  value  as  1  ng/mL  and  10  ng/mL 
norbuprenorphine  was  identified  from  reading  off  the  graphs.  Cross  reactivity 
was  then  calculated  by  dividing  this  buprenorphine  concentration  by  the 
norbuprenorphine  concentration  and  multiplying  by  100  to  express  as  a 
percentage.  Cross  reactivity  was  calculated  at  1  ng/mL  and  10  ng/mL 
norbuprenorphine  for  comparison  with  the  manufacturer's  results  which  were 
provided  at  these  concentrations. Buprenorphine  in  Urine  Chapter  5,71 
5.8  ELISA  Results  and  Discussion 
5.8.1  Dose  Response  Curve 
A  dose  response  curve  was  generated  for  blank  urine  spiked  at  buprenorphine 
concentrations  of  0.5,1,10,25,50  and  100  ng/mL  (Figure  5-2).  The  B/Bo  (%) 
values  were  calculated  where  B  is  the  absorbance  value  of  the  bound  calibrator 
and  Bo  is  the  absorbance  value  of  the  blank  calibrator.  The  results  were 
obtained  in  duplicate  and  an  average  B/Bo  (%)  value  was  calculated.  The  optical 
density  values  showed  a  hyperbolic  decrease  with  increasing  buprenorphine 
concentration.  This  is  because  at  higher  concentrations,  more  buprenorphine  is 
bound  to  the  antibody  sites  compared  to  enzyme  conjugate,  producing  lower 
optical  density  values. 
Figure  5-2  Buprenorphine  dose  response  curve  (linear  scale) 
The  same  set  of  data  is  shown  in  Figure  5-3  only  plotted  on  log  scale  for  both 
axes.  The  graph  is  an  S-shaped  ligand  reaction  curve.  200  As  seen  from  this 
graph,  the  immunoassay  has  a  short  linearity  range  and  low  precision  at  both 
ends  of  the  range.  Usually  a  cut-off  value  is  chosen  in  the  linear  range,  which 
would  be  10-50  ng/mL  in  this  graph.  This  is  the  optimum  region  for 
discriminating  between  true  positive  (TP)  and  true  negative  (TN)  samples. 
However  a  cut-off  <  10  ng/mL  is  required  for  buprenorphine  screening  due  to  its 
potentially  low  levels  and  therefore  0.5  ng/mL  was  chosen  as  the  cut-off  value. Chapter  5,72 
Figure  5-3  Buprenorphine  dose  response  curve  (log-log  scale) 
5.8.2  LOD  and  Assay  Precision 
The  LOD  was  calculated  as  0.5  ng/mL  buprenorphine  using  Equation  5-1. 
Within-sample  precision  (n=10)  was  calculated  as  5.3  %  from  10  readings  of  the 
same  spiked  urine  sample.  Intra-day  precision  (n=20)  of  the  absorbance  readings 
was  calculated  as  6.4  %  from  duplicate  readings  of  10  spiked  urine  samples.  The 
intra-day  precision  experiment  was  carried  out  on  five  separate  days  to 
calculate  the  inter-day  precision  (n=100)  of  12.9  %. 
5.8.3  Cross  Reactivity 
A  high  degree  of  cross  reactivity  was  observed  for  norbuprenorphine  at  low  and 
high  concentrations,  although  this  was  greater  at  the  higher  concentration.  The 
results  were  comparable  to  the  manufacturer's  values  (Table  5-2).  As 
mentioned  previously  in  section  5.4,  this  high  degree  of  norbuprenorphine  cross 
reactivity  is  advantageous  in  an  ELISA  screening  assay  as  norbuprenorphine 
concentrations  detected  in  urine  are  generally  higher  than  buprenorphine 
concentrations. 
Buprenorphine  in  Urine Buprenorphine  in  Urine 
Table  5-2  Cross  reactivity  of  buprenorphine  ELISA 
Chapter  5,73 
Analyte  Concentration  %  Cross  Reactivity  %  Cross  Reactivity 
Quoted  by  (ng/mL)  Found  Manufacturer 
1  78  80 
Norbuprenorphine 
10  116  120 
A  high  concentration  of  dihydrocodeine,  codeine,  morphine,  propoxyphene, 
tramadol,  methadone  and  EDDP  (10,000  ng/mL)  did  not  cross  react  with  the 
assay.  This  concentration  was  also  tested  by  the  kit  manufacturers.  The 
average  absorbance  values  observed  for  these  drugs  are  given  in  Table  5-3. 
None  of  these  were  equal  to  or  less  than  the  average  absorbance  value  of  1.58 
observed  for  the  assay  sensitivity  level  of  0.5  ng/mL  buprenorphine.  Although 
the  average  values  are  relatively  close  to  the  average  value  for  the  cut-off,  the 
concentration  of  drugs  tested  would  not  usually  be  as  high  in  actual  case 
samples. 
Table  5-3  Absorbance  values  for  opiate  drugs  at  10,000  ng/mL 
Analyte  Absorbance  Value  (n=2) 
Dihydrocodeine  1.67 
Codeine  1.75 
Morphine  1.66 
6-MAM  1.67 
Propoxyphene  1.71 
Tramadol  1.74 
Methadone  1.63 
EDDP  1.76 Buprenorphine  in  Urine 
5.8.4  Sensitivity  and  Specificity 
Chapter  5,74 
The  number  of  true  positive  (TP),  true  negative  (TN),  false  positive  (FP)  and 
false  negative  (FN)  results  are  usually  tallied  and  applied  to  Equation  5-2  and 
Equation  5-3  to  determine  the  sensitivity  and  specificity  of  an  analytical  system. 
A  TP  result  is  defined  as  one  where  both  the  screening  and  confirmation  result 
are  positive.  Conversely,  a  TN  result  is  one  in  which  the  screening  and 
confirmation  result  are  both  negative.  The  greatest  number  of  TP  and  TN  results 
can  be  obtained  by  choosing  the  optimum  cut-off  concentration  for  a  particular 
system.  Although  there  were  no  FP  or  FN  results  found  in  this  particular  study,  a 
FP  result  is  one  in  which  screening  is  positive  and  confirmation  negative  and  a 
FN  is  where  screening  is  negative  and  confirmation  is  positive.  It  is  essential 
that  cut-off  levels  are  low  enough  to  eliminate  FN  screening  results. 
Furthermore,  this  is  more  important  than  the  elimination  of  FP  screening  results. 
Equation  5-2  Sensitivity  =  (TP  x  100  /(TP  +  FN) 
Equation  5-3  Specificity  =  (TN  x  100)/(TN  +  FP) 
Of  the  69  urine  samples  screened  as  part  of  this  study,  there  were  21  TP  and  48 
TN  results.  Therefore  the  sensitivity  and  specificity  of  the  ELISA  system  as 
calculated  using  Equation  5-2  and  Equation  5-3  were  both  100  %  using  a  cut-off 
value  of  0.5  ng/mL  buprenorphine.  This  cut-off  value  was  recommended  by  the 
manufacturers  and  was  found  in  this  study  to  be  the  optimum  concentration  for 
achieving  the  highest  number  of  TP  and  TN  results  compared  to  higher  cut-off 
concentrations. 
In  a  review  on  hair  analysis  by  immunological  methods  up  until  the  year  2000,  it 
was  recommended  that  the  cut-off  is  not  set  at  the  limit  of  detection  due  to  the 
very  large  incidence  of  false  positive  results.  20°  It  was  also  pointed  out  that  the 
precision  at  both  ends  of  the  dose  response  curve  is  low  due  to  the  S-shaped 
graph.  In  this  study  the  assay  sensitivity  level  of  0.5  ng/mL  buprenorphine  was 
selected  as  the  cut-off  as  it  produced  100  %  TP  and  TN  results,  it  was 
recommended  as  the  cut-off  by  the  manufacturer  and  the  precision  of  the 
system  was  well  within  the  published  acceptance  criteria  of  10  %  for  intra-day 
precision  and  20  %  for  inter-day  precision.  201 Buprenorphine  in  Urine 
5.8.5  Case  Samples 
Chapter  5,75 
The  ELISA  and  LC-MS-MS  results  for  the  case  samples  are  provided  in  Table  5-4. 
5.8.5.1  ELISA 
14  out  of  21  samples  screened  as  positive  at  levels  greater  than  the  highest 
calibrator  (>  5  ng/mL  buprenorphine).  However  the  ELISA  concentration 
detected  in  5  out  of  21  samples  were  in  the  range  0.61-0.93  ng/mL 
buprenorphine  equivalents.  These  samples  contained  low  levels  of 
buprenorphine  in  some  cases  levels  <  LOQ  of  the  LC-MS-MS  method  and  did  not 
contain  norbuprenorphine.  This  finding  supports  the  use  of  a  low  cut-off  level  of 
0.5  ng/mL  buprenorphine  as  the  samples  would  have  screened  as  negative  at 
higher  cut-off  levels. 
The  buprenorphine  equivalent  concentrations  obtained  by  the  ELISA  test  for 
samples  5,7,17  and  18  were  lower  than  those  obtained  by  LC-MS-MS.  Apart 
from  ELISA  being  a  semi-quantitative  test,  a  possible  reason  for  this  could  be 
that  the  ELISA  kit  does  not  cross-react  with  buprenorphine  and  norbuprenorphine 
glucuronide  conjugates  which  may  have  been  present  in  these  particular  urine 
samples.  The  ELISA  extraction,  unlike  the  LC-MS-MS  extraction  did  not  involve  a 
hydrolysis  step  in  order  to  reduce  the  time  required  for  sample  preparation  prior 
to  screening. 
5.8.5.2  LC-MS-MS 
Buprenorphine  and  norbuprenorphine  concentrations  in  the  urine  case  samples, 
as  determined  by  LC-MS-MS,  ranged  from  1-  1931  ng/mL  and  7-  7550  ng/mL 
respectively.  Most  concentrations  detected  were  in  the  ranges  reported  in  the 
literature.  "'''"  However  the  concentrations  determined  for  sample  20  are  higher 
than  reported  concentrations.  This  sample  was  collected  from  a  patient  on  a 
Subutex®  treatment  programme. 
Buprenorphine  concentrations  in  samples  2,6,9  and  11  could  not  be  quantified 
by  LC-MS-MS.  The  LC-MS-MS  concentrations  found  for  these  samples  were  higher 
than  the  LOD  (0.4  ng/mL)  but  lower  than  the  LOQ  (1.3  ng/mL).  As 
buprenorphine  was  detected  in  these  samples,  they  were  counted  as  TPs. Buprenorphine  in  Urine 
5.8.5.3  ELISA  vs  LC-MS-MS 
Chapter  5,76 
The  excellent  qualitative  agreement  between  the  ELISA  and  LC-MS-MS  results  is 
demonstrated  in  Table  5-4.  As  mentioned  in  section  5.8.4,  the  sensitivity  and 
specificity  of  the  ELISA  kit  tested  in  this  study  were  both  found  to  be  100  %. 
Another  study  which  tested  138  urine  samples  using  the  same  cut-off  value  but  a 
different  ELISA  kit  (One  Step")  to  the  one  used  in  this  work  detected  26.5  %  FP 
results.  "'  The  One  StepTM'  ELISA  kit  demonstrated  a  low  cross  reactivity  (<  1  %) 
with  norbuprenorphine  at  50  ng/mL  buprenorphine.  This  cannot  be  compared 
directly  to  the  cross  reactivity  observed  with  the  Immunalysis®  kit  tested  in  this 
study  as  the  cross  reactivity  varies  with  concentration.  No  cross  reactivity  was 
observed  with  the  drugs  shown  in  Table  5-3  using  this  kit. 
5.9  Conclusion 
The  Buprenorphine  Direct  ELISA  kit  from  Immunalysis®  is  a  highly  sensitive  and 
specific  screening  procedure  for  detecting  buprenorphine  in  urine  using  a  cut-off 
value  of  0.5  ng/mL  buprenorphine.  The  method  has  been  validated  and  applied 
successfully  in  the  semi-quantitative  analysis  of  21  TP  case  samples.  The  assay 
is  capable  of  detecting  buprenorphine  concentrations  in  both  therapeutic  and 
abuse  situations.  The  assay  also  demonstrated  a  high  degree  of  cross  reactivity 
with  norbuprenorphine  which  is  advantageous  as  it  is  usually  present  at  higher 
levels  than  buprenorphine. Buprenorphine  in  Urine 
Table  5-4  ELISA  vs  LC-MS-MS  results  for  positive  buprenorphine  case  samples 
Chapter  5,77 
ELISA  LC-MS-MS 
Sample 
Number 
BUP  Equivalents 
(ng/mL) 
BUP  (ng/mL)  NBUP  (ng/mL)  Source 
1  >5  40  48  Routine 
2  >5  <  LOQ  7  Routine 
3  >5  12  125  Routine 
4  >5  8  34  Routine 
5  2.50  1  22  Routine 
6  0.61  <  LOQ  NEG  Routine 
7  0.93  8  NEG  Routine 
8  >5  31  131  Routine 
9  0.63  <LOQ  NEG  Routine 
10  >5  12  NEG  Routine 
11  0.77  <LOQ  NEG  Routine 
12  >5  179  97  Routine 
13  >5  246  2288  Crisis 
Centre 
14  >5  130  1001 
Crisis 
Centre 
15  >5  146  2195 
Crisis 
Centre 
16  >5  123  1835  Crisis 
Centre 
17  0.63  6  NEG  Routine 
18  2.15  21  82  Routine 
19  >5  531  5730 
Crisis 
Centre 
20  >5  1931  7550  Crisis 
Centre 
21  >5  167  2255 
Crisis 
Centre 
"BUP"=Buprenorphine,  "NBUP"=Norbuprenorpmne,  "*Nt(i-=Negative 78 
6  Drugs  of  Abuse  in  Hair  by  ELISA 
6.1  Introduction 
Historically  radioimmunoassay  (RIA)  was  used  for  screening  drugs  of  abuse  in 
hair.  The  first  report  was  the  detection  of  opiates  in  197910  and  since  this  initial 
study,  there  has  been  many  more  publications  in  this  area.  61'197'198'199  In  the  last 
decade,  several  groups  have  used  RIA  to  detect  opiates  and  cocaine  in  hair  for 
the  purposes  of  proving  the  illegal  consumption  of  heroin  and  cocaine.  "',  ", 
Another  more  recent  publication  used  RIA  to  screen  for  amphetamines  in  the 
hair  of  known  users  and  workplace  subjects.  '  Benzodiazepine  detection  in  hair 
by  RIA  has  also  been  reported.  "'  Although  RIA  is  a  sensitive  and  robust  method, 
the  use  of  radioactive  materials  has  imposed  strict  safety  regulations  and  has 
limited  its  application  out  with  safe  areas.  It  is  therefore  only  cost  effective 
when  used  for  a  large  number  of  samples.  For  these  reasons,  there  is  currently 
an  increasing  trend  towards  non-radioactive  alternatives  such  as  ELISA. 
ELISA  is  now  being  routinely  applied  as  a  screening  method  for  the  detection  of 
drugs  of  abuse  in  hair81'105'106'107'108,109,110,179,203  as  it  is  safe,  simple,  highly  sensitive, 
uses  relatively  small  sample  sizes  and  can  be  automated.  Other  immunoassay 
systems  including  enzyme  multiplied  immunoassay  technique  (EMIT)204,205  and 
fluorescence  polarisation  immunoassays  (FPIA)205,206  have  also  been  used  for  this 
purpose.  One  group  developed  an  LC-MS-MS  screening  method  for  drugs  of  abuse 
as  an  alternative  to  immunoassay  before  confirming  any  positive  screens  with 
GC-MS.  94 
ELISA  kits  have  been  specifically  designed  for  detecting  drugs  of  abuse  in  hair. 
As  mentioned  previously,  conventional  urinary  immunoassays  are  targeted 
towards  the  detection  of  hydrophilic  metabolites  whereas  it  is  usually  the  parent 
drug  which  is  found  in  higher  concentrations  in  hair.  A  hair  immunoassay  test 
should  have  a  sensitivity  and  specificity  greater  than  90  %  at  the  selected  cut- 
off.  195  Some  urinary  ELISA  kits,  when  applied  for  the  purposes  of  hair  testing, 
have  been  shown  to  lack  the  required  specificity.  ",  "'  This  is  in  contrast  to  other 
reports  which  found  excellent  ELISA  sensitivity  and  specificity  of  greater  than 
90  %.  107009 Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,79 
There  are  three  main  requirements  for  immunoassays  used  for  hair  testing:  they 
cross  react  with  the  drugs  actually  present  in  hair;  they  are  not  affected  by 
sample  matrix  interference;  and  they  must  be  capable  of  detecting  the  drug 
concentrations  in  hair.  200 
ELISA  kits  for  hair  usually  demonstrate  cross  reactivity  with  the  parent  drug  and 
lipophilic  metabolites  actually  found  in  hair.  A  comparison  of  EIA  and  FPIA  for 
the  detection  of  cocaine  in  hair  found  that  EIA  was  more  sensitive,  specific  and 
efficient.  "'  The  authors  proposed  that  the  differences  in  results  were  due  to  the 
cross  reactivity  towards  the  parent  drug,  cocaine.  The  EIA  kit  was  designed  for 
oral  fluid  testing  and  had  a  high  cross  reactivity  with  cocaine  of  100  %,  while  the 
FPIA  was  designed  for  urinary  analysis  and  had  a  very  low  cocaine  cross 
reactivity  of  1  %.  Only  kits  with  relatively  high  cross  reactivity  with  the  parent 
drug  should  be  validated  for  hair  screening.  However  the  exception  is  the  ELISA 
screening  test  for  cannabis  in  hair.  This  kit  cross  reacts  100  %  with  the 
11-nor-delta(9)-tetrahydrocannabinolcarboxylic  acid  (09THC-COOH)  metabolite 
instead  of  the  delta  (9)-tetrahydrocannibinol  (19THC)  parent  drug  to  avoid 
screening  false  positive  hair  samples  that  have  been  contaminated  through 
exposure  to  cannabis  smoke. 
ELISA  demonstrates  minimal  matrix  interference  because  of  the  wash  step  after 
the  competitive  incubation.  This  removes  the  sample  matrix  and  any  unbound 
label  before  the  addition  of  the  substrate  and  subsequent  colour  development. 
The  use  of  an  enzyme  label  amplifies  the  signal  during  catalysis  and  this  reduces 
the  limits  of  detection  to  the  extremely  low  levels  (pg/mg  range)  required  for 
hair  testing.  The  sensitivity  required  for  the  immunoassay  screening  test  for 
opiates,  cocaine  and  amphetamines  has  been  stipulated  in  the  most  recent 
publication  by  the  SoHT.  10°  The  following  cut-off  concentrations  must  result  in  a 
positive  screening  result:  0.2  ng/mg  morphine  or  6-MAM;  0.5  ng/mg  cocaine; 
0.2  ng/mg  MDMA,  MDEA,  MDA,  methamphetamine  or  amphetamine;  and 
0.1  ng/mg  THC. 
6.2  Alm 
The  aim  of  this  to  study  was  to  validate  an  ELISA  method  for  the  detection  of 
drugs  of  abuse  in  hair  and  apply  it  in  the  analysis  of  case  samples. Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,80 
6.3  Experimental 
6.3.1  Samples 
The  post-mortem  scalp  hair  samples  screened  for  amphetamine, 
benzodiazepines,  cocaine,  opiates  and  methadone  were  routine  samples 
submitted  to  the  laboratory  at  the  University  of  Glasgow.  They  were  tested  for 
diagnostic  purposes  and  the  results  were  reported  to  the  Procurator  Fiscal. 
The  hair  samples  screened  for  methamphetamine  as  part  of  a  collaboration  with 
the  National  Institute  of  Scientific  Investigation  in  Seoul,  South  Korea  were 
routine  samples  submitted  to  the  Korean  lab  which  had  been  collected  from 
living  individuals  suspected  of  drug  abuse. 
6.3.2  Chemicals 
Amphetamine  (AMP),  benzodiazepine,  cocaine,  methamphetamine  (MAMP)  and 
opiate  direct  ELISA  kits  were  obtained  from  the  Immunalysis  Corporation 
(Pomona,  CA,  USA).  The  kits  contained  a  96-well  antibody-coated  microplate, 
enzyme  conjugate  labelled  with  horseradish  peroxidase  (HRP),  substrate  solution 
containing  3,3',  5,5'-tetramethylbenzidine  (TMB)  and  hydrogen  peroxide  and  stop 
solution  containing  1N  hydrochloric  acid.  Hair  extraction  buffer  (0.025  M 
mondbasic  phosphate  buffer  pH  2.7),  neutralising  buffer  (0.5  M  dibasic 
phosphate  buffer  pH  9.0)  and  phosphate  buffer  saline  (0.1  M,  pH  7.0)  used  to 
dilute  hair  extracts  in  the  ELISA  test  were  also  obtained  from  the  Immunalysis 
Corporation.  Disposable  borosilicate  glass  culture  tubes  (75  x  12  mm)  were 
obtained  from  VWR  International,  UK.  The  drug  standards  used  to  assess  kit 
cross  reactivity  were  purchased  from  LGC  Promochem  (Teddington,  UK). 
6.3.3  Instrumentation 
A  Mint  Prep  75  automatic  pipettor  from  Tecan  (San  Jose,  CA)  was  used.  The 
microplate  wells  were  washed  and  read  using  a  Columbus  Plus  washer  system 
and  a  Sunrise  Remote  EIA  autoreader  also  from  Tecan  (Grödlg,  Austria). Drugs  of  abuse  in  Hair  by  ELISA 
6.4  ELISA  Method 
Chapter  6,81 
The  post-mortem  hair  samples  were  firstly  analysed  by  LC-MS-MS  as  described  in 
chapters  7  and  8.  Only  samples  which  had  a  sufficient  amount  of  sample  left 
were  analysed  by  ELISA. 
6.4.1  Sample  Preparation 
The  root-0.5  cm  segment  was  removed  from  each  hair  sample  and  the  remaining 
hair  segmented  depending  on  the  length.  The  decontamination  procedure  used 
was  the  same  as  the  LC-MS-MS  procedure  for  the  purposes  of  method 
comparison.  Each  section  was  washed  once  with  0.1  %  sodium  dodecyl  sulfate 
with  a  10  minute  ultrasonication,  twice  with  deionised  water  with  a  10  minute 
uttrasonication  and  twice  with  dichloromethane  with  a  10  minute 
ultrasonication.  Dichloromethane  was  chosen  for  the  organic  washes  since  it 
was  demonstrated  that  no  more  than  10  %  of  cocaine,  opiates  and 
benzodiazepines  were  extracted  when  dichloromethane  was  used  to  wash  real 
hair  samples.  "'  It  was  not  however  known  if  the  drugs  detected  in  the 
dichloromethane  washes  were  incorporated  through  use  or  passive  exposure. 
After  decontamination,  the  hair  segments  were  cut  into  smaller  segments  of  2-3 
mm  in  length  using  a  pair  of  clean  scissors.  A  previously  published  aqueous 
extraction  method  was  used  which  had  been  applied  in  the  ELISA  screening  of 
cocaine  and  amphetamine  in  hair.  108,119  Spiked  hair  calibrators  were  prepared  for 
each  assay  at  the  cut-off  value,  2x  cut-off  value  and  5x  cut-off  value  by  adding 
the  appropriate  concentration  of  target  drug  to  10  mg  blank  decontaminated 
hair.  The  concentrations  used  for  the  calibrators  are  given  in  Table  6-1.  A  blank 
calibrator  was  also  prepared.  Negative  and  positive  spiked  controls  were 
prepared  in-house  and  these  were  distributed  across  the  plate  to  ensure 
consistent  system  performance. 
The  cut-off  values  used  for  cocaine  and  opiates  were  recommended  by  the 
Society  of  Hair  Testing  (SoHT)  and  SAMHSA.  10°'101  The  cut-off  values  used  for  the 
amphetamines  was  the  GC-MS  cut-off  used  by  the  toxicology  laboratory  in  Seoul" 
and  had  to  be  the  same  for  the  purposes  of  comparing  the  ELISA  and  GC-MS 
methods  as  discussed  in  section  6.6.4.4.  The  same  screening  cut-off  was Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,82 
proposed  for  amphetamines  by  SAMHSA.  101  ELISA  cut-off  values  have  not  yet 
been  recommended  for  methadone  or  benzodiazepine  screening  in  hair  by  the 
SoHT  or  SAMHSA. 
The  methadone  cut-off  selected  was  therefore  the  same  as  the  opiates 
(0.2  ng/mg).  This  concentration  produced  a  B/Bo  (%)  value  just  above  70  %  but 
was  still  in  the  linear  portion  of  the  dose  response  curve.  The  benzodiazepine 
cut-off  was  0.1  ng/mg  as  this  concentration  produced  the  optimum  sensitivity 
and  specificity  for  13  positive  hair  samples  compared  with  a  validated  LC-MS-MS 
reference  method  as  discussed  later  in  section  7.6.4.11' 
Table  6-1  ELISA  cut-off  values 
ELISA  kit  Cut-off  (ng/mg) 
2x  Cut-off 
(ng/mg) 
5x  Cut-off 
(ng/mg) 
Amphetamines  0.5  1  2.5 
Benzodiazepines  0.1  0.2  0.5 
Cocaine  0.5  1  2.5 
Methamphetamine  0.5  1  2.5 
Methadone  0.2  0.4  1.0 
Opiates  0.2  0.4  1.0 
0.5  mL  of  monobasic  phosphate  buffer  was  added  to  each  sample,  calibrator  and 
control  then  the  vials  were  capped  and  incubated  at  60  °C  for  1  hour  in  an  oven. 
After  cooling,  50  pL  of  dibasic  phosphate  buffer  was  added  to  neutralise  the 
acidic  buffer  and  the  extracts  were  transferred  to  labelled  EIA  glass  culture 
tubes.  ALL  extracts  were  then  diluted  1:  5  on-Line  by  adding  800  pL  phosphate 
buffer  saline  to  200  pL  hair  extract.  The  diluted  extracts  were  then  vortex 
mixed. 
6.4.2  ELISA  Assay 
An  aliquot  of  the  diluted  extract  was  added  to  the  individual  micro-plate  well 
coated  with  the  target  drug  specific  antibody,  depending  on  the  ELISA  kit  used. 
The  aliquot  volume  used  was  dependent  on  the  ELISA  test  for  a  particular  drug 
class  and  the  sensitivity  required.  The  sample  volumes  used  for  each  drug  class 
(Table  6-2)  gave  good  separation  of  absorbance  values  between  the  blank 
calibrator  and  the  spiked  cut-off  calibrator. Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,83 
After  adding  the  aliquots  of  diluted  extract,  100  pL  of  HRP  enzyme  labelled 
target  drug  derivative  (specific  to  the  ELISA  test)  was  added  to  each  well.  After 
a1  hour  incubation  period  at  room  temperature,  the  micro-plate  wells  were 
washed  6  times  with  deionised  water  (6  x  300  pL).  100  pL  TMB  was  added  to 
each  well  and  the  plate  incubated  in  the  dark  at  room  temperature  for  a  further 
30  minutes.  The  reaction  was  stopped  using  100  pL  1N  hydrochloric  acid  and 
the  plate  read  at  450  nm  with  a  reference  wavelength  of  650  nm.  The  case 
samples  were  considered  to  be  presumptively  positive  if  the  B/Bo  (%)  value  was 
lower  than  the  B/Bo  (%)  value  of  the  cut-off  calibrator. 
Table  6-2  Aliquot  volumes  used  in  each  ELISA  test 
ELISA  Test  Aliquot  volume  (NL) 
AMP  25 
Benzodiazepines  50 
Cocaine  20 
Methadone  50 
MAMP  25 
Opiates  25 
6.5  ELISA  Method  Validation 
6.5.1  Dose  Response  Graph 
Dose  response  curves  were  generated  for  all  drugs  of  abuse  assays  over  the 
concentration  range  0.05-5  ng/mg  target  drug  (dependent  on  the  assay).  The 
target  drug  demonstrated  100  %  cross  reactivity  with  a  particular  assay  according 
to  the  ELISA  kit  manufacturers  and  these  are  named  in  Table  6-3  for  each  kit.  A 
blank  was  also  prepared  as  a  reference  for  calculating  the  B/Bo  (%)  values.  The 
B/Bo  (%)  values  were  calculated  where  Bo  is  the  absorbance  value  of  the  blank 
calibrator  and  B  is  the  absorbance  value  of  the  bound  calibrator.  Although  the 
methadone  assay  cross  reacts  100  %  with  I-methadone,  d,  1-methadone  was  used 
to  spike  calibrators  since  methadone  is  usually  consumed  in  the  racemic  form. 
As  discussed  in  section  6.6.2,  an  acceptable  sensitivity  level  was  achieved  using 
d,  (-methadone. 
The  curves  were  generated  by  spiking  10  mg  of  blank  decontaminated  hair  with 
the  appropriate  volume  of  target  drug  solution  at  0.1  lag/mL  (5,10,25,50  pL) 
for  the  lower  concentrations  and  1  pg/mL  (10,25,50  NL)  for  the  higher Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,84 
concentrations.  The  spiked  hair  standards  were  0.05,0.1,0.25,0.5,1.0,2.5 
and  5.0  ng/mg  target  drug. 
Table  6-3  Target  drugs  for  particular  ELISA  kits 
ELISA  kit  Target  drug 
AMP  d-Amphetamine 
Benzodiazepine  Oxazepam 
Cocaine  Cocaine 
Methadone  l-Methadone 
MAMP  d-Methamphetamine 
Opiate  Morphine 
6.5.2  LOD  and  Assay  Precision 
The  LOD  was  calculated  from  the  mean  B/Bo  (%)  value  (Ao)  and  standard 
deviation(s)  of  the  B/Bo  (%)  values  for  10  x  10  mg  confirmed  negative  hair 
samples.  This  has  been  recommended  as  the  minimum  number  of  blank  wells 
that  should  be  run  when  estimating  the  LOD.  102  10  mg  spiked  blank  hair  samples 
were  prepared  at  low  concentrations  (0.025,0.05,0.075  and  0.1  ng/mg  target 
drug)  and  the  B/Bo  (%)  value  calculated  for  the  LOD  for  each  assay  was  matched 
with  the  B/Bo  (%)  value  of  the  spiked  calibrator  to  determine  the  LOD  in  ng/mg. 
The  precision  was  tested  at'  x  cut-off,  the  cut-off  and  2x  cut-off  as  the  SOFT 
guidelines  state  that  the  precision  of  a  screening  assay  must  be  demonstrated  at 
and  around  the  cut-off  value.  "  The  cut-off  concentrations  are  provided  in  Table 
6-1.  Within-sample  precision  (n=10)  was  calculated  from  10  B/Bo  (%)  readings  of 
the  same  spiked  hair  sample.  Intra-day  precision  (n=20)  of  the  B/Bo  (%)  was 
calculated  from  duplicate  readings  of  10  spiked  hair  samples.  The  intra-day 
precision  experiment  was  carried  out  on  five  separate  days  to  calculate  the 
inter-day  precision  (n=100). Drugs  of  abuse  in  Hair  by  ELISA 
6.5.3  Cross  Reactivity 
Chapter  6,85 
The  cross-reactivity  of  the  ELISA  kits  was  tested  and  the  results  compared  with 
those  provided  by  the  manufacturers.  The  drugs  tested  were  considered 
analogues  of  the  target  drug  and  were  included  in  the  validated  LC-MS-MS 
method  described  in  chapter  8.  Other  common  drugs  of  abuse  with  no  obvious 
structural  similarity  to  the  target  drug  were  also  tested.  The  list  of  drug 
analogues  tested  for  each  assay  is  given  in  Table  6-7-6-12. 
Cross  reactivity  was  calculated  by  constructing  a  target  drug  dose  response  curve 
and  a  dose  response  curve  for  the  drug  to  be  tested.  The  drugs  were  spiked  into 
phosphate  buffer  saline  (pH  7.0)  for  testing.  The  concentration  of  target  drug 
producing  the  same  B/Bo  (%)  value  as  the  drug  being  tested  was  determined  at  a 
given  concentration.  The  cross  reactivity  was  then  calculated  by  dividing  this 
target  drug  concentration  by  the  concentration  of  drug  being  tested  and 
multiplying  by  100  to  express  as  a  percentage. 
6.6  ELISA  Validation  Results  and  Discussion 
6.6.1  Dose  Response  Curves 
Dose  response  curves  were  generated  for  all  drugs  of  abuse  assays  (Figure  6-1  - 
Figure  6-6).  The  results  were  obtained  in  duplicate  for  each  concentration  and 
an  average  B/Bo  (%)  value  was  calculated.  The  B/Bo  (%)  values  showed  a 
hyperbolic  decrease  for  all  assays  with  increasing  target  drug  concentration.  As 
discussed  in  chapter  5,  this  is  because  of  the  inverse  relationship  that  exists 
between  absorbance  and  drug  concentration  when  using  ELISA.  From  the  dose 
response  curves,  the  B/Bo  (%)  values  for  the  cut-off  calibrators  were  all  below  70 
%  and  were  in  the  linear  portion  of  the  curve.  The  ELISA  kit  manufacturers 
recommend  that  the  selected  cut-off  concentration  produces  a  B/Bo  (%)  below 
70  %  to  ensure  the  highest  number  of  true  results. Drugs  of  abuse  in  Hair  by  ELISA 
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Figure  6-3  Cocaine  dose  response  curve 
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Figure  6-4  d,  /-Methadone  dose  response  curve 
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Figure  6-6  Morphine  dose  response  curve 
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6.6.2  LOD  and  Assay  Precision 
Chapter  6,88 
The  LOD  values  for  the  drugs  of  abuse  assays  are  shown  in  Table  6-4.  With  the 
exception  of  the  benzodiazepines  assay,  the  LOD  values  were  lower  than  the 
cut-off  concentrations  used  for  screening.  Although  the  cut-off  concentration 
used  for  the  benzodiazepine  assay  was  the  same  as  the  LOD,  the  B/Bo  (%)  was 
70  %.  Furthermore  this  cut-off  concentration  was  found  to  produce  the  greatest 
number  of  true  results  when  compared  to  a  validated  LC-MS-MS  method  as 
discussed  later  in  section  7.6.4.11' 
Precision  data  is  shown  in  Table  6-5  and  Table  6-6.  There  are  currently  no 
published  guidelines  on  acceptable  levels  of  precision  for  drug  screening  by 
ELISA  however  all  within  sample  and  intra-day  data  was  <9%  at  all  levels 
tested,  which  is  accepted  as  good  precision  in  chromatographic  methods 
according  to  SOFT  guidelines.  "  Inter-day  precision  was  higher  as  expected  due 
to  the  greater  number  of  results  and  the  fact  that  the  tests  were  carried  out  on 
five  separate  days. 
Table  6-4  ELISA  LOD  values 
ELISA  Assay  LOD  (ng/mg) 
AMP  0.05 
Benzodiazepine  0.1 
Cocaine  0.05 
Methadone  0.1* 
MAMP  0.05 
Opiate  0.05 
*n=8  for  blank  samples Drugs  of  abuse  in  Hair  by  ELISA 
Table  6-5  ELISA  within-sample  precision 
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ELISA  A 
Within-sample  Precision  (%  RSD  for  n=10) 
ssay 
/x  Cut-Off  Cut-Off  2x  Cut-Off 
AMP  4.9  3.1  4.1 
Benzodiazepine  4.1  3.9  3.1 
Cocaine  6.5  5.5  4.3 
Methadone  6.0  4.0  6.9 
MAMP  3.0  4.0  3.6 
Opiate  6.4  6.9  6.1 
Table  6-6  ELISA  intra-day  and  inter-day  Precision 
Intra-day  Precision  (n=20)  Inter-day  Precision  (n=100) 
ELISA  Assay  Yx 
Cut-Off  Cut-Off 
2x 
Cut-Off 
fix 
Cut-Off  Cut-Off 
2x 
Cut-Off 
AMP  8.0  8.3  7.4  8.7  9.7  11.9 
Benzodiazepine  6.9  4.6  2.3  8.6  8.2  5.9 
Cocaine  7.7  6.9  5.9  10.5  11.9  13.5 
Methadone  8.3  7.3  6.5  10.9  13.2  17.4 
MAMP  8.8  7.4  5.7  6.6  7.6  6.7 
Opiate  8.7  8.4  7.6  11.9  10.9  14.1 Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,90 
6.6.3  Cross  Reactivity 
Table  6-7  Cross  reactivity  of  amphetamine  analogues  with  amphetamine  ELISA  kit 
Compound 
Approx.  ng/mL 
equivalent  to 
25  ng  d-AMP 
%  Cross  Reactivity 
quoted  by 
Immunalysis® 
%  Cross  Reactivity 
Found 
1-AMP  1700  2.5  1.5 
d-MAMP  >  1000  6.5  <  1.0 
1-MAMP  >  2000  2.0  <  1.0 
d,  1-MDA  11  250  263 
d,  (-MDMA  >  2500  <  1.0  <  1.0 
d,  1-MDEA  >2500  <1.0  <1.0 
Overall,  the  cross  reactivity  values  determined  for  the  amphetamine  specific  kit 
were  comparable  to  the  values  quoted  by  the  manufacturers.  A  relatively  high 
cross  reactivity  was  demonstrated  for  MDA  however  the  kit  had  less  than  1% 
cross  reactivity  with  d-  and  1-methamphetamine,  d,  1-MDMA  and  d,  1-MDEA.  The 
kit  manufacturers  have  two  different  ELISA  kits  to  accommodate  regional 
differences  in  amphetamine  abuse  which  are  the  amphetamine  specific  and  the 
methamphetamine  specific  kits.  As  mentioned  previously,  the  amphetamine 
specific  ELISA  is 100  %  cross  reactive  with  d-amphetamine,  which  is  the  illicit 
form.  As  the  cross  reactivity  of  the  licit  1-AMP  enantiomer  is  very  low,  this  ELISA 
test  is  an  excellent  means  of  distinguishing  between  illegal  amphetamine  use 
and  medication.  Furthermore  it  could  eliminate  the  need  for  chiral  separation 
of  the  amphetamine  enantiomers  in  the  confirmation  method.  The 
methamphetamine  specific  ELISA  kit  which  is 100  %  cross  reactive  with  the  illicit 
d-methamphetamine  should  be  used  in  tandem  with  the  d-amphetamine  specific 
kit. Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,91 
Table  6-8  Cross  reactivity  of  oxazepam  analogues  with  benzodiazepine  ELISA  kit 
Compound 
Approx.  ng/mL 
equivalent  to 
100  ng  oxazepam 
%  Cross  Reactivity 
quoted  by 
Immunalysis® 
%  Cross  Reactivity 
Found 
7-aminoflunitrazepam 
(7-AF) 
1300  Not  given  8 
Chtordiazepoxide  750  17  13 
Diazepam  125  91  80 
Ftunitrazepam  310  31  32 
Lorazepam  860  13  12 
Nitrazepam  320  33  31 
Nordiazepam  70  150  143 
Temazepam  130  83  77 
The  experimental  cross  reactivity  values  were  comparable  with  the 
manufacturer's  values  for  the  benzodiazepine  ELISA  kit.  As  shown  in  chapters  7 
and  8,  the  majority  of  hair  samples  tested  positive  for  diazepam  and  its 
metabolites  by  LC-MS-MS  so  this  kit  is  ideally  suited  for  screening. 
The  kit  may  not  be  suitable  for  screening  hair  samples  positive  for 
chlordiazepoxide,  flunitrazepam  and  its  metabolite,  lorazepam  or  nitrazepam  as 
they  cross-react  to  a  relatively  lower  extent  than  diazepam  and  its  metabolites. 
This  study  did  not  investigate  this  potential  problem  due  to  a  lack  of  positive 
samples  for  these  drugs  atone. 
There  is  a  commercially  available  flunitrazepam  ELISA  kit  which  should  ideally 
be  used  in  tandem  with  the  benzodiazepine  ELISA  kit  for  screening.  These  kits 
cross  react  100  %  with  the  7-aminoflunitrazepam  (7-AF)  metabolite  which  has 
generally  been  found  in  higher  concentrations  in  hair,  due  to  its  higher  basicity. 
The  kit  was  not  tested  for  the  purposes  of  this  study  since  there  were  no  LC-MS- 
MS  positives  for  flunitrazepam  or  7-AF  as  shown  in  chapters  7  and  8. Drugs  of  abuse  in  Hair  by  ELISA 
Table  6-9  Cross  reactivity  of  cocaine  metabolites  with  cocaine  ELISA  kit 
Chapter  6,92 
Approx.  ng/mL  %  Cross  Reactivity  %  Cross  Reactivity  Compound  equivalent  to  quoted  by 
Found  50  ng  cocaine  Immunalysis® 
Benzoylecgonine  960  7.6  5.2 
Cocaethylene  40  110  125 
Ecgonine  methyl  ,  5000  <  1.0  <  1.0 
ester  (EME) 
This  cocaine  specific  ELISA  kit  was  developed  for  the  detection  of  cocaine  in 
hair.  It  is  well  known  that  parent  drug  concentrations  are  higher  than 
metabolite  concentrations  in  hair  so  it  is  more  appropriate  for  a  screening  test 
to  be  calibrated  towards  the  parent  drug.  Cocaine  and  cocaethylene  are  the 
primary  analytes  found  in  hair  after  cocaine  ingestion  hence  the  high  %  cross 
reactivity  for  cocaethylene.  Benzoylecgonine  is  present  at  lower  levels  but  has 
been  shown  to  be  an  artefact  of  some  sample  treatment  and  extraction 
procedures  involving  acidic  and  alkaline  hydrolysis.  Cocaethylene  is  only  present 
when  the  individual  has  used  both  cocaine  and  alcohol  at  the  same  time  and  is  a 
useful  marker  of  cocaine  use.  EME  levels  have  not  been  widely  reported  in  hair. 
In  this  study  as  discussed  in  chapter  8,  it  was  detected  in  a  very  small  number  of 
samples  at  low  levels. 
Table  6-10  Cross  reactivity  of  methadone  analogue  with  methadone  ELISA  kit 
Approx.  ng/mL  %  Cross  Reactivity 
Compound  equivalent  to 
quoted  by  %  Cross  Reactivity 
300  ng  Immunalysis®  Found 
methadone 
EDDP  13,000  <  5.0  2.3 
Like  other  drugs  of  abuse,  methadone  is  found  in  hair  at  higher  levels  in  hair 
than  EDDP.  In  fact,  EDDP  is  not  detected  in  some  cases  where  methadone  is 
present.  "'  Reported  concentration  ratios  of  the  EDDP  metabolite  and 
methadone  parent  drug  are  0.05-0.67.9° Drugs  of  abuse  in  Hair  by  ELISA 
Table  6-11  Cross  reactivity  of  MAMP  analogues  with  MAMP  ELISA  kit 
Chapter  6,93 
Compound 
Approx.  ng/mL 
equivalent  to 
50  ng  d-MAMP 
%  Cross 
Reactivity  quoted 
by  Immunalysis® 
%  Cross 
Reactivity  Found 
d,  1-MAMP  80  65  63 
1-MAMP  >  2000  8.0  <1.0 
d,  1-MDMA  38  135  132 
d-AMP  >  10,000  2.0  <  1.0 
1-AMP  >  2000  3.4  <  1.0 
d,  1-MDA  >  10,000  <  1.0  <  1.0 
d,  1-MDEA  1500  10  3.3 
As  shown  in  Table  6-11,  the  methamphetamine  specific  ELISA  kits  cross  reacts 
with  the  racemic  mixture  of  methamphetamine  and  MDMA  to  a  relatively  high 
extent  but  to  a  low  extent  with  the  other  designer  drugs  MDA  and  MDEA  and 
amphetamine  enantiomers.  The  experimental  values  were  mostly  comparable 
to  those  provided  by  the  manufacturer.  However  there  was  a  greater  difference 
in  the  value  obtained  for  l-methamphetamine.  The  cross  reactivity  determined 
experimentally  was  lower  than  the  cross  reactivity  quoted  by  the  manufacturers. 
This  is  an  advantage  when  screening  samples  for  illicit  methamphetamine  as  it  is 
unlikely  that  the  licit  form  would  be  detected  in  the  screen  due  to  its  low  cross 
reactivity. 
Table  6-12  Cross  reactivity  of  morphine  analogues  with  opiate  ELISA  kit 
Approx.  ng/mL  %  Cross  Reactivity 
%  Cross  Reactivity 
Compound  equivalent  to  quoted  by  Found  25  ng  morphine  Immunalysis® 
Codeine  11  200  227 
Dihydrocodeine  58  Not  given  43 
6-MAM  320  83  69 
After  heroin  use,  hair  often  contains  primarily  6-MAM,  with  smaller  quantities  of 
diamorphine  and  morphine.  Therefore  this  opiates  ELISA  is  suited  to  hair Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,94 
screening  due  to  its  relatively  high  cross  reactivity  with  6-MAM.  The  kit  is  also 
highly  cross  reactive  with  codeine  which  can  be  present  in  the  hair  of  heroin 
abusers.  Morphine  and  codeine  which  are  extracted  from  the  Papaver 
Somniferum  poppy  are  acetylated  during  the  production  of  illicit  heroin. 
Acetylcodeine  is  metabolised  to  codeine  after  heroin  use. 
Dihydrocodeine  was  tested  as  it  is  commonly  prescribed  as  a  narcotic  analgesic 
in  Scotland  and  is  frequently  detected  in  blood  and  urine  samples  submitted  to 
the  laboratory  for  routine  testing. 
6.6.3.1  Cross  Reactivity  of  Structurally  Unrelated  Drugs 
Various  drugs  of  abuse,  which  are  not  structurally  related  to  the  target  drug  in  a 
particular  assay,  were  tested  at  10,000  ng/mL.  This  included  amitriptyline, 
d-amphetamine,  buprenorphine,  cocaine,  codeine,  6-MAM,  MDMA,  methadone, 
morphine,  A9THC-COON  and  tramadol.  All  of  the  compounds  tested  for  a 
particular  assay  were  tested  in  duplicate  and  did  not  produce  a  B/Bo  (%)  value 
that  was  less  than  that  produced  from  the  assay  sensitivity  levels  shown  in  Table 
6-4. 
6.6.4  Case  Samples 
ELISA  results  are  provided  for  post-mortem  hair  samples  submitted  to  the 
laboratory  for  opiates,  cocaine  and  methadone  testing.  These  were  initially 
compared  to  GC-MS  results  obtained  by  in-house  methods  used  within  the 
Forensic  Medicine  and  Science  Section  at  the  University  of  Glasgow.  In  brief, 
this  involved  incubating  the  hair  in  methanol  overnight  at  45  °C,  removing  the 
methanol  then  incubating  the  hair  overnight  in  0.1  M  hydrochloric  acid  at  45  °C. 
The  combined  extracts  were  cleaned  up  using  Bond  Elut  Certify"'  SPE  cartridges. 
Opiates  were  derivatised  using  N,  O-Bis  (Trimethylsilyl)  trifluoroacetamide 
(BSTFA)  with  1%  trimethytchlorosilane  (TMCS).  Cocaine  and  its  metabolites 
were  derivatised  using  pentaftuoropropionic  anhydride  (PFPA)  and  pentaftuoro-1- 
propanot  (PFPOH)  prior  to  GC-MS  analysis. 
Methamphetamine  ELISA  results  for  the  collaboration  with  the  Korean  laboratory 
are  provided  in  section  6.6.4.4.  Results  for  other  post-mortem  samples  screened 
for  amphetamines,  benzodiazepines,  cocaine  and  opiates  are  provided  in Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,95 
chapters  7  and  8  respectively  as  these  were  compared  to  LC-MS-MS  methods 
which  were  developed  and  validated  as  part  of  the  work  for  this  thesis. 
6.6.4.1  Opiates 
The  results  for  opiate  screening  in  20  post-mortem  hair  samples  are  provided  in 
Table  6-13.10  drug-free  samples  collected  from  volunteers  working  in  the 
laboratory  were  also  screened.  The  root-0.5  cm  section  was  removed  in  each 
case  and  was  not  analysed  as  the  sample  weight  was  generally  less  than  5  mg. 
The  remaining  hair  sample  was  decontaminated  using  the  procedure  described  in 
section  6.4.1,  cut  up  into  2-3  mm  segments,  extracted  and  analysed  by  ELISA. 
Table  6-13  ELISA  vs  in-house  GC-MS  method  for  opiates 
ELISA  GC-MS 
Sample 
Number 
Weight 
(mg) 
MOR 
Equivalents 
(ng/mg) 
Weight 
(mg) 
MOR  6-MAM  COD  DHC 
1  7.50  >  1.0  17.89  17.9  39.9  3.2  0.2 
2  5.21  <  0.2  39.71  -  -  -  0.4 
3  13.98  0.25  34.20  0.5  1.1  -  - 
4  15.60  >  1.0  31.00  0.7  0.4  3.4  4.6 
5  2.93  >  1.0  15.42  5.2  7.3  1.8  - 
6  10.40  >  1.0  82.96  3.8  6.5  7.6  4.2 
7  10.46  >  1.0  19.62  18.8  18.8  5.0  4.0 
8  6.04  >  1.0  14.52  13.5  23.3  2.5  - 
9  8.83  <  0.2  10.04  -  -  -  - 
10  18.66  >  1.0  38.42  3.8  9.2  0.8  - 
11  7.18  0.38  58.08  0.7  1.7  -  - 
12  1.98  >  1.0  5.99  6.8  7.5  1.8  1.7 
13  10.03  >  1.0  13.83  0.2  0.6 
14  6.36  >  1.0  12.07  0.3  1.4  0.8  1.6 
15  10.45  >  1.0  47.66  35.4  38.5  17.1  0.4 
16  20.74  >  1.0  67.73  10.9  23.3  4.7  0.2 
17  10.23  >  1.0  25.43  -  -  4.55  - 
18  6.68  0.37  10.55  -  -  -  0.6 
19  5.51  >  1.0  9.56  0.7  1.9  -  - 
20  9.05  0.24  9.52  1.5  2.7  0.4  - 
"MOR"=Morphine,  "6-MAM"=6-Monoacetylmorphine,  "COD  "=Codeine,  "DHC"=  Dihydrocodeine 
The  ELISA  sensitivity  and  specificity  were  95  %  and  100  %  respectively  using  the 
SoHT  cut-off  of  0.2  ng/mg  morphine.  Sample  2  produced  a  FN  ELISA  result 
however  the  sample  weight  and  the  dihydrocodeine  level  detected  by  GC-MS 
were  both  low.  The  cross  reactivity  of  dihydrocodeine  with  the  opiates  kit  was 
found  to  be  43  %,  further  explaining  this  result. Drugs  of  abuse  in  Hair  by  ELISA 
6.6.4.2  Cocaine 
Chapter  6,96 
The  results  for  cocaine  screening  of  16  post-mortem  hair  samples  tested  in 
section  6.6.4.1  are  presented  in  Table  6-14.  The  sample  numbers  correspond  to 
the  ones  given  in  Table  6-13. 
Table  6-14  ELISA  vs  in-house  GC-MS  method  for  cocaine 
ELISA  GC-MS-MS 
Sample 
Number 
Weight 
(mg) 
Ecoc  quivalents 
(ng/mg) 
Weight 
(mg) 
COC  BZE  COCAETH 
1  7.50  <  0.5  17.89  -  -  - 
2  5.21  <  0.5  39.71  -  -  - 
4  15.60  0.57  31.00  0.7  -  - 
5  2.93  <  0.5  15.42  -  -  - 
6  10.40  >  2.5  82.96  32.5  14.1  - 
7  10.46  <  0.5  19.62  0.2  0.03  - 
8  6.04  >  2.5  14.52  172.0  17.1  - 
10  18.66  <  0.5  38.42  -  -  - 
11  7.18  <  0.5  58.08  -  -  - 
12  1.98  <  0.5  5.99  -  -  - 
13  10.03  >  2.5  13.83  1.2  -  0.2 
14  6.36  >  2.5  12.07  0.5  -  - 
15  10.45  <  0.5  47.66  0.4  -  - 
17  10.23  >  2.5  25.43  2.0  -  0.1 
18  6.68  <  0.5  10.55  -  -  - 
19  5.51  <  0.5  9.56  -  -  - 
"COC"=Cocaine,  "BZE"=Benzoylecgonine,  "COCAETH  "=Cocaethylene 
There  were  a  smaller  number  of  cocaine  positive  samples  (n=8)  compared  to  the 
number  of  opiate  positive  samples  (n=19).  All  of  the  cocaine  positive  samples 
were  also  positive  for  opiates.  The  ELISA  sensitivity  and  specificity  for  this  small 
number  of  positive  cocaine  samples  compared  to  the  in-house  validated  GC-M5 
method  was  75  %  and  100  %  using  the  recommended  SoHT  and  SAMHSA  cut-off  of 
0.5  ng/mg  cocaine.  A  greater  number  of  positive  cocaine  samples  need  to  be 
screened  to  determine  if  a  lower  cut-off  value  is  required  for  future  screenings. 
However  from  the  GC-MS  results  for  the  2  FN  samples  (samples  7  and  15),  it 
would  appear  that  this  was  necessary. Drugs  of  abuse  in  Hair  by  ELISA 
6.6.4.3  Methadone 
Chapter  6,97 
The  results  for  methadone  screening  for  20  post-mortem  hair  samples  tested  in 
6.6.4.1  and  6.6.4.2  are  presented  in  Table  6-15.  The  sample  numbers 
correspond  to  the  ones  given  in  Table  6-13  and  Table  6-14. 
Table  6-15  ELISA  vs  in-house  GC-MS  method  for  methadone 
ELISA  GC-MS-MS 
Sample 
Number 
Weight 
(mg) 
d,  l-MD 
Equivalents 
(ng/mg) 
Weight 
(mg)  MD  EDDP 
1  7.50  >  1.0  17.89  70.6  10.9 
2  5.21  <  0.2  39.71  -  - 
3  13.98  <  0.2  34.20  -  - 
4  15.60  <  0.2  31.00  -  - 
6  9.89  0.27  82.96  2.8  0.6 
7  10.46  0.82  19.62  11.5  2.2 
8  1.03  <  0.2  14.52  3.7  0.4 
9  8.83  <  0.2  10.04  -  - 
10  18.66  0.51  38.42  7.7  0.7 
11  7.18  <  0.2  58.08  -  - 
14  6.36  <  0.2  12.07  -  - 
15  10.45  <  0.2  47.66  -  - 
16  20.74  >  1.0  67.73  25.6  6.4 
17  10.23  <  0.2  25.43  -  - 
18  6.68  <  0.2  10.55  -  - 
19  5.51  <  0.2  9.56  -  - 
20  9.05  <  0.2  9.52  -  - 
"MD"=Methadone,  "EDDP"=2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
There  was  a  small  number  of  hair  samples  which  tested  positive  for  methadone 
(n=6).  5  out  of  6  of  these  tested  positive  by  ELISA  and  GC-MS  to  give  an  ELISA 
sensitivity  of  83  %  at  a  cut-off  of  0.2  ng/mg  d,  l-methadone.  The  FN  result 
produced  by  sample  8  is  due  to  an  insufficient  sample  weight  for  ELISA.  All  of 
the  methadone  positive  samples  also  tested  positive  for  opiates. 
6.6.4.4  Methamphetamine:  Korean  Collaboration 
29  hair  samples  were  screened  for  methamphetamine  using  ELISA  as  part  of  a 
collaboration  with  the  National  Institute  of  Scientific  Investigation  in  Seoul, 
South  Korea.  The  samples  had  been  submitted  to  the  laboratory  in  Seoul  by  the 
police  force.  The  reason  for  the  collaboration  was  that  there  is  currently  an 
insufficient  number  of  methamphetamine  positive  hair  samples  in  Scotland  as  it Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,98 
is  not  a  common  drug  of  abuse.  In  addition,  9  drug  free  samples  were  collected 
from  laboratory  personnel  and  these  were  all  screened  and  confirmed  as 
negative. 
The  ELISA  results  obtained  within  the  Forensic  Medicine  and  Science  Section  at 
the  University  of  Glasgow  were  compared  with  a  validated  GC-MS  method  that  is 
currently  used  in  the  in  the  National  Institute  of  Scientific  Investigation  in  Seoul 
(Table  6-16).  12 
Table  6-16  ELISA  vs  GC-MS  methamphetamine  positive  hair  results 
ELISA  GC-MS 
Sample 
Number 
Weight 
(mg) 
d-MAMP 
Equivalents 
(ng/mg) 
Weight 
(mg) 
d,  I-MAMP 
(ng/mg) 
d,  1-AMP 
(ng/mg) 
1  7.01  >  5.0  4.6  19.5  0.9 
2  9.00  <  0.5  12.7  1.2  0.1 
3  7.08  0.7  7.0  2.2  0.0 
4  8.10  >  5.0  12.7  9.4  1.1 
5  7.04  >  5.0  2.0  22.7  0.9 
6  9.57  >  5.0  17.2  12.7  0.3 
7  9.51  >  5.0  19.0  2.4  0.2 
8  9.37  1.6  6.5  20.4  0.8 
9  9.50  2.7  18.5  3.3  0.2 
10  7.73  >  5.0  4.4  8.0  0.4 
11  9.86  2.9  19.3  6.6  1.0 
12  8.05  >  5.0  10.2  11.9  0.8 
13  7.18  >  5.0  9.9  45.3  2.5 
14  8.13  1.6  12.2  4.1  0.3 
15  9.28  3.0  19.2  7.2  0.5 
16  8.51  2.8  14.5  4.4  0.2 
17  8.10  >  5.0  7.8  9.3  0.9 
18  9.09  >  5.0  12.8  10.6  0.4 
19  9.73  3.0  19.0  12.7  0.4 
20  9.06  >  5.0  19.8  27.5  2.4 
21  10.40  2.4  20.1  2.7  0.2 
22  9.83  1.5  19.4  8.1  1.0 
23  7.11  >  5.0  16.6  12.5  0.4 
24  10.15  >  5.0  16.5  10.2  0.3 
25  9.27  >  5.0  16.6  11.7  0.6 
26  10.21  >  5.0  18.8  20.4  0.9 
27  6.68  >  5.0  14.0  8.1  0.60 
28  10.77  0.6  19.0  1.8  0.1 
29  10.89  >  5.0  19.5  6.9  1.1 
"MAMP"=Metamphetamine,  "AMP"=Amphetamine Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,99 
The  ELISA  method  is  described  previously  in  section  6.4.1  and  section  6.4.2.  The 
same  decontamination  method  was  used  by  the  Korean  tab  to  enable  accurate 
ELISA  and  GC-MS  comparison.  In  brief  for  the  GC-MS  analysis,  the  samples  were 
incubated  in  methanol  containing  I%  v/v  hydrochloric  acid  for  20  hours  at  45  °C. 
The  methanol  extracts  were  blown  down  under  nitrogen  and  derivatised  with 
trifluoroacetic  acid  (TFA)  for  15  minutes  at  65  °C. 
The  ELISA  sensitivity  and  specificity  were  97  %  and  100  %  respectively,  which  are 
in  the  accepted  range  of  values200  however  the  FN  sample  (sample  2)  would  have 
screened  as  positive  at  a  lower  cut-off  value  and  this  supports  the 
recommendation  by  the  SoHT.  28  out  of  29  samples  were  screened  and 
confirmed  as  positive  using  the  cut-off  in  place  in  the  Korean  lab  of  0.5  ng/mg 
d,  1-methamphetamine.  GC-MS  analysis  found  that  this  sample  contained  the 
lowest  quantity  of  methamphetamine  of  all  the  samples  tested  (1.2  ng/mg). 
Average  ELISA  absorbance  values  for  this  sample  and  the  cut-off  calibrator  were 
very  close  to  each  other  (1.30  and  1.25  respectively).  Furthermore,  one  of  the 
duplicate  sample  absorbance  values  was  1.22  (a  positive  result)  but  the  average 
absorbance  value  meant  the  screening  result  was  negative.  The  sample  was  re- 
run  on  another  day  with  similar  results.  Samples  that  screen  at  or  near  the 
ELISA  cut-off  should  be  further  tested  by  confirmation.  '  The  FN  result  may  be  a 
result  of  using  different  ELISA  and  GC-MS  extraction  methods. 
A  study  published  by  the  National  Institute  of  Scientific  Investigation  in  2006 
determined  criteria  for  obtaining  positive  results  using  the  metabolite-to-  parent 
drug  ratios  for  methamphetamine  in  scalp  hair.  "'  2389  positive  scalp  hair 
samples  collected  from  methamphetamine  abusers  were  examined  in  the  study. 
Amphetamine  to  methamphetamine  drug  ratios  ranged  from  0.04-1.16  (mean 
0.09).  The  hair  samples  were  washed  twice  with  water  for  5  minutes  and  twice 
with  methanol  for  5  minutes.  The  authors  propose  that  the  detection  of 
metabolites  and  parent  drug  within  this  ratio  range  is  a  useful  means  of 
distinguishing  between  external  contamination  and  drug  incorporation  through 
ingestion. 
In  the  collaborative  work  presented  in  this  thesis,  the  amphetamine  to 
methamphetamine  ratios  ranged  from  0.02-0.159  (mean  0.07).  As  the  same  GC- 
MS  extraction  method  was  used,  the  difference  in  the  ratio  range  is  probably  due Drugs  of  abuse  in  Hair  by  ELISA  Chapter  6,100 
to  the  different  decontamination  procedure  used.  I  sample  only  contained 
methamphetamine. 
SAMHSA  guidelines  stipulate  that  a  hair  sample  which  has  been  confirmed  as 
positive  for  methamphetamine  using  a  cut-off  concentration  of  0.3  ng/mg  should 
also  contain  amphetamine  levels  >_  LOD  of  the  method.  "' 
6.6.5  Conclusion 
An  aqueous  extraction  method  was  validated  for  the  purposes  of  ELISA  screening 
of  amphetamine,  benzodiazepines,  cocaine,  methadone,  methamphetamine  and 
opiates  in  hair.  The  assays  demonstrated  high  sensitivity,  good  precision  and 
appropriate  cross  reactivity  with  the  analytes  found  in  hair.  The  ELISA  method 
was  applied  successfully  for  the  screening  of  post-mortem  samples  for  cocaine, 
methadone  and  opiates  in  this  chapter.  There  was  an  excellent  correlation 
observed  between  the  ELISA  and  in-house  GC-MS  method  for  opiates,  with  a 
sensitivity  and  specificity  of  95  %  and  100  %  respectively.  There  was  a  small 
number  of  cocaine  (n=8)  and  methadone  (n=6)  positive  samples.  This 
preliminary  study  suggested  that  a  lower  cut-off  value  may  be  required  for 
cocaine  screening  as  2  FN  results  were  produced  using  the  SoHT  and  SAMHSA 
currently  recommended  cut-off  of  0.5  ng/mg.  A  cut-off  value  of  0.2  ng/mg 
appears  to  be  suitable  for  methadone  screening.  The  1  FN  result  was  probably  a 
result  of  a  very  low  sample  weight  of  approximately  1  mg.  However  more  data 
is  required  to  determine  if  the  cut-off  values  recommended  by  the  SoHT  and 
SAMHSA  for  opiates  and  cocaine  are  suitable  for  screening  hair  samples. 
Hair  samples  collected  from  living  methamphetamine  abusers  were  also 
screened  successfully  using  this  ELISA  method.  Excellent  correlation  was 
observed  between  the  ELISA  and  GC-MS  methods,  with  a  sensitivity  and 
specificity  of  97  %  and  100  %  respectively.  The  amphetamine  to 
methamphetamine  ratios  ranged  from  0.02-0.159  (mean  0.07). 101 
7  Benzodiazepines  in  Hair 
7.1  Benzodiazeplnes 
Benzodiazepines  are  the  most  frequently  prescribed  drugs  for  the  treatment  of 
anxiety  and  insomnia.  "*  They  are  also  used  as  sedatives,  muscle  relaxants  and 
anticonvulsants  prior  to  surgery  and  other  medical  procedures.  Drug  abusers 
take  benzodiazepines  as  illicit  replacement  drugs,  sometimes  simultaneously 
with  alcohol  and  other  drugs  such  as  opiates,  sedatives,  antidepressants  and 
neuroleptics21  to  either  calm  themselves  down  or  amplify  the  drug  induced  high. 
Benzodiazepines  are  highly  addictive,  cheap  and  widely  available  and  are 
therefore  widely  abused.  "'  One  study  in  the  west  of  Scotland  in  1995-1998 
found  that  45  %  of  drug  related  deaths  tested  positive  for  diazepam  while  33  % 
of  these  cases  tested  positive  for  temazepam.  ''  An  assessment  of  drug 
prevalence  in  the  same  region  during  the  same  time  period  found 
benzodiazepines  to  be  present  in  82  %  of  cases.  "'  A  more  recent  evaluation  of 
drug-related  deaths  in  the  Greater  Glasgow  National  Health  Board  Area  in  2006 
found  benzodiazepines  to  be  present  in  79  %  of  cases21',  a  figure  which  is  similar 
to  the  findings  of  the  earlier  study  in  the  west  of  Scotland  in  1995-1998.  A 
study  in  Denmark,  Iceland,  Finland,  Norway  and  Sweden  in  2002  frequently 
detected  benzodiazepines  in  addition  to  the  main  intoxicant.,  "  Diazepam  and 
flunitrazepam  were  most  commonly  associated  with  drug-related  deaths. 
Ch  lord  iazepoxide  is  the  prototype  of  the  benzodiazepine  drug  class  and  was  the 
first  commercially  available  benzodiazepine  which  was  approved  for  human  use 
in  1960.17'  The  Scottish  Health  Statistics  for  2006-2007  show  that  diazepam  is 
currently  the  most  commonly  prescribed  benzodiazepine  in  Scotland.  "  Newer 
and  shorter-acting  benzodiazepine  drugs  included  in  this  study  such  as 
temazepam,  oxazepam,  lorazepam,  nitrazepam  and  flunitrazepam  are  also 
prescribed  in  the  UK  and  in  many  other  countries  worldwide. 
7.2  Pharmacokinetics,  Metabolism  and  Excretion 
The  molecular  structures  are  given  for  the  nine  benzodiazepines  included  in  this 
study  in  Figure  7-1.  The  pharmacokinetic  and  physicochemical  data  are  also Benzodiazepines  in  Hair  Chapter  7,102 
provided  for  these  benzodiazepines.  No  data  is  available  for  7-AF  however  the 
data  can  be  assumed  to  be  similar  to  that  for  flunitrazepam. 
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Figure  7.1  Molecular  structures  of  benzodiazepines 
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Table  7.1  Pharmacokinetic  and  physicochemical  data  for  benzodiazepines176 
Chapter  7,103 
Half  Life  (hr)  Vd  (L/kg) 
Protein 
Binding  (96)  pK. 
Ch  lordiazepoxide  6.27  0.3.0.5  94  4.8 
Diazepam  21-37  0.7-2.6  96  3.4 
Flunitrazepam  9-25  3.4-5.5  78  1.8 
Lorazepam  9.16  0.9-1.3  80  1.3,11.5 
Nitrazepam  17-48  2-5  87  3.2,10.8 
Nordiazepam  31.97  -  97  3.5,12.0 
Oxazepam  4-11  0.7-1.6  87-94  1.7,11.6 
Temazepam  3.13  0.8.1.0  97  1.3 
Chlord  iazepoxide  is  metabolised  by  N-demethylation  to  form 
norchlordiazepoxide,  which  is  then  further  metabolised  to  demoxepam  by 
deamination.  These  2  major  metabolites  are  as  pharmacologically  active  as  the 
parent  drug.  The  reduction  of  demoxepam  will  produce  nordiazepam  which  is 
also  an  active  metabolite  and  is  found  in  the  plasma  of  patients  undergoing  long- 
term  therapy  treatment.  Oxazepam  is  produced  by  the  hydroxylation  of 
nordiazepam  but  has  not  been  detected  in  plasma.  Less  than  1%  of  a  dose  is 
excreted  as  the  parent  drug;  about  6%  is  excreted  as  demoxepam  while  most  is 
excreted  as  glucuronide  conjugates  of  oxazepam.  "b 
Diazepam  is  converted  to  nordiazepam  by  N-demethylation  in  the  liver.  Both  of 
these  compounds  are  further  converted  to  oxazepam  and  temazepam  by 
hydroxylation.  The  3-hydroxy  derivatives  oxazepam  and  temazepam  do  not 
accumulate  in  plasma  or  blood  to  any  significant  extent.  Trace  amounts  of 
diazepam  and  nordiazepam  are  found  in  urine;  about  33  %  of  the  dose  is 
excreted  as  oxazepam  glucuronide  conjugates  and  about  20  %  as  conjugates  of 
nordiazepam,  4'-hydroxydiazepam  and  temazepam.  "b 
Flunitrazepam  and  nitrazepam  are  both  metabolised  by  reduction  of  the  nitro 
group  to  form  7-amino  metabolites.  A  single  2  mg  dose  of  flunitrazepam 
produces  a  7-AF  concentration  of  50-500  ng/mL  within  6-24  hours.  16 
Lorazepam  is  rapidly  conjugated  with  glucuronic  acid  following  ingestion  to  form 
an  inactive  metabolite.  This  accumulates  in  plasma  to  a  greater  extent  than  the 
parent  drug.  "'  Trace  amounts  of  unchanged  lorazepam  are  found  in  urine.  Most Benzodiazepines  in  Hair  Chapter  7,104 
of  the  dose  is  eliminated  as  lorazepam  gtucuronide  with  the  rest  being 
conjugates  of  minor  hydroxylation  metabolites. 
Oxazepam  conjugates  are  also  rapidly  formed  following  ingestion  but  is  found  to 
a  limited  extent  in  serum.  Most  of  the  excreted  drug  in  urine  after  48  hours  is 
oxazepam  glucuronide.  Temazepam  is  converted  to  oxazepam  during 
metabolism.  Both  compounds  form  glucuronide  conjugates.  The  majority  of 
excreted  drug  in  urine  is  temazepam  glucuronide. 
7.3  Previously  Reported  Methods  of  Analysis 
The  detection  of  benzodiazepines  in  hair  is  relatively  difficult  due  to  the  low 
levels  which  incorporate  in  the  hair.  Sramek  first  reported  the  detection  of 
diazepam  in  hair  by  RIA  In  1992.202  This  work  was  followed  by  the  analysis  of 
benzodiazepines  in  hair  using  highly  sensitive  analytical  methods. 
Benzodiazepines  have  been  detected  in  the  hair  of  living  and  deceased  users  by 
GC-/viS214,215  216,2t7,2t1,  HPLCZ19,220,  and  LC.  M5.  MS.  91,94,108,  "2,  "5,147,221  Various  extraction 
methods  have  been  reported  including  alkaline  digestionu",  acid  hydrolysis223, 
enzymatic  treatments40'2"  and  Soerensens  buffer.  224,217.219 
There  have  been  a  number  of  studies  using  gas  chromatography-negative  ion 
chemical  ionisation-mass  spectrometry  (GC-NCI-MS)  for  the  detection  of 
benzodiazepines  in  hair  as  it  is  more  sensitive  than  positive-ion  chemical 
ionisation  (PCI).  21e.  m.  224.5,226  These  were  published  in  the  mid  to  late  1990s  prior 
to  the  increasing  trend  towards  using  LC-MS-MS  for  this  purpose.  One  group 
achieved  very  low  LOD  values  in  the  range  1-20  pg/mg  for  alprazolam, 
bromazepam,  diazepam,  flunitrazepam,  lorazepam,  nordiazepam,  oxazepam  and 
triazolam  using  a  Soerensens  buffer  extraction.  =1°  A  study  by  another  group 
investigating  alprazolam  in  rat  hair  also  used  a  very  sensitive  method  achieving 
an  LOD  of  25  pg/mg.  =u  An  overnight  alkaline  digestion  with  sodium  hydroxide  at 
40  °C  was  used  to  extract  the  alprazolam. 
A  GC-MS  method  was  reported  for  the  detection  of  benzodiazepines  and  other 
psychotropic  drugs  in  hair.  114  The  LOD  values  ranged  from  0.01-2  ng/mg  and  the 
authors  proposed  that  this  method  could  be  used  for  screening. Benzodiazepines  in  Hair  Chapter  7,105 
The  use  of  an  on-line  restricted  access  extraction  column  coupled  with  an  HPLC- 
diode  array  detector  (DAD)  has  been  reported.  226  Ammoniated  methanol  was 
found  to  produce  optimum  extraction  recoveries  from  hair  spiked  with 
clonazepam,  diazepam,  flunitrazepam,  midazolam  and  oxazepam.  The  LOD  was 
0.2  ng/mg  for  all  benzodiazepines  in  the  study  and  acceptable  recovery  values  (> 
90  %)  were  achieved  using  spiked  hair.  The  validated  method  was  applied  to  2 
case  samples.  In  one  of  the  cases,  flunitrazepam  (Rohypnole)  was  detected  in  3 
hair  segments  with  the  concentration  ranging  from  3.2-3.9  ng/mg.  The  other 
case  sample  was  collected  from  an  individual  who  sometimes  used  oxazepam 
(Semesta®).  Two  segments  were  analysed  in  this  case  and  no  oxazepam  was 
detected.  It  was  proposed  that  this  was  because  oxazepam  has  a  shorter  half 
life  compared  to  other  benzodiazepines  and  is  a  polar  compound  which  would 
not  readily  incorporate  into  hair.  The  simultaneous  determination  of  these 
benzodiazepines  using  this  HPLC  method  was  rapid  and  therefore  suitable  for 
routine  analyses.  It  was  proposed  that  the  use  of  a  MS  detector  would  improve 
the  results.  Seven  extraction  methods  were  compared  for  the  extraction  of 
incorporated  benzodiazepines  from  rat  hair  by  HPLC  and  GC-M5.  '2  The  method 
which  produced  the  highest  recovery  for  diazepam,  flurazepam  and  medazepam 
was  an  overnight  extraction  in  methanol-TFA  (50:  1  v/v)  followed  by  LLE  with 
dichloromethane. 
Another  HPLC  method  for  the  detection  of  psychotropic  drugs  in  hair  (including 
benzodiazepines)  found  that  the  method  was  not  sensitive  enough  to  detect 
diazepam,  nitrazepam  and  oxazepam  in  post-mortem  samples  collected  from 
individuals  who  were  known  to  be  taking  psychotropic  drugs  prior  to  death.  u' 
This  study  compared  extraction  techniques  from  post-mortem  hair  samples  and 
found  that  alkaline  digestion  with  sodium  hydroxide  was  more  effective  at 
recovering  benzodiazepines  from  case  hair  than  acidic  (dilute  hydrochloric  acid), 
methanolic  or  enzymatic  (Subtilisin)  treatments.  This is  in  agreement  with  the 
findings  of  another  study.  116  The  authors  did  however  recommend  the  use  of 
alternative  procedures  to  sodium  hydroxide  digestion  for  the  optimal  detection 
of  benzodiazepines  in  hair  since  all  benzodiazepines  were  degraded  under 
alkaline  conditions. 
As  discussed  in  chapter  4,  LC-MS  is  becoming  increasingly  popular  due  to  simpler 
sample  preparation  requirements,  its  ability  to  analyse  compounds  not  suitable Benzodiazepines  in  Hair  Chapter  7,106 
for  GC  and  its  excellent  sensitivity  and  specificity.  Reports  on  benzodiazepine 
detection  in  hair  using  LC-MS  have  recently  become  more  common  than  GC-MS. 
An  LC-MS-MS  method  was  reported  for  the  detection  of  sedatives  (including 
benzodiazepines)  in  hair  and  nail  samples.  Dichloromethane  was  used  as  the 
organic  solvent  in  the  LLE.  The  hair  samples  were  initially  incubated  overnight 
in  methanol/TFA  (50:  1  v/v)  at  room  temperature.  The  LOD  values  for  the 
selected  benzodiazepines  were  very  low;  in  the  range  of  0.20-6.00  pg/mg.  227  A 
mixture  of  diethyl  ether/dichloromethane  (10:  90  v/v)  was  used  by  another  group 
as  the  organic  phase  in  a  LLE  for  16  benzodiazepines  following  incubation  of  the 
hair  in  Soerensens  buffer.  "'  The  LOD  values  in  this  study  were  in  the  range  of 
0.5-5  pg/mg.  It  was  proposed  that  this  method  would  be  suitable  for  screening 
purposes  and  is  capable  of  monitoring  single  dose  exposures. 
SPE  methods  have  also  been  reported  for  extraction  of  benzodiazepines  from 
hair.  9192'108"41  One  group  reported  an  extraction  method  using  Bond  Elut  Certify' 
SPE  columns  for  sample  clean-up  after  enzymatic  digestion  with  proteinase  K.  141 
The  method  was  applied  to  hair  samples  collected  from  forensic  and  clinical 
psychiatric  patients.  The  LOD  values  ranged  from  0.025-0.125  ng/mg.  Recent 
work  carried  out  within  the  Forensic  Medicine  and  Science  Section  at  the 
University  of  Glasgow  has  involved  the  use  of  molecularly  imprinted  solid  phase 
extraction  (MISPE)  for  extracting  benzodiazepines  from  hair.  91'92  The  results  were 
compared  with  a  classical  SPE  method  as  discussed  in  section  7.6.6  of  this 
chapter. 
7.4  Aim 
There  were  two  aims  of  this  study.  The  first  was  to  develop  and  validate  an 
ELISA  and  LC-MS-MS  method  to  screen  and  confirm  9  benzodiazepines  in  post- 
mortem  hair  samples.  The  second  aim  was  to  compare  this  validated  SPE 
method  with  a  novel  MISPE  method  for  the  detection  of  benzodiazepines  in  10 
post-mortem  samples.  The  MISPE  method  was  developed  and  validated  by  Dr 
Marinah  Ariffin,  a  colleague  within  the  Forensic  Medicine  and  Science  Section  at 
the  University  of  Glasgow  at  the  time  of  the  study.  " Benzodiazepines  in  Hair 
7.5  Experimental 
7.5.1  Samples 
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All  samples  were  post-mortem  scalp  hair  samples  submitted  to  the  toxicology 
laboratory  of  the  Forensic  Medicine  and  Science  Section  at  the  University  of 
Glasgow  for  routine  testing.  The  samples  were  tested  for  diagnostic  purposes 
and  the  results  were  reported  to  the  Procurator  Fiscal. 
7.5.2  Chemicals 
Methanol,  acetonitrile,  acetic  acid,  ammonium  hydroxide,  cyclohexane,  ethyl 
acetate,  formic  acid,  dichloromethane,  toluene  and  propan-2-ol  were  purchased 
from  BDH  (Poole,  UK)  and  were  of  analytical  grade.  Ammonium  formate  and 
sodium  dodecyl  sulfate  were  purchased  from  Sigma-Aldrich  (Dorset,  UK).  7-AF, 
flunitrazepam,  oxazepam,  lorazepam,  ch  lord  iazepoxide,  temazepam,  diazepam, 
nordiazepam  and  nitrazepam,  7-AF-d7,  flunitrazepam-d7,  oxazepam-d5, 
lorazepam-d4i  temazepam-d5,  diazepam-d5  and  nordiazepam-d5  used  in  the  LC- 
MS-MS  confirmation  were  obtained  from  Promochem  (Teddington,  England). 
Clean  Screen®  (ZSDAU  020)  mixed  mode  SPE  columns  were  purchased  from 
United  Chemical  Technologies  Incorporation  (Pennsylvania,  US). 
Benzodiazepine  Direct  ELISA  kits  were  purchased  from  Immunalysis  (Pomona,  CA, 
USA).  The  kits  contained  a  96-well  antibody-coated  microplate,  benzodiazepine 
conjugate  labelled  with  horseradish  peroxidase  (HRP),  substrate  solution 
containing  3,3',  5,5'-  tetra  methyl  benzidine  (TMB)  and  stop  solution  containing 
1N  hydrochloric  acid.  Hair  extraction  buffer  (0.025  M  monobasic  phosphate 
buffer  pH  2.7),  neutralising  buffer  (0.5  M  dibasic  phosphate  buffer  pH  9.0)  and 
phosphate  buffer  saline  (0.1  M,  pH  7.0)  used  to  dilute  hair  extracts  in  the  ELISA 
test  were  also  obtained  from  the  Immunalysis  Corporation.  Disposable 
borosilicate  glass  culture  tubes  (75  x  12  mm)  were  obtained  from  VWR 
International,  UK. 
Diazepam  for  polymer  synthesis  in  the  MISPE  work  was  obtained  from  Roche 
(Hertfordshire,  UK).  Methacrylic  acid  (MAA)  and  ethylene  glycol  dimethacrylate 
(EGDMA)  were  from  Aldrich  (Steinheim,  Germany),  chloroform  was  from Benzodiazepines  in  Hair  Chapter  7,108 
Rathburn  (Peebles,  UK)  and  2,2'-azobisisobutyronitrile  (AIBN)  was  from  Acros 
Organics  (Gee[,  Belgium).  1  mL  polyethylene  SPE  cartridges  without  sorbent  and 
frits  (20  pm  mean  pore  size)  for  diazepam  MISPE  were  purchased  from 
International  Sorbent  Technology  Limited  (Mid  Glamorgan,  UK). 
7.5.3  Standard  Solutions 
Individual  drug  stock  standard  solutions  and  deuterated  drug  standards  were 
obtained  as  100  pg/mL  prepared  in  methanol.  For  LC-MS-MS  confirmation,  a 
combined  working  drug  solution  of  7-AF,  chlordiazepoxide,  diazepam, 
flunitrazepam,  lorazepam,  nitrazepam,  nordiazepam,  oxazepam  and  temazepam 
was  prepared  at  1  pg/mL  by  100-fold  dilution  with  methanol.  This  was  achieved 
by  adding  25  pL  of  each  100  pg/mL  drug  solution  into  a  25  mL  volumetric  flask 
and  making  up  the  volume  to  the  25  mL  mark  with  methanol.  A  combined 
working  deuterated  standard  solution  of  the  7-AF-d7,  diazepam-d5, 
flunitrazepam-d7,  lorazepam-d4i  nordiazepam-d5,  oxazepam-d5  and  temazepam- 
d5  was  also  prepared  at  1  pg/mL  in  the  same  way  as  the  working  drug  solution. 
It  was  not  financially  viable  to  use  chlordiazepoxide-d5  therefore  oxazepam-d5 
was  selected  for  ch  lord  iazepoxide  quantitation  since  its  retention  time  (tR)  was 
close  to  the  tR  for  chlordiazepoxide  (5.1  and  6.2  minutes  respectively).  The  m/z 
of  the  nitrazepam-d5  precursor  ion  is  the  same  m/z  of  the  oxazepam  precursor 
ion  (m/z  =  287)  and  both  have  a  similar  tR  of  5.8  minutes,  resulting  in  co-elution. 
Therefore  oxazepam-d5  was  used  for  nitrazepam  quantitation. 
7.5.4  Extraction  Solutions  and  Mobile  Phase 
7.5.4.1  Preparation  of  0.1  M,  pH  6.0  Phosphate  Buffer 
The  solution  was  prepared  as  described  in  section  5.6.4.3. 
7.5.4.2  Preparation  of  Mobile  Phase 
The  mobile  phase  consisted  of  a  mixture  of  aqueous  buffer  and  acetonitrile.  To 
prepare  the  3  mM  ammonium  formate  +  0.001  %  formic  acid  aqueous  buffer, 
0.189  g  of  ammonium  formate  and  10  µL  of  concentrated  formic  acid  were 
added  to  a1L  volumetric  flask  and  made  up  to  the  mark  with  deionised  water. Benzodiazepines  in  Hair 
7.5.5  Instrumentation 
7.5.5.1  ELISA 
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A  MiniPrep  75  automatic  pipettor  from  Tecan  (San  Jose,  CA)  was  used.  The 
microplate  wells  were  washed  using  a  Columbus  Plus  washer  system  and  read 
with  a  Sunrise  Remote  EIA  autoreader  also  from  Tecan  (Grödlg,  Austria). 
7.5.5.2  LC-MS-MS 
LC-MS-MS  analysis  was  carried  out  using  a  Surveyor  HPLC  system  with  an  LCQ 
Deca  XP  Pluslm  ion  trap  mass  spectrometer  (Thermo  Finnigan,  San  Jose,  CA,  USA). 
Chromatographic  separation  was  performed  using  a  Gemini  C18  column  (150  mm 
x  2.0  mm  ID,  5  µm  particle  size),  fitted  with  a  guard  column  with  identical 
packing  material  (4  mm  x  2.0  mm,  5  pm  particle  size)  (Phenomenex,  Torrance, 
CA,  USA). 
7.5.6  ELISA  and  LC-MS-MS  Methods 
7.5.6.1  ELISA  Development 
As  there  are  generally  low  levels  of  benzodiazepines  detected  in  hair,  the 
benzodiazepines  assay  was  optimised  to  achieve  maximum  sensitivity.  Sample 
volumes  (25,50  NL)  and  pre-incubation  times  (30,60,120  minutes)  were 
optimised.  The  parameters  which  produced  the  best  separation  of  absorbance 
values  between  blank  hair  and  the  cut-off  calibrator  of  0.1  ng/mg  oxazepam 
were  used  for  analysis  (Table  7-2). 
Table  7-2  Sample  volume  and  pre-incubation  optimisation  results 
Sample  Volume  (NL)  Pre-incubation  time 
(min) 
Average  B/BO  (%) 
for  n=5 
25  30  88.6 
25  60  86.9 
25  120  82.0 
50  30  74.3 
50  60  71.9 
50  120  70.8 Benzodiazepines  in  Hair  Chapter  7,110 
As  shown  in  Table  7-2,50  pL  sample  volume  with  a  pre-incubation  time  of  2 
hours  produced  the  best  separation  of  absorbance  values  between  the  blank  and 
cut-off  calibrator.  However  50  pL  sample  volume  with  a  pre-incubation  time  of 
1  hour  produced  a  marginally  smaller  difference  and  this  was  selected  for 
validation  due  to  the  shorter  analysis  time.  The  optimised  ELISA  procedure  for 
benzodiazepine  screening  in  hair  is  described  below.  This  method  was  used  to 
validate  the  assay  and  was  applied  in  the  screening  of  post-mortem  hair 
samples.  The  sample  preparation  method  was  described  in  section  6.4.1. 
50  pL  of  diluted  extract  of  calibrator,  control  or  sample  was  added  to  the 
microplate  wells  in  duplicate  and  left  to  infiltrate  the  antibodies  at  room 
temperature  for  1  hour.  Subsequently,  100  pL  of  enzyme  conjugate  was  added 
to  each  well  and  the  plate  was  left  to  incubate  for  a  further  hour  at  room 
temperature.  After  this  time,  the  wells  were  washed  6  times  with  deionised 
water  (6  x  300  pL).  100  pL  TMB  was  added  to  each  well  and  the  plate  incubated 
in  the  dark  at  room  temperature  for  30  minutes.  The  reaction  was  stopped  using 
100  pL  1N  hydrochloric  acid  and  the  plate  was  read  at  450  nm  with  a  reference 
wavelength  of  650  nm. 
The  case  samples  were  considered  to  be  presumptively  positive  if  the  B/Bo  (%) 
value  was  lower  than  the  B/Bo  (%)  value  of  the  0.1  ng/mg  oxazepam  cut-off 
calibrator. 
7.5.6.2  LC-MS-MS 
7.5.6.2.1  Sample  Preparation 
The  decontamination,  segmentation  and  cutting  up  of  the  hair  samples  was 
described  previously  in  section  6.4.1.  After  cutting,  each  sample  was  split  into  3 
separate  vials  for  ELISA,  SPE  and  MISPE  procedures.  As  the  likelihood  of 
benzodiazepine  contamination  is  low,  the  dichloromethane  washings  were  not 
analysed. 
An  alkaline  incubation  using  methanol  with  25  %  ammonium  hydroxide  was  used 
prior  to  benzodiazepine  extraction  by  solid  phase.  42  Furthermore,  ammoniated 
methanol  was  found  to  produce  slightly  higher  recoveries  than  just  methanol  for 
diazepam,  oxazepam  and  flunitrazepam  in  another  study.  226  1.5  mL  of  methanol: 
25  %  ammonium  hydroxide  solution  (20:  1  v/v)  was  added  to  each  calibrator  and Benzodiazepines  in  Hair  Chapter  7,111 
sample,  left  to  sonicate  for  one  hour  and  stored  at  room  temperature  overnight. 
The  solvent  was  removed  from  the  vials  and  transferred  to  a  test  tube.  The  hair 
was  washed  twice  with  0.75  mL  solvent  and  the  washings  removed  and 
transferred  to  a  test  tube.  The  contents  of  the  test  tubes  were  evaporated  to 
dryness  under  nitrogen  and  reconstituted  in  I  mL  of  phosphate  buffer. 
7.5.6.2.2  SPE 
The  solid  phase  extraction  method  for  this  study  operates  by  a  mixed-mode 
cationic  exchange  mechanism.  The  sorbent  is  composed  of  C8  chains  and 
benzene  sulfonic  acid.  The  benzodiazepines  adsorb  onto  the  column  via  both 
hydrophobic  and  ionic  attraction. 
Clean  Screen®  columns  (ZSDAU  020)  were  conditioned  sequentially  with  3  mL 
methanol,  3  mL  distilled  water  and  1  mL of  phosphate  buffer.  The  vortexed 
samples  were  loaded  onto  the  columns  and  allowed  to  drip  through  without  the 
presence  of  a  vacuum.  The  columns  were  washed  sequentially  with  2  mL 
distilled  water,  2  mL  phosphate  buffer:  acetonitrile  (80:  20  v/v),  2  mL 
cyclohexane  and  2  mL  distilled  water.  The  columns  were  dried  under  full 
vacuum  for  5  minutes  after  the  second  wash  step,  for  1  minute  after  the  third 
wash  step  and  for  5  minutes  after  the  final  wash  step.  The  benzodiazepines 
were  eluted  using  1.5  mL  2%  ammoniated  ethyl  acetate  (followed  by  a2  minute 
drying  step  under  full  vacuum)  and  1.5  mL  dichloromethane:  isopropanol: 
ammonium  hydroxide  (78:  20:  2  v/v).  The  eluted  samples  were  blown  down  to 
dryness  under  a  stream  of  nitrogen  and  reconstituted  in  100  pL  of  the  mobile 
phase  (initial  conditions  3  mM  ammonium  formate  (65  %)  and  acetonitrile  (35 
%)).  20  pL  of  the  reconstituted  extract  was  injected  for  analysis. 
7.5.6.2.3  MISPE 
The  molecularly  imprinted  polymer  (MIP)  is  synthesised  in  the  presence  of  a 
template  molecule  (in  this  study  diazepam)  and  consists  of  a  highly  cross-Linked 
porous  polymer  network.  After  the  polymerisation,  the  template  is  removed, 
leaving  a  polymer  network  with  strategically  positioned  functional  groups  in 
binding  sites  that  are  complementary  in  size  and  shape  to  the  template 
molecule.  These  binding  sites  have  the  potential  to  re-bind  with  the  template 
molecule  or  other  molecules,  which  have  a  similar  molecular  structure  to  the 
template  molecule,  in  a  strong  and  selective  way. Benzodiazepines  in  Hair  Chapter  7,112 
Diazepam  MIP  cartridges  were  prepared  as  detailed  in  another  study.  94  The 
cartridges  were  conditioned  using  0.5  mL  toluene.  The  vortexed  samples  were 
added  to  the  columns  and  allowed  to  drip  through  without  the  application  of  a 
vacuum.  The  columns  were  washed  with  0.3  mL  toluene  and  eluted  using  0.5  mL 
15  %  (v/v)  acetic  acid  in  acetonitrile.  The  eluted  samples  were  blown  down 
under  nitrogen  and  reconstituted  with  100  pL  of  the  mobile  phase  (initial 
conditions  3  mM  ammonium  formate  (65  %)  and  acetonitrile  (35  %)).  20  pL  of  the 
reconstituted  extract  was  injected  for  analysis. 
7.5.7  LC-MS-MS  Analysis 
The  C18  column  was  maintained  at  25  °C.  The  mobile  phase  consisted  of  3  mM 
ammonium  formate  +  0.001  %  formic  acid  (A)  and  acetonitrile  (B)  at  a  flow  rate 
of  0.3  mL/min.  The  initial  gradient  conditions  were  65  %  A,  decreasing  to  20  %A 
after  13  minutes.  The  mobile  phase  composition  was  10  %A  from  13.5  to  16.5 
minutes.  Initial  gradient  conditions  were  restored  from  16.5  to  20  minutes  as 
this  was  sufficient  time  to  allow  the  system  to  equilibrate.  The  total  run  time 
was  20  minutes.  A  divert  valve  taking  LC  flow  to  waste  was  used  for  the  last  7 
minutes  of  the  run  to  preserve  the  MS  source. 
All  mass  spectral  data  was  acquired  in  electrospray  positive  ion  mode.  The 
capillary  temperature,  sheath  and  auxiliary  gas  flow  rates  and  collision  energies 
were  optimised  for  each  analyte.  The  probe  voltage  used  was  4.5  W.  Internal 
standard  data  was  acquired  in  selective  ion  monitoring  (SIM)  mode  and  analytes 
were  identified  on  the  basis  of  their  full  MS-MS  spectra.  2  product  ions  were 
monitored  where  possible,  to  gain  qualitative  identification  data.  The  major 
product  ion  was  used  for  quantitation.  Optimum  tuning  parameters,  precursor 
and  product  ions  are  shown  in  Table  7-3. Benzodiazepines  in  Hair 
Table  7-3  Optimum  tuning  parameters,  precursor  and  product  ions 
NT.  090-e00  SM.  50 
Analyte 
Sheath 
Gas 
(AU) 
Auxiliary 
Gas 
(AU) 
Capillary 
Temp 
(°C) 
Collision 
Energy 
(ý) 
Precursor 
m/z 
Product 
m/z 
7-AF  20  20  280  40  284  264,256 
Chlordiazepoxide  20  20  300  29  300  283*,  241 
Diazepam  20  20  300  42  285  257*,  222 
Ftunitrazepam  20  20  280  43  314  286*,  268 
Lorazepam  30  20  290  30  321  303*,  275 
Nitrazepam  30  20  300  42  282  254,236* 
Nordiazepam  20  15  300  41  271  243*,  140 
Oxazepam  20  20  300  29  287  269*,  241 
Temazepam  20  20  300  29  301  283*,  255 
`=  quantitation  ion 
LC-MS-MS  chromatograms  of  the  product  quantitation  ions  are  shown  in  Figure 
7-2  for  the  lowest  standard  concentration  (2  ng/  30  mg  blank  hair). 
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Figure  7-2  Chromatograms  of  product  quantitation  ions  for  2  ng/  30  mg  standard 
7.6  Method  Validation 
7.6.1  ELISA 
The  ELISA  method  was  validated  for  the  benzodiazepines  assay  as  described  in 
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section  6.5. Benzodiazepines  in  Hair 
7.6.2  LC-MS-MS 
7.6.2.1  Linearity 
Chapter  7,114 
Linearity  was  established  over  the  concentration  range  of  2-100  ng/30  mg  of 
blank  hair  to  produce  a  regression  line  for  each  analyte.  This  was  achieved  by 
adding  2,5,10,25,50  and  100  pL  of  1  pg/mL  working  drug  solution  to  30  mg 
blank  decontaminated  hair.  100  ng  of  deuterated  internal  standard  was  also 
added  by  adding  100  pL  of  1  pg/mL  working  deuterated  standard  solution.  A 
blank  containing  only  internal  standard  and  a  blank  containing  no  standards  were 
also  extracted  and  analysed. 
7.6.2.2  Recovery 
Recovery  was  calculated  for  each  benzodiazepine  at  10  ng/30  mg  and 
50  ng/30  mg.  Each  concentration  was  extracted  five  times  without  the  internal 
standard  present.  Two  unextracted  standards  were  also  prepared  at  each 
concentration  without  internal  standard  and  were  kept  in  the  fridge  throughout 
the  extraction.  Before  evaporating  the  samples  to  dryness  with  nitrogen,  100  ng 
of  internal  standard  was  added  to  each  tube,  including  the  unextracted 
standards.  After  the  samples  were  dry,  they  were  reconstituted  in  100  pL  of 
mobile  phase  and  20  pL  was  injected  for  analysis. 
The  recovery  was  expressed  as  a  percentage  by  dividing  the  average  peak  area 
ratio  of  five  extracted  standards  with  the  average  peak  area  ratio  of  two 
unextracted  standards  and  multiplying  by  100. 
An  additional  recovery  experiment  was  carried  out  for  one  post-mortem  hair 
sample  to  determine  the  efficiency  of  the  extraction.  The  sample  was  cut  up 
into  four  portions.  Each  portion  was  left  to  incubate  in  the  alkaline  extraction 
medium  for  1,2,4  and  16  hours  and  subsequently  extracted  using  the  SPE 
method  described  in  section  7.5.6.2.2. Benzodiazepines  in  Hair 
7.6.2.3  Stability 
Chapter  7,115 
The  stability  of  the  benzodiazepines  was  assessed  during  the  alkaline  overnight 
incubation  by  comparing  the  average  peak  area  ratio  of  four  extracted  samples 
at  50  ng/30  mg  with  the  average  peak  area  ratio  of  two  unextracted  samples. 
The  stability  during  evaporation  was  also  determined.  The  total  extraction 
recovery  of  benzodiazepine  amino  metabolites  was  found  to  be  at  least  25  % 
lower  than  the  extraction  recovery  of  their  respective  parent  drugs.  235  This  was 
attributed  to  loss  of  the  7-amino  metabolites  during  evaporation  and  the  authors 
added  tartaric  acid  to  prevent  this.  In  this  current  study,  evaporation  of  the  SPE 
eluant  was  investigated  as  a  potential  means  of  lowering  analyte  recovery.  Four 
tubes  containing  SPE  eluant  were  spiked  at  50  ng  and  evaporated  under  nitrogen 
at  40  °C.  The  peak  area  ratio  results  were  compared  with  two  samples  spiked  at 
the  same  concentration  which  were  not  prepared  in  eluant  and  were  left  to 
evaporate  at  room  temperature. 
7.6.2.4  Intra-Day  Precision  between  Extracts 
Five  extracted  standards  were  prepared  at  10  ng/30  mg  and  50  ng/30  mg. 
Standards  were  prepared  at  2,5,10,25  50  and  100  ng/30  mg  to  produce 
linearity  data.  A  blank  was  prepared  containing  no  standards  as  well  as  a  blank 
containing  only  internal  standard.  The  extracts  were  reconstituted  in  100  pL  of 
mobile  phase  and  20  pL  was  injected  for  analysis. 
Intra-day  precision  for  each  extracted  standard  (n=5)  was  calculated  by 
substituting  the  average  peak  area  ratio  value  into  the  regression  equation  for  a 
particular  drug.  The  mean  concentration  and  %  RSD  were  calculated. 
7.6.2.5  Inter-Day  Precision 
The  inter-day  precision  was  calculated  at  10  ng/30  mg  and  50  ng/30  mg  using 
five  sets  of  linearity  data  acquired  on  five  different  days  (n=25).  The  average 
peak  area  ratio  value  for  the  five  days  was  substituted  into  the  regression 
equation  for  a  particular  drug.  The  mean  concentration  and  %  RSD  was 
calculated. Benzodiazepines  in  Hair 
7.6.2.6  LOD  and  LOQ 
Chapter  7,116 
The  LOD  for  each  drug  was  calculated  statistically  as  the  intercept  of  the 
calibration  graph  plus  three  times  the  standard  error  of  the  line  as  shown  in 
Equation  7-1  and  Equation  7-2.236  The  LOQ  was  calculated  statistically  as  the 
intercept  of  the  calibration  graph  plus  five  times  the  standard  error  of  the  line 
as  shown  in  Equation  7-3  and  Equation  7-4.236  The  values  were  calculated  where 
YB  is  the  intercept,  s6  is  the  standard  error  of  the  regression  line  and  m  is  the 
gradient.  30  mg  blank  hair  portions  were  spiked  with  0.1,0.2,0.3,0.4,0.5, 
0.75,1,2  and  5  ng  to  produce  the  regression  lines  used  to  calculate  the  LOD  and 
LOQ. 
Equation  7-1  YLOD  =  YB  +  3s 
Equation  7-2  LOD  = 
(YLOD 
-Ya) 
m 
Equation  7-3  YLOQ  =  YB  +  5s 
Equation  7-4  LOQ  =  "'  LOQ  -Ya 
m 
7.6.2.7  Matrix  Effect 
A  previously  published  quantitative  assessment  of  the  hair  matrix  effect  (ME) 
was  carried  out  for  the  LC-MS-MS  method-`  The  aim  of  the  experiment  was  to 
obtain  more  accurate  data  on  the  extent  of  the  hair  ME  between  individuals. 
Drug  free  hair  was  collected  from  five  individuals.  Each  sample  was 
decontaminated  according  to  the  procedure  described  in  section  6.4.1. 
An  unextracted  set  of  five  50  ng  standards  containing  100  ng  internal  standards 
was  prepared  to  assess  the  MS-MS  response  for  neat  standards  of  the  analytes  of 
interest  (set  1).  The  contents  of  the  vials  were  evaporated  to  dryness  using 
nitrogen  and  reconstituted  in  100  pL  of  mobile  phase  initial  conditions.  An 
extracted  set  of  five  50  ng  standards  containing  100  ng  internal  standards  was 
also  prepared  in  hair  extracts  obtained  from  five  individuals  (set  2).  For  set  2, 
approximately  30  mg  of  blank,  decontaminated  hair  was  weighed  out  and  taken 
through  the  extraction  process.  The  analytes  and  internal  standards  were  spiked Benzodiazepines  in  Hair  Chapter  7,117 
into  these  after  the  SPE.  The  eluants  were  evaporated  to  dryness  using  nitrogen 
and  reconstituted  in  100  pL  of  mobile  phase  (initial  conditions  3  mM  ammonium 
formate  (65  %)  and  acetonitrile  (35  %)).  20  pL  of  the  reconstituted  extract  was 
injected  for  analysis. 
The  average  peak  area  ratio  was  compared  between  the  two  data  sets  to  assess 
the  absence  or  presence  of  ME.  The  absolute  ME  (%  ME)  was  calculated  using 
Equation  7-5  where  A  is  the  standard  response  obtained  from  neat  solutions  in 
set  1  and  B  is  the  corresponding  response  for  standards  spiked  into  hair  extracts 
after  SPE. 
Equation  7-5  ME(%)  =Äx  100 
The  absolute  ME  calculated  in  this  way  takes  into  account  ion  suppression  and 
ion  enhancement.  It  is  described  as  the  "absolute"  ME  as  it  compares  the 
response  of  standard  present  in  the  hair  extract  to  the  response  of  a  standard 
prepared  in  neat  solutions  without  the  presence  of  the  matrix.  A  value  of  100  % 
indicates  that  the  standard  response  from  the  neat  solution  was  the  same  as  the 
standard  response  in  the  hair  extracts  and  no  absolute  ME  was  observed.  A  value 
<100  %  indicates  ion  suppression  while  a  value  >100  %  indicates  ion 
enhancement. 
The  relative  ME  (%  RME)  was  also  calculated  as  it  is  very  important  to  compare 
ME  values  between  hairs  collected  from  different  individuals  to  assess  any  inter- 
individual  variations  that  may  exist.  Hair  collected  from  different  individuals 
may  contain  different  endogenous  compounds  that  may  not  necessarily  have 
been  present  in  the  hair  used  to  validate  the  method.  If  these  compounds  are 
undetected  and  co-elute  with  the  analytes  of  interest,  the  efficiency  of  analyte 
ionisation  could  be  affected,  resulting  in  a  decreased  or  increased  MS-MS 
response. Benzodiazepines  in  Hair 
7.6.3  Results 
7.6.3.1  Linearity 
Chapter  7,118 
The  gradient  and  intercept  values  are  shown  in  Table  7-4  along  with  the 
correlation  coefficient  (R2)  values  for  the  regression  lines.  All  regression  lines 
had  an  RI  >  0.99. 
Table  7-4  Gradient,  intercept  and  R2  values  for  regression  lines 
Analyte  Equation  of  line  R 
7-AF  y=0.0017x-0.0028  0.9981 
Chlordiazepoxide  y=0.0129x-0.0156  0.9994 
Diazepam  y=0.0016x-0.0032  0.9984 
Flunitrazepam  y=0.0019x-0.0011  0.9992 
Lorazepam  y=0.0092+0.0106  0.9974 
Nitrazepam  y=0.0036x+0.0082  0.9977 
Nordiazepam  y=0.0012x-0.0009  0.9995 
Oxazepam  y=0.0093x-0.0122  0.9996 
Temazepam  y=0.01  13x-0.0323  0.9985 
7.6.3.2  Recovery 
The  recovery  for  each  analyte  is  given  in  Table  7-5  for  10  ng/30  mg  and  50  ng/30 
mg  and  ranged  from  53-98  %.  Generally  the  analytes  had  recoveries  >  70  %  at 
both  concentrations.  7-AF  and  chtordiazepoxide  recoveries  were  lower  than  the 
other  analytes. Benzodiazepines  in  Hair 
Table  7-5  Recovery  in  spiked  hair 
Chapter  7,119 
Analyte 
Average  %  Recovery  for  n=5  (%  RSD) 
10  ng/30  mg  50  ng/30  mg 
7-AF  53  (13)  55  (10) 
Chlordiazepoxide  59  (19)  63  (5) 
Diazepam  77  (13)  69  (2) 
Flunitrazepam  90  (11)  89  (6) 
Lorazepam  76(11)  94(10) 
Nitrazepam  98  (10)  91  (9) 
Nordiazepam  88  (12)  82  (5) 
Oxazepam  71  (10)  83  (8) 
Temazepam  73  (16)  88  (8) 
The  experiment  carried  out  on  the  post-mortem  hair  sample  to  assess  the 
efficiency  of  the  extraction  found  that  the  greatest  concentration  of  diazepam 
and  nordiazepam  was  detected  following  16  hour  incubation  (4.26  and  1.67 
ng/mg  respectively).  The  diazepam  and  nordiazepam  concentrations  detected 
after  1,2  and  4  hour  incubation  were  similar  and  were  within  a  small  range 
(2.40-2.70  ng/mg  and  0.90-1.16  ng/mg  respectively).  This  incubation  time  of  16 
hours  was  selected  for  method  validation. 
7.6.3.3  Stability 
The  recovery  for  all  benzodiazepines  following  the  alkaline  overnight  extraction 
ranged  from  89-103  %  as  shown  in  Table  7-6.  These  results  show  that  the  milder 
alkaline  extraction  using  methanol/25  %  ammonium  hydroxide  (20:  1)  is  suitable 
for  benzodiazepine  extraction.  The  lower  7-AF  and  chlordiazepoxide  recoveries 
were  not  a  result  of  alkaline  hydrolysis.  Lorazepam  was  hydrolysed  to  a  greater 
extent  than  temazepam  or  oxazepam,  which  have  a  similar  molecular  structure 
to  lorazepam.  It  is  possible  that  the  presence  of  an  electron  withdrawing 
chlorine  atom  on  both  aromatic  rings  of  the  lorazepam  structure  (Figure  7-1) 
increases  the  lability  of  the  ring  C=N  to  attack  by  the  base  used  in  the 
extraction,  promoting  hydrolysis.  Temazepam  and  oxazepam  only  have  one 
electron  withdrawing  chlorine  atom  and  are,  therefore,  less  susceptible  to 
hydrolysis. Benzodiazepines  in  Hair  Chapter  7,120 
For  the  evaporation  experiment,  all  benzodiazepines  with  the  exception  of  7-AF 
and  chlordiazepoxide  had  a  recovery  >_  95  %.  7-AF  recovery  was  73  %  and 
chlord  iazepoxide  recovery  was  87  %,  which  partly  explains  the  lower  extraction 
recoveries  found  for  these  analytes.  The  recovery  values  for  the  evaporation 
step  are  shown  in  Table  7-6. 
Table  7-6  Benzodiazepine  stability  during  alkaline  incubation  and  evaporation  step 
Analyte 
Average  %  Recovery  (%  RSD)  for  n=4 
Alkaline  Incubation  Evaporation  Step 
7-AF  100  (2)  73  (6) 
Chlordiazepoxide  98  (2)  87  (8) 
Diazepam  96  (4)  100  (5) 
Flunitrazepam  99  (4)  107  (1) 
Lorazepam  89  (9)  104  (5) 
Nitrazepam  103  (6)  102  (4) 
Nordiazepam  98  (12)  95  (12) 
Oxazepam  98  (6)  99  (4) 
Temazepam  91  (3)  104  (7) 
7.6.3.4  Intra-Day  and  Inter-Day  Precision 
As  shown  in  Table  7-7  and  Table  7-8,  the  intra-day  and  inter-day  precision  were 
all  generally  acceptable  within  SOFT  regulations  of  ±  20  %.  "  The  %  RSD  values 
were  generally  lower  at  the  higher  concentrations.  As  expected,  the  intra-day 
precision  was  lower  than  the  inter-day  precision. Benzodiazepines  in  Hair 
Table  7-7  Intra-day  precision  between  extracts 
Chapter  7,121 
Analyte 
Intra-Day  Precision  (%  RSD)  for  n=5 
10  ng/30  mg  50  ng/30  mg 
7-AF  10.9  (5.2)  50.1  (1.4) 
Chlordiaze  oxide  9.6  (9.7)  45.3  (6.1) 
Diazepam  9.6  (4.5)  51.4  (4.0) 
Flunitrazepam  8.5  (3.0)  49.3  (2.1) 
Lorazepam  9.5  (7.1)  49.1  (5.8) 
Nitrazepam  10.0  (9.0)  52.4  (4.1) 
Nordiazepam  9.7  (8.8)  45.9  (3.1) 
Oxazepam  7.0  (10.8)  58.6  (7.1) 
Temazepam  9.1  (12.3)  53.3  (4.3) 
Table  7-8  Inter-day  precision  between  extracts 
Inter-Day  Precision  (%  RSD)  for  n=25  Analyte  10  ng/30  mg  50  ng/30  mg 
7-AF  10.3  (9.9)  50.7  (4.5) 
Chlordiazepoxide  8.0  (19.9)*  53.3  (16.5) 
Diazepam  9.2  (21.1)*  45.9  (11.8) 
Flunitrazepam  9.1  (9.8)  48.8  (6.5) 
Lorazepam  7.9  (21.2)  50.6  (13.5) 
Nitrazepam  8.9  (7.7)  47.9  (11.1) 
Nordiazepam  9.2  (9.3)  48.0  (5.5) 
Oxazepam  6.3  (13.0)  49.2  (19.6) 
Temazepam  7.8  (18.6)  48.2  (10.0) 
'n=24 
7.6.3.5  LOD  and  LOQ 
The  LOD  and  LOQ  for  all  the  benzodiazepines  tested  ranged  from 
0.03-0.62  ng/30  mg  and  0.05-1.02  ng/30  mg  respectively.  The  values  are  shown 
in  Table  7-9. Benzodiazepines  in  Hair 
Table  7-9  LOD  and  LOQ 
Chapter  7,122 
Analyte  LOD  (ng/30  mg)  LOQ  (ng/30  mg) 
7-AF  0.14  0.23 
Chlordiazepoxide  0.07  0.13 
Diazepam  0.13  0.22 
Flunitrazepam  0.30  0.50 
Lorazepam  0.62  1.02 
Nitrazepam  0.03  0.05 
Nordiazepam  0.24  0.41 
Oxazepam  0.11  0.19 
Temazepam  0.09  0.16 
7.6.3.6  Matrix  Effect 
The  %  ME  and  %  RME  are  shown  in  Table  7-10.  %  RME  was  calculated  as  the 
%  RSD  of  the  responses  for  the  hair  from  5  individuals.  The  %  RSD  for  five 
unextracted  standards  is  also  shown  in  Table  7-10  to  compare  against  the  %  RME. 
Table  7-10  Hair  matrix  effect 
Analyte  %  ME  %  RME 
%  RSD  for  n=5 
unextracted 
standards 
7-AF  94  1.6  3.4 
Chlordiazepoxide  77  10.8  12.7 
Diazepam  84  10.5  3.4 
Ftunitrazepam  88  5.7  2.1 
Lorazepam  105  6.5  5.1 
Nitrazepam  79  9.3  8.7 
Nordiazepam  88  5.2  2.0 
Oxazepam  93  9.3  3.9 
Temazepam  96  10.5  1.6 
The  %  ME  results  show  that  there  is  some  ion  suppression  for  most  of  the 
benzodiazepines.  In  contrast,  the  lorazepam  response  shows  slight 
enhancement.  The  %  RME  values  were  within  the  range  of  1.6-  10.8  %.  These 
values  show  that  the  method  allows  an  acceptable  level  of  precision  between 
hair  samples  collected  from  five  different  individuals  according  to  the  intra-day 
and  inter-day  precision  guidelines  recommended  by  SOFT.  "  However  acceptable 
%  ME  and  %  RME  ranges  have  not  been  specified  for  LC-MS-MS  yet  as  there  is 
currently  not  enough  data  to  provide  these  guidelines.  Small  differences 
between  the  values  for  the  standards  spiked  into  hair  extracts  after  SPE  (B 
values  according  to  Equation  7-5)  indicate  that  the  MS-MS  response  from  the Benzodiazepines  in  Hair  Chapter  7,123 
same  quantity  of  analyte  is  similar  in  different  hair  samples.  The  difference  in 
variability  was  higher  for  chlordiazepoxide,  diazepam  and  temazepam.  This 
indicates  that  the  interferent  from  the  hair  matrix  that  co-elutes  at  the  same 
time  as  these  benzodiazepines  is  present  in  different  quantities  between 
individuals. 
7.6.4  ELISA  vs  LC-MS-MS  Results 
The  validated  ELISA  and  LC-MS-MS  methods  for  the  detection  of  benzodiazepines 
in  hair  were  successfully  applied  to  13  post-mortem  positive  hair  samples.  "' 
Overall,  the  ELISA  and  LC-MS-MS  results  correlated  well.  13  of  the  16  hair 
samples  were  screened  and  confirmed  as  TP  using  a  cut-off  value  of  0.1  ng/mg 
oxazepam.  This  cut-off  value  was  used  as  it  produced  no  FN  results.  Higher  cut- 
off  values  of  0.2  and  0.5  ng/mg  oxazepam  produced  1  FN  and  2  FN  results 
respectively.  Using  a  0.1  ng/mg  cut-off,  the  sensitivity  and  specificity  of  the 
ELISA  method  were  100  %  and  81  %  respectively  versus  LC-MS-MS.  The  results 
are  shown  in  Table  7-11. 
Table  7-11  ELISA  vs  LC-MS-MS  results  for  benzodiazepine  positive  hair  samples 
ELISA  LC-MS-MS  (ng/m  g) 
Sample 
Number 
Weight 
(mg)  Equivalents 
OXAZ 
(ng/mg) 
Weight 
(  g) 
1  8.96  >  0.5  13.23  -  -  0.35  -  -  - 
2  10.18  >  0.5  9.88  <LOD  0.28  0.22  -  -  - 
3  8.19  >  0.5  9.29  0.65  1.20  0.24  -  0.24  - 
4  4.30  >  0.5  7.13  <LOD  0.36  0.31  0.89  -  0.38 
5  10.03  >  0.5  9.90  <LOQ  0.27  -  -  -  - 
6  6.36  >  0.5  5.94  0.32  0.47  0.36  -  -  - 
7  10.33  >  0.5  9.86  0.46  -  -  -  -  - 
8  10.45  >  0.5  6.47  2.86  1.79  0.73  0.35  -  - 
9  20.74  >  0.5  40.56  0.39  1.07  0.30  -  -  - 
10  10.23  >  0.5  9.95  <  LOQ  0.31  0.22  -  -  - 
11  9.94  >  0.5  10.02  0.03  0.43  -  -  -  - 
12  9.89  >  0.5  9.80  0.06  0.28  0.23  0.59  -  - 
13  5.51  0.48  7.96  <  LOQ  -  0.27  -  -  - 
DZ=diazepam,  Nuc=nomiazepam,  I  ML=temazepam,  UXAL=oxazepam,  NTZ=nitrazepam, 
LOR=lorazepam 
The  benzodiazepines  detected  by  LC-MS-MS  included  diazepam  (10  samples), 
nordiazepam  (10  samples),  oxazepam  (3  samples),  temazepam  (10  samples), 
lorazepam  (1  sample)  and  nitrazepam  (1  sample).  The  diazepam  levels  detected Benzodiazepines  in  Hair  Chapter  7,124 
in  3  of  the  10  positive  samples  were  below  the  LOQ  therefore  only  7  samples 
were  reported  as  positive.  Concentrations  ranged  from  0.01-2.86  ng/mg 
diazepam,  0.27-1.79  ng/mg  nordiazepam,  0.35-0.89  ng/mg  oxazepam  and  0.22- 
0.73  ng/mg  temazepam.  One  sample  tested  positive  for  lorazepam  at 
0.38  ng/mg  while  another  sample  tested  positive  for  nitrazepam  at  0.24  ng/mg. 
Chromatograms  are  shown  for  a  blank  hair  sample  spiked  with  temazepam  at  the 
lowest  standard  concentration  (Figure  7-3),  a  negative  sample  (Figure  7-4),  a 
temazepam  positive  case  sample  (Figure  7-5)  and  a  temazepam-d5  internal 
standard  (Figure  7-6). 
Figure  7-3  Blank  hair  sample  spiked  with  temazepam  at  2  ng/  30  mg 
D0®3ý  001 
I.  - 
Figure  7-4  Negative  hair  sample Benzodiazepines  in  Hair 
Figure  7-5  Temazepam  positive  case  sample 
{  ,- 
Figure  7-6  Temazepam-d5  internal  standard 
7.6.5  Discussion 
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Chapter  7,125 
A  comparison  of  the  hair  and  blood  results  shown  in  Table  7-12  (provided  at  the 
end  of  this  chapter),  found  that  diazepam  was  detected  in  10  hair  samples 
where  a  diazepam  positive  result  was  found  in  blood.  1  hair  sample  contained  a 
diazepam  level  <  LOD  (0.13  ng/30  mg).  Nordiazepam  was  not  detected  in  1 
sample  in  which  the  blood  result  was  positive.  Interestingly,  temazepam  was 
detected  in  4  hair  samples  in  which  the  blood  result  was  negative.  There  was 
however  1  sample  where  the  hair  tested  negative  for  temazepam  in  which  the 
blood  results  were  positive.  The  levels  of  temazepam  in  blood  were  very  low  in 
these  cases  (0.02  mg/L).  These  blood  levels  could  have  been  from  a  naive  user Benzodiazepines  in  Hair  Chapter  7,126 
but  there  was  no  information  in  the  police  report  to  support  this.  Oxazepam 
was  detected  in  1  hair  sample  in  which  the  blood  result  was  positive. 
Interestingly,  it  was  detected  in  2  hair  samples  where  the  blood  result  was 
negative.  In  contrast,  5  hair  samples  tested  negative  for  oxazepam  where  the 
blood  result  was  positive.  The  blood  results  were  very  low  in  three  of  these 
cases  (samples  3,5  and  13).  Lorazepam  and  nitrazepam  were  detected  in  1  hair 
sample  in  which  the  blood  result  was  negative. 
In  general,  benzodiazepine  levels  were  in  the  ranges  reported  in  the  literature. 
With  the  exception  of  sample  8,  nordiazepam  was  detected  at  a  higher 
concentration  than  diazepam.  This  finding  is  consistent  with  other  studies.  ",  " 
Oxazepam  was  only  detected  in  3  samples.  A  possible  reason  for  this  low 
detection  rate  may  be  that  oxazepam  has  a  relatively  short  half  life  compared  to 
nordiazepam  for  example  and  is  a  polar  compound  which  may  not  readily 
incorporate  into  hair.  22B  Temazepam  levels  have  not  been  widely  reported  in 
hair.  In  this  study,  temazepam  levels  were  present  within  a  relatively  small 
range  of  0.22-0.36  ng/mg  with  the  exception  of  sample  8  which  had  a  higher 
temazepam  level  of  0.73  ng/mg.  A  possible  reason  for  the  lower  temazepam 
levels  found  in  this  study  is  that  temazepam  is  likely  to  be  present  as  a 
metabolite  of  diazepam,  rather  than  the  parent  compound.  In  addition  steady. 
state  serum  levels  of  oxazepam  (0.05-0.40  mg/L)  and  temazepam  (0.1-0.6  mg/L) 
are  much  lower  than  nordiazepam  following  diazepam  use.  116  Lorazepam  and 
nitrazepam  levels  in  hair  have  also  not  been  widely  reported.  The  lorazepam 
positive  sample  was  found  to  contain  0.38  ng/mg,  which  is  slightly  higher  than 
the  reported  range  of  31-300  pg/mg.  224'23'  The  nitrazepam  level  detected  in 
sample  3  (0.24  ng/mg)  was  also  higher  than  the  range  found  in  another  study 
(0.05-0.13  ng/mg).  235 
Overall,  it  is  difficult  to  directly  compare  the  benzodiazepine  levels  detected  in 
this  study  with  those  reported  by  other  authors  because  of  the  range  of 
extraction  and  analytical  methods  used  which  will  have  varying  recoveries  of  the 
drugs  from  hair. 
It  is  also  difficult  to  interpret  the  hair  results  since  the  amount  and  type  of  drug 
taken  over  the  months  prior  to  death  is  not  known  in  the  majority  of  cases.  The 
individual  from  which  sample  8  was  collected  was  being  prescribed  4x5  mg Benzodiazepines  in  Hair  Chapter  7,127 
diazepam  tablets  a  day  and  5  mg  nitrazepam  at  night.  It  is  not  known  how  long 
the  individual  had  been  under  this  treatment.  The  highest  diazepam  level  of  all 
the  hair  samples  tested  was  found  in  this  particular  sample  however  no 
nitrazepam  was  detected.  The  individual  from  which  sample  12  was  collected 
had  been  prescribed  diazepam  6  months  prior  to  death.  From  the  background 
report,  it  is  not  known  if  the  individually  had  been  prescribed  diazepam  for 
chronic  or  single  use. 
Another  problem  with  the  interpretation  of  results  is  that  diazepam  is 
metabolised  to  nordiazepam  and  temazepam  which  can  both  be  further 
metabolised  to  oxazepam.  As  well  as  potentially  being  present  in  hair  samples 
due  to  diazepam  metabolism,  nordiazepam,  temazepam  and  oxazepam  can  also 
be  ingested  as  parent  drugs  or  could  be  present  as  an  association  with  both 
metabolism  and  parent  drug  use. 
7.6.6  MISPE  and  SPE  Case  Results 
The  MIP  produced  was  selective  for  not  only  diazepam  (the  template)  but  also 
for  nordiazepam,  oxazepam,  temazepam  and  nitrazepam  because  they  are  close 
structural  analogues  of  diazepam. 
10  post-mortem  hair  samples  were  tested  using  MISPE  to  compare  with  the  SPE 
method.  The  other  samples  did  not  have  sufficient  sample  weight  to  test  using 
MISPE  as  welt.  The  same  incubation  method  as  described  in  section  7.5.6.2.1 
was  used  prior  to  extraction.  Benzodiazepines  were  detected  in  9  samples  using 
the  MISPE  method  and  in  7  samples  using  the  classial  SPE  method.  No 
benzodiazepines  were  detected  by  either  extraction  method  in  sample  3  where  a 
very  low  level  of  nordiazepam  was  detected  in  the  blood  (0.01  mg/L). 
Diazepam  was  detected  in  4  samples  using  MISPE  where  none  was  detected  using 
SPE.  Nordiazepam  and  oxazepam  were  also  detected  in  1  sample  (samples  4  and 
2  respectively)  at  low  levels  using  MISPE  where  none  was  detected  using  SPE. 
The  results  for  sample  10  did,  however,  show  a  significantly  lower  oxazepam 
concentration  using  MISPE  compared  to  SPE.  Temazepam  was  detected  in  2 
samples  by  SPE  where  none  was  detected  by  MISPE.  The  nitrazepam  results  for 
the  two  methods  showed  good  correlation. Benzodiazepines  in  Hair  Chapter  7,128 
The  MISPE  and  SPE  results  are  provided  in  Table  7-13  (at  the  end  of  this  chapter) 
along  with  the  corresponding  blood  concentrations.  The  sample  numbers  in 
Table  7-13  do  not  correspond  to  the  same  samples  provided  in  Table  7-12.  In 
general,  the  hair  results  are  in  good  qualitative  agreement  using  both  extraction 
methods. 
7.6.7  MISPE  vs  SPE  Discussion 
The  MISPE  demonstrated  higher  extraction  recoveries  for  6  out  of  9  analytes, 
whereas  the  SPE  method  achieved  lower  LOD  values  for  6  out  of  9  analytes.  The 
recovery,  LOD  and  LOQ  values  for  both  extractions  are  given  in  Table  7-14. 
Table  7-14  Spiked  recovery,  LOD  and  LOQ  of  benzodiazepines  using  MISPE  and  SPE 
Analyte 
Mean  %  Recovery 
(%  RSD)  for  n=5  at 
50  ng/30  mg 
LOD  (ng/30  mg)  LOQ  (ng/30  mg) 
MISPE  SPE  MISPE  SPE  MISPE  SPE 
7-AF  92  (2)  55  (10)  0.03  0.14  0.06  0.23 
Chlordiaze  oxide  62  (14)  63  (5)  0.33  0.07  0.57  0.13 
Diazepam  93  (2)  69  (2)  0.09  0.13  0.14  0.22 
Flunitrazepam  39  (5)  89  (6)  0.78  0.30  1.32  0.50 
Lorazepam  97(17)  94(10)  0.66  0.62  1.11  1.02 
Nitrazepam  92  (5)  91  (9)  0.06  0.03  0.11  0.05 
Nordiazepam  103  (10)  82  (5)  0.21  0.24  0.33  0.41 
Oxazepam  73  (9)  83  (8)  0.13  0.11  0.21  0.19 
Temazepam  90  (13)  88  (8)  0.39  0.09  0.63  0.16 
In  this  study,  benzodiazepine  concentrations  were  measured  in  9  post-mortem 
hair  samples  using  MISPE  and  SPE  sample  preparation  methods.  The  results  show 
that  diazepam  was  most  frequently  detected,  followed  by  its  metabolite 
nordiazepam. 
Both  the  MISPE  and  SPE  methods  were  validated  for  9  benzodiazepines.  94.  "' 
However,  only  diazepam,  its  metabolites  and  nitrazepam  were  detected  in  the 
samples.  The  greater  number  of  diazepam  and  nordiazepam  positive  samples 
detected  using  MISPE  could  be  attributed  to  the  higher  extraction  recovery  and 
lower  LOD  values  obtained  when  using  this  protocol  compared  to  SPE. 
Conversely,  temazepam  was  detected  in  less  samples  using  MISPE  compared  to 
SPE  due  to  the  higher  LOD  value  using  MISPE.  Temazepam  recoveries  for  the  two 
methods  were  comparable. Benzodiazepines  in  Hair  Chapter  7,129 
In  the  samples  which  tested  positive  for  diazepam  using  both  extraction 
methods,  the  concentration  detected  using  MISPE  was  generally  similar  to  those 
detected  using  SPE.  The  excellent  recognition  of  the  template  molecule  by  the 
MIP  resulting  in  a  higher  extraction  recovery  and  lower  LOD  meant  that 
diazepam  was  detected  in  4  samples  at  low  levels  where  SPE  detected  none.  For 
the  samples  where  both  extraction  methods  tested  positive  for  nordiazepam, 
temazepam  and  oxazepam,  the  concentrations  were  always  higher  for  SPE. 
Interestingly,  oxazepam  was  detected  in  1  sample  using  MISPE  where  none  was 
detected  using  SPE  despite  its  slightly  lower  LOD.  Nitrazepam  levels  detected 
by  the  MISPE  and  SPE  methods  were  comparable. 
Although  the  MISPE  and  SPE  methods  are  in  good  qualitative  agreement,  there 
are  some  quantitative  differences  between  the  two  extraction  methods, 
particularly  for  diazepam  metabolites.  Concentration  differences  of  this  type 
can  be  due  to  systematic  bias  or  else  they  may  reflect  some  degree  of  selectivity 
by  the  MIP  between  the  analyte  and  internal  standard  during  the  extraction 
process.  Taking  the  classical  SPE  method  as  the  Gold  Standard  procedure,  the 
new  MISPE  method  shows  in  most  cases  a  negative  bias,  which,  in  percentage 
terms,  is  high  in  some  cases.  The  bias  is  not  completely  systematic  as  the  %  bias 
varies  with  concentration.  Most  of  the  large  differences  relate  to  cases  in  which 
the  concentrations  measured  are  low  and  close  to  the  LOQ. 
The  most  likely  explanation  is  that  the  MIP  procedure  results  in  extracts  with 
less  interference  than  the  SPE  procedure  (Figure  7-7)  and  that  these 
interferences  augment  the  peak  areas  in  the  product  ion  chromatograms 
obtained  for  classical  SPE  extracts.  This  implies  that  the  classical  procedure 
may  show  lower  selectivity  than  the  MIP  procedure. 
The  results  show  that  the  MISPE  method  is  selective  for  diazepam  metabolites 
and  other  benzodiazepine  analogues.  It  detected  diazepam  and  oxazepam  in 
samples  which  tested  negative  using  the  classical  SPE  approach.  Overall,  the 
MISPE  method  appears  to  be  significantly  more  streamlined  than  the  SPE 
method,  providing  a  simpler  and  more  time  efficient  procedure. Benzodiazepines  in  Hair 
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Figure  7-7  Chromatograms  of  the  SPE  and  MISPE  extracts  showing  LC-MS-MS  interference 
in  the  nordiazepam  and  diazepam  scan  segment  for  the  SPE  extract  only 
7.7  Conclusion 
The  validated  ELISA  and  LC-MS-MS  methods  detected  6  therapeutic 
benzodiazepines  in  hair.  13  samples  screened  as  TP  using  the  ELISA  versus 
LC-MS-MS  method.  The  ELISA  method  showed  100  %  sensitivity  and  81  % 
specificity  using  a  cut-off  value  of  0.1  ng/mg  oxazepam. 
The  LC-MS-MS  method  provided  the  sensitivity  necessary  for  quantitation  of 
benzodiazepines  in  post-mortem  hair  samples.  It  appears  that  mild  alkaline 
extraction  conditions  are  suitable  for  benzodiazepines  and  do  not  result  in  any 
significant  hydrolysis.  An  incubation  time  of  16  hours  in  the  alkaline  medium 
produced  the  greatest  diazepam  and  nordiazepam  recoveries  compared  to 
shorter  incubation  times  for  one  case  sample.  The  evaporation  step  in  the  SPE 
method  resulted  in  a  relatively  high  loss  of  7-AF  and  chlordiazepoxide,  which  is 
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Chapter  7,130 
partly  responsible  for  the  lower  recoveries  for  these  analytes. Benzodiazepines  in  Hair  Chapter  7,131 
The  comparison  of  the  hair  and  blood  results  showed  that  some  benzodiazepines 
were  detected  in  hair  but  not  in  blood  and  vice  versa.  Hair  analysis  for 
benzodiazepines  should  be  used  to  complement  blood  analysis. 
The  preliminary  study  into  the  use  of  a  diazepam  MIP  for  the  detection  of 
benzodiazepines  in  post-mortem  hair  case  samples  has  shown  that  it  can  be 
applied  successfully  for  this  purpose.  The  MISPE  method  detected  a  higher 
number  of  diazepam  positive  case  samples  than  the  classical  SPE  method 
because  of  the  higher  extraction  recovery  of  the  MISPE  method  and  the  excellent 
molecular  recognition  of  the  template  molecule  (diazepam)  imparted  by  the 
imprinting  process.  The  MISPE  method  has  demonstrated  selectivity  for  other 
benzodiazepine  analogues  and  detected  nordiazepam  and  oxazepam  in  one 
sample  where  SPE  detected  none.  The  MISPE  method  was,  however,  not  as 
selective  for  temazepam  as  the  SPE  method.  Nordiazepam,  oxazepam  and 
temazepam  concentrations,  when  detected  using  both  extraction  methods,  were 
higher  using  the  SPE  method.  The  most  likely  explanation  for  this  is  that  the 
MISPE  method  has  a  higher  selectivity  than  the  SPE  method,  with  fewer  matrix 
interferences.  Further  work  is  required  to  investigate  the  possibility  of  mixing 
two  or  more  MISPE  sorbents  in  one  cartridge  to  detect  a  particular  drug  class  and 
also  the  ability  of  the  MISPE  to  detect  benzodiazepines  in  single  dose  hair 
samples. N 
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8  Drugs  of  Abuse  in  Hair 
8.1  Introduction 
Reports  on  hair  testing  in  literature  generally  restrict  analysis  to  one  or  a  few 
drug  groups.  One  of  the  reasons  for  this  is  that  with  hair  analysis  the  possible 
number  of  examinations  is  limited  due  to  a  lack  of  sample.  In  addition,  the 
reproducibility  of  quantitative  analysis  of  a  hair  sample  is  limited  by  the  amount 
of  sample  and  the  unknown  recovery  of  the  extraction  procedure.  Therefore, 
semi-quantitative  estimations  of  drug  concentrations  based  on  single  injections 
are  more  typical  than  validated  high  throughput  assays.  13,230 
The  usual  procedure  for  hair  analysis  for  drugs  of  abuse  involves  an  initial  screen 
by  immunoassay  followed  by  confirmation  with  a  more  sensitive  and  specific 
technique.  GC-MS11'231  and  LC-MS-MS94  methods  have  been  reported  for 
qualitative  analysis  of  the  common  drugs  of  abuse  in  hair  and  simultaneous 
quantification  of  two  or  three  targeted  drug  groups.  22,71,232  A  recently  published 
article  does  however  describe  the  simultaneous  extraction,  identification  and 
quantification  of  four  commonly  abused  drug  groups  in  hair  by  GC-MS.  233 
LC-MS-MS  methods  have  also  been  developed  in  some  laboratories  for  analysing 
more  than  four  commonly  abused  drug  groups94  but  this  technique  is  not 
routinely  available  in  most  toxicology  laboratories. 
For  the  analysis  of  hair  taken  from  poly-drug  users  including  drug-related  deaths 
and  patients  undergoing  therapy  on  drug  treatment  programmes,  where  several 
drug  classes  could  be  present  in  each  sample,  it  is  more  efficient  to 
simultaneously  screen  and  quantify  the  different  drug  classes  using  a  single 
extraction  and  analysis.  The  LC-MS-MS  method  described  in  this  work  has  been 
validated  for  the  simultaneous  identification  and  quantification  of: 
amphetamines,  including  amphetamine,  methamphetamine,  MDA,  MDMA  and 
MDEA;  the  most  commonly  abused  benzodiazepine  in  Scotland,  diazepam  and  its 
metabolites;  cocaine  and  its  metabolites  namely  benzoylecgonine,  cocaethylene 
and  ecgonine  methyl  ester;  and  opiates  including  codeine,  dihydrocodeine, 
6-MAM  and  morphine. Drugs  of  Abuse  in  Hair  Chapter  8,135 
Several  papers  have  evaluated  different  methods  for  extracting 
amphetamines  1,112,  benzodiazepines226,227,  cocaine243,244  and  heroin 
metabolites"'  79,245  from  hair.  The  methods  used  were  carried  out  at  various 
temperatures  and  involved  solvent  extraction,  enzymatic  digestion  and  acidic  or 
basic  digestion  from  cut  or  pulverised  hair.  Basic  extraction  conditions  were 
found  to  degrade  some  drugs  such  as  heroin,  cocaine  and  benzodiazepines  while 
the  enzymatic  digestion  and  solvent  extraction  methods  demonstrated  a  very 
small  amount,  if  any,  degradation.  Direct  solvent  extractions  were  found  to  give 
the  lowest  drug  recoveries  while  complete  dissolution  of  the  hair  matrix 
produced  the  highest  recoveries  for  substances  that  could  withstand  the  extreme 
conditions.  After  extraction  of  the  drugs  from  the  hair  matrix,  the  analysis  is 
carried  out  using  very  similar  procedures  to  those  used  to  extract  drugs  from 
blood  or  urine. 
8.2  Drugs  of  Abuse 
8.2.1  Amphetamines 
Amphetamines  are  central  nervous  system  stimulants  used  therapeutically  in  the 
treatment  of  obesity,  narcolepsy  and  hypotension  however  they  are  also  abused 
by  athletes,  addicts  and  mainly  young  people  at  "raves"  to  enhance  their 
performance.  Amphetamine  abuse  has  been  prevalent  in  some  particular 
geographic  areas  such  as  Japan,  Far  East  and  the  United  States.  However,  there 
is  an  increasing  consumption  of  amphetamine  in  Europe  where  it  is  reported  to 
be  the  second  most  commonly  abused  drug  after  cannabis.  246  In  this  study,  the 
classical  amphetamines,  amphetamine  and  methamphetamine,  as  well  as  the 
methylenedioxy-substituted  amphetamines  methylenedioxyethylamphetamine 
(MDEA),  methylenedioxymethamphetamine  (MDMA)  and 
methylenedioxyamphetamine  (MDA)  were  investigated  in  post-mortem  hair 
samples.  The  common  route  of  administration  for  these  drugs  is  by  oral  means. 
However,  amphetamine  and  methamphetamine  have  also  been  taken 
intranasally  and  by  intravenous  injection  to  produce  euphoric  effects. 
Methamphetamine  is  manufactured  as  the  hydrochloride  salt  and  is  smoked.  It 
resembles  colourless  fragments  of  ice  (Figure  8-1)  and  hence  is  known  by  this 
streetname.  The  methylenedioxy-substituted  amphetamines  such  as  MDMA Drugs  of  Abuse  in  Hair  Chapter  8,136 
(Figure  8-2)  produce  effects  such  as  euphoria,  enhanced  energy  and  lowers 
inhibitions. 
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Figure  8-1  Methamphetamine  HCI  ("Ice")  Figure  8-2  MDMA  ("ecstasy")  tablets 
8.2.1.1  Pharmacokinetics  and  Metabolism 
Pharmacokinetic  data  for  amphetamine,  methamphetamine  and  MDMA  is  given  in 
Table  8-1.  There  has  been  little  research  on  the  pharmacokinetics  of  MDA  and 
MDEA  and  so  the  data  for  these  two  compounds  is  not  provided. 
Table  8-1  Pharmacokinetic  and  physicochemical  data  for  amphetamines  176 
Half  Life  (hr)  Vd  (L/kg) 
Protein 
Binding  (%)  P, 
7-34 
Amphetamine  (urine  pH  3.2-5.6  16  9.9 
dependent) 
6-15 
Methamphetamine  (urine  pH  3.0-7.0  10-20  9.9 
dependent) 
MDMA  6-9  5.0-8.0  -  - 
Amphetamines  are  weak  bases  with  low  molecular  weights  and  low  protein 
binding.  Therefore,  they  can  easily  diffuse  across  the  cell  membrane  and 
become  incorporated  in  samples  such  as  hair,  nails,  sweat  and  oral  fluid.  Hair  is 
a  very  useful  sample  for  determining  an  individual's  past  history  of  amphetamine 
abuse. 
Amphetamine  is  metabolised  by  hydroxylation  of  the  aromatic  ring  to 
p-hydroxyamphetamine  and  by  deamination  to  phenylacetone,  with  subsequent 
oxidation  to  benzoic  acid.  16  Glucuronide  conjugates  are  also  formed  during 
metabolism.  Methamphetamine  is  partially  metabolised  to  amphetamine,  which Drugs  of  Abuse  in  Hair  Chapter  8,137 
is  an  active  metabolite,  then  further  metabolised  in  the  same  way  as  described 
for  amphetamine.  MDMA  and  MDEA  are  metabolised  to  form  MDA.  These 
metabolic  pathways  are  shown  in  Figure  8-3-Figure  8-6. 
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8.2.2  Benzodiazepines 
As  discussed  in  chapter  7,  benzodiazepines  are  commonly  prescribed  and  abused 
drugs.  Diazepam  is  prescribed  under  the  trade  name  Valium®  as  an  anti-anxiety 
agent,  muscle  relaxant  or  anticonvulsant.  Temazepam,  oxazepam  and 
nordiazepam  are  metabolites  of  diazepam  and  can  also  be  prescribed  for  these 
purposes  but  this  is  less  frequent  in  Scotland.  179 
8.2.2.1  Pharmacokinetics  and  Metabolism 
The  pharmacokinetic  properties  of  the  drugs  are  summarised  in  the  previous 
chapter  in  Table  7-1.  Diazepam  metabolism  is  described  in  section  7.2  and  the 
molecular  structures  of  diazepam  metabolites  are  shown  in  Figure  7-1. 
8.2.3  Cocaine 
Cocaine  is  the  most  potent  naturally  occurring  central  nervous  system  stimulant 
and  therefore  has  a  long  history  of  use  and  abuse.  13  Cocaine  is  extracted  from 
the  leaves  of  Erythroxylon  coca  (Figure  8-7)  which  is  a  South  American  shrub  and 
constitutes  up  to  2%  of  the  leaf's  weight.  "b 
It  was  first  produced  as  pure  cocaine  in  1855  and  has  been  widely  used  by  drug 
users  as  it  produces  feelings  of  euphoria.  Illicit  cocaine  when  taken  by  drug 
users  is  usually  administered  intranasally,  intravenously  or  through  smoking  the 
free  base  which  is  known  as  "crack  cocaine"  (Figure  8-8).  Only  30-70  %  of  a  dose 
of  "crack  cocaine"  is  absorbed  by  smoking  due  to  pyrolysis.  "b  Intranasal  and  oral 
routes  of  administration  produced  lower  plasma  concentrations  than  intravenous 
routes  due  to  slower  absorption.  176 Chapter  8,139 
Figure  8-7  Erythroxylon  coca  shrub  Figure  8-8  "Crack  cocaine" 
8.2.3.1  Pharmacokinetics  and  Metabolism 
Cocaine  is  rapidly  hydrolysed  by  one  or  both  of  the  ester  linkages  to  produce 
benzoylecgonine  and  ecgonine  methyl  ester  which  are  its  two  main  metabolites 
(Figure  8-9).  Both  of  these  are  pharmacologically  inactive.  A  number  of  minor 
metabolites  are  also  produced.  "' 
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The  pharmacokinetic  and  physicochemical  data  is  presented  for  cocaine  in  Table 
8-2 
Drugs  of  Abuse  in  Hair Drugs  of  Abuse  in  Hair  Chapter  8,140 
Table  8-2  Pharmacokinetic  and  physicochemical  data  for  cocaine  176 
Half  Life  (hr)  Vd  (L/kg)  Protein 
Pý  Binding  (%) 
Cocaine  0.7-1.5  1.6-2.7  92  8.6 
Cocaine  is  a  highly  lipophilic  compound  and  consequently  accumulates  in  fatty 
tissues  during  chronic  use  for  a  period  of  2-3  weeks  before  excretion.  247 
8.2.4  Opiates 
The  term  opiate  describes  natural  opium  alkaloids  and  the  semisynthetics 
derived  from  them.  Opium  is  a  resin  collected  from  the  Papaver  Somniferum 
poppy  (Figure  8-10).  It  contains  morphine,  codeine,  papaverine  and  noscapine. 
Morphine  is  acetylated  in  clandestine  laboratories  to  produce  diamorphine  for 
the  black  market  (Figure  8-11).  Codeine  is  also  acetylated  to  produce 
acetytcodeine  during  this  process.  In  the  UK,  heroin  is  commonly  defined  as  a 
mixture  of  impurities,  reaction  intermediates,  and  breakdown  products 
manufactured  during  the  synthesis  of  diamorphine,  including  the  excipients  and 
adulterants  used  to  dilute  or  cut  the  drugs.  248 
Figure  8-10  Papaver  Somniferum  poppy  Figure  8-11  Diamorphine 
Opiates  have  been  used  medicinally  for  the  treatment  of  acute  pain.  They  have 
also  been  used  to  ease  the  chronic  and  severe  pain  of  cancer  patients.  Some 
opiates  are  widely  abused  for  their  euphoria-producing  properties  which  result 
through  oral,  intravenous,  intranasal  or  smoking  routes  of  administration.  The 
feeling  of  euphoria  gained  through  opiate  use  has  been  associated  with  the 
psychological  dependence  and  subsequent  addiction  to  these  drugs.  13  Opiate 
tolerance  is  known  to  rapidly  develop  to  the  extent  that  rapid  dose  increases  are 
required  to  achieve  the  euphoric  state. Drugs  of  Abuse  in  Hair  Chapter  8,141 
8.2.4.1  Pharmacokinetics  and  Metabolism 
Diamorphine  is  rapidly  absorbed  and  metabolised  in  the  liver  following 
intravenous  injection  (t112  in  plasma  is  2-6  minutes).  Due  to  its  rapid 
metabolism,  it  is  not  usually  targeted  as  evidence  of  opiate  use  in  body  fluids. 
Diamorphine  is  rapidly  metabolised  via  deacetylation  to  6-MAM  and  then  more 
slowly  metabolised  to  morphine,  which  is  the  main  pharmalogicalty  active 
metabolite.  6-MAM  is  therefore  used  as  a  marker  of  diamorphine  use.  The 
metabolic  pathway  for  diamorphine  is  shown  in  Figure  8-12.  As  mentioned  in 
section  8.4.2,  illicit  heroin  is  not  just  composed  of  diamorphine  but  also 
impurities.  Codeine  is  extracted  from  the  Papaver  Somniferum  poppy  as  well  as 
morphine,  papaverine  and  noscapine.  During  the  acetylation  of  morphine  to 
diamorphine,  codeine  is  also  acetylated  to  produce  acetylcodeine.  Therefore 
codeine  can  be  present  as  a  result  of  acetylcodeine  metabolism.  "b 
Codeine  is  metabolised  in  the  liver  by  0-demethylation  to  produce  morphine  and 
by  N-demethylation  to  produce  norcodeine.  Both  compounds  are  excreted  as 
free  drug  and  as  glucuronide  conjugates.  Small  amounts  of  hydrocodone, 
dihydrocodeine  and  hydromorphone  have  also  been  detected  in  urine.  "  Codeine 
is  commonly  prescribed  for  pain  relief  and  has  been  used  in  cough  remedies.  The 
metabolic  pathway  for  codeine  is  given  in  Figure  8-13. 
Dihydrocodeine  is  a  semisynthetic  narcotic  analgesis  which  is  produced  from  the 
hydrogenation  of  codeine.  It  has  been  used  for  pain  relief  for  example  in  the 
treatment  of  post-operative  pain.  It  has  also  been  used  as  an  alternative  to 
methadone  in  the  treatment  of  heroin  addiction.  249  It  is  metabolised  by  0-  and 
N-dealkylation  in  the  same  set  of  steps  as  codeine.  It  also  forms  glucuronide  and 
sulphate  conjugates  at  the  3-  and  6-hydroxy  ring  positions.  The  metabolic 
pathway  for  dihydrocodeine  is  given  in  Figure  8-14. Drugs  of  Abuse  in  Hair 
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The  pharmacokinetic  and  physicochemical  data  for  these  opiates  is  shown  in 
Table  8-3. 
Table  8-3  Pharmacokinetic  and  physicochemical  data  for  opiates 
Half  Life  (hr)  Vd  (L/kg)  Protein 
Binding  (%)  PK 
Diamorphine  0.03-0.1  25  40  7.6 
Morphine  1.3-6.7  2-5  35  8.1,10.0 
Codeine  1.9-3.9  3.5  7-25  8.2 
Dihydrocodeine  3.4-4.5  1.0-1.3  -  8.8 Drugs  of  Abuse  in  Hair 
8.2.5  Methadone 
Chapter  8,145 
Methadone  is  a  morphine  substitute  and  has  been  made  clinically  available  in  the 
United  States  since  1947.16  It  has  many  of  the  pharmacological  properties  of 
morphine  but  unlike  morphine,  it  accumulates  in  the  body  with  repeated  use, 
causing  sedative  effects.  Daily  dosages  as  high  as  180  mg  have  been  used  in  the 
maintenance  treatment  of  heroin  addicts  but  doses  of  50  mg  or  less  can  be  fatal 
in  naive  adult  users.  176  The  drug  is  produced  commercially  as  the  hydrochloride 
salt  of  the  dl-racemic  mixture  but  all  pharmacological  activity  is  due  to  the 
1-isomer.  Methadone  is  metabolised  mainly  by  mono-  and  di-N-demethylation 
with  spontaneous  cyclisation  of  the  unstable  metabolites  to  form  EDDP  and  EMDP 
(Figure  8-15).  These  metabolites  are  pharmacologically  inactive  and  are  not 
present  to  any  significant  extent  in  plasma  during  therapeutic  methadone 
treatment.  16 
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The  pharmacokinetic  and  physicochemical  data  for  methadone  are  shown  in 
CH3 
N  'a 
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Table  8-4  Pharmacokinetic  and  physicochemical  data  for  methadone  176 
Half  Life  (hr)  Vd  (L/kg)  Protein 
Pý  Binding  (%) 
Methadone  15-55  4-5  87  8.6 
8.3  Aim  of  Study 
There  were  two  main  aims  of  this  study.  The  first  was  to  develop  and  validate 
an  LC-MS-MS  method  for  the  identification  and  quantification  of  common  drugs 
of  abuse  in  hair  and  apply  the  method  to  routine  post-mortem  hair  samples.  The 
second  aim  was  to  compare  the  results  of  the  LC-MS-MS  method  with  in-house 
GC-MS  methods  for  these  post-mortem  samples. 
8.4  Experimental 
8.4.1  Samples 
All  samples  were  post-mortem  scalp  hair  samples  submitted  to  the  toxicology 
Laboratory  of  the  Forensic  Medicine  and  Science  Section  at  the  University  of 
Glasgow  for  routine  testing.  The  samples  were  tested  for  diagnostic  purposes 
and  the  results  were  reported  to  the  Procurator  Fiscal. 
8.4.2  Chemicals 
Methanol,  acetone,  acetonitrile,  acetic  acid,  ammonium  hydroxide,  ethyl 
acetate,  formic  acid,  dichloromethane  and  propan-2-ol  were  purchased  from 
BDH  (Poole,  UK)  and  were  of  analytical  grade.  Ammonium  formate  and  sodium 
dodecyl  sulfate  were  purchased  from  Sigma-Aldrich  (Dorset,  UK). 
d,  (-amphetamine,  d,  (-methamphetamine,  d,  1-MDA,  dl-MDMA,  d,!  -MDEA, 
diazepam,  nordiazepam,  oxazepam,  temazepam,  cocaine,  benzoylecgonine, 
ecgonine  methyl  ester,  cocaethylene,  morphine,  6-MAM,  codeine, 
dihydrocodeine,  methadone  and  EDDP  were  obtained  from  Promochem 
(Teddington,  UK).  Deuterated  internal  standards  including  d,  (-amphetamine-ds, 
d,  l-methamphetamine-d5i  d,  1-MDA-d5,  dl-MDMA-d5,  dl-MDEA-d5,  diazepam-d5, 
nordiazepam-d5,  oxazepam-d5,  temazepam-ds,  cocaine-d3,  benzoylecgonine-d3i Drugs  of  Abuse  in  Hair  Chapter  8,147 
ecgonine  methyl  ester-d3,  cocaethylene-d3,  morphine-d3,6-MAM-d3,  codeine-d3, 
dihydrocodeine-d6,  methadone-d9  and  EDDP-d3  were  obtained  from  Promochem 
(Teddington,  UK).  World  Wide  Monitoring  Clean  Screen"  SPE  columns  were 
purchased  from  United  Chemical  technologies  Incorporation  (Pennsylvania,  US). 
Bond  Elut  CertifyTM'  SPE  columns  were  purchased  from  Crawford  Scientific 
(Strathaven,  UK).  Potassium  dihydrogen  phosphate  was  obtained  from  BDH 
(Poole,  UK). 
8.4.3  Standard  Solutions 
Individual  drug  stock  standard  solutions  and  deuterated  drug  standards  were 
obtained  as  100  pg/mL  prepared  in  methanol.  For  LC-MS-MS  confirmation,  a 
combined  working  drug  solution  of  dl-amphetamine,  dl-methamphetamine,  d,  1- 
MDA,  d,  l-MDMA,  d,  l-MDEA,  diazepam,  nordiazepam,  oxazepam,  temazepam, 
cocaine,  benzoylecgonine,  ecgonine  methyl  ester,  cocaethylene,  morphine, 
6-MAM,  codeine,  dihydrocodeine,  methadone  and  EDDP  was  prepared  at  1  pg/mL 
by  100-fold  dilution  with  methanol.  This  was  achieved  by  adding  25  pL  of 
100  pg/mL  drug  solution  into  a  25  mL  volumetric  flask  and  making  up  the  volume 
to  the  25  mL  mark  with  methanol.  A  combined  working  deuterated  standard 
solution  of  d,  l-amphetamine-ds,  d,  l-methamphetamine-d5,  d,  1-MDA-d5,  d,  1- 
MDMA-d5,  d,  1-MDEA-d5,  diazepam-d5,  nordiazepam-d5,  oxazepam-d5,  temazepam- 
ds,  cocaine-d3,  benzoylecgonine-d3,  ecgonine  methyl  ester-d3,  cocaethylene-d3i 
morphine-d3,6-MAM-d3i  codeine-d3,  dihydrocodeine-d6,  methadone-d9  and  EDDP- 
d3  was  also  prepared  at  1  pg/mL  in  the  same  way  as  the  working  drug  solution. 
8.4.4  Extraction  Solutions  and  Mobile  Phase 
8.4.4.1  Preparation  of  Phosphate  Buffer 
Phosphate  buffer  (0.1  M,  pH  6.0)  was  prepared  as  described  in  section  5.6.4.3. 
The  same  procedure  was  followed  to  prepare  the  phosphate  buffer  (0.1  M,  pH 
5.0)  however  the  buffer  pH  was  altered  to  pH  5.0  using  orthophosphoric  acid. Drugs  of  Abuse  in  Hair 
8.4.4.2  Preparation  of  Mobile  Phase 
Chapter  8,148 
Three  mobile  phases  were  investigated  as  part  of  the  method  development 
work.  The  mobile  phases  used  in  system  A  and  B  consisted  of  a  mixture  of 
aqueous  buffer  and  acetonitrile.  The  buffers  used  were:  3  mM  ammonium 
formate  +  0.001  %  formic  acid  (system  A);  10  mM  ammonium  acetate  +  0.001  % 
formic  acid  (system  B).  The  mobile  phase  used  in  system  C  consisted  of  (1) 
methanol:  acetonitrile:  20  mM  ammonium  formate  (10:  10:  80  v/v)  and  (2) 
methanol:  acetonitrile:  20  mM  ammonium  formate  (35:  35:  65  v/v). 
The  buffer  used  in  system  A  was  prepared  as  described  in  section  7.5.4.2.  To 
prepare  buffer  B,  0.77  g  of  ammonium  acetate  and  10  µL  of  concentrated  formic 
acid  were  added  to  a1L  volumetric  flask  which  was  then  filled  up  to  the  mark 
with  deionised  water.  To  prepare  the  20  mM  ammonium  formate  component  of 
mobile  phase  system  C,  1.26  g  of  ammonium  formate  was  added  to  a1L 
volumetric  flask  and  the  flask  filled  up  to  the  mark  with  deionised  water. 
8.4.5  Instrumentation 
8.4.5.1  ELISA 
A  MiniPrep  75  automatic  pipettor  from  Tecan  (San  Jose,  CA)  was  used.  The 
microplate  wells  were  washed  and  read  using  a  Columbus  Plus  washer  system 
and  a  Sunrise  Remote  EIA  autoreader  also  from  Tecan  (Grödlg,  Austria). 
8.4.5.2  LC-MS-MS 
LC-MS-MS  analysis  was  carried  out  using  a  Surveyor  HPLC  system  with  an  LCQ 
Deca  XP  PlusTM'  ion  trap  mass  spectrometer  (Thermo  Finnigan,  San  Jose,  CA,  USA). 
During  method  development,  3  different  LC  columns  were  tested  with  each 
mobile  phase  described  in  section  8.4.4.2.  The  Gemini  and  Synergi  Hydro  RP 
columns  were  purchased  from  Phenomenex  (Torrance,  CA,  USA).  Both  were  C18 
columns  but  the  Synergi  Hydro  RP  column  also  had  polar  end-capping.  The 
Zorbax  Stablebond  (SB)  Phenyl  column  was  purchased  from  ChromTech 
(Cheshire,  UK).  This  was  a  non-endcapped  phenyl  modified  silica  column.  These 
columns  were  fitted  with  guard  columns  with  identical  packing  material  which Drugs  of  Abuse  in  Hair  Chapter  8,149 
were  purchased  from  the  same  companies  as  the  LC  columns.  Guard  column 
dimensions  were:  4  mm  x  2.0  mm,  5  Nm  particle  size  for  the  Gemini  column;  4 
mm  x  2.0  mm,  4  pm  particle  size  for  the  Synergi  Hydro  RP  column;  and  12.5  x 
2.1  mm,  5  pm  particle  size  for  the  Zorbax  SB  Phenyl  column.  A  list  of  the  mobile 
phases  and  LC  columns  is  summarised  in  Table  8-5. 
Table  8-5  Mobile  phases  and  LC  columns 
LC  Column 
Mobile  Phase 
System  A 
Mobile  Phase 
System  B 
Mobile  Phase 
System  C 
1.10:  10:  80 
1.3  mM  1.10  mm  Methanol: 
1.  Gemini  C18  ammonium  ammonium  Acetonitrile:  20  mM 
2.  Synergi  Hydro  RP  formate  +  0.001  acetate  +  0.001  ammonium  formate 
3.  Zorbax  SB  Phenyl  %  formic  acid  %  formic  acid  2.35:  35:  65 
2.  Acetonitrile  2.  Acetonitrile  Methanol:  Acetonitrile: 
20  mM  ammonium 
formate 
8.5  LC-MS-MS  Method  Development 
8.5.1  Optimisation  of  LC  Column  and  Mobile  Phase  Combination 
Optimum  tuning  parameters,  precursor  and  product  quantitation  ions  are  shown 
in  Table  8-6  for  the  drugs  tested  in  the  method.  There  was  only  1  product  ion 
produced  during  fragmentation  for  the  amphetamines  due  to  their  low  molecular 
weight. Drugs  of  Abuse  in  Hair  Chapter  8,150 
Table  8-6  Optimum  tuning  parameters,  precursor  and  product  ions  for  each  drug  of  abuse 
Analyte 
Sheath 
Gas 
(AU) 
Auxiliary 
Gas 
(AU) 
Capillary 
Temp 
(°C) 
Collision 
Energy 
(%) 
Precursor 
m/z 
Product 
m/z 
EME  10  10  210  29  200  182*,  168 
Cocaine  10  10  300  30  304  182*,  150 
Cocaethylene  10  10  210  30  318  196*,  150 
Benzoylecgonine  10  10  300  28  290  168*,  150 
Morphine  20  10  200  33  286  201*,  229 
6-MAM  20  10  210  34  328  211  *,  268 
Codeine  10  5  240  34  300  215*,  243 
Dihydrocodeine  10  5  240  33  302  245*,  201 
Diazepam  20  20  300  42  285  257*,  222 
Nordiazepam  20  15  300  41  271  243*,  140 
Oxazepam  20  20  300  29  287  269*,  241 
Temazepam  20  20  300  29  301  283*,  255 
Amphetamine  15  5  210  23  136  119* 
Methamphetamine  15  5  210  28  150  119* 
MDA  15  15  220  21  180  163* 
MDMA  15  15  280  25  194  163* 
MDEA  15  15  220  20  208  163* 
*=  quantitation  ion 
The  analytes  shown  in  Table  8-6  were  analysed  in  3  separate  injections.  This 
was  done  to  minimise  the  number  of  scan  events  per  time  window  to  achieve 
maximum  sensitivity.  It  is  also  to  maximise  the  number  of  points  across  the 
peak  to  obtain  more  accurate  analyte  quantifications.  The  first  injection  was 
for  cocaine  and  its  metabolites,  opiates,  methadone  and  EDDP.  The  second 
injection  was  for  amphetamines  and  the  third  for  benzodiazepines. 
Initially,  3  mobile  phase  systems  and  3  LC  columns  (Table  8-5)  were  investigated 
to  determine  which  mobile  phase  system  and  column  produced  the  greatest  peak 
area  response  for  the  target  analytes.  Column  1  and  mobile  phase  system  A 
were  used  for  the  analysis  of  opiates,  cocaine  and  metabolites,  amphetamines 
and  benzodiazepines  in  oral  fluid  by  LC/MS/MS.  143  Column  2  and  mobile  phase Drugs  of  Abuse  in  Hair  Chapter  8,151 
system  B  were  used  for  the  quantification  of  opiates  and  cocaine  and 
metabolites  in  hair  by  LC-APCI-MS/MS.  241  Column  3  and  mobile  phase  system  C 
was  used  for  screening  of  drugs  of  abuse  in  hair  using  LC-ESI-MS/MS.  3 
3x  20  pL  injections  of  50  ng  drug/200  pL  mobile  phase  were  run  for  each  column 
and  mobile  phase  system.  The  peak  area  response  (PAR)  data  and  retention 
times  for  the  various  columns  and  mobile  phase  systems  is  given  in  Table  8-7-8- 
9.  The  mobile  phase  system  producing  the  greatest  average  peak  area  response 
for  each  drug  was  recorded  as  being  100  %  and  the  average  peak  area  responses 
for  the  other  two  mobile  phase  systems  were  calculated  as  a%  of  the  optimum 
mobile  phase  system  response. 
Table  8-7  Relative  %  peak  area  response  using  Gemini  C18  column 
System  A  System  B  System  C 
Analyte  PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
EME  100.0  3.8  51.2  2.2  90.7  1.8 
Cocaine  31.5  13.7  100.0  18.1  44.5  11.5 
Cocaethylene  16.8  15.9  100.0  19.4  20.1  15.9 
Benzoylecgonine  16.4  10.6  100.0  13.3  24.5  5.7 
Morphine  100.0  5.2  42.0  8.0  45.1  2.3 
6-MAM  77.9  8.6  2.7  12.9  100.0  4.8 
Codeine  76.2  8.2  70.8  11.7  100.0  4.1 
Dihydrocodeine  93.1  7.8  81.6  10.4  100.0  3.4 
Methadone  35.4  18.7  100.0  21.4  52.6  23.8 
EDDP  48.0  17.9  77.5  20.6  100.0  20.7 
Oxazepam  81.2  19.2  100.0  21.4  25.5  23.6 
Temazepam  12.7  20.4  100.0  22.5  59.1  25.1 
Nordiazepam  100.0  20.4  17.7  22.7  2.9  25.8 
Diazepam  100.0  21.5  45.1  23.8  4.9  27.2 
Amphetamine  6.1  7.7  56.2  10.7  100.0  4.2 
Methamphetamine  20.1  8.8  100.0  11.6  96.7  4.9 
MDA  10.0  8.3  26.9  11.5  100.0  4.5 
MDMA  35.8  9.3  92.4  12.2  100.0  5.1 
MDEA  28.2  10.3  86.0  13.7  100.0  6.2 Drugs  of  Abuse  in  Hair  Chapter  8,152 
Using  the  Gemini  C18  column,  mobile  phase  system  C  produced  the  optimum 
response  for  the  greatest  number  of  analytes  compared  to  the  other  two  mobile 
phase  systems. 
Table  8-8  Relative  %  peak  area  response  using  Synergi  Hydro  RP  column 
System  A  System  B  System  C 
Analyte  PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
EME  70.6  4.9  13.1  5.8  100.0  1.9 
Cocaine  69.1  19.4  100.0  20.7  48.2  16.8 
Cocaethylene  94.3  20.8  100.0  22.1  50.8  19.9 
Benzoylecgonine  100.0  10.5  99.8  13.4  49.5  6.2 
Morphine  74.7  10.3  44.6  13.9  100.0  3.4 
6-MAM  30.5  15.2  28.7  17.5  100.0  8.5 
Codeine  41.4  14.7  33.8  17.3  100.0  7.9 
Dihydrocodeine  55.4  13.8  48.4  16.6  100.0  5.7 
Methadone  86.6  24.4  48.7  26.2  100.0  26.6 
EDDP  46.7  23.3  20.0  25.2  100.0  23.5 
Oxazepam  100.0  19.2  87.4  21.3  20.3  23.8 
Temazepam  100.0  20.4  78.5  22.6  1.5  25.7 
Nordiazepam  100.0  20.6  65.7  22.8  9.6  26.4 
Diazepam  100.0  21.9  29.9  24.3  7.9  28.3 
Amphetamine  100.0  10.8  30.0  15.3  22.3  5.2 
Methamphetamine  100.0  12.1  13.9  17.2  23.9  6.5 
MDA  46.6  11.7  45.3  15.8  100.0  5.6 
MDMA  100.0  13.2  52.8  17.1  48.8  6.7 
MDEA  100.0  13.6  44.1  18.0  47.0  8.2 
Using  the  Synergi  Hydro  RP  column,  mobile  phase  system  A  produced  the 
optimum  response  for  the  greatest  number  of  analytes. Drugs  of  Abuse  in  Hair  Chapter  8,153 
Table  8-9  Relative  %  peak  area  response  using  Zorbax  Phenyl  column 
System  A  System  B  System  C 
Analyte  PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
PAR  for 
n=3 
tR  in 
mins 
EME  79.2  3.7  83.1  3.2  100.0  1.3 
Cocaine  100.0  22.9  89.8  21.7  43.2  13.9 
Cocaethylene  100.0  24.3  58.4  23.8  42.2  18.2 
Benzoylecgonine  100.0  9.2  99.6  11.7  68.5  4.5 
Morphine  51.8  11.5  33.7  9.5  100.0  2.1 
6-MAM  89.1  18.1  40.9  16.1  100.0  6.0 
Codeine  60.2  17.1  39.8  14.3  100.0  4.4 
Dihydrocodeine  73.4  16.9  48.1  13.3  100.0  3.9 
Methadone  100.0  28.3  21.5  29.9  91.5  25.2 
EDDP  50.0  28.6  4.4  30.0  100.0  23.4 
Oxazepam  44.8  17.4  100.0  19.4  9.0  18.9 
Temazepam  92.1  18.6  100.0  20.5  14.7  21.2 
Nordiazepam  100.0  18.6  62.8  20.5  18.1  21.6 
Diazepam  100.0  19.7  63.6  21.7  22.5  23.5 
Amphetamine  14.4  13.9  100.0  9.6  40.8  3.0 
Methamphetamine  5.7  18.3  100.0  12.3  25.6  3.8 
MDA  80.8  16.2  100.0  12.1  40.5  3.7 
MDMA  61.5  19.9  100.0  14.5  53.9  5.0 
MDEA  36.5  20.7  100.0  16.7  44.3  6.4 
Using  the  Zorbax  Phenyl  column,  mobile  phase  system  B  produced  the  optimum 
response  for  the  greatest  number  of  analytes. 
The  average  peak  area  response  was  then  compared  for  each  drug  using  the 
optimum  mobile  phase  system  determined  for  each  of  the  three  columns.  The 
mobile  phase  system  and  column  producing  the  greatest  average  peak  area 
response  was  recorded  as  being  100  %  and  the  average  peak  area  responses  for 
the  other  two  mobile  phase  systems  and  columns  were  calculated  as  a%  of  the 
optimum  mobile  phase  system  and  column  response. Drugs  of  Abuse  in  Hair  Chapter  8,154 
Table  8-10  Relative  %  peak  area  response  for  the  3  optimum  mobile  phase  and  column 
combinations 
Relative  %  Pe  ak  Area  Response  (n=3) 
Analyte 
Gemini  + 
Mobile 
Phase 
System  C 
Synergi 
Hydro  RP  + 
Mobile 
Phase 
System  A 
Zorbax 
Phenyl  + 
Mobile 
Phase 
System  B 
EME  100.0  59.5  62.9 
Cocaine  46.6  67.8  100.0 
Cocaethylene  48.1  100.0  71.0 
Benzoylecgonine  42.4  100.0  72.3 
Morphine  100.0  89.7  47.3 
6-MAM  100.0  28.2  33.5 
Codeine  100.0  34.2  31.2 
Dihydrocodeine  100.0  43.2  43.3 
Methadone  89.3  100.0  18.7 
EDDP  100.0  50.5  3.2 
Oxazepam  45.1  100.0  79.9 
Temazepam  37.8  59.0  100.0 
Nordiazepam  4.0  100.0  83.4 
Diazepam  4.3  100.0  49.5 
Amphetamine  85.2  68.7  100.0 
Methamphetamine  31.3  71.4  100.0 
MDA  89.2  33.8  100.0 
MDMA  46.2  57.5  100.0 
MDEA  54.0  53.6  100.0 
The  Zorbax  Phenyl  column  and  mobile  phase  system  B  produced  the  greatest 
average  peak  area  response  for  the  greatest  number  of  analytes  compared  to  the 
other  two  columns  and  mobile  phase  systems.  This  column  and  mobile  phase 
combination  was  therefore  selected  for  further  optimisation. 
8.5.2  Mobile  Phase  Optimisation 
Since  the  Zorbax  SB  Phenyl  column  and  mobile  phase  system  B  produced  the 
greatest  average  peak  area  response  for  the  greatest  number  of  analytes,  it  was Drugs  of  Abuse  in  Hair  Chapter  8,155 
decided  to  investigate  the  effect  of  using  different  concentrations  of  ammonium 
acetate  and  formic  acid  in  the  mobile  phase  on  analyte  response. 
The  ammonium  acetate  buffer  concentrations  tested  were  2,5,10  and  25  mM. 
These  concentrations  were  prepared  by  adding  0.15,0.30,0.77,1.6  g  of 
ammonium  acetate  to  a1L  volumetric  flask  and  filling  the  flask  up  to  the  mark 
with  deionised  water.  The  formic  acid  concentration  of  0.001  %  was  kept 
constant  to  determine  the  effects  of  changing  buffer  concentration  only.  The 
average  peak  area  (n=3)  was  calculated  for  each  analyte.  The  ammonium 
acetate  concentration  and  the  relative  average  %  peak  area  response  for  a 
selection  of  analytes  from  different  drug  classes  are  shown  in  Figure  8-16. 
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Figure  8-16  Analyte  responses  for  increasing  ammonium  acetate  concentration 
With  the  exception  of  the  opiates,  analyte  response  decreased  with  the  lower 
ammonium  acetate  concentrations.  The  highest  opiate  response  was  observed 
using  25  mM  ammonium  acetate.  Higher  responses  were  observed  using  2  mM 
than  5  mM  or  10  mM  ammonium  acetate. 
Higher  concentrations  of  ammonium  acetate  were  not  tested  since  the  use  of 
high  concentrations  of  electrolytes  has  the  disadvantage  of  forming  salt  clusters 
and  cluster  ions  by  direct  solvent  evaporation.  166  10  mM  ammonium  acetate  was 
selected  for  further  work  since  the  greatest  analyte  response  was  observed  for 
the  highest  number  of  analytes  at  this  concentration. 
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The  concentration  of  formic  acid  was  then  investigated  to  determine  the  effect, 
if  any,  on  analyte  response.  The  10  mM  ammonium  acetate  was  prepared  using 
three  formic  acid  concentrations-  0.001,0.005  and  0.01  %.  The  average  peak 
area  response  (n=3)  was  compared  for  each  formic  acid  concentration.  The 
formic  acid  concentration  which  produced  the  greatest  average  peak  area 
response  was  recorded  as  being  100  %  and  the  average  peak  area  responses  for 
the  other  two  formic  acid  concentrations  were  calculated  as  a%  of  the  optimum 
formic  acid  concentration  response. 
The  relative  average  %  peak  area  response  for  a  selection  of  analytes  from 
different  drug  classes  is  given  in  Figure  8-17.  The  results  showed  that  the 
optimum  formic  acid  concentration  was  0.001  %  for  most  anatytes. 
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Figure  8-17  Analyte  responses  for  increasing  formic  acid  concentration 
As  the  Zorbax  SB  phenyl  column  is  narrow-bore,  it  has  a  smaller  internal  volume 
than  a  standard  bore  column  and  the  flow  rate  for  optimal  column  efficiency  is 
proportionately  smaller.  The  flow  rates  recommended  by  the  column 
manufacturer  are  0.15  to  0.25  mL/min  as  the  column  has  an  internal  diameter  of 
2.1  mm.  A  flow  rate  of  0.25  mL/min  was  therefore  selected  for  future  work 
since  faster  flow  rates  result  in  faster  sample  throughput. 
Although  the  Zorbax  phenyl  column  was  initially  selected  for  further  work,  a 
pressure  problem  was  encountered  during  method  development.  The  pressure 
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would  not  stabilise  and  exceeded  the  instrument's  maximum  pressure  setting  of 
5800  psi. 
The  manufacturers  recommend  using  mobile  phases  such  as  acetonitrile/water 
mixtures  as  the  column  is  moderately  non-polar  in  nature  so  the  mobile  phase 
selection  was  theoretically  suitable.  However  it  was  not  feasible  to  use  this 
column  in  practice.  The  Synergi  Hydro  RP  column  and  mobile  phase  system  A 
were  selected  for  further  work  since  this  column  and  mobile  phase  combination 
produced  a  higher  relative  average  %  peak  area  response  for  more  analytes 
compared  with  the  Gemini  column  and  mobile  phase  system  C  (Table  8-10). 
8.5.3  Selection  of  Incubation  Medium 
A  previously  published  SPE  method  which  was  used  for  the  extraction  of  common 
drugs  of  abuse  from  oral  fluid  was  used  to  clean  up  hair  samples  which  had  been 
incubated  in  various  media.  143  The  elution  step  was  modified  slightly  from  3  mL 
ethyl  acetate  with  2%  ammonia  to  1.5  mL  ethyl  acetate  with  2%  ammonia  and 
1.5  mL  dichloromethane/isopropanol/ammonium  hydroxide  (78:  20:  2  v/v). 
In  order  to  assess  the  suitability  of  the  methanol/25  %  aqueous  ammonium 
hydroxide  (20:  1  v/v)  incubation  used  for  benzodiazepines  in  chapter  7  for 
extracting  other  drugs  of  abuse  in  hair,  2  post-mortem  hair  samples  with  positive 
blood  results  were  extracted. 
The  hair  samples  were  tested  for  the  drug  classes  found  in  the  corresponding 
blood  sample.  The  results  are  shown  in  Table  8-11. Drugs  of  Abuse  in  Hair  Chapter  8,158 
Table  8-11  Hair  samples  incubated  in  methanol/25  %  aqueous  ammonium  hydroxide 
Hair  Sample  Number  Blood  result  (mg/L)  Hair  result  (ng/mg) 
Morphine  0.27 
Morphine  5.89 
Codeine  0.04 
Codeine  1.55 
Methadone  0.37 
6-MAM  70.70 
EME  0.20 
Diazepam  0.29 
Nordiazepam  0.79 
Codeine  0.06 
Temazepam  0.05 
2  Nordiazepam  1.40 
Oxazepam  0.06 
Dihydrocodeine  0.26 
Morphine  0.14 
Codeine  0.01 
The  methanol/25  %  aqueous  ammonium  hydroxide  incubation  successfully 
extracted  opiates  and  benzodiazepines  from  post-mortem  hair  samples.  6-MAM, 
a  useful  marker  for  heroin  use,  was  detected  in  hair  sample  1  but  was  not 
detected  in  the  corresponding  blood  sample.  This  is  because  the  6-MAM  half-life 
is  short  in  blood,  between  6-25  minutes.  "' 
Dihydrocodeine  was  detected  in  hair  sample  2  and  was  not  detected  in  blood. 
This  provided  additional  information  on  the  individual's  prior  drug  use. 
One  concern  with  using  the  MeOH/25  %  aqueous  NH40H  incubation  was  the 
potential  for  analyte  hydrolysis,  in  particular  cocaine  and  6-MAM,  as  the 
hydrolysis  of  6-MAM  to  morphine  and  also  cocaine  to  BZE  and  EME  has  been 
demonstrated  at  alkaline  pH.  208  The  stability  of  cocaine  and  6-MAM  was 
therefore  investigated  using  this  incubation  medium. 
8.5.3.1  Stability  of  6-MAM  and  cocaine  using  the  methanol/25 
ammonium  hydroxide  incubation 
Three  samples  were  prepared  by  spiking  1.5  mL  of  MeOH/25  %  aqueous 
ammonium  hydroxide  with  50  ng  of  cocaine  and  6-MAM  and  these  were 
subsequently  left  to  incubate  for  18  hours  at  room  temperature.  After  this  time, 
50  ng  of  cocaine-d3  and  6-MAM-d3  were  added  to  the  vials  and  the  vial  contents Drugs  of  Abuse  in  Hair  Chapter  8,159 
were  evaporated  to  dryness  at  room  temperature  under  nitrogen.  The 
deuterated  internal  standards  were  added  at  this  point  in  the  experiment  so  that 
the  results  obtained  were  only  affected  by  degradation  during  the  incubation 
step.  Three  unextracted  standards  were  prepared  at  the  same  concentration 
and  kept  in  the  fridge  during  the  incubation  period.  50  ng  of  deuterated 
internal  standard  was  added  to  the  unextracted  standards  at  the  same  time  as 
the  incubated  samples  and  the  vial  contents  evaporated  to  dryness  under 
nitrogen.  The  samples  once  dry  were  reconstituted  in  200  pL  of  mobile  phase 
initial  conditions  and  20  pL  was  injected. 
The  results  from  this  experiment  showed  that  6-MAM  was  hydrolysed  to  a  great 
extent  (=  95  %)  using  this  incubation  medium.  Cocaine  was  also  significantly 
hydrolysed  (=  22  %).  Therefore  this  method  does  not  produce  true 
representative  concentrations  of  6-MAM,  morphine,  cocaine  or  benzoylecgonine 
in  hair.  Partial  hydrolysis  of  6-MAM  will  have  occurred  in  hair  sample  1  shown  in 
Table  8-11.  It  was  decided  not  to  use  this  incubation  and  hence  other 
incubations  were  investigated.  The  %  recovery  values  are  shown  in  Table  8-12  . 
Table  8-12  %  Recovery  of  6-MAM  and  cocaine  without  matrix 
Cocaine  (%  Recovery,  n=3)  6-MAM  (%  Recovery,  n=3) 
Mean  S.  D.  Mean  S.  D. 
77.6  2.3  4.9  0.4 
8.5.3.2  Stability  of  6-MAM  and  cocaine  in  different  incubation  media 
This  alkaline  methanol/25  %  aqueous  ammonium  hydroxide  extraction  is  suitable 
for  extracting  opiates  and  benzodiazepines  from  authentic  hair  samples  as  shown 
in  section  8.5.3,  although  it  significantly  degrades  6-MAM  and  cocaine. 
Therefore,  the  same  stability  experiment  as  described  in  section  8.5.3.1  was 
carried  out  using  1,2,5  and  10  %  aqueous  ammonium  hydroxide  in  methanol.  In 
addition  to  this,  the  stability  was  assessed  in  aqueous  acidic  media  (0.01,0.1 
and  1M  HCl),  methanol  and  phosphate  buffer  (0.1  M,  pH  5.0)  by  incubating  for 
18  hours  at  45  °C. 
The  %  recovery  of  6-MAM  and  cocaine  in  the  different  incubation  media  are  given 
in  Table  8-13. Drugs  of  Abuse  in  Hair  Chapter  8,160 
Table  8-13  %  Recovery  of  cocaine  and  6-MAM  in  various  incubation  media 
Incubation  Cocaine  %  Recovery  (n=3)  6-MAM  %  Recovery  (n=3) 
Medium  Mean  S.  D.  Mean  S.  D. 
Methanol  99.4  5.5  88.6  4.2 
Phosphate 
102.3  1.4  102.9  10.9 
Buffer  pH  5 
0.1  M  HCL  101.5  5.2  47.3  5.5 
0.05  M  HCl  100.6  1.1  59.1  3.1 
0.01  M  HCl  103.7  4.3  87.4  5.3 
Methanol/ 
97.5  3.2  67.2  5.0 
1%  NH4OH 
Methanol/ 
91.8  3.5  37.2  3.1 
2%NH40H 
Methanol/ 
89.7  2.8  18.5  1.2 
5%NH40H 
Methanol/ 
86.1  0.5  5.5  0.5 
10%NH40H 
Methanol/ 
77.6  2.3  4.9  0.4 
25  %  NH4OH 
The  extent  of  6-MAM  and  cocaine  degradation  was  negligible  using  the  methanol 
and  phosphate  buffer  incubations.  In  contrast,  all  concentrations  of  aqueous 
acidic  media  resulted  in  significant  6-MAM  hydrolysis  whereas  cocaine 
degradation  was  negligible.  This  result  was  in  agreement  with  previously 
published  results.  "' 
The  results  obtained  for  the  aqueous  alkaline  media  showed  an  increased  6-MAM 
and  cocaine  hydrolysis  with  increasing  concentration  of  aqueous  ammonium 
hydroxide.  6-MAM  was  hydrolysed  to  a  greater  extent  than  cocaine  under 
alkaline  conditions.  Graphs  of  %  recovery  vs  %  aqueous  ammonium  hydroxide  in 
methanol  are  shown  in  Figure  8-18.  The  6-MAM  graph  demonstrates  a  hyperbolic 
decrease  in  %  recovery  with  increasing  ammonium  hydroxide  concentration, 
whereas  the  cocaine  graph  shows  a  linear  decrease,  with  a  good  correlation 
between  %  recovery  and  %  ammonium  hydroxide  in  methanol  (R2=0.9117). Drugs  of  Abuse  in  Hair 
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Figure  8-18  %  Recovery  vs  %  aqueous  NH4OH  in  methanol  for  6-MAM  and  cocaine 
Both  the  acidic  and  alkaline  incubation  media  produced  significant  hydrolysis  of 
6-MAM.  Cocaine  showed  significant  hydrolysis  using  25  %  aqueous  ammonium 
hydroxide  in  methanol.  It  was  therefore  decided  to  compare  the  methanol  and 
phosphate  buffer  incubation  media  for  future  work  since  both  cocaine  and 
6-MAM  were  relatively  stable  using  these  methods.  The  methanol  and  phosphate 
buffer  incubation  media  produced  6-MAM  recoveries  of  88.6  %  and  102.9  % 
respectively  while  cocaine  recoveries  were  99.4  and  102.3  %  respectively. 
8.5.3.3  Methanol  vs  Phosphate  Buffer  Incubation 
3  post-mortem  hair  samples  which  had  positive  blood  results  were 
decontaminated  as  described  before  in  section  6.4.1.  The  root-0.5  cm  segment 
was  removed  and  the  0.5-3.5  cm  segment  was  cut  up  into  smaller  segments  of 
2-3  mm  in  length.  This  cut  up  segment  was  subsequently  split  to  compare  the 
methanol  and  phosphate  buffer  incubation  methods.  The  samples  were  analysed 
for  the  drug  classes  detected  in  the  blood.  The  blood  and  hair  results  are  shown 
in  Table  8-14  and  Table  8-15  respectively. 
With  the  exception  of  the  cocaine  concentration  detected  in  hair  sample  1  and 
the  methadone  concentration  in  hair  sample  3,  the  phosphate  buffer  extraction 
produced  higher  quantitative  results  overall,  extracting  greater  concentrations 
of  EME,  benzoylecgonine,  6-MAM,  codeine  and  amphetamine.  Furthermore,  the 
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methadone  metabolite,  EDDP  was  detected  using  the  phosphate  buffer 
incubation  where  none  was  detected  using  the  methanol  incubation.  Morphine 
was  not  detected  in  hair  sample  3  by  either  incubation  method.  A  possible 
explanation  for  this  is  the  low  levels  of  6-MAM  detected  in  the  samples.  The 
6-MAM/morphine  ratios  observed  in  the  case  samples  tested  in  section  8.9.1.2 
ranged  from  0.14-28.00  (5.47  mean).  If  this  mean  6-MAM/morphine  ratio  was 
applied  to  calculate  a  predicted  morphine  concentration  from  the  6-MAM 
concentration  found,  it  would  be  0.15  ng/mg,  a  concentration  which  is  lower 
than  the  LOQ  of  the  method. 
Table  8-14  Blood  results  for  post-mortem  hair  case  samples  (mg/L) 
Hair  Sample  Cocaine  +  Opiates  and 
Amphetamines  Benzodiazepines 
Number  Metabolites  Methadone 
EME  5.13 
1  COC  3.58  -  -  - 
BZE  3.98 
2  -  -  AMP  0.66 
MOR  0.37  DZ  0.06 
3  -  COD  0.01  -  NDZ  0.09 
MD  0.17  TMZ  0.02 
"EME"=  Ecgonine  Methyl  Ester,  "CUL"=  cocaine,  **bLt"=  tsenzoyLecgomne,  **MUK"=  Morphine, 
"COD"=  Codeine,  "MD"=  Methadone,  "AMP"=  Amphetamine,  "DZ"=  Diazepam, 
"N  DZ"=Nordiazepam,  "TMZ"=Temazepam an 
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Overall,  the  phosphate  buffer  incubation  was  better  for  the  simultaneous 
detection  of  cocaine  and  its  metabolites,  amphetamine  and  opiates.  In  addition, 
EDDP  was  detected  in  sample  3  using  the  phosphate  buffer  incubation  while  none 
was  detected  using  the  methanol  incubation.  Benzodiazepines  were  not 
detected  in  any  of  the  samples  to  compare  the  two  incubations.  Furthermore, 
the  stability  data  using  the  phosphate  buffer  incubation  is  excellent  for  6-MAM 
and  cocaine  which  have  been  shown  to  hydrolyse  under  acidic  and  basic 
conditions245,  the  hair  extracts  are  cleaner  and  the  analysis  is  simpler  with  less 
sample  manipulation.  Analyte  recoveries  for  the  methanol  incubation  were 
generally  lower  for  most  analytes  as  reported  in  various  studies.  11,111,245  It  has 
been  proposed  that  the  generally  higher  recoveries  obtained  using  a  phosphate 
buffer  incubation  is  a  result  of  the  water  molecules  penetrating  the  keratinised 
hair  to  a  greater  extent  than  an  organic  solvent.  "  Furthermore,  the  non- 
keratinous  hair  regions  could  potentially  provide  diffusion  channels,  both  into 
and  out  of  the  hair,  for  small  drug  molecules  in  the  presence  of  water.  61 
8.5.4  Comparison  of  SPE  methods 
Bond  Elut  Certifym  and  Clean  Screen®  DAU  SPE  columns  were  investigated  for  the 
simultaneous  extraction  of  the  drugs  of  abuse  from  hair.  Both  columns  are 
mixed-mode  bonded  silica,  with  both  hydrophobic  and  ion-exchange  properties, 
which  are  suitable  for  the  extraction  of  acidic,  neutral  and  basic  analytes.  The 
silanol  groups  in  these  columns  are  partially  derivatised  with  medium  length 
alkyl  chains  and  cation  exchange  substituents  which  allow  at  least  two  types  of 
analyte-sorbent  interactions.  250 
8.5.4.1  Bond  Elut  Certify""  SPE 
This  method  is  previously  published  and  was  applied  in  the  simultaneous 
screening  of  acidic,  neutral  and  basic  drugs  from  oral  fluid.  143  Bond  But  Certify" 
LRC  cartridges  were  conditioned  sequentially  with  2  mL  methanol  and  2  mL 
phosphate  buffer  (0.1  M,  pH  6.0).  2  mL  of  sample  in  phosphate  buffer  (0.1  M, 
pH  6.0)  was  applied  to  the  cartridge  and  allowed  to  drip  through  without  the 
presence  of  a  vacuum.  The  cartridges  were  then  washed  with  1  mL  deionised Drugs  of  Abuse  in  Hair  Chapter  8,165 
water,  0.5  mL  0.01  M  acetic  acid  and  dried  for  10  minutes  under  full  vacuum. 
50  pL  of  methanol  was  added  and  the  cartridges  were  dried  for  a  further  2 
minutes  under  full  vacuum.  The  acidic/neutral  fraction  was  eluted  using  4  mL 
acetone/dichloromethane  (1:  1  v/v)  while  the  basic  drugs  were  eluted  using 
Ix1.5  mL  ethyl  acetate  with  2%  aqueous  ammonium  hydroxide  and  Ix1.5  mL 
dichloromethane:  isopropanot:  aqueous  ammonium  hydroxide  (78:  20:  2  v/v),  with 
a2  minute  drying  step  between  the  two  basic  eluants.  The  acidic/neutral  and 
the  basic  fractions  were  combined.  This  was  particularly  significant  since  the 
benzodiazepines  were  eluted  in  both  fractions. 
8.5.4.2  Clean  Screen®  SPE 
This  SPE  was  a  modified  version  of  an  extraction  procedure  for  drugs  of  abuse  in 
urine  provided  by  the  SPE  manufacturers.  Clean  Screen®  (ZSDAU  020)  extraction 
cartridges  were  conditioned  sequentially  with  3  mL  methanol,  3  mL  deionised 
water  and  1  mL  phosphate  buffer  (0.1  M,  pH  5.0).  The  vortexed  samples  were 
loaded  in  2  mL  phosphate  buffer  (0.1  M,  pH  5.0)  and  allowed  to  drip  through 
without  vacuum.  The  columns  were  then  washed  with  3  mL  phosphate  buffer 
(0.1  M,  pH  5.0),  1  mL  acetic  acid  (1.0  M)  and  dried  for  5  minutes  under  full 
vacuum.  The  drugs  were  eluted  using  2  mL  methanol/2  %  aqueous  ammonium 
hydroxide. 
8.5.4.3  Analyte  recovery  without  hair  matrix 
To  ensure  that  the  SPE  methods  were  appropriate  for  the  drugs  of  abuse,  the 
recovery  was  investigated  in  an  experiment  without  hair  matrix. 
50  ng  of  drug  was  added  to  two  test  tubes  along  with  2  mL  phosphate  buffer 
(0.1  M,  pH  5.0).  Two  unextracted  samples  were  prepared  at  the  same 
concentration  and  kept  in  the  fridge  during  the  extractions.  50  ng  of  deuterated 
internal  standard  was  added  to  the  eluant  after  the  extraction  and  also  to  the 
unextracted  samples.  The  samples  were  evaporated  to  dryness  at  room 
temperature  under  nitrogen  and  subsequently  reconstituted  in  200  pL  of  mobile 
phase  initial  conditions.  20  pL  was  injected  for  each  sample.  The  results  are 
displayed  in  Table  8-16. Drugs  of  Abuse  in  Hair  Chapter  8,166 
Table  8-16  Bond  ElutT.  and  Clean  Screen  recovery  without  matrix  (n=2) 
Mean  %  Recovery  (n=2) 
Analyte 
Bond  Elut  Certify'  Clean  Screen® 
EME  76.6  100.7 
Cocaine  100.7  84.0 
Cocaethylene  96.4  95.8 
Benzoylecgonine  95.2  97.8 
Morphine  77.4  87.2 
6-MAM  74.1  74.6 
Codeine  102.4  83.9 
Dihydrocodeine  91.6  97.6 
Methadone  92.9  82.6 
EDDP  70.1  98.6 
Oxazepam  82.9  92.7 
Temazepam  94.5  99.0 
Nordiazepam  93.3  97.6 
Diazepam  95.9  95.2 
Amphetamine  95.6  98.9 
Methamphetamine  78.7  90.4 
MDA  88.8  84.2 
MDMA  97.6  101.2 
MDEA  90.7  100.4 
Without  matrix,  the  Clean  Screen'  method  produced  higher  recoveries  for  a 
greater  number  of  analytes  compared  to  the  Bond  Elut  Certify  v  method.  The 
experiment  was  then  repeated  with  hair  matrix  as  discussed  in  section  8.5.4.4. 
8.5.4.4  Analyte  Recovery  with  Hair  Matrix 
10  mg  ±  0.1  mg  blank  hair  was  weighed  out  into  three  vials  and  it  was  then 
spiked  with  50  ng  analyte.  Two  unextracted  samples  were  prepared  at  the  same Drugs  of  Abuse  in  Hair  Chapter  8,167 
concentration  and  kept  in  the  fridge  during  the  extractions.  The  samples  were 
then  incubated  in  phosphate  buffer  (pH  5.0)  as  detailed  in  section  8.5.3.2  and 
extracted  by  the  Bond  Elut  Certify"  and  Clean  Screen'  methods  previously 
described  in  sections  8.5.4.1  and  8.5.4.2.50  ng  of  deuterated  internal  standard 
was  added  to  the  eluant  after  the  extractions  and  also  to  the  unextracted 
samples.  The  samples  were  evaporated  to  dryness  at  room  temperature  under 
nitrogen  and  subsequently  reconstituted  in  200  pL  of  mobile  phase  initial 
conditions.  20  pL  was  injected  for  each  sample.  The  results  are  shown  in  Table 
8-17. 
Table  8-17  Bond  ElutM  and  Clean  Screen®  recovery  with  matrix 
Analyte 
Mean  %  Recovery  (%  RSD)  (n=3)  at  50  ng 
Bond  Elut  Certify  Clean  Screen 
Ecgonine  methyl  ester  73.7  (0.5)  101.1  (5.6) 
Cocaine  92.3  (5.0)  98.6  (4.8) 
Cocaethylene  100.3  (6.1)  104.9  (11.1) 
Benzoylecgonine  91.8  (10.0)  98.0  (6.5) 
Morphine  75.9  (3.8)  94.5  (5.4) 
6-MAM  94.6  (6.1)  98.3  (6.3) 
Codeine  90.1  (2.2)  95.0  (6.2) 
Dihydrocodeine  94.8  (5.4)  107.4  (3.6) 
Methadone  124.6  (12.6)  87.8  (15.5) 
EDDP  80.2  (8.3)  86.8  (3.3) 
Oxazepam  90.3  (14.2)  77.0  (5.5) 
Temazepam  99.3  (7.9)  107.6  (2.0) 
Nordiazepam  79.8  (2.8)  99.1  (8.7) 
Diazepam  81.4  (8.4)  80.5  (4.1) 
Amphetamine  97.9  (8.3)  109.9  (11.9) 
Methamphetamine  91.6  (3.1)  109.1  (1.5) 
MDA  88.3  (2.1)  78.8  (6.0) 
MDMA  78.5  (1.0)  99.5  (2.2) 
MDEA  95.4  (2.8)  85.9  (2.5) Drugs  of  Abuse  in  Hair  Chapter  8,168 
The  Clean  Screen®  method  produced  higher  recoveries  for  a  greater  number  of 
analytes  compared  to  the  Bond  Elut®  method  for  spiked  hair.  All  of  these  were 
77  %  or  greater. 
8.5.4.5  SPE  Clean-Up 
Hair  was  collected  from  five  members  of  laboratory  personnel.  10  mg  ±  0.1  mg 
hair  was  washed  via  the  procedure  described  previously  in  section  6.4.1  and 
subsequently  extracted  using  the  Bond  Elut  Certify"  and  Clean  Screen"  methods. 
The  chromatograms  for  each  blank  hair  extract  using  both  SPE  methods  were 
compared  visually  to  determine  which  method  produced  the  cleanest  extracts 
overall. 
The  Clean  Screen®  method  produced  the  cleanest  extracts  overall  for  all  drug 
classes  and  for  hair  from  all  five  individuals.  An  example  LC-MS-MS 
chromatogram  of  blank  hair  collected  from  one  individual  using  both  the  Bond 
Elut  Certify'  and  Clean  Screen®  extraction  methods  is  shown  in  Figure  8-19.  At 
the  time  of  using  this  particular  LC  column,  the  diazepam  retention  time  (tR)  was 
22.7  minutes.  It  is  apparent  from  the  chromatograms  that  there  was  greater 
matrix  interference  at  the  diazepam  tR,  as  indicated  by  the  larger  peak  area, 
using  the  Bond  Elut  Certify1m  column  compared  with  the  Clean  Screen'  column. 
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Figure  8-19  Bond  Elut  CertifyTM  vs  Clean  Screen®  interference  at  diazepam  tR Drugs  of  Abuse  in  Hair 
8.5.4.6  LOD  and  LOQ 
Chapter  8,169 
The  LOD  was  calculated  for  each  analyte  using  Equation  7-1  and  Equation  7-2. 
The  LOQ  was  calculated  for  each  analyte  using  Equation  7-3  and  Equation  7-4, 
however  ten  standard  deviations  (10sg)  of  the  blank  was  used  in  Equation  7-3. 
The  LOD  and  LOQ  values  are  shown  in  Table  8-18  for  both  SPE  methods. 
The  Clean  Screen®  SPE  method  produced  lower  LOD  and  LOQ  values  for  the 
majority  of  analytes.  The  LOD  range  was  0.15-0.92  ng/10  mg  hair  and  the  LOQ 
range  was  0.51-3.07  ng/10  mg  hair.  Furthermore,  there  was  a  relatively  large 
difference  for  cocaine,  oxazepam  and  MDA.  This  is  because  of  reduced  matrix 
interference  observed  using  the  Clean  Screen"  method  compared  to  the  Bond 
Elut  Certify"'  method.  The  Clean  Screen  method  was  therefore  validated  in 
further  work. 
Table  8-18  LOD  and  LOQ  values  for  the  Bond  Elut  CertifyTm  and  Clean  Screen®  SPE  methods 
Bond  Elut  Certify  Clean  Screen' 
Analyte  LOD 
(ng/10  mg) 
LOQ 
(ng/10  mg) 
LOD 
(ng/10  mg) 
LOQ 
(ng/10  mg) 
EME  0.33  1.08  0.25  0.83 
Cocaine  1.02  3.41  0.37  1.25 
Cocaethylene  0.37  1.24  0.42  1.39 
Benzoylecgonine  0.34  1.12  0.15  0.51 
Morphine  0.97  3.24  0.68  2.25 
6-MAM  1.14  3.80  0.92  3.07 
Codeine  0.68  2.26  0.64  2.15 
Dihydrocodeine  0.32  1.05  0.48  1.62 
Methadone  0.48  1.59  0.40  1.32 
EDDP  0.59  1.96  0.54  1.79 
Oxazepam  0.94  3.13  0.17  0.57 
Temazepam  0.35  1.18  0.77  2.56 
Nordiazepam  0.82  2.73  0.69  2.31 
Diazepam  0.33  1.10  0.56  1.56 Drugs  of  Abuse  in  Hair  Chapter  8,170 
Table  8-19  LOD  and  LOQ  values  for  the  Bond  Elut  CertifyTM  and  Clean  Screen®  SPE  methods 
(continued) 
Bond  Elut  Certify  Clean  Screen 
Analyte  LOD 
(ng/10  mg) 
LOQ 
(ng/10  mg) 
LOD 
(ng/10  mg) 
LOQ 
(ng/10  mg) 
Amphetamine  0.79  2.64  0.30  1.00 
Methamphetamine  0.39  1.31  0.38  1.26 
MDA  0.97  3.24  0.20  0.67 
MDMA  0.24  0.78  0.37  1.25 
MDEA  0.26  0.88  0.26  0.86 
8.6  LC-MS-MS  Method  Validation 
In  the  method  validation,  the  sample  was  reconstituted  in  150  pL  of  mobile 
phase  instead  of  200  pL  as  used  in  the  method  development.  This  was  to  enable 
maximum  assay  sensitivity  by  injecting  a  greater  quantity  of  drug  onto  the  LC 
column. 
8.6.1  Linearity 
Linearity  was  determined  over  the  concentration  range  2-100  ng/10  mg  hair. 
This  sample  weight  was  chosen  for  the  validation  since  the  hair  case  samples 
were  analysed  in  segments  and  the  sample  weights  were  generally  low. 
8.6.2  Recovery 
The  %  recovery  was  determined  for  each  analyte  at  5,10  and  50  ng.  Drug 
standard  solution  was  spiked  into  10  mg  blank  hair  prior  to  or  following  SPE. 
50  ng  of  deuterated  internal  standard  was  added  after  SPE.  %  Recovery  was 
calculated  as  the  mean  peak  area  ratio  of  product  ion/internal  standard  for  the 
samples  in  which  the  standard  solution  was  added  before  SPE  (n=3)  divided  by 
the  mean  peak  area  ratio  of  product  ion/internal  standard  for  the  samples  in 
which  the  standard  solution  was  added  following  SPE  (n=3).  The  recovery  from Drugs  of  Abuse  in  Hair  Chapter  8,171 
authentic  hair  samples  will  however  be  lower  than  those  quoted  for  spiked  hair 
since  the  drug  is  incorporated. 
8.6.3  Matrix  Effect 
Matrix  effect  was  assessed  by  comparing  the  mean  peak  area  ratio  of  product 
ion/internal  standard  of  extracted  blank  hair  samples  spiked  with  standard 
solution  following  SPE  (A)  (n=6)  versus  the  mean  peak  area  ratio  of  product 
ion/internal  standard  of  unextracted  standards  prepared  in  mobile  phase  at 
equivalent  concentrations  (B)  (n=6).  Matrix  effect  (%)  was  calculated  for  a  low 
standard  concentration  of  5  ng  by  dividing  A  by  B  (Equation  7-5)  and  multiplying 
by  100  to  express  it  as  a  percentage. 
8.6.4  Intra-  and  Inter-Day  Precision  and  Accuracy 
Intra-and  inter-day  precision  and  accuracy  were  assessed  over  the  linear  range 
for  5  extracted  hair  spikes  at  a  low,  medium  and  high  concentration  (5,10  and 
50  ng).  The  intra-day  precision  was  expressed  as  a%  RSD  calculated  using  the  5 
individual  values  obtained  on  the  same  day.  Inter-day  precision  was  evaluated 
for  five  replicate  hair  extracts  spiked  at  these  concentrations  on  five  separate 
days  (ntotat  =  25).  It  was  expressed  as  a%  RSD  value  which  was  calculated  using 
all  25  individual  values. 
Accuracy  was  calculated  by  dividing  the  mean  measured  concentration  of  5  or  25 
extracts  (intra-  and  inter-day  precision)  by  the  theoretical  spike  concentration 
and  was  expressed  as  a  percentage  of  the  theoretical  spike  concentration. 
8.7  Validation  Problems  for  Methadone  and  EDDP 
Methadone  and  EDDP  were  not  included  in  the  method  validation  as  problems 
were  encountered  with  the  reproducibility  of  the  product  quantitation 
ion/internal  standard  ratio  for  both  compounds.  As  demonstrated  in  Figure  8-20, 
the  linearity  was  poor  for  methadone  and  EDDP  over  the  range  2-100  ng.  The 
variability  of  internal  standard  peak  areas  was  assessed  by  calculating  %  RSD  for Drugs  of  Abuse  in  Hair  Chapter  8,172 
the  peak  areas  of  3  consecutive  injections  of  unextracted  methadone-d9  and 
EDDP-d3  internal  prepared  in  mobile  phase  at  a  concentration  of  50  ng.  The  % 
RSD  was  <  20  %  for  both  internal  standards  and  this  is  acceptable  precision 
according  to  published  SOFT  guidelines.  "  However,  the  %  RSD  for  the  peak  areas 
of  3  consecutive  injections  of  unextracted  methadone  and  EDDP  standards 
prepared  in  mobile  phase  at  the  same  concentration  as  the  internal  standards 
(50  ng)  were  >  120  %  for  both  compounds.  Therefore  the  fragmentation  of  the 
methadone  and  EDDP  was  not  consistent  throughout  and  this  resulted  in  poor 
linearity.  The  average  peak  area  response  for  the  methadone  and  EDDP  product 
ions  and  the  %  RSD  for  these  values  are  shown  in  Table  8-20. 
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Figure  8-20  Methadone  and  EDDP  calibration  plots 
Table  8-20  Methadone  and  EDDP  product  ion  reproducibility 
"  Methadon 
EDDP 
Methadone  EDDP 
Peak  Area 
(mlz  265) 
Average 
Peak 
Area 
Standard 
Deviation  %  RSD 
Peak  Area 
(m/z  249) 
Average 
Peak  Area 
Standard 
Deviation  %  RSD 
55314657  446705203 
6910990  21496050  29379853  136.7  82689910  187304511  226043876  120.7 
2262503  32518419 
Only  one  product  ion  was  investigated  for  methadone  and  EDDP  as  the  mass 
spectrums  identified  these  as  the  only  product  ions  produced  after 
fragmentation. 
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8.8  LC-MS-MS  Validation  Results 
8.8.1  Linearity 
Examples  of  the  gradient  and  intercept  values  are  shown  in  Table  8-21,  along 
with  the  correlation  coefficient  (R2)  values  for  the  analyte  regression  lines.  All 
regression  lines  had  an  R2  >  0.99.  Graphs  of  regression  lines  for  selected  analytes 
are  shown  in  Figure  8-21. 
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Figure  8-21  Regression  lines  for  selected  analytes 
Table  8-21  Gradient,  intercept  and  R2  values  for  regression  lines 
"  Amphetamine 
Codeine 
Diazepam 
Cocaine 
Linear 
_(A 
pph  tamine) 
L  r(Codeine) 
Linear  (Diazepam) 
-  Linear  (Cocaine) 
Analyte  Equation  of  line  R 
EME  y=0.0057x-0.0055  0.9996 
Cocaine  y=0.0082x-0.0023  0.9989 
Cocaethylene  y=0.0065x-0.0045  0.9998 
Benzoylecgonine  y=0.0074x+0.0019  0.9981 
Morphine  y=0.0033x-0.0037  0.9924 
6-MAM  y=0.0018x+0.0028  0.9916 
Codeine  y=0.0019x+0.0115  0.9934 
Dihydrocodeine  y=0.0044x+0.011  0.9960 
Oxazepam  y=0.0172x-0.0531  0.9933 
Temazepam  y=0.0145x+0.0017  0.9983 
Nordiazepam  y=0.0023x-0.0002  0.9987 
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Table  8-21  Gradient,  intercept  and  R2  values  for  regression  lines  (continued) 
Analyte  Equation  of  line  R 
Diazepam  y=0.001  9x-0.003  0.9974 
Amphetamine  y=0.0273x-0.0346  0.9975 
Methamphetamine  y=0.01  15x-0.0396  0.9902 
MDA  y=0.0019x+0.002  0.9990 
MDMA  y=0.0133x-0.0446  0.9972 
MDEA  y=0.0018x-0.0043  0.9955 
The  reason  why  the  ratios  for  drug  -to-deuterated  internal  standard  is  not  1:  1 
when  both  are  present  in  equal  amounts  is  due  to  the  different  types  of  scan 
mode  used  for  the  drugs  and  deuterated  internal  standard.  As  mentioned 
previously,  the  drugs  were  analysed  in  full  MS-MS  mode  whereas  the  deuterated 
internal  standards  were  analysed  in  SIM  mode. 
8.8.2  Recovery 
The  recovery  values  for  all  the  analytes  in  spiked  hair  are  given  in  Table  8-22. 
All  gave  high  recoveries  (>  79  %)  at  all  three  concentrations  and  %  RSD  values  for 
these  were  <_  17  %. 
Table  8-22  Recovery  for  drugs  of  abuse  extracted  from  hair  (n=3) 
Analyte 
%  Recovery  (n=3) 
5  ng/10  mg  10  ng/10  mg  50  ng/10  mg 
EME  99.2  (6.6)  96.4  (3.7)  97.7  (1.0) 
Cocaine  87.2  (8.9)  91.8  (4.9)  97.3  (3.1) 
Cocaethylene  79.4  (13.5)  97.8  (6.6)  92.5  (2.8) 
Benzoylecgonine  95.3  (8.5)  100.7  (4.5)  99.4  (3.2) 
Morphine  91.2  (2.2)  80.1  (6.7)  92.3  (1.1) 
6-MAM  109.6  (7.7)  104.5  (4.6)  94.3  (2.5) 
Codeine  99.6  (2.3)  94.4  (5.4)  99.3  (0.2) 
Dihydrocodeine  86.5  (7.5)  80.9  (3.2)  100.2  (0.7) 
Oxazepam  108.0  (8.8)  96.1  (3.8)  100.6  (3.3) Drugs  of  Abuse  in  Hair 
Table  8-22  Recovery  for  drugs  of  abuse  extracted  from  hair  (n=3)  (continued) 
Chapter  8,175 
Analyte 
%  Recovery  (n=3) 
5  ng/10  mg  10  ng/10  mg  50  ng/10  mg 
Temazepam  76.3  (7.2)  96.5  (9.4)  95.7  (6.4) 
Nordiazepam  97.9  (5.6)  94.7  (3.7)  93.2  (2.7) 
Diazepam  96.9  (6.0)  98.3  (2.1)  94.7  (0.6) 
Amphetamine  108.1  (17.0)  99.6  (6.0)  91.0  (0.6) 
Methamphetamine  93.6  (2.2)  106.0  (0.8)  94.2  (2.3) 
MDA  82.8  (7.9)  106.2  (12.5)  97.6  (6.1) 
MDMA  98.3  (12.6)  100.0  (9.7)  98.2  (0.6) 
MDEA  102.5  (13.2)  104.3  (10.3)  90.8  (1.6) 
8.8.3  Matrix  Effect 
Most  analytes  (12  out  of  17)  demonstrated  ion  suppression,  some  being  affected 
to  a  greater  extent  than  others.  Oxazepam  and  temazepam  product  ions  were 
suppressed  the  most.  The  product  ions  for  5  analytes  demonstrated 
enhancement.  Nordiazepam  and  methamphetamine  product  ions  were  enhanced 
the  most.  The  results  are  given  in  Table  8-23. 
The  existence  of  the  matrix  effect  demonstrates  the  importance  of  using 
deuterated  internal  standards  in  the  method.  Deuterated  internal  standards  will 
be  affected  by  ion  suppression  or  enhancement  to  a  similar  extent  as  the 
corresponding  standard.  The  use  of  deuterated  internal  standards  will  therefore 
minimise  fluctuations  in  instrument  readings  and  will  standardise  analyte 
responses  with  respect  to  the  response  provided  by  the  deuterated  internal 
standard. Drugs  of  Abuse  in  Hair 
Table  8-23  %  Matrix  effect  at  5  ng  spiked  hair  extracts  (n=6) 
Chapter  8,176 
Analyte  %  Matrix  Effect 
EME  119.2 
Cocaine  96.4 
Cocaethytene  82.9 
Benzoylecgonine  85.1 
Morphine  85.4 
6-MAM  110.6 
Codeine  92.6 
Dihydrocodeine  102.8 
Oxazepam  67.6 
Temazepam  63.5 
Nordiazepam  130.3 
Diazepam  95.5 
Amphetamine  97.9 
Methamphetamine  135.6 
MDA  76.4 
MDMA  90.4 
MDEA  91.1 
8.8.4  Intra-day  Accuracy  and  Precision 
The  intra-day  accuracy  and  precision  values  were  acceptable  within  SOFT 
regulations  of  ±  20  %"  for  the  3  concentrations  tested.  The  results  are  given  in 
Table  8-24.  Intra-day  accuracy  ranged  from  80-116  %.  Precision  (%  RSD)  ranged 
from  1.4-18.7  %.  As  expected,  lower  precision  was  observed  at  the  lower 
concentrations. Drugs  of  Abuse  in  Hair 
Table  8-24  Intra-day  accuracy  and  precision  (n=5) 
Chapter  8,177 
Analyte 
Spiked 
Quantity 
(ng) 
Mean 
Measured 
Concentration 
(ng) 
%  RSD  %  Accuracy 
5  5.3  5.5  106.0 
EME  10  9.9  4.9  99.0 
50  54.8  3.8  109.6 
5  4.1  7.2  82.0 
Cocaine  10  9.6  5.8  96.0 
50  46.8  3.0  93.6 
5  4.8  10.0  96.0 
Cocaethylene  10  10.3  5.0  103.0 
50  48.1  3.7  96.2 
5  4.6  7.1  92.0 
BZE  10  9.2  6.3  92.0 
50  49.8  3.6  99.6 
5  4.7  8.4  94.0 
Morphine  10  9.1  7.5  91.0 
50  50.3  6.9  100.6 
5  4.5  11.4  90.0 
6-MAM  10  8.7  5.2  87.0 
50  50.8  4.8  101.6 
Codeine  5  4.7  8.9  94.0 
10  10.7  6.5  107.0 
50  54.2  2.0  108.4 
Dihydrocodeine  5  4.9  7.0  98.0 
10  11.6  5.3  116.0 
50  50.2  1.4  100.4 
Oxazepam  5  5.0  11.6  100.0 
10  10.6  8.9  106.0 
50  50.8  6.0  101.6 Drugs  of  Abuse  in  Hair 
Table  8-24  Intra-day  accuracy  and  precision  (n=5)  (continued) 
Chapter  8,178 
Analyte 
Spiked 
Quantity 
(ng) 
Mean 
Measured 
Concentration 
(ng) 
%  RSD  %  Accuracy 
Temazepam  5  4.4  18.7  88.0 
10  9.4  13.9  94.0 
50  52.9  9.4  105.8 
Nordiazepam  5  5.7  14.4  114.0 
10  11.0  9.6  111.0 
50  48.8  6.6  97.6 
Diazepam  5  4.8  6.6  96.0 
10  9.8  5.6  98.0 
50  48.6  2.9  97.2 
Amphetamine  5  5.6  9.2  112.0 
10  8.0  6.7  80.0 
50  52.1  7.0  104.2 
Methamphetamine  5  5.8  6.0  116.0 
10  9.2  6.1  92.0 
50  44.3  4.4  88.6 
MDA  5  4.4  9.1  88.0 
10  9.5  5.0  95.0 
50  49.6  7.1  99.2 
MDMA 
5  5.2  10.6  104.0 
10  8.9  6.6  89.0 
50  50.8  5.9  101.6 
5  5.7  6.7  114.0 
MDEA  10  8.8  6.6  88.0 
50  55.0  3.5  110.0 Drugs  of  Abuse  in  Hair  Chapter  8,179 
8.8.5  Inter-Day  Precision 
The  inter-day  precision  was  generally  acceptable  within  SOFT  regulations  of 
±  20  %h1  for  the  3  concentrations  tested.  Nordiazepam  was  slightly  higher  at  the 
lower  concentrations  however  the  SOFT  regulations  also  state  that  ±  25-30  %  may 
be  acceptable  for  some  analytes.  Precision  (%  RSD)  ranged  from  5.6-24.3  %.  As 
found  in  the  intra-day  precision  experiment,  the  %  RSD  was  higher  at  lower 
concentrations.  The  %  RSD  range  was  higher  for  inter-day  precision  compared  to 
intra-day  precision  due  to  instrumental  and  extraction  inter-day  variation  and 
also  a  greater  number  of  data  values.  Some  analyte  data  in  Table  8-25  was 
calculated  for  n=24.  This  was  due  to  the  removal  of  an  outlier  in  the  data  sets. 
Table  8-25  Inter-day  precision  (n=25) 
Analyte 
Inter-day  Precision  (%  RSD) 
5  ng  10  ng  50  ng 
EME  5.5  (18.3)  8.8  (9.9)  49.4  (5.6) 
Cocaine  4.5  (10.1)  10.1  (7.7)  50.9  (7.1) 
Cocaethylene  5.1  (19.0)*  10.0  (15.8)  50.5  (10.2) 
BZE  5.3  (22.5)  10.1  (12.0)  48.6  (8.8) 
Morphine  5.1  (16.4)  9.8  (15.5)*  55.2  (11.0) 
6-MAM  4.6  (20.5)  10.5  (13.6)  51.9  (8.2) 
Codeine  5.0  (18.7)  10.9  (17.5)  54.3  (9.3) 
DHC  4.8  (18.2)  10.6  (12.9)  51.9  (8.5) 
Oxazepam  5.2  (16.8)  9.9  (14.2)*  49.7  (10.8)* 
Temazepam  5.2  (20.2)*  10.1  (18.9)  51.9  (10.6) 
Nordiazepam  5.6  (24.3)*  9.2  (22.9)*  47.4  (10.6) 
Diazepam  4.7  (13.3)  9.8  (12.2)  47.3  (9.2) 
AMP  5.0  (16.9)  9.3  (15.7)  48.9  (12.2) 
MAMP  4.9  (20.7)  8.9  (8.9)  51.5  (8.6) 
MDA  5.6  (20.8)  10.6  (19.4)  52.0  (19.6) 
MDMA  5.1  (15.9)  8.9  (10.8)  52.6  (10.0) 
MDEA  4.8  (15.1)  9.4  (11.0)  52.4  (9.8) 
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8.8.6  LOD  and  LOQ 
The  LOD  and  LOQ  values  for  the  Clean  Screen®  method  are  provided  in  Table  8- 
19.  The  LOD  values  ranged  from  0.15-0.92  ng/10  mg  hair  and  the  LOQ  ranged 
from  0.51-3.07  ng/10  mg  hair. 
8.9  Case  Samples 
The  validated  LC-MS-MS  method  was  used  to  analyse  17  post-mortem  scalp  hair 
samples.  All  samples  were  submitted  to  the  toxicology  laboratory  of  the 
Forensic  Medicine  and  Science  Section  at  the  University  of  Glasgow  for  routine 
testing.  The  samples  were  tested  for  diagnostic  purposes  and  the  results  were 
reported  to  the  Procurator  Fiscal. 
The  hair  samples  were  decontaminated  as  described  in  section  6.4.1,  segmented 
and  split  between  3  vials  where  sufficient  sample  was  available.  This  was 
carried  out  for  the  purposes  of  comparing  the  LC-MS-MS  results  with  GC-MS 
results  obtained  using  routine  in-house  methods  and  also  with  ELISA  screening 
results  obtained  using  the  validated  methods  described  in  chapters  6  and  7. 
8.9.1  Comparison  of  LC-MS-MS  vs  Routine  GC-MS  Methods 
8.9.1.1  Methods 
The  validated  LC-MS-MS  method  analysed  each  case  sample  for  amphetamines, 
benzodiazepines,  cocaine  and  its  metabolites  and  opiates  while  the  GC-Ms 
methods  analysed  individual  drug  groups. 
The  GC-MS  methods  for  opiates  and  cocaine  were  detailed  in  section  6.6.4.  In 
brief,  the  GC-MS  method  for  amphetamine  extraction  from  hair  involved 
ultrasonicating  the  hair  for  1  hour  in  phosphate  buffer  (pH  6.0)  then  incubating 
at  40  °C  for  2  hours.  The  extracts  were  cleaned  up  using  Bond  Elut  Certify'M  SPE 
cartridges.  The  amphetamines  were  derivatised  at  60  °C  for  20  minutes  using 
PFPA/ethyl  acetate  (2:  1  v/v)  prior  to  GC-MS  analysis. Drugs  of  Abuse  in  Hair  Chapter  8,181 
The  LOD  and  LOQ  were  approximately  1  ng/30  mg  and  2  ng/30  mg  respectively 
for  all  compounds  in  the  in-house  GC-MS  methods. 
8.9.1.2  Results 
The  LC-MS-MS  and  GC-MS  results  are  given  in  Table  8-26.  The  drug  groups 
analysed  by  GC-MS  are  provided  in  the  footnote  for  Table  8-26.  The 
abbreviations  in  Table  8-26  are  as  follows:  "MOR"=Morphine;  "6-MAM"=6- 
Monoacetylmorphine;  "COD"=Codeine;  "DHC"=Dihydrocodeine;  "COC"=Cocaine; 
"BZE"=Benzoylecgonine;  "COCAETH"=Cocaethylene;  "EME"=Ecgonine  Methyl 
Ester;  "AMP"=Amphetamine;  "DZ"=Diazepam;  "NDZ"=Nordiazepam; 
"OXAZ"=Oxazepam;  and  "TMZ"=Temazepam. 
Table  8-26  LC-MS-MS  vs  GC-MS  results 
LC-MS-MS 
Hair  Sample  LC-MS-MS  GC-MS  Weight  GC-MS  Results 
Results 
Number  Weight  (mg)  (mg)  (ng/mg) 
(ng/mg) 
(1)t  2.85  0.91  MOR  2.56  NEG  for  MOR 
Root-  0.5  cm  0.97  6-MAM  NEG  for  6-MAM 
1.38  COD  0.08  COD 
2.93  DHC  4.98  DHC 
(1)t  23.80  2.02  MOR  23.36  6.14  MOR 
0.5-3.5  cm  1.31  6-MAM  2.87  6-MAM 
0.37  COD  1.08  COD 
1.22  DHC  3.32  DHC 
0.10  DZ 
0.37  NDZ 
(2)t  2.05  1.67  MOR  2.21  0.18  MOR 
Root-0.5  cm  1.96  6-MAM  NEG  for  6-MAM 
NEG  for  COD  0.41  COD 
0.34  DZ 
2.26  NDZ 
TGC-MS  ana[ysis  or  opiates  ana  cocaine  onLy,  NI  =Not  I  estea,  NEG=Negative Drugs  of  Abuse  in  Hair 
Table  8-26  LC-MS-MS  vs  GC-MS  results  (continued) 
Chapter  8,182 
LC-MS-MS 
Hair  Sample  LC-MS-MS  GC-MS  Weight  GC-MS  Results 
Results 
Number  Weight  (mg)  (mg)  (ng/mg) 
(ng/mg) 
(2)  t  25.45  1.23  MOR  25.63  3.11  MOR 
0.5-3.5  cm  0.12  6-MAM  NEG  for  6-MAM 
0.45  COD  0.75  COD 
0.13  DHC  0.16  DHC 
0.06  COC  0.09  COC 
0.42  BZE  0.63  BZE 
1.03  MDMA 
0.22  OXAZ 
0.10  TMZ 
0.52  DZ 
0.67  NDZ 
(3)  fi  2.74  NEG  for  all  2.76  NEG  for  opiates 
Root-0.5  cm  drug  groups  and  cocaine 
(3)  t  19.09  0.09  MOR  19.48  0.01  MOR 
0.5-3.5  cm  0.52  6-MAM  0.72  6-MAM 
0.21  COD  0.13  COD 
NEG  for  DHC  0.05  DHC 
0.29  COC  1.28  COC 
0.16  BZE  0.29  BZE 
1.26  MDMA 
0.12  DZ 
0.36  NDZ 
(3)  t  18.60  NEG  for  MOR  18.97  0.08  MOR 
3.5-6.5  cm  0.53  6-MAM  1.06  6-MAM 
NEG  for  COD  0.05  COD 
NEG  for  DHC  0.05  DHC 
0.96  COC  3.85  COC 
0.45  BZE  0.64  BZE 
1.60  MDMA  NT 
tGC-MS  analysis  tor  opiates  ana  cocaine  only,  NT=Not  Tested,  NW=Negative Drugs  of  Abuse  in  Hair 
Table  8-26  LC-MS-MS  vs  GC-MS  results  (continued) 
Chapter  8,183 
Hair  Sample  LC-MS-MS  LC-MS-MS 
Results  GC-MS  Weight  GC-MS  Results 
Number  Weight  (mg)  (ng/mg)  (mg)  (ng/mg) 
(4)  t  3.21  0.58  MOR  3.39  NEG  for  MOR 
Root-0.5  cm  0.77  6-MAM  NEG  for  6-MAM 
0.32  DHC  NEG  for  DHC 
1.40  NDZ 
(4)  j-  21.12  0.16  MOR  21.11  0.24  M0R 
0.5-3.5  cm  0.58  6-MAM  0.71  6-MAM 
0.20  COD  0.09  COD 
0.09  DHC  0.19  DHC 
0.86  COC  0.61  COC 
0.11  BZE  0.21  BZE 
0.19  AMP 
1.42  MDMA 
0.04  DZ 
0.29  NDZ 
(5)$  1.71  1.39  6-MAM  2.11  NEG  for  6-MAM 
Root-0.5  cm 
(5)  1  12.62  0.22  MOR  12.47  0.11  MOR 
0.5-3.5  cm  0.49  6-MAM  NEG  for  6-MAM 
0.32  COD  0.10  COD 
10.18  COC 
3.11  BZE 
0.43  COCAETH 
0.24  EME 
0.11  MDMA 
0.17  DZ 
0.52  NDZ 
(6)  fi  1.03  NEG  for  all  1.33  NEG  for  opiates 
Root-0.5  cm  drug  groups 
fGC-AAS  analysis  for  opiates  and  cocaine  only,  #  GC-MS  analysis  for  opiates  only,  NT=Not  tested, 
NEG=Negative Drugs  of  Abuse  in  Hair 
Table  8-26  LC-MS-MS  vs  GC-MS  results  (continued) 
Chapter  8,184 
Hair  Sample  LC-MS-MS  LC-MS-MS  Results  GC-MS  Weight  GC-MS  Results 
Number  Weight  (mg)  (ng/mg)  (mg)  (ng/mg) 
(6)  t  18.49  2.32  COD  18.31  5.52  COD 
0.5-3.5  cm 
(7)4  1.49  NEG  for  MOR  1.68  5.23  MOR 
Root-0.5  cm  NEG  for  6-MAM  3.03  6-MAM 
0.13  COD  1.75  COD 
(7)$  8.38  1.10  MOR  8.62  2.77  M0R 
0.5-3.5  cm  4.55  6-MAM  3.36  6-MAM 
0.11  COD  0.32  COD 
(8)$  1.05  NEG  for  DHC  1.52  1.91  DHC 
Root-0.5  cm 
(8)$  9.24  NEG  for  MOR  9.34  0.24  MOR 
0.5-3.5  cm  0.58  6-MAM  0.85  6-MAM 
0.08  COD  NEG  for  COD 
0.21  DHC  1.07  DHC 
(9)t  3.16  0.71  6-MAM  3.24  1.49  6-MAM 
Root-0.5  cm  2.05  COC  4.78  COC 
0.31  BZE  1.56  BZE 
0.25  COCAETH  NEG  for 
COCAETH 
(9)t  28.55  0.04  MOR  28.72  0.45  MOR 
0.5-3.5  cm  1.12  6-MAM  1.55  6-MAM 
NEG  for  COD  0.13  COD 
13.99  COC  19.34  COC 
4.73  BZE  4.92  BZE 
0.21  EME  Not  reported 
0.54  COCAETH  1.07  COCAETH 
0.21  AMP 
0.18  DZ 
0.17  NDZ 
tGC-MS  analysis  for  opiates  and  cocaine  only  $  GC-MS  analysis  for  opiates  only,  NT=Not  Tested, 
NEG=Negative Drugs  of  Abuse  in  Hair 
Table  8-26  LC-MS-MS  vs  GC-MS  results  (continued) 
Chapter  8,185 
Hair  LC-MS-MS  Weight  LC-MS-MS  GC-MS  Weight  GC-MS  Results 
Sample  (mg)  Results  (mg)  (ng/mg) 
Number  (ng/mg) 
(10)t  3.27  0.60  COC  3.34  2.40  COC 
Root-0.5  cm  0.18  BZE  1.25  BZE 
0.24  COCAETH  NEG  for  COCAETH 
0.31  DZ 
0.34  NDZ 
(10)t  29.47  0.08  6-MAM  29.71  0.20  6-MAM 
0.5-3.5  cm  2.50  COC  5.09  COC 
1.88  BZE  2.35  BZE 
0.05  COCAETH  0.10  COCAETH 
0.15  EME  Not  reported 
0.26  OXAZ 
0.14  TMZ 
0.24  DZ 
0.64  NDZ 
(11)1  8.55  NEG  for  COD  8.86  0.27  COD 
0.5-3.5  cm  0.49  MDMA 
(11)1  8.69  0.02  COD  9.00  0.48  COD 
3.5-6.5  cm 
(12)1  0.35  14.48  DHC  0.84  11.26  DHC 
Root-0.5  cm 
(12)  1  10.40  0.87  MOR  10.36  0.64  M0R 
0.5-3.5  cm  0.12  6-MAM  NEG  for  6-MAM 
16.18  DHC  14.60  DHC 
0.46  MDMA 
3.51  OXAZ 
0.68  DZ 
0.92  NDZ 
tGC-MS  analysis  for  opiates  and  cocaine  only,  $  GC-MS  analysis  for  opiates  only,  NT=Not  Tested, 
NEG=Negative Drugs  of  Abuse  in  Hair 
Table  8-26  LC-MS-MS  vs  GC-MS  results  (continued) 
Chapter  8,186 
Hair  Sample  LC-MS-MS  LC-MS-MS 
Results  GC-MS  Weight  GC-MS  Results 
Number  Weight  (mg)  (ng/mg)  (mg)  (ng/mg) 
(13)$  0.21  NEG  for  all  0.54  NEG  for 
Root-0.5  cm  drug  groups  opiates 
(13)t  3.79  NEG  for  MOR  3.58  0.05  MOR 
0.5-3.5  cm  0.71  6-MAM  0.19  6-MAM 
(14)1  1.25  NEG  for  COD  1.47  2.57  COD 
0.5-1.5  cm 
(15)t  1.75  3.54  MOR  2.45  5.71  MOR 
Root-0.5  cm  1.31  6-MAM  1.05  6-MAM 
NEG  for  COD  2.59  COD 
NEG  for  DHC  0.83  DHC 
(15)t  18.66  1.03  MOR  18.94  3.01  MOR 
0.5-3.5  cm  1.32  6-MAM  2.28  6-MAM 
0.31  COD  1.27  COD 
10.72  DHC  12.45  DHC 
(16)  t  4.90  NEG  for  all  5.36  NEG  for 
Root-0.5  cm  drug  groups  opiates 
(16)  t  20.62  NEG  for  all  21.10  NEG  for 
0.5-3.5  cm  drug  groups  opiates 
(16)  t  17.30  NEG  for  all  25.63  NEG  for 
3.5-6.5  cm  drug  groups  opiates 
(17)  *  2.49  5.59  AMP  3.02  NEG  for  AMP 
Root-0.5  cm 
(17)*  18.21  7.29  AMP  18.01  1.75  AMP 
0.5-3.5  cm 
TGC-MS  analysis  for  opiates  and  cocaine  only,  $  GC-MS  analysis  for  opiates  only,  NT=Not  Tested, 
NEG=Negative 
In  general,  the  LC-MS-MS  method  was  better  for  detecting  a  wider  range  of 
analytes  compared  to  the  GC-MS  methods  which  targeted  individual  drug  groups 
using  similar  sample  weights  between  the  two  methods. Drugs  of  Abuse  in  Hair 
8.9.1.3  Qualitative  Root  Results 
Chapter  8,187 
Some  analytes  were  detected  in  root  samples  of  low  weight  by  LC-MS-MS 
(<_  3.27  mg)  due  to  the  low  LOD/LOQ  of  the  method  where  none  were  detected 
using  GC-MS:  morphine  in  root  samples  1  and  4;  6-MAM  in  root  samples  2,4  and 
5;  dihydrocodeine  in  root  sample  4;  and  cocaethylene  in  root  samples  9  and  10. 
Morphine  was  detected  in  the  blood  samples  corresponding  to  root  samples  1  and 
4.6-MAM  was  detected  in  the  blood  samples  corresponding  to  root  samples  2 
and  5.  No  6-MAM  was  detected  in  the  blood  sample  corresponding  to  root 
sample  4,  probably  due  to  its  short  half  life  of  2-4  minutes  in  blood.  176  There  was 
no  dihydrocodeine  detected  in  the  blood  sample  corresponding  to  root  sample  4. 
The  routine  blood  method  does  not  analyse  for  cocaethylene  so  it  is  not  possible 
to  compare  cocaethylene  results  for  blood  with  the  root  results  for  samples  9 
and  10. 
The  GC-MS  method  detected  opiates  in  root  samples  of  low  weight  (<_  2.05  mg) 
where  LC-MS-MS  detected  none:  morphine  and  6-MAM  in  root  sample  7;  codeine 
in  root  samples  2  and  15;  and  dihydrocodeine  in  root  samples  8  and  15.  The 
blood  results  for  morphine,  6-MAM  and  codeine  showed  excellent  correlation 
with  the  root  samples  however  no  dihydrocodeine  was  detected  in  the  blood 
samples  corresponding  to  root  samples  8  and  10.  The  GC-MS  method  has  a 
higher  opiate  recovery  than  the  LC-MS-MS  method  as  it  is  targeting  the  opiate 
drug  group  so  this  could  explain  the  detection  of  these  opiates  by  GC-MS  where 
LC-MS-MS  failed  to  detect  them.  However  the  opiate  concentrations  detected  by 
GC-MS  in  these  root  samples  were  relatively  high  and  so  another  explanation  for 
the  LC-MS-MS  results  being  negative  for  these  samples  may  be  due  to  uneven 
splitting  of  root  segments  between  the  two  methods.  The  root-0.5  cm  segment 
of  a  growing  hair  would  contain  incorporated  drug  whereas  a  hair  at  the  end  of 
its  growth  cycle  would  not  have  incorporated  drug  into  the  root  segment. 
8.9.1.4  Qualitative  results  for  segments  excluding  roots 
A  higher  GC-MS  recovery  for  opiates  and  cocaine  and  its  metabolites  was 
observed  in  the  0.5-3.5  cm  (and  in  1  case  3.5-6.5  cm  segment)  which  had  a Drugs  of  Abuse  in  Hair  Chapter  8,188 
sufficiently  high  sample  weight  compared  with  root  segments.  Although  the 
LC-MS-MS  method  produced  lower  recoveries  for  opiates  and  cocaine  and  its 
metabolites  compared  to  the  GC-MS  method,  it  generally  detected  the  analytes 
in  the  0.5-3.5  cm  segments  which  were  detected  by  GC-MS.  However,  the 
analytes  that  were  detected  by  GC-MS  but  not  LC-MS-MS  were  morphine  (sample 
3,8  and  13),  codeine  (sample  3,9  and  11)  and  dihydrocodeine  (sample  3).  The 
analyte  concentrations  in  these  samples  as  determined  by  GC-MS  were  low.  The 
blood  results  corresponding  to  hair  samples  3,8  and  13  were  positive  for 
morphine.  Codeine  was  detected  in  the  blood  samples  corresponding  to  hair 
samples  9  and  11.  The  blood  and  hair  results  for  hair  sample  3  were  both 
negative  for  codeine  and  dihydrocodeine  where  the  hair  results  for  GC-MS  were 
positive.  The  better  opiate  recovery  obtained  using  the  GC-MS  method  explains 
the  positive  GC-MS  results  where  the  LC-MS-MS  results  were  negative. 
The  LC-MS-MS  method  did  however  detect  some  analytes  in  the  0.5-3.5  cm 
segments  where  GC-MS  failed  to  detect  them.  This  was  6-MAM  in  samples  2,5 
and  12  and  codeine  in  sample  8.  The  concentrations  detected  in  these  samples 
as  determined  by  LC-MS-MS  were  also  low.  The  results  for  the  blood  samples 
corresponding  to  hair  samples  2  and  5  were  positive  for  6-MAM.  However  no 
6-MAM  was  found  in  the  blood  sample  corresponding  to  hair  sample  12  and  no 
codeine  was  detected  in  the  blood  sample  corresponding  to  hair  sample  8. 
The  LC-MS-MS  and  GC-MS  results  showed  excellent  qualitative  correlation  for 
cocaine,  benzoylecgonine  and  cocaethylene  in  the  5  positive  samples  tested  for 
these  analytes  by  both  methods.  The  GC-MS  method  recovery  was  higher  than 
that  for  LC-MS-MS  as  higher  quantities  of  cocaine,  benzoylecgonine  and 
cocathylene  were  detected  in  the  0.5-3.5  cm  segments.  EME  was  identified  and 
quantified  in  samples  9  and  10  by  LC-MS-MS  however  the  GC-MS  method  was 
incapable  of  identifying  and  quantifying  EME  due  to  a  co-eluting  peak  in  the 
method  and  therefore  EME  concentrations  were  not  reported  for  GC-MS.  The 
corresponding  blood  results  for  hair  sample  9  did  not  detect  EME  but  did  detect 
benzoylecgonine.  The  corresponding  blood  results  for  hair  sample  10  detected 
EME  as  well  as  cocaine  and  benzoylecgonine. Drugs  of  Abuse  in  Hair  Chapter  8,189 
A  higher  quantity  of  amphetamine  was  recovered  in  sample  17  using  the  LC-MS- 
MS  method.  This  was  the  only  sample  that  was  tested  for  amphetamines  using 
GC-MS.  The  LC-MS-MS  method  also  detected  amphetamine  in  the  root  where 
none  was  detected  by  GC-MS.  The  LC-MS-MS  method  involved  incubating  the 
hair  overnight  in  phosphate  buffer  (pH  5.0)  while  the  GC-MS  method  involved 
incubating  the  hair  for  2  hours  in  phosphate  buffer  (pH  6.0).  The  higher 
amphetamine  recovery  for  the  LC-MS-MS  method  could  be  a  result  of  the  longer 
incubation  time  or  the  pH  of  the  extraction.  The  blood  result  for  this  hair 
sample  was  also  positive  for  amphetamine  at  a  concentration  of  0.66  mg/L.  The 
LC-MS-MS  method  also  detected  amphetamine  in  samples  4  and  9  but  as  the  GC- 
MS  method  did  not  test  for  amphetamine  and  there  was  a  lack  of  sample  to 
analyse  using  the  routine  GC-MS  method  for  amphetamine,  it  was  not  possible  to 
compare  these.  The  blood  results  corresponding  to  hair  samples  4  and  9  were 
negative  for  amphetamine.  MDMA  was  detected  by  LC-MS-MS  in  6  of  the  17 
samples  (samples  2,3,4,5,10  and  12)  which  were  not  tested  for  amphetamines 
by  GC-MS.  The  corresponding  blood  results  for  these  6  samples  were  negative 
for  MDMA. 
The  GC-MS  method  did  not  test  for  benzodiazepines.  However  the  LC-MS-MS 
method  detected  diazepam  and  nordiazepam  in  the  0.5-3.5  cm  (and  in  1  case 
3.5-6.5  cm)  segments  of  8  samples.  Oxazepam  and  temazepam  were  also 
detected  in  2  of  these  8  samples. 
8.9.1.5  Discussion 
8.9.1.5.1  Points  to  consider  for  interpretation 
It  is  not  possible  to  directly  correlate  the  amount  of  drug  taken  with  the  amount 
of  drug  detected  in  hair  because  the  dose  is  unknown  in  all  cases.  Also  studies 
have  demonstrated  that  different  quantities  of  drug  incorporate  into  hair  of 
individuals  who  have  received  the  same  dose.  25,  '" 
Using  the  LC-MS-MS  method,  each  of  the  12  opiate  positive  samples  tested 
positive  for  6-MAM,  which  is  a  marker  of  heroin  use.  The  detection  of  6-MAM  is Drugs  of  Abuse  in  Hair  Chapter  8,190 
however  not  definitive  of  heroin  use  as  it  is  possible  that  6-MAM  could  be  present 
as  a  reaction  side-product  of  the  incomplete  conversion  of  morphine  to 
diamorphine  during  the  acetylation  process.  In  hair  samples  collected  from  20 
known  heroin  users,  6-MAM  was  predominantly  found  over  morphine  and  codeine 
and  usually  in  higher  concentrations.  13,252  In  one  study  it  was  proposed  that  to 
confirm  heroin  use,  a  morphine/codeine  ratio  of  5:  1  should  be  in  place  for  low 
morphine  levels  (<  1  ng/mg)  and  2:  1  for  morphine  concentrations  >1  ng/mg. 
The  same  authors  also  found  a  6-MAM/morphine  ratio  range  of  1.3-10.0.  ' 
Another  group  of  authors  proposed  that  6-MAM/morphine  ratios  and 
6-MAM/codeine  ratios  should  be  greater  than  7.14  and  50  respectively  to 
interpret  the  results  as  consistent  with  heroin  use.  In  another  study,  the  same 
authors  defined  three  levels  of  use  (low,  medium  and  high)  in  relation  to  the  6- 
MAM  marker  found  in  hair  after  heroin  use.  253  Low  use  was  defined  as  containing 
<2  ng/mg,  medium  2-10  ng/mg  and  high  >  10  ng/mg  6-MAM.  The  cut-off 
proposed  in  this  study  was  0.5  ng/mg  6-MAM.  An  important  point  of 
consideration  when  applying  these  recommended  ratios  is  the  type  of  extraction 
used.  In  both  of  these  papers  proposing  6-MAM/morphine  and  6-MAM/codeine 
ratios,  the  opiates  were  extracted  by  acidic  hydrolysis.  6-MAM  can  hydrolyse  to 
some  extent  under  acidic  conditions  so  the  ratios  proposed  using  acidic 
extraction  will  be  different  to  the  ratios  observed  using  a  phosphate  buffer 
extraction  in  which  6-MAM  is  stable.  It  is  more  meaningful  to  compare  the  ratios 
obtained  using  the  same  type  of  extraction  medium. 
7  out  of  8  cocaine  positive  samples  tested  positive  for  benzoylecgonine  which 
suggests  cocaine  use.  The  presence  of  benzoylecgonine  is  not  however  definitive 
of  cocaine  use  as  it  was  shown  in  one  study  that  small  quantities  of 
benzoylecgonine  were  formed  in  hair  as  a  result  of  environmental  contamination 
with  cocaine-"'  In  addition,  this  study  also  found  that  benzoylecgonine  could  be 
absorbed  from  illicit  cocaine  contamined  with  benzoylecgonine.  Current  Society 
of  Hair  guidelines  propose  a  benzoylecgonine/cocaine  ratio  of  5  %.  10°  It  was 
proposed  that  this  value  was  not  appropriate  for  some  cocaine  users'  hair  which 
can  produce  levels  <5%.  255 Drugs  of  Abuse  in  Hair  Chapter  8,191 
Amphetamine  and  MDMA  were  detected  in  8  out  of  17  samples.  No  MDA  was 
detected  in  the  MDMA  positive  hair  samples;  however,  these  would  be  reported 
as  positive  according  to  current  SoHT  guidelines  which  recommend  a  cut-off  of 
0.2  ng/mg  for  individual  amphetamines.  10°  There  are  no  recommendations  in 
these  guidelines  for  a  cut-off  value  for  the  MDMA  metabolite,  MDA. 
Diazepam  and  nordiazepam  were  detected  in  8  out  of  17  samples  which  also 
contained  heroin  metabolites.  There  are  currently  no  recommended  cut-off 
values  for  benzodiazepines  in  hair. 
MDMA,  EME,  oxazepam  and  temazepam  were  not  detected  in  the  root-0.5  cm 
segments  by  LC-MS-MS  where  the  0.5-3.5  cm  segments  were  positive.  The  drug 
group  specific  GC-MS  methods  did  not  detect  cocaethylene  or  amphetamine  in 
the  root-0.5  cm  segments  where  the  0.5-3.5  cm  segments  were  positive.  LC-MS- 
MS  found  these  root  segments  positive  for  cocaethylene  and  amphetamine. 
As  there  are  no  definitive  markers  of  heroin  or  cocaine  use  in  hair  per  se,  it  is 
very  useful  to  examine  an  individual's  past  drug  use  history  if  provided  in  the 
pathologist's  background  report.  Other  additional  information  from  the  police 
reports  may  include  drug  findings  at  the  location  of  death  which  could  aid  the 
toxicology  interpretation.  An  example  is  the  recovery  of  a  syringe  filled  with 
heroin  in  situ.  This  information  would  be  very  useful  in  a  suspected  heroin  death 
where  no  6-MAM  was  found  in  the  hair.  Table  8-27  provides  information  on  the 
individual  case  histories. Drugs  of  Abuse  in  Hair 
Table  8-27  Case  Histories 
Chapter  8,192 
Case  Age  Prescription  and  Illicit  Drugs  Useful  Cause  of  Death 
Number  findings  in 
situ/at 
post- 
mortem 
32  History  of  heroin  abuse.  Needles  in  Bronchopneumonia 
a  small  bag  due  to  heroin 
History  of  overdoses  and  recovered  intoxication. 
depression.  from  his 
bedroom. 
Not  on  any  prescribed 
medication  at  the  time  of  3  recent 
death.  needle 
puncture 
marks  on 
arms. 
2  -  -  -  - 
3  30  History  of  multi-substance  Heroin  and  alcohol 
abuse  including  heroin  and  intoxication. 
cocaine. 
History  of  extensive  alcohol 
abuse. 
Not  on  any  prescribed 
medication  at  the  time  of 
death. 
4  27  Not  known.  Needle  Bronchopneumonia 
puncture  due  to  aspiration  of 
History  of  mental  illness.  mark  in  gastric  contents  due 
right  groin.  to  morphine 
Being  treated  for  intoxication. 
schizophrenia. 
5  30  Known  to  abuse  anabolic  Various  Heroin  intoxication. 
steroids  and  possibly  heroin.  tablets 
He  was  taking  a  large  number  found  in  his 
of  herbal  tablets  and  other  house  plus 
substances,  including  a  box  of 
Tamoxifen.  needles. 
Not  known. 
6  33  History  of  chronic  alcohol  Not  Gastrointestinal 
abuse.  applicable.  haemorrhage  due  to 
Using  street  methadone  oesophageal  ulcers 
(about  150  mL  per  week).  due  to  chronic 
alcohol  abuse. 
Liver  problems. 
"-"=  No  information  (external  post-mortem) Drugs  of  Abuse  in  Hair 
Table  8-27  Case  Histories  (continued) 
Chapter  8,193 
Case  Age  Prescription  and  Illicit  Useful  findings  Primary  cause  of 
Number  Drugs  in  situ/at  post-  death 
mortem  to  aid 
toxicology 
interpretation 
7  39  History  of  heroin  abuse.  A  syringe  was  Heroin 
found  on  the  intoxication. 
floor  next  to  the 
fireplace. 
A  sharps 
container  with 
syringes  was  also 
found. 
Potential  needle 
marks  noted  on 
the  hands,  feet 
and  bend  of 
right  elbow. 
8  35  History  of  drug  misuse.  2  puncture  Heroin 
wounds  in  the  intoxication. 
bend  of  the  right 
elbow. 
9  20  History  of  drug  abuse.  A  number  of  Morphine  (heroin) 
drug  productions  intoxication. 
Prescribed  olanzapine.  were  recovered 
from  the  scene. 
Regular  cannabis  user. 
Never  known  to  have  taken 
heroin. 
Taking  olanzapine  for 
schizophrenia. 
10  16  No  previous  history  of  Drug  Cocaine,  heroin 
heroin  use.  paraphernalia  at  and  diazepam 
scene  including  intoxication. 
On  day  of  death,  took  a  bag  tinfoil  and  citric 
of  Valium  tablets  and  3g  acid  found  in 
cocaine  to  step-brother's  bedroom 
house.  however  step- 
brother  was 
known  to  be  an 
intravenous  drug 
user. 
Multiple  needle 
puncture  marks 
in  body. Drugs  of  Abuse  in  Hair 
Table  8-27  Case  Histories  (continued) 
Chapter  8,194 
Case 
Number 
Age  Prescription  and  Illicit  Drugs  Useful 
findings  in 
situ/at  post- 
mortem  to 
aid  toxicology 
interpretation 
Primary 
cause  of 
death 
11  32  History  of  alcohol  and  heroin  Drug  Heroin  and 
dependency.  paraphernalia  alcohol 
found  in  the  intoxication. 
Prescribed  campral,  room. 
chlordiazepoxide,  propanolol, 
dothiepin  and  vitamins.  Tourniquet 
around  the 
History  of  self-harm,  depression.  right  arm  with 
a  syringe  lying 
A  number  of  previous  overdose  on  the  floor 
attempts.  between  the 
legs  and  arms. 
Placed  on  methadone  programme 
in  2002,  taking  50  mg  daily.  Several  needle 
puncture 
Liver  tests  abnormal  in  2005.  marks  in  the 
bend  of  the 
right  elbow 
and  a 
tourniquet 
round  the 
lower  arm. 
12  32  Previously  addicted  to  heroin.  Large  quantity  Sertraline, 
of  medication  methadone 
Prescribed  methadone  20  mL  next  to  bed  and 
daily,  oxazepam,  epilim,  including  morphine 
dihydrocodeine,  diazepam,  sertraline,  overdose. 
sertraline  and  olanzapine.  olanzapine 
and  a 
Severe  brain  injury  following  a  methadone 
road  traffic  accident  from  which  bottle. 
he  subsequently  had  epilepsy  and 
a  compound  fracture  in  his  left 
leg. 
Long  history  of  self-harm. 
Been  on  methadone  programmes 
had  a  number  of  episodes  where 
he  cut  himself  and  overdoses. Drugs  of  Abuse  in  Hair 
Table  8-27  Case  Histories  (continued) 
Chapter  8,195 
Case  Age  Prescription  and  Illicit  Drugs  Useful  findings  Primary 
Number  in  situ/at  post-  cause  of 
mortem  to  aid  death 
toxicology 
interpretation 
13  36  Heroin  addiction.  Needle  puncture  Heroin 
mark  in  the  bend  intoxication. 
Not  on  any  prescribed  of  the  left 
medication.  elbow. 
Known  to  have  smoked  hash. 
14  34  Chronic  alcohol  abuse.  -  Cerebro- 
vascular 
Prescribed  several  medications  accident 
for  hypertension  and  ('stroke') 
depression. 
Chronic  alcohol  abuse, 
depression  and  hypertyension 
15  35  Longstanding  drug  abuse  since  Drug  Heroin 
1988.  Initially  Temgesic  and  paraphernalia  intoxication. 
temazepam  but  subsequently  associated  with 
diamorphine  and  the  body,  an 
benzodiazepines.  empty  syringe 
pack  and  a  used 
Currently  prescribed  syringe  below  it. 
beclometasone  and  salbutamol  An  empty 
inhalers,  dihydrocodeine  and  diazepam  box 
diazepam.  and  a 
nitrazepam 
History  of  asthma.  bottle  were  also 
found. 
Attended  numerous 
rehabilitation  centres.  Possible  needle 
puncture  mark 
detected  and 
there  was  a 
blood  trail  on 
the  right  arm. 
16  37  Alcoholic  for  15  years.  Cannabis  resin  Fatty 
found  on  bedside  degeneration 
Used  cannabis  in  past.  cabinet  nearby  of  liver  due 
along  with  2  to  chronic 
empty  Buckfast  alcohol 
bottles  and  abuse. 
several  empty 
beer  cans. Drugs  of  Abuse  in  Hair 
Table  8-27  Case  Histories  (continued) 
Chapter  8,196 
Case 
Number 
Age  Prescription  and  Illicit  Drugs  Useful 
findings  in 
situ/at  post- 
mortem  to 
aid  toxicology 
interpretation 
Primary 
cause  of 
death 
17  52  Known  to  use  cannabis.  Several  Amphetamine 
syringes  found  intoxication. 
Past  history  of  depression  and  lying  near  to 
arthritis.  the  deceased. 
Also  some  foil, 
plastic  cup 
with  a  residue 
and  a  burner. 
Drugs  found 
were 
citalopram, 
Celecoxib  and 
Arthrotec. 
8.9.1.5.2  Quantitative  Root  Results 
The  opiate  ranges  and  number  of  positive  root-0.5  cm  segments  found  by  LC-MS- 
MS  and  GC-MS  are  shown  in  Table  8-28. 
Table  8-28  Opiate  concentration  ranges  and  number  of  opiate  positive  root  segments  for 
LC-MS-MS  and  GC-MS 
LC-MS-MS  GC-MS 
Analyte  Concentration 
Range 
(ng/mg) 
Number  of 
Positive 
Samples 
Concentration 
Range 
(ng/mg) 
Number  of 
Positive 
Samples 
Morphine  0.58-3.54  4  0.18-5.71  3 
6-MAM  0.71-1.96  6  1.05-3.03  3 
Codeine  0.13-1.38  2  0.08-2.59  4 
Dihydrocodeine  0.32-14.48  3  0.83-11.26  4 
The  results  in  Table  8-28  show  that  the  LC-MS-MS  method  detected  morphine 
and  6-MAM  in  a  greater  number  of  root-0.5  cm  segments  compared  to  the  GC-MS 
method.  Conversely,  the  GC-MS  method  detected  codeine  and  dihydrocodeine  in 
a  greater  number  of  root-0.5  cm  segments.  The  lowest  concentration  from  the Drugs  of  Abuse  in  Hair  Chapter  8,197 
LC-MS-MS  and  GC-MS  ranges  for  6-MAM  and  dihydrocodeine  was  found  using  LC- 
MS-MS.  In  contrast,  the  lowest  concentration  from  the  LC-MS-MS  and  GC-MS 
ranges  for  morphine  and  codeine  was  found  using  GC-MS.  The  method  sensitivity 
appears  to  be  better  for  6-MAM  and  dihydrocodeine  using  LC-MS-MS  while  the 
method  sensitivity  appears  to  be  better  for  morphine  and  codeine  using  GC-MS. 
The  difference  in  method  sensitivity  may  however  be  due  to  the  uneven  splitting 
of  root-0.5  segments  between  the  two  methods.  As  mentioned  previously,  drugs 
ingested  when  a  hair  is  in  its  growth  phase  would  be  incorporated  into  the  hair 
whereas  no  drugs  would  be  incorporated  into  the  hair  at  the  end  of  its  growth 
cycle.  The  highest  concentration  from  the  LC-MS-MS  and  GC-MS  ranges  for 
morphine,  6-MAM  and  codeine  was  found  using  the  GC-MS  method.  The  higher 
opiate  recovery  of  the  GC-MS  method  would  explain  this. 
In  the  4  root  samples  (samples  1,2,4  and  15)  containing  both  6-MAM  and 
morphine,  the  6-MAM/morphine  ratios  ranged  from  0.37-1.33  (mean  0.99)  using 
the  LC-MS-MS  method.  A  6-MAM/morphine  ratio  range  of  0.37-6.45  was  observed 
for  hair  samples  in  another  study  which  used  a  phosphate  buffer  (pH  5.0) 
extraction.  "  6-MAM  and  morphine  were  detected  together  in  2  root  samples 
(samples  7  and  15)  using  GC-MS.  The  6-MAM/morphine  ratios  were  0.58  and  0.18 
(mean  0.38)  in  these  samples.  These  ratios  are  lower  than  the  ratios  proposed  in 
other  studies  which  used  acidic  hydrolysis  to  extract  opiates  from  hair,  as 
discussed  in  section  8.9.1.5.1.  As  expected,  the  mean  6-MAM/morphine  ratio  for 
the  GC-MS  method  was  lower  than  that  for  the  LC-MS-MS  method.  This  is 
because  of  the  different  extraction  methods  used  in  the  two  methods.  The  GC- 
MS  method  used  hydrochloric  acid  for  part  of  the  extraction  and  this  may  have 
resulted  in  some  hydrolysis  of  6-MAM  to  morphine,  leading  to  lower  ratios.  On 
the  other  hand,  the  phosphate  buffer  extraction  used  in  the  LC-MS-MS  method 
does  not  cause  hydrolysis  of  6-MAM  so  the  ratios  should  be  higher.  Acetylated 
opiates  (6-MAM  and  acetylcodeine)  were  found  to  significantly  decompose  (70-86 
%)  using  0.1  M  hydrochloric  acid  at  55  °C  for  16  hours  and  the  reproducibility  of 
the  hydrolysis  was  poor.  82 
Codeine  was  only  detected  in  1  root  sample  (sample  1)  using  LC-MS-MS.  6-MAM 
and  morphine  were  also  present  in  this  root  sample  by  LC-MS-MS.  The Drugs  of  Abuse  in  Hair  Chapter  8,198 
morphine/codeine  ratio  was  0.66  in  this  sample  which  is  in  the  reported  range  of 
0.38-6.45  which  was  found  for  hair  samples  extracted  using  a  phosphate  buffer 
extraction.  "  Codeine  was  detected  in  4  root  samples  (samples  1,2,7  and  15) 
using  GC-MS.  In  root  sample  1,  codeine  was  found  by  GC-MS  without  any  other 
heroin  metabolites  so  the  results  could  have  been  interpreted  as  codeine  use. 
However  the  LC-MS-MS  results  for  this  root  sample  detected  6-MAM,  morphine 
and  codeine  which  could  indicate  heroin  use.  Heroin  metabolites  were  detected 
in  the  other  3  root  samples.  2  of  these  root  samples  (samples  7  and  15)  would 
have  been  reported  as  positive  using  the  criteria  proposed  in  section  8.9.1.5.1. 
As  the  GC-MS  method  results  in  the  partial  hydrolysis  of  6-MAM  to  morphine,  the 
morphine/codeine  ratios  should  be  higher  using  this  method  compared  to  the  LC- 
MS-MS  method  which  uses  a  phosphate  buffer  extraction  which  does  not  cause  6- 
MAM  hydrolysis. 
Dihydrocodeine  was  detected  in  root  segment  8  (1.9  ng/mg)  where  LC-MS-MS 
failed  to  detect  it.  The  LC-MS-MS  sample  weight  and  GC-MS  sample  weight  were 
very  low  in  this  case  therefore  the  better  recovery  of  the  GC-MS  method  could 
explain  this  result.  Alternatively,  the  root-0.5  cm  segments  may  not  have  been 
split  evenly  between  the  two  methods.  Hair  growing  at  the  time  of  ingestion 
would  have  incorporated  dihydrocodeine  whereas  hair  at  the  end  of  its  growth 
cycle  would  not.  There  are  a  limited  number  of  scientific  papers  concerning 
dihydrocodeine  levels  in  hair.  One  study  found  13  hair  samples  collected  from 
suspected  heroin  users  positive  for  dihydrocodeine  in  the  range  1.2-31.2 
ng/mg.  256  Both  the  LC-MS-MS  and  GC-MS  methods  detected  lower  dihydrocodeine 
concentrations  in  root  segments  4  and  15  respectively  than  the  lowest 
concentration  reported  in  this  study.  The  rest  of  the  positive  samples  did 
however  have  concentrations  within  this  reported  range. 
Cocaine  and  benzoylecgonine  were  detected  in  2  root  segments  (samples  9  and 
10)  using  LC-MS-MS  and  GC-MS.  The  root  sample  weights  were  >3  mg  for  both 
methods.  Cocaethytene  was  also  detected  in  these  samples  by  LC-MS-MS  but  not 
by  GC-MS.  Root  segment  9  contained  2.05  ng/mg  cocaine,  0.31  ng/mg 
benzoylecgonine  and  0.25  ng/mg  cocaethylene  as  determined  by  LC-MS-MS.  The 
GC-MS  method  detected  higher  cocaine  and  benzoytecgonine  levels  (4.78  ng/mg Drugs  of  Abuse  in  Hair  Chapter  8,199 
cocaine  and  1.56  ng/mg  benzoylecgonine)  in  root  sample  9.  The  higher  recovery 
of  the  extraction  method  could  explain  these  results.  As  the  root  segment 
weights  were  similar  for  LC-MS-MS  and  GC-MS  analysis,  it  appears  that  the  LC- 
MS-MS  method  sensitivity  is  better  for  cocaethylene  however  the  result  could 
also  be  due  to  uneven  splitting  of  the  root  segments.  The  ratio  of 
benzoylecgonine/cocaine  was  >  0.05  in  the  positive  root  samples  analysed  by 
both  methods.  This  ratio  is  recommended  cut-off  proposed  by  the  SoHT.  10° 
As  mentioned  previously,  amphetamine  was  detected  in  root  sample  17  where 
none  was  detected  by  GC-MS.  GC-MS  did  not  test  for  benzodiazepines  however 
the  LC-MS-MS  method  detected  diazepam  (samples  2  and  10)  and  nordiazepam 
(samples  2,4  and  10)  were  detected  in  the  ranges  of  0.31-0.34  ng/mg  and  0.34- 
2.26  ng/mg  respectively.  Nordiazepam/diazepam  ratios  were  1.10  and  6.65  for 
these  samples.  These  ratios  are  within  the  ranges  reported  by  other  studies.  "' 
8.9.1.5.3  Quantitative  results  for  segments  excluding  roots 
The  drug  ranges  and  number  of  segments  excluding  roots  found  positive  by  LC- 
MS-MS  and  GC-MS  are  summarised  in  Table  8-29.  The  opiate  ranges  were  much 
broader  than  the  ranges  obtained  for  the  root  segments  shown  in  Table  8-28. 
Table  8-29  Drug  ranges  and  number  of  positive  segments  excluding  roots 
LC-MS-MS  GC-  MS 
Analyte 
Concentration 
Range 
(ng/mg) 
Number  of 
Positive 
Segments 
Concentration 
Range 
(ng/mg) 
Number  of 
Positive 
Segments 
Morphine  0.04-2.02  10  0.01-6.14  12 
6-MAM  0.08-4.55  12  0.19-3.36  10 
Codeine  0.02-2.32  10  0.05-5.52  13 
Dihydrocodeine  0.09-16.18  6  0.05-14.60  8 
Cocaine  0.06-13.99  7  0.09-19.34  6 
Benzoytecgonine  0.11-4.73  7  0.21-4.92  6 
Cocaethylene  0.04-0.53  3  0.10-1.07  2 
EME  0.21-0.24  2  Not  reported  N/A 
Amphetamine  0.19-7.29  3  1.75  1 
MDMA  0.46-1.60  6  Not  tested  N/A 
Diazepam  0.04-0.52  7  Not  tested  N/A Drugs  of  Abuse  in  Hair  Chapter  8,200 
Table  8-29  Drug  ranges  and  number  of  positive  segments  excluding  roots  (continued) 
Nordiazepam  0.17-0.67  7  Not  tested  N/A 
Oxazepam  0.22-0.26  2  Not  tested  N/A 
Temazepam  0.10-0.14  2  Not  tested  N/A 
Using  LC-MS-MS,  6-MAM  was  detected  in  12  segments  without  roots  in  this 
current  study  which  suggests  heroin  use.  7  of  these  samples  contained  morphine 
and  codeine  which  can  support  heroin  consumption  when  6-MAM  is  also  present. 
The  morphine  and  codeine  ranges  as  determined  by  LC-MS-MS  were  0.04-2.02 
ng/mg  and  0.02-2.32  ng/mg.  For  GC-MS,  the  morphine  and  codeine  ranges  were 
0.01  -6.14  ng/mg  and  0.05-5.52  ng/mg  respectively.  The  higher  range  for  GC-MS 
for  morphine  and  codeine  highlights  the  better  extraction  capability  of  the  GC- 
MS  method  compared  to  the  LC-MS-MS  method.  The  morphine/codeine  ratios  in 
these  samples  ranged  from  0.43-10.00  (mean  3.35).  Morphine  was  detected  at  a 
higher  concentration  than  codeine  in  4  of  these  7  samples.  As  well  as  being  a 
metabolite  of  6-MAM,  morphine  is  also  a  metabolite  of  codeine.  In  samples  3 
and  4,  the  codeine  concentration  is  higher  than  the  morphine  concentration. 
However  due  to  the  possible  consumption  of  codeine,  these  ratios  can  be  higher 
and  as  found  in  samples  3  and  4,  can  be  found  at  a  greater  concentration  than 
morphine.  In  these  cases,  it  is  extremely  important  to  detect  6-MAM  to 
distinguish  heroin  use  from  codeine  use.  The  morphine/codeine  ratios  reported 
in  another  study  ranged  from  0.38-6.45  as  reported  for  23  morphine  and  codeine 
positive  hair  samples  which  used  a  method  involving  a  phosphate  buffer  (pH  5.0) 
extraction.  "  According  to  the  criteria  discussed  in  section  8.9.1.5.1,  a  sample 
should  be  reported  positive  for  heroin  use  when  there  is  a  morphine  /codeine 
ratio  of  5:  1  in  cases  where  the  morphine  level  is  <1  ng/mg.  Samples  3  and  4 
would  be  reported  as  negative  for  heroin  use  according  to  these  reported  ratios. 
However  6-MAM  was  found  in  these  samples  and  the  6-MAM/morphine  ratios 
were  5.8  and  3.6  respectively  which  would  fit  the  criteria  proposed  by  one  of 
the  studies'  for  reporting  heroin  use  but  not  the  other  study  which  proposes  a 
6-MAM/morphine  ratio  >  7.14.253  The  information  provided  in  the  pathology 
reports  for  sample  3  was  that  the  individual  had  a  past  history  of  multi- 
substance  abuse,  including  heroin  abuse.  Morphine,  diazepam,  nordiazepam  and 
alcohol  were  found  in  the  blood  sample.  The  information  provided  in  the Drugs  of  Abuse  in  Hair  Chapter  8,201 
pathology  report  for  sample  4  provided  no  information  on  past  drug  abuse 
history.  Morphine,  diazepam,  nordiazepam,  oxazepam  and  procyclidine  were 
detected  in  the  blood  sample.  It  would  appear  that  the  proposed 
morphine  /codeine  ratios  of  5:  1  are  not  appropriate  in  these  cases  where  the 
background  information  indicates  past  heroin  use  and  where  no  information  to 
support  codeine  use  was  found. 
Using  LC-MS-MS,  9  out  of  12  opiate  positive  segments  without  roots  contained 
both  morphine  and  6-MAM.  In  contrast  using  GC-MS,  5  out  of  12  opiate  positive 
segments  without  roots  contained  both  6-MAM  and  morphine.  In  general  there 
was  good  correlation  between  the  qualitative  opiate  results  for  LC-MS-MS  and 
GC-MS.  However  some  analytes  were  detected  by  LC-MS-MS  where  GC-MS  failed 
to  detect  them  and  vice  versa. 
The  6-MAM  concentrations  detected  by  LC-MS-MS  and  GC-MS  were  in  the  range 
0.08-4.55  ng/mg  and  0.19-3.36  ng/mg  respectively,  with  most  being  categorised 
as  low  (91.6  %)  users  according  to  the  proposals  in  the  previously  mentioned 
study.  253  The  concentrations  detected  in  sample  7  by  LC-MS-MS  and  GC-MS  were 
indicative  of  medium  level  use.  According  to  this  proposed  categorisation,  3  of 
the  segments  would  be  reported  as  negative  using  the  LC-MS-MS  method  and  1  of 
these  segments  would  be  reported  as  positive  since  the  6-MAM  concentrations 
were  <  0.5  ng/mg.  This  finding  highlights  the  importance  of  establishing  cut-off 
values  appropriate  to  a  particular  method.  However,  recent  recommendations 
by  the  SoHT  state  that  a  cut-off  of  0.2  ng/mg  6-MAM  is  acceptable  for 
interpreting  heroin  use.  10°  Using  LC-MS-MS,  6-MAM  levels  detected  in  3  segments 
(samples  2,10  and  12)  were  below  this  cut-off  level.  The  GC-MS  results  for 
samples  2  and  12  did  not  detect  any  6-MAM  so  these  results  would  have  been 
reported  as  negative  by  both  methods.  The  GC-MS  method  detected  6-MAM  at 
the  SoHT  cut-off  concentration  of  0.2  ng/mg  in  sample  10  where  the  LC-MS-MS 
found  a  concentration  <  0.2  ng/mg. 
There  was  no  background  information  available  for  sample  2.  There  was  drug 
paraphernalia  and  multiple  needle  marks  on  the  individual  from  which  sample  10 
was  collected,  which  is  consistent  with  heroin  use.  Morphine,  codeine,  EME, Drugs  of  Abuse  in  Hair  Chapter  8,202 
cocaine,  benzoylecgonine,  diazepam,  nordiazepam,  oxazepam  and  temazepam 
were  found  in  the  blood  sample.  Information  from  the  pathology  reports 
revealed  that  hair  sample  12  was  collected  from  an  individual  with  a  previous 
addiction  to  heroin  and  had  been  attending  methadone  programmes.  Morphine 
was  detected  in  the  blood  sample,  as  well  as  diazepam,  nordiazepam, 
oxazepam,  temazepam,  methadone,  sodium  valproate  and  sertraline. 
The  6-MAM/morphine  ratios  are  shown  in  Table  8-30.  With  the  exception  of 
sample  3,  the  ratios  for  the  GC-MS  method  are  lower  than  those  for  the  LC-MS- 
MS  method.  This  is  a  result  of  the  different  extraction  methods  used.  The  LC- 
MS-MS  ratios  for  6-MAM/morphine  are  mostly  higher  than  the  ratios  determined 
in  another  study  which  used  a  phosphate  buffer  (pH  5.0)  extraction. 
Table  8-30  6-MAM/morphine  ratios  in  hair  by  LC-MS-MS  and  GC-MS 
Hair  Sample  Number  6-MAM/Morphine  by 
LC-MS-MS 
6-MAM/Morphine  by 
GC-MS 
(1)  0.5-3.5  cm  0.65  0.47 
(2)  0.5-3.5  cm  0.10  N/A 
(3)  0.5-3.5  cm  5.78  72.00 
(3)  3.5-6.5  cm  N/A  13.30 
(4)  0.5-3.5  cm  3.63  2.96 
(7)  0.5-3.5  cm  4.14  0.58 
(8)  0.5-3.5  cm  N/A  3.54 
(9)  0.5-3.5  cm  28.00  3.44 
(12)  0.5-3.5  cm  0.14  N/A 
(13)  0.5-3.5  cm  N/A  3.80 
(15)  0.5-3.5  cm  1.28  0.76 
As  mentioned  previously,  dihydrocodeine  levels  have  not  been  commonly 
reported  in  hair.  The  LC-MS-MS  and  GC-MS  concentrations  found  in  the  segments 
excluding  roots  ranged  from  0.09-16.18  ng/mg  and  0.05-14.60  ng/mg.  The  LC- 
MS-MS  method  appears  to  extract  more  dihydrocodeine  than  the  GC-MS  method. 
The  concentrations  found  by  both  methods  were  lower  than  the  range  reported 
in  another  study.  24'  Dihydrocodeine  was  found  in  hair  samples  12  and  15  at 
relatively  high  levels.  The  background  reports  stated  that  the  individuals  from 
which  samples  12  and  15  were  collected  were  being  currently  prescribed 
dihydrocodeine. Drugs  of  Abuse  in  Hair  Chapter  8,203 
Cocaine  and  benzoylecgonine  were  detected  in  7  segments  excluding  roots  by 
LC-MS-MS.  The  benzoylecgonine/cocaine  metabolite  to  parent  drug  ratios  were 
>_  0.05  in  all  samples  which  is  the  cut-off  value  proposed  by  the  SoHT.  97  Further 
suggestion  of  cocaine  use  was  the  presence  of  cocaethylene  in  3  of  these 
segments  (samples  5,9  and  10)  and  the  presence  of  EME  in  2  segments  (samples 
9  and  10).  Cocaine  concentrations  by  LC-MS-MS  ranged  from  0.06-13.99  ng/mg, 
benzoylecgonine  from  0.11-4.73  ng/mg,  cocaethylene  from  0.04-0.53  ng/mg  and 
0.21-0.24  ng/mg  EME.  These  ranges  correspond  with  other  studies.  '  133  One 
study  which  used  phosphate  buffer  (pH  5.0)  incubation  for  the  extraction  of 
cocaine  and  its  metabolites  from  103  hair  samples  from  known  drug  users 
detected  cocaine  levels  in  74  of  these  samples  ranging  between  0.01-21.37 
ng/mg,  benzoylecgonine  levels  between  0.03-10.51  ng/mg  and  cocaethylene 
levels  between  0.05-1.26  ng/mg.  81  The  method  did  not  analyse  for  EME. 
Benzoylecgonine/cocaine  ratios  in  this  study  ranged  form  0.43-1.85.  There  was 
excellent  qualitative  agreement  between  the  LC-MS-MS  and  GC-MS  results  for 
cocaine  and  benzoylecgonine.  The  GC-MS  method  was  applied  for  the  analysis  of 
cocaine  and  its  metabolites  in  6  segments  excluding  roots.  Cocaine  and 
benzoylecgonine  were  detected  in  these  segments  also  found  to  be  positive  by 
LC-MS-MS.  Cocaethylene  was  also  detected  in  samples  9  and  10.  As  mentioned 
previously,  EME  results  were  not  reported  for  the  GC-MS  method  due  to  an 
interferent  at  the  EME  retention  time.  Quantitatively,  the  GC-MS  method 
generally  extracted  greater  quantities  of  cocaine  and  its  metabolites  due  to  a 
higher  extraction  recovery.  The  benzoylecgonine/cocaine  metabolite  to  parent 
drug  ratios  were  >_  0.05  in  all  samples.  Cocaine  concentrations  by  GC-MS  ranged 
from  0.09-19.34  ng/mg,  benzoylecgonine  from  0.21-4.92  ng/mg  and 
cocaethylene  from  0.10-1.07  ng/mg.  The  cocaine  range  found  is  lower  than 
reported  in  another  study  which  used  acidic  hydrolysis  with  hydrochloric  acid  at 
50  °C  overnight  to  extract  cocaine  and  its  metabolites  from  hair.  248 
Benzoylecgonine  concentrations  were  however  within  the  range  reported  in  this 
study. 
For  the  segments  excluding  roots,  the  LC-MS-MS  concentrations  of  amphetamine 
in  hair  ranged  from  0.19-7.29  ng/mg  which  is  in  agreement  with  other  studies. 
The  GC-MS  method  was  only  applied  to  sample  17  and  found  a  concentration  of Drugs  of  Abuse  in  Hair  Chapter  8,204 
1.75  ng/mg  where  the  LC-MS-MS  detected  a  level  of  7.29  ng/mg.  Amphetamine 
was  also  found  in  the  blood  sample  at  a  concentration  of  0.66  mg/L  and  the 
cause  of  death  was  amphetamine  intoxication.  One  study  reported 
amphetamine  concentrations  of  0.01-4.46  ng/mg  in  hair  of  40  volunteers  who 
were  on  drug  rehabilitation  programmes  and  were  known  drug  users.  ' 
The  GC-MS  method  for  amphetamines  was  only  applied  to  sample  17  however 
the  LC-MS-MS  method  analysed  for  amphetamines  in  all  hair  samples.  MDMA  was 
detected  in  4  samples  (samples  2,3,4  and  5)  by  LC-MS-MS.  Concentrations 
ranged  from  0.46-1.60  ng/mg  which  corresponds  with  other  scientific  literature. 
According  to  the  current  SoHT  guidelines  these  would  be  reported  as  positive.,, 
1  of  the  samples  (sample  4)  was  positive  for  both  MDMA  and  amphetamine.  The 
presence  of  amphetamine  in  this  sample  could  be  due  to  ingesting  amphetamine 
tablets  or  alternatively  the  amphetamine  could  be  present  as  an  impurity  in  the 
MDMA  tablets.  There  was  no  MDMA  metabolite,  MDA  detected  in  the  samples.  A 
possible  explanation  for  this  is  the  low  levels  of  MDMA  detected  in  the  samples. 
One  study  examined  MDA/MDMA  metabolite  to  parent  drug  ratios  in  hair  samples 
collected  from  40  suspected  drug  users.  249  The  MDA/MDMA  ratios  ranged  from 
0.03-1.10  (mean  0.15).  If  this  mean  MDA/MDMA  ratio  was  applied  to  calculate  a 
predicted  MDA  concentration  range  from  the  MDMA  concentration  range  found,  it 
would  be  0.70-2.4  ng/mg.  The  lower  value  in  this  range  is  the  LOQ  of  the 
method  and  this  may  explain  why  MDA  was  not  reported  as  positive  in  this 
sample.  In  one  study,  MDMA  concentrations  ranging  from  0.12-6.4  ng/mg  were 
detected  in  the  hair  of  20  known  users.  25°  The  range  of  MDMA  concentrations  in 
another  study  analysing  hair  collected  from  suspected  abusers  was  0.56-34.06 
ng/mg.  249  MDA  was  also  detected  in  this  study  in  the  range  0.13-6.44  ng/mg. 
The  GC-MS  method  did  not  analyse  for  benzodiazepines.  The  LC-MS-MS  method 
however  detected  nordiazepam  most  frequently  in  the  hair  samples  tested  in 
this  study  and  was  generally  present  at  a  higher  level  than  diazepam,  as  found  in 
other  studies.  '",  "'  These  results  were  consistent  with  the  findings  of  the 
benzodiazepine  study  carried  out  in  chapter  7.  Diazepam  concentrations  ranged 
from  0.04-0.52  ng/mg,  nordiazepam  from  0.17-0.67  ng/mg,  0.22-0.26  ng/mg 
oxazepam  and  0.10-0.14  ng/mg  temazepam.  Oxazepam  and  temazepam  were Drugs  of  Abuse  in  Hair  Chapter  8,205 
generally  detected  at  lower  levels  than  found  in  the  other  study  in  chapter  7  as 
a  result  of  the  different  extraction  method  used.  They  were  also  detected  in 
fewer  samples  compared  to  diazepam  and  nordiazepam.  This  would  suggest 
diazepam  use  in  these  cases.  However,  oxazepam  was  detected  at  a  higher 
concentration  in  sample  12  compared  to  diazepam  and  nordiazepam  which  may 
indicate  combined  diazepam  and  oxazepam  use. 
The  LC-MS-MS  chromatograms  for  hair  samples  that  were  positive  for  each  drug 
class  are  given  in  Figures  8-22-8-25. 
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Figure  8-22  Hair  sample  positive  for  amphetamine Drugs  of  Abuse  in  Hair 
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Figure  8-23  Hair  sample  positive  for  diazepam  and  nordiazepam  (left  to  right) 
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Figure  8-24  Hair  sample  positive  for  morphine,  codeine,  dihydrocodeine  and  6-MAM  (left  to 
right) Drugs  of  Abuse  in  Hair  Chapter  8,207 
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Figure  8-25  Hair  sample  positive  for  EME,  cocaine,  cocaethylene  and  benzoylecgonine  (left 
to  right) 
8.9.2  ELISA  vs  LC-MS-MS 
The  validated  ELISA  and  LC-MS-MS  method  for  the  detection  of  drugs  of  abuse  in 
hair  were  successfully  applied  to  7  post-mortem  positive  hair  samples.  The  hair 
samples  were  screened  by  ELISA  when  there  was  sufficient  sample  present  after 
quantification  by  LC-MS-MS.  The  results  are  given  in  Tables  8-31-8-35. 
Table  8-31  Amphetamines  ELISA  results 
ELISA  LC-MS-MS  (ng/mg) 
Sample 
Number 
Weight 
(  g) 
Equivalents 
(ng/mg) 
Weight 
(  g) 
AMP  P  MDA  MDMA  MDEA 
(9)0.5-3.5  5.14  <  0.2  28.55  0.21  -  -  -  - 
(3)  0.5-3.5  5.71  <  0.2  19.09  -  -  -  1.26  - 
(10)0  5-3.5  4.14  <  0.2  29.47  -  -  -  -  - 
(8)  0.5-3  2.02  <  0.2  9.24  -  -  -  -  - 
(12)  0.5-3.5  3.89  <  0.2  10.40  -  -  -  0.46  - 
(1)  0.5-3.5  4.41  <  0.2  23.80  -  -  -  -  - 
(15)  0.5-3.5  7.43  <  0.2  18.66  -  -  -  -  - 
"AMP"=Amphetamine,  "MAMP"=Methamphetamine Drugs  of  Abuse  in  Hair 
Table  8-32  Benzodiazepine  ELISA  results 
Chapter  8,208 
ELISA  LC-MS-MS  (ng/mg) 
Sample 
Number 
Weight 
(mg) 
OXAZ 
Equivalents 
(ng/mg) 
Weight 
(mg)  DZ  NDZ  OXAZ  TMZ 
(9)  0.5-3.5  5.14  0.27  28.55  0.18  0.17  -  - 
(3)  0.5-3.5  5.71  0.14  19.09  0.12  0.36 
(10)  0.5-3.5  4.14  >  0.5  29.47  0.24  0.64  0.26  0.14 
(8)  0.5-3  2.02  0.13  9.24  -  -  -  - 
(12)  0.5-3.5  3.89  >  1.0  10.40  0.68  0.92  3.51  - 
(1)  0.5-3.5  4.41  0.36  23.80  0.10  0.37  -  - 
(15)  0.5-3.5  7.43  0.12  18.66  -  -  -  - 
"DZ"=  Diazepam,  "NDZ"=  Nordiazepam,  "OXAZ"=Oxazepam,  "TMZ"=Temazepam 
Table  8-33  Cocaine  ELISA  Results 
ELISA  LC-MS-MS  (ng/mg) 
Sample 
Number 
Weight 
(mg) 
Ecoc  quivalents 
(ng/mg) 
Weight 
(mg) 
COC  BZE  COCAETH  EME 
(9)  0.5-3.5  5.14  >  2.5  28.55  13.99  4.73  0.53  - 
(3)  0.5-3.5  5.71  0.64  19.09  0.29  0.16  -  - 
(10)  0.5-3.5  4.14  >  2.5  29.47  0.60  0.18  0.04  - 
(8)  0.5-3  2.02  <  0.5  9.24  0.08  -  -  - 
(12)  0.5-3.5  3.89  <  0.5  10.40  -  -  -  - 
(1)  0.5-3.5  4.41  <  0.5  23.80  -  -  -  - 
(15)  0.5-3.5  7.43  <  0.5  18.66  -  -  -  - 
"COC"=  Cocaine,  "BZE"=  Benzoylecgonine,  "COCAETH"=  Cocaethylene,  "EME"=Ecgonine  Methyl 
Ester Drugs  of  Abuse  in  Hair 
Table  8-34  Methamphetamine  ELISA  results 
Chapter  8,209 
ELISA  LC-MS-MS  (ng/m  g) 
Sample 
Number 
Weight 
(mg) 
d-MAMP 
Equivalents 
(ng/mg) 
Weight 
(mg) 
AMP  MAMP  MDA  MDMA  MDEA 
(9)  0.5-3.5  5.14  0.24  28.55  0.21  -  -  -  - 
(3)  0.5-3.5  5.71  0.60  19.09  -  -  -  1.26  - 
(10)  0.5-3.5  4.14  <  0.2  29.47  -  -  -  -  - 
(8)  0.5-3  2.02  <  0.2  9.24  -  -  -  -  - 
(12)  0.5-3.5  3.89  0.31  10.40  -  -  -  0.46 
(1)  0.5-3.5  4.41  <  0.2  23.80  -  -  -  -  - 
(15)  0.5-3.5  7.43  0.42  18.66  -  -  -  -  - 
"AMP"=Amphetamine,  "MAMP"=Methamphetamine 
Table  8-35  Opiate  ELISA  Results 
ELISA  LC-MS-MS  (ng/mg) 
Sample 
Number 
Weight 
(mg) 
MOR 
Equivalents 
(ng/mg) 
Weight 
(mg)  MOR  6-MAM  COD  DHC 
(9)  0.5-3.5  5.14  0.43  28.55  0.04  1.12  -  - 
(3)  0.5-3.5  5.71  <  0.2  19.09  0.09  0.52  -  - 
(10)  0.5-3.5  4.14  <  0.2  29.47  -  0.08 
(8)6.  -5-3  2.02  <  0.2  9.24  -  0.58  -  - 
(12)  0.5-3.5  3.89  >  1.0  10.40  0.87  0.12  -  16.18 
(1)  0.5-3.5  4.41  0.20  23.80  2.02  -  -  - 
(15)  0.5-3.5  7.43  >  1.0  18.66  1.03  1.32  0.31  10.72 
"MOR"=Morphine,  "6-MAM"=  6-monoacetytmorphine,  "COD"=  Codeine,  "DHC"=  Dihydrocodeine 
The  sample  weights  used  for  ELISA  were  low  (<  10  mg  and  in  most  cases  <5  mg). 
The  drug  levels  detected  in  some  samples  using  LC-MS-MS  were  low  even  using  a 
higher  sample  weight  of  10-30  mg  therefore  the  sample  weight  limited  the  ELISA 
method. 
The  methamphetamine  kit  produced  a  greater  number  of  true  results  compared 
with  the  amphetamine  kit  which  produced  3  FN  results.  This  is  due  to  the Drugs  of  Abuse  in  Hair  Chapter  8,210 
different  cross  reactivity  of  the  2  kits.  The  methamphetamine  kit  has  a  very 
high  cross  reactivity  with  MDMA  and  2  of  the  samples  were  confirmed  as  positive 
using  LC-MS-MS  for  MDMA. 
The  benzodiazepine  kit  produced  5  TP  and  2  FP  results  using  a  cut-off  of 
0.1  ng/mg  oxazepam.  The  2  FP  concentrations  were  calculated  as  the  actual 
cut-off  value.  There  may  have  been  benzodiazepines  present  in  these  samples 
other  than  diazepam  and  its  metabolites  which  could  have  cross  reacted  with 
the  ELISA  kit  to  produce  these  FP  results. 
Using  the  recommended  SoHT  cut-off  value  of  0.5  ng/mg  cocaine,  the  kit 
detected  3  TP,  3  TN  and  I  FN  result.  The  FN  result  produced  a  low  positive 
result  for  cocaine  and  so  using  this  cut-off,  the  sample  would  have  been 
reported  as  negative. 
The  opiates  kit  detected  4  TP  and  3  FN  results  using  a  cut-off  of  0.2  ng/mg 
morphine.  The  FN  results  were  samples  which  contained  low  levels  of  opiates  as 
determined  by  LC-MS-MS. 
On  the  whole,  ELISA  is  a  useful  method  for  screening  provided  there  is  sufficient 
sample  (>  10  mg).  The  validated  LC-MS-MS  method  was  capable  of  detecting 
drug  levels  in  very  low  weight  root  samples  as  shown  in  Table  8-26.  This  was  not 
the  case  for  ELISA  screening  of  low  sample  weights  as  there  were  FN  results  for 
all  drug  classes  tested  except  benzodiazepines.  Furthermore  the  superior  LC-MS- 
MS  specificity  means  that  screening  and  quantification  could  be  carried  out  using 
the  LC-MS-MS  method  described. 
8.10  Conclusion 
The  developed  and  validated  LC-MS-MS  method  is  capable  of  simultaneously 
identifying  and  quantifying  amphetamines,  diazepam  and  its  metabolites, 
cocaine  and  its  metabolites  and  opiates  from  one  hair  sample  of  8-30  mg.  It  is 
also  capable  of  detecting  these  drug  groups  in  root  segments  of  low  weight  (in 
some  cases  <1  mg).  Although  the  opiate  and  cocaine  recoveries  are  generally 
lower  from  real  hair  samples  using  the  LC-MS-MS  compared  to  the  in-house  GC- Drugs  of  Abuse  in  Hair  Chapter  8,211 
MS  methods  targeting  specific  drug  groups,  the  sensitivity  and  therefore  the 
qualitative  data  was  better,  especially  for  morphine,  6-MAM  and  cocaethylene  in 
low  weight  root  samples. 
As  a  result  of  the  lower  opiate  and  cocaine  recoveries  using  this  LC-MS-MS 
method  compared  to  GC-MS,  it  should  be  borne  in  mind  that  there  may  be  cases 
where  the  GC-MS  method  would  detect  the  analyte  where  the  LC-MS-MS  method 
would  not.  This  has  been  shown  in  a  few  samples  for  morphine  and  codeine. 
Dihydrocodeine  was  however  detected  in  2  samples  where  LC-MS-MS  failed  to 
detect  it.  The  LC-MS-MS  and  GC-MS  data  showed  excellent  qualitative 
correlation  for  cocaine,  benzoylecgonine  and  cocaethylene  but  the  GC-MS 
method  extracted  greater  quantities  of  cocaine  and  benzoylecgonine. 
Cocaethylene  and  EME  were  detected  in  some  samples  by  LC-MS-MS  were  GC-MS 
detected  none.  A  disadvantage  of  the  GC-MS  method  is  its  inability  to  report 
EME  levels  due  to  a  co-eluting  interferent  peak  at  the  EME  retention  time. 
Amphetamine  recovery  was  higher  using  the  LC-MS-MS  in  1  sample  compared  to 
GC-MS. 
The  method  was  useful  for  the  analysis  of  17  drugs  of  abuse  from  post-mortem 
hair  in  forensic  toxicology  cases.  Maximum  information  is  obtained  from  1  hair 
sample  which  is  extremely  useful  when  the  sample  weight  is  limited.  As  it  is 
currently  not  possible  to  relate  the  quantity  of  drug  detected  in  hair  with 
amount  of  drug  ingested  or  the  frequency  of  drug  use,  a  qualitative  screening 
method  may  provide  all  the  required  information  for  as  accurate  an 
interpretation  as  possible  at  this  time.  The  ability  of  the  LC-MS-MS  method  to 
extract  and  analyse  a  greater  number  of  drug  groups  from  one  hair  sample 
highlights  the  advantages  of  using  this  method  over  GC-MS  which  targets 
individual  drug  groups  and  requires  splitting  the  sample. 212 
9  Conclusion 
An  investigation  was  carried  out  into  the  potential  use  of  ELISA  and  LC-MS-MS  for 
the  analysis  of  biological  samples  in  forensic  toxicology.  Both  analytical 
techniques  have  been  found  to  be  extremely  useful  however  as  with  any 
technique,  each  has  its  own  set  of  benefits  and  limitations. 
A  highly  sensitive  and  specific  ELISA  method  was  developed  for  the  successful 
detection  of  buprenorphine  in  21  urine  samples.  This  level  of  sensitivity  is 
essential  as  therapeutic  concentrations  of  buprenorphine  can  be  low.  The  limit 
of  detection  was  0.5  ng/mL.  Norbuprenorphine  cross  reactivity  was  relatively 
high  which  is  a  good  feature  of  the  kit  since  norbuprenorphine  levels  in  urine  are 
generally  higher  than  buprenorphine  levels.  Using  0.5  ng/mL  as  the  ELISA  cut 
off,  the  sensitivity  and  specificity  were  both  100  %  compared  with  an  in-house 
LC-MS  method. 
A  single  ELISA  method  was  successfully  validated  for  amphetamines, 
benzodiazepines,  cocaine,  methamphetamine,  methadone  and  opiates  in  hair 
and  subsequently  applied  to  the  screening  of  case  samples.  The  kits  were  found 
to  be  very  sensitive  with  LOD  values  _< 
0.1  ng/mg  using  a  10  mg  hair  sample. 
Intra-day  precision  and  inter-day  precision  levels  were  acceptable  (<  9%  and 
<  18  %  respectively)  and  appropriate  cross  reactivity  was  demonstrated  with 
drugs  and  drug  metabolites  relevant  to  hair. 
The  ELISA  cut-off  values  used  for  the  post-mortem  hair  samples  in  chapters  6 
and  8  were  recommended  by  the  Society  of  Hair  Testing  (SoHT)  for 
amphetamines,  cocaine  and  opiates.  The  ELISA  sensitivity  and  specificity  were 
89  %  and  79  %  for  27  opiate  positive  samples.  The  3  FN  results  could  be 
explained  by  low  sample  weights  <_  5  mg  and  in  1  case,  the  presence  of  a  low 
level  of  dihydrocodeine  which  has  been  shown  to  cross  react  with  the  kit  by  43 
%.  The  ELISA  sensitivity  for  20  benzodiazepine  positive  hair  samples  was  100  % 
however  specificity  was  67  %  using  a  cut-off  value  of  0.1  ng/mg.  It  was  shown 
that  FN  results  were  produced  at  higher  ELISA  cut-off  values.  In  the 
collaboration  with  the  Korean  laboratory,  29  methamphetamine  positive  hair Conclusion  213 
samples  were  screened  at  a  cut-off  of  0.5  ng/mg.  28  out  of  29  samples  were  TP 
results  and  there  was  1  FN  which  was  very  close  to  the  ELISA  cut-off  value. 
There  were  a  relatively  small  number  of  cocaine,  methadone  and  amphetamine 
positive  hair  samples  available  for  ELISA  screening  as  the  majority  of  the  sample 
required  to  be  analysed  by  a  more  specific  confirmatory  method  first.  Therefore 
no  substantiated  conclusions  can  be  drawn  regarding  the  recommended  SoHT 
cut-off  values  for  cocaine  and  amphetamine.  Interestingly,  2  of  the  3  FN 
cocaine  results  contained  only  cocaine  at  concentrations  <  0.5  ng/mg  as 
determined  by  GC-MS.  This  could  be  a  result  of  contamination  or  low  use. 
According  to  current  SoHT  guidelines,  these  2  samples  would  be  reported  as 
negative  as  the  guidelines  stipulate  that  a  benzoylecgonine/cocaine  ratio  z  0.05 
should  be  used  as  a  cut-off.  There  were  only  3  samples  confirmed  as  positive  for 
amphetamines  by  LC-MS-MS.  2  of  these  samples  were  positive  for  MDMA  and 
tested  negative  using  the  amphetamines  ELISA  due  to  very  low  MDMA  cross 
reactivity  but  tested  positive  using  the  methamphetamine  kit  which  has  a  high 
MDMA  cross  reactivity.  1  sample  was  positive  for  amphetamine  and  only  tested 
positive  using  the  methamphetamine  kit.  The  LC-MS-MS  concentration 
calculated  for  amphetamine  was  the  actual  cut-off  so  this  explains  the  negative 
result  using  the  amphetamines  kit.  5  out  of  6  methadone  positive  samples 
screened  as  positive  at  a  cut-off  of  0.2  ng/mg.  The  1  FN  result  was  probably  a 
result  of  a  very  low  sample  weight  (1  mg)  as  the  GC-MS  concentration  detected 
was  3.7  ng/mg. 
The  ELISA  method  was  applied  successfully  for  the  detection  of 
methamphetamine  in  hair  of  methamphetamine  abusers.  The  kit  demonstrated 
a  sensitivity  and  specificity  of  97  %  and  100  %  respectively  using  a  cut-off  value 
of  0.5  ng/mg  d-methamphetamine.  The  amphetamine  to  methamphetamine 
ratios  ranged  from  0.02-0.159  in  28  samples  excluding  roots. 
An  LC-MS-MS  method  was  successfully  validated  for  the  detection  of  9 
benzodiazepines  in  hair  as  described  in  chapter  7.  The  method  was  sufficiently 
sensitive  for  their  detection  in  post-mortem  hair  samples.  13  post-mortem 
samples  were  found  to  be  positive  for  benzodiazepines  using  this  method.  A Conclusion  214 
mild  alkaline  incubation  lasting  16  hours  was  shown  to  be  most  suitable  for 
benzodiazepine  extraction  and  there  was  no  significant  hydrolysis  observed. 
Recoveries  in  spiked  hair  ranged  from  53-98  %  and  the  LOD  range  was  0.03-0.62 
ng/30  mg  hair.  The  matrix  effect  ranged  from  77-105  %  with  most  analytes 
displaying  ion  suppression.  The  evaporation  step  in  the  SPE  method  was 
identified  as  means  of  7-aminoflunitrazepam  and  chlordiazepoxide  loss,  which  is 
partly  responsible  for  the  lower  recoveries  of  these  analytes. 
Also  in  chapter  7,  a  preliminary  study  was  carried  out  into  the  use  of  a  diazepam 
molecularly  imprinted  polymer  for  the  detection  of  benzodiazepines  in  post- 
mortem  hair  case  samples.  It  was  shown  that  it  can  be  applied  successfully  for 
this  purpose  and  detected  a  higher  number  of  diazepam  positive  cases  compared 
to  the  classical  SPE  method  because  of  higher  extraction  recovery  and  the 
excellent  molecular  recognition  of  the  template  molecule  (diazepam)  imparted 
by  the  imprinting  process. 
The  method  developed  in  chapter  8  was  successfully  validated  for  17  drugs  of 
abuse  in  hair.  It  enabled  the  simultaneous  identification  and  quantification  of 
amphetamines,  diazepam  and  its  metabolites,  cocaine  and  its  metabolites  and 
opiates  from  1  hair  extract  using  3  LC-MS-MS  injections.  3  injections  were  used 
to  enhance  assay  sensitivity  by  minimising  the  number  of  scan  events  per  time 
window.  This  also  maximised  the  number  of  points  across  the  peak  to  obtain 
more  accurate  analyte  quantifications. 
17  post-mortem  hair  samples  were  analysed  using  this  method  and  the  results 
were  compared  to  the  GC-MS  results  obtained  by  in-house  methods.  At  least  one 
drug  class  was  detected  in  16  out  of  17  samples.  1  sample  was  negative  by  both 
the  LC-MS-MS  and  GC-MS  methods.  In  general,  there  was  a  good  qualitative 
correlation  between LC-MS-MS  and  GC-MS  results  for  opiates,  cocaine  and 
amphetamine,  particularly  in  the  0.5-3.5  cm  segments  which  were  of  sufficiently 
high  sample  weight.  Morphine  and  codeine  were  detected  in  2  segments 
excluding  roots  using  GC-MS  where  LC-MS  detected  none.  However  this  did  not 
affect  the  reported  result  in  accordance  with  current  SoHT  guidelines. 
Dihydrocodeine  was  also  detected  in  2  segments  excluding  roots  by  GC"MS  where Conclusion  215 
LC-MS-MS  failed  to  detect  it.  On  the  other  hand,  the  LC-MS-MS  method  detected 
cocaethylene  and  EME  in  2  samples  where  GC-MS  did  not  detect  any  and  in  the 
case  of  EME  could  not  report  the  GC-MS  result  due  to  co-eluting  interferent  at 
the  EME  retention  time.  Overall,  the  LC-MS-MS  method  was  capable  of  testing 
for  more  drug  groups  using  one  hair  sample  and  extraction  method  compared  to 
the  drug  class  specific  GC-MS  methods  which  involved  splitting  the  hair  sample 
and  the  use  of  different  extraction  methods.  On  the  other  hand,  the  GC-MS 
methods  generally  extracted  greater  quantities  of  opiates  and  cocaine  and  its 
metabolites  since  they  were  targeting  these  particular  drug  groups.  The 
methods  had  been  developed  and  validated  with  a  view  to  detecting  one 
particular  drug  group  therefore  the  extraction  and  analysis  conditions  were 
optimum  for  that  drug  group.  The  LC-MS-MS  method  however  was  developed 
and  validated  with  a  view  to  detecting  4  different  drug  groups.  Therefore,  a 
compromise  on  extraction  and  analysis  conditions  had  to  be  reached  for  the  LC- 
MS-MS  method.  The  LC-MS-MS  method  detected  amphetamine,  MDMA,  diazepam 
and  its  metabolites  in  some  samples  however  the  GC-MS  method  did  not  test  for 
these  drug  groups  as  there  was  insufficient  sample  after  testing  for  opiates  and 
in  some  cases  cocaine  and  its  metabolites.  The  ability  of  the  LC-MS-MS  method 
to  extract  and  analyse  a  greater  number  of  drug  groups  from  one  hair  sample 
highlights  the  advantages  of  using  this  method  over  GC-MS  which  targets 
individual  drug  groups  and  requires  splitting  the  sample. 
In  conclusion,  ELISA  screening  is  a  highly  sensitive  method  which  can  be  applied 
for  the  detection  of  drugs  of  abuse  in  hair  and  urine.  LC-MS-MS  has 
demonstrated  excellent  reliability,  sensitivity  and  specificity  and  it  is  an 
extremely  useful  instrument  in  a  forensic  toxicology  laboratory.  Using  LC-MS-MS, 
the  sensitivity  and  therefore  the  qualitative  data  was  better  for  post-mortem 
samples  discussed  in  chapter  8,  especially  for  6-MAM  and  morphine  in  low  weight 
root  samples.  The  LC-MS-MS  method  was  useful  for  the  analysis  of  targeted 
unknown  drugs  from  hair  in  forensic  toxicology  cases  and  could  even  be  used  in 
place  of  ELISA  for  a  more  specific  screening  procedure  or  in  cases  where 
minimum  sample  is  available.  However  GC-MS  is  still  better  for  some  compounds 
and  should  ideally  be  used  in  tandem  with  LC-MS-MS  to  enable  the  analysis  of  a 
large  number  of  compounds. 216 
10  Further  Work 
The  application  of  ELISA  for  the  detection  of  drugs  of  abuse  in  hair  has  been 
demonstrated.  The  ELISA  study  in  this  thesis  was  limited  by  the  number  of 
samples  available  and  the  weight  of  the  sample.  It  was  therefore  not  possible  to 
draw  any  definitive  conclusions  about  the  suitability  of  proposed  cut-off  values 
by  the  Society  of  Hair  Testing  (SoHT).  Screening  a  greater  number  of  samples  of 
sufficient  weight  (>  10  mg)  in  order  to  recommend  appropriate  in-house  values 
would  therefore  be  an  area  of  interest  for  future  work.  In  addition,  ELISA  kits 
which  have  recently  become  commercially  available  e.  g.  zolpidem  and 
fluoxetine  should  be  tested  for  potential  use  in  hair  screening. 
Although  the  LC-MS-MS  method  in  chapter  7  was  successfully  validated  and 
applied  in  the  analysis  of  13  post-mortem  hair  samples  from  chronic  users,  only  6 
of  the  9  benzodiazepines  included  in  the  method  were  detected  in  the  samples. 
The  method  should  be  applied  to  hair  samples  containing  chlord  iazepoxide, 
flunitrazepam  and  7-aminoflunitrazepam  to  ensure  that  the  method  is  suitable 
for  extracting  these  drugs  when  they  are  actually  incorporated.  As  some 
7-aminoflunitrazepam  and  chlordiazepoxide  were  lost  during  the  evaporation 
step  in  the  method,  an  experiment  should  be  carried  out  to  test  their  recovery 
when  tartaric  acid  is  added  to  the  extract  prior  to  evaporating  the  extracts  to 
dryness  using  nitrogen.  Further  work  is  also  required  to  investigate  the 
detection  of  single  dose  benzodiazepine  in  hair  which  can  be  used  to  sedate  a 
victim  in  a  "date-rape"  situation.  With  respect  to  the  molecularly  imprinted 
polymer  work,  the  possibility  of  mixing  two  or  more  sorbents  in  one  cartridge  to 
detect  a  particular  drug  group  should  be  investigated.  Further  work  is  also 
required  to  investigate  the  ability  of  the  MISPE  to  detect  benzodiazepines  in 
single  dose  hair  samples. 
The  newly  validated  LC-MS-MS  method  described  in  chapter  8  should  be  applied 
to  a  greater  number  of  hair  samples  and  the  results  compared  with  current 
GC-MS  methods  to  obtain  more  statistically  valid  data.  This  data  could  be  used 
to  establish  whether  the  guidelines  and  cut-offs  proposed  by  the  Society  of  Hair 
Testing  are  appropriate  for  the  LC-MS-MS  method.  There  is  scope  for  the Further  Work  217 
inclusion  of  other  analytes  in  the  method  which  would  improve  the  method's 
screening  capability.  An  in-house  LC-MS-MS  library  could  be  built  up  for  this 
method  although  this  is  more  difficult  than  for  GC-MS  as  the  LC-MS  spectra  vary 
depending  on  instrument,  chromatographic  conditions  and  fragmentation 
voltages.  However  if  the  instrument  used  in  chapter  8  was  to  be  used  for  all 
routine  hair  analysis  then  this  would  be  possible.  The  matrix  effect  observed  for 
17  drugs  of  abuse  in  the  method  ranged  between  64-136  %.  An  experiment  using 
an  atmospheric  pressure  chemical  ionisation  (APCI)  source  could  be  carried  out 
to  compare  validation  results  with  the  electrospray  (ESI)  results  as  APCI  is 
thought  to  produce  less  matrix  effects  than  ESI.  This  is  because  of  the  presence 
of  excess  reagent  ions  which  produce  charged  species  in  APCI,  making  it  less 
susceptible  to  matrix  effects. 218 
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TECHNICAL  NOTE:  Validation  of  the  Immunalysiso  Microplate 
ELISA  for  the  Detection  of  Buprenorphine  and  Its  Metabolite 
Norbuprenorphine  in  Urine 
Miller,  Eleanor  1.1,  Torrance,  Hazel  J.  1,  Oliver,  John  S 
1  Forensic  Medicine  and  Science  Department,  University  of  Glasgow,  University 
Place,  Glasgow,  G12  8QQ,  Scotland 
The  purpose  of  this  study  was  to  validate  the  Immunalysis  Buprenorphine 
Microplate  enzyme-Linked  immunosorbent  assay  (ELISA)  for  the  detection  of 
buprenorphine  in  urine  samples.  Sixty-nine  urine  samples  were  obtained  from 
volunteers  on  the  Subutexo  treatment  program  and  from  routine  samples 
submitted  to  the  laboratory  for  buprenorphine  testing.  For  ELISA  analysis, 
samples  were  diluted  1:  10  with  K2HPO4  (0-1M,  pH  7.0).  The  limit  of  detection 
was  calculated  as  0.5  ng/mL  buprenorphine.  The  intra-assay  and  interday 
precision  was  3.8%  (n  =  10)  and  8.6%  (n  =  50)  respectively  at  1  ng/mL 
buprenorphine.  At  a  low  concentration  of  norbuprenorphine  (1  ng/mL),  the 
immunoassay  demonstrated  a  cross-  reactivity  of  78%.  A  higher  cross  -reactivity  of 
116%  was  observed  at  a  higher  concentration  of  norbuprenorphine  (10  ng/mL). 
Dihydrocodeine,  codeine,  tramadol,  morphine,  propoxyphene,  methadone,  and 
EDDP  were  tested  at  concentrations  of  10  ng/mL  and  10,000  ng/mL  and 
demonstrated  no  cross-  reactivity  with  the  assay.  For  liquid  chromatography- 
tandem  mass  spectrometry  (LC-MS-MS),  deuterated  internal  standard  mixture, 
1M  acetate  buffer  (pH  5.0),  and  b-glucuronidase  were  added  to  the  standards 
and  samples,  which  were  then  incubated  for  3h  at  600C.  After  incubation,  3  mL 
K2HP04  (0.1M,  pH  6.0)  was  added  and  the  pH  altered  to  pH  6.0  using  IM  KOH. 
Buprenorphine  and  norbuprenorphine  were  subsequently  extracted  by  solid- 
phase.  Twenty-one  samples  were  confirmed  positive  and  48  samples  were 
confirmed  negative  by  LC-MS-MS.  Using  a  cut-off  value  of  0.5  ng/mL 
buprenorphine,  the  immunoassay  demonstrated  a  sensitivity  and  specificity  of 
100%. 257 
VaLidation  of  the  ImmunaLysise  Microplate  ELISA  for  the 
Detection  of  Metharnphetarnine  in  Hair 
Han,  Eunyoung',  Miller,  Eleanor  2,  Lee,  Juseon',  Park,  Yonghoon',  Lim, 
Miael,  Chung,  Heesun',  Wylie,  Fiona  M.  21  Oliver,  John  S.  2 
1  Department  of  Narcotics  Analysis,  National  Institute  of  Scientific  Investigation, 
331  -1  Shinwol  7-Dong,  Yang-Chun  Gu,  Seoul,  South  Korea  2  Forensic  Medicine  and 
Science  Department,  University  of  Glasgow,  University  Place,  Glasgow,  G12  8QQ, 
Scotland 
The  object  of  this  study  was  to  validate  the  Immunalysis  Methamphetamine 
Microptate  ELISA  for  detecting  methamphetamine  in  hair.  Twenty-nine  scalp  hair 
samples  were  obtained  as  routine  cases  submitted  to  the  National  Institute  of 
Scientific  Investigation  in  Seoul  by  the  police.  The  hair  samples  were  washed 
with  0.1%  sodium  dodecyl  sulfate,  distilled  water,  and  dichtoromethane.  The 
samples  were  screened  using  the  Immunalysis  Methamphetamine  Microplate 
ELISA  and  confirmed  using  gas  chromatography-  mass  spectrometry  (GC-MS). 
Twenty-eight  hair  samples  were  screened  and  confirmed  as  positive  for 
methamphetamine.  For  ELISA  analysis,  the  samples  were  extracted  by  incubation 
in  monobasic  phosphate  buffer  for  1h  at  600C.  For  GC-MS,  the  samples  were 
extracted  for  20  h  in  methanol  containing  1%  hydrochloric  acid.  The 
methanot/acid  solution  was  evaporated  to  dryness  and  the  resulting  residue  was 
derivatized  with  triftuoroacetic  anhydride.  Methamphetamine  and  amphetamine 
were  detected  using  selective  ion  monitoring  (SIM)  mode.  The  Immunatysis 
Methamphetamine  Microptate  ELISA  demonstrated  a  sensitivity  and  specificity  of 
97%  and  100%,  respectively,  using  a  cut-off  concentration  of  0.5  ng/mg  d. 
methamphetamine.  The  ELISA  kit  showed  63%  cross-  reactivity  with  dJ- 
methamphetamine  and  did  not  cross-react  to  any  significant  extent  with  the  licit 
t-methamphetamine  isomer.  The  intra-  and  interassay  precisions  were  2.5%  and 
3.7%,  respectively. 258 
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This  study  was  designed  to  validate  an  enzyme-linked  immunosorbent  assay 
(ELISA)  and  liquid  ch  romatography-  tandem  mass  spectrometry  (LC-MS-MS) 
method  for  the  detection  of  nine  benzodiazepines  in  hair.  Sixteen  hair  case 
samples  were  tested  from  drug-related  deaths  where  a  positive  benzodiazepine 
blood  result  was  obtained.  The  case  samples  were  decontaminated  with  0.1  % 
sodium  dodecyL  sulfate,  distilled  water,  and  dichloromethane.  For  ELISA 
analysis,  the  samples  were  extracted  by  incubation  in  monobasic  phosphate 
buffer  for  1h  and  then  neutralized  with  dibasic  phosphate  buffer.  They  were 
diluted  1:  5  with  phosphate  buffer  saline  (PBS)  prior  to  analysis.  For  LC-MS-MS, 
the  samples  were  incubated  overnight  in  methanol/25%  ammonium  hydroxide 
(20:  1).  The  benzodiazepines  were  extracted  by  solid  phase.  Thirteen  samples 
were  confirmed  positive  by  LC-MS-MS.  The  benzodiazepines  detected  included 
diazepam,  nordiazepam,  temazepam,  oxazepam,  nitrazepam,  and  lorazepam. 
Using  a  cut-off  concentration  of  0.1  ng/mg  oxazepam,  the  Immunalysis" 
Benzodiazepine  Microptate  ELISA  demonstrated  a  sensitivity  and  specificity  of 
100%  and  81%,  respectively,  compared  with  LC-MS-MS  results. 259 
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Abstract 
Background:  This  preliminary  study  compares  the  results  of  benzodiazepine 
analysis  in  scalp  hair  samples  in  ten  post-mortem  cases  using  a  validated 
conventional  solid-phase  extraction  (SPE)  system  and  an  anti-diazepam 
molecularly  imprinted  polymer  solid-phase  extraction  (MISPE)  system. 
Methods:  The  ten  hair  samples  tested  were  from  drug-related  deaths  in  which  a 
positive  benzodiazepine  blood  result  was  obtained.  The  case  samples  were 
decontaminated  with  0.1  %  sodium  dodecyt  sulfate,  distilled  water  and 
dichloromethane,  incubated  overnight  in  methanol/25  %  ammonium  hydroxide 
(20:  1)  and  subsequently  extracted  by  SPE  or  MISPE  followed  by  LC-MS-MS 
analysis. 
Results:  Diazepam,  nordiazepam,  oxazepam,  temazepam  and  nitrazeparn  were 
detected  in  the  samples  using  both  extraction  methods.  The  recovery  values  for 
diazepam,  nordiazepam,  oxazepam,  temazeparn  and  nitrazeparn  in  MISPE  and 
SPE  methods  were  between  73-103  %  and  69-91  %  respectively.  LOD  levels 
between  0.06-0.39  ng/30  mg  hair  and  0.03-0.24  ng/30  mg  hair  were  obtained 
with  the  MISPE  and  SPE  methods,  respectively.  Diazeparn  was  detected  in  more 
case  samples  using  MISPE  due  to  the  lower  LOD  values  and  higher  extraction 
recovery,  as  a  result  of  excellent  recognition  of  the  template.  The  LOD  and 
recovery  values  for  diazepam  by  MISPE  are  0.09  ng/30  mg  hair  and  93  %P 
respectively  compared  to  0.13  ng/30  mg  and  69  %  by  SPE.  Nitrazepam  levels 
detected  by  both  methods  were  very  similar.  The  MISPE  method  however  was 260 
less  sensitive  for  temazepam,  nordiazepam  and  oxazepam  determination 
compared  to  the  conventional  SPE  method. 
Conclusion:  The  molecularly  imprinted  polymer  used  for  this  study 
demonstrated  good  selectivity  for  the  5  benzodiazepines  tested,  especially  the 
template  substance,  diazepam.  The  MISPE  method  coutod  be  used  as  an 
alternative  to  conventional  SPE  extraction  for  the  analysis  of  benzodiazepine 
positive  hair  samples  collected  from  chronic  users. 
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A  liquid  chromatography  tandem  mass  spectrometry  (LC-MS/MS)  method  was 
developed  and  validated  for  the  simultaneous  identification  and  quantification 
of  opiates,  cocainics,  amphetamines  and  diazepam  and  its  metabolites  from  a 
single  hair  extract.  Three  different  LC  columns  (Gemini  C18,  Synergi  Hydro  RP 
and  Zorbax  Phenyl)  and  three  different  mobile  phase  combinations  were 
investigated.  Two  mixed  mode  SPE  extraction  cartridges  (Bond  Elut  Certifyo  and 
Clean  Screeno'ZSDAU  020)  were  compared,  with  the  Clean  Screen"  cartridge 
producing  higher  recoveries,  lower  LODs  and  cleaner  extracts.  Methanol  and 
phosphate  buffer  (pH  5)  incubation  methods  were  compared  for  three  authentic 
hair  samples,  with  the  phosphate  buffer  incubation  producing  better  qualitative 
and  quantitative  results.  The  optimised  validated  method  used  the  Synergi 
Hydro  RP  column  with  3  mM  ammonium  formate  +  0.001  %  formic 
acid  /Acetonitrile  mobile  phase,  Clean  Screen  extraction  cartridge  and  phosphate 
buffer  incubation. 
The  authentic  hair  samples  used  in  the  validation  were  from  cases  where  the 
blood  result  was  positive  for  at  least  one  drug  class.  After  segmentation,  the 
samples  were  decontaminated  by  washing  with  0.1  %  sodium  dodecyl  sulfate, 
deionised  water  and  dichloromethane.  Drugs  were  extracted  for  18  h  at  45  OC 
using  phosphate  buffer  (pH  5),  followed  by  SPE  clean-up  using  a  mixed  mode 
Clean  Screeno  extraction  cartridge.  Analytes  were  identified  by  their  full  MS/MS 
spectra  and  quantification  was  based  on  data  from  the  major  product  ion. 
Deuterated  internal  standards  were  used  for  all  analytes  and  the  data  was 
collected  using  selected  ion  monitoring  (SIM)  mode.  The  method  was  applied  to 262 
15  authentic  post-mortem  scalp  samples,  detecting  at  least  one  drug  class  in 
each  sample. 